{"docstore/data": {"2c7921ac-edc5-4133-bba2-f4f6debdb32c": {"__data__": {"id_": "2c7921ac-edc5-4133-bba2-f4f6debdb32c", "embedding": null, "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Fir st Quar ter Results\n1/30/2020\nRevenues of $47.9 Billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $0.90 and Adjusted Diluted EPS of $1.76\nAdjusted Diluted EPS Guidance Range Raised to $7.55 to $7.80 for Fiscal 2020\nThe Board of Directors Increased the Quarterly Dividend Rate by 5% to $0.42 per share\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020 first\nquarter ended December 31, 2019, revenue increased 5.4 percent to $47.9 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $0.90 for the December quarter of fiscal 2020, compared to $1.84\nin the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n", "original_text": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Fir st Quar ter Results\n1/30/2020\nRevenues of $47.9 Billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $0.90 and Adjusted Diluted EPS of $1.76\nAdjusted Diluted EPS Guidance Range Raised to $7.55 to $7.80 for Fiscal 2020\nThe Board of Directors Increased the Quarterly Dividend Rate by 5% to $0.42 per share\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020 first\nquarter ended December 31, 2019, revenue increased 5.4 percent to $47.9 billion. ", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4192cde9b247c7ff5b90edee097a6793618c60f62297c3327437064401daf2f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22b9e2c7-576c-4dff-bfdd-fb6c75621b8b", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Fir st Quar ter Results\n1/30/2020\nRevenues of $47.9 Billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $0.90 and Adjusted Diluted EPS of $1.76\nAdjusted Diluted EPS Guidance Range Raised to $7.55 to $7.80 for Fiscal 2020\nThe Board of Directors Increased the Quarterly Dividend Rate by 5% to $0.42 per share\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020 first\nquarter ended December 31, 2019, revenue increased 5.4 percent to $47.9 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $0.90 for the December quarter of fiscal 2020, compared to $1.84\nin the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n \"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen. ", "original_text": "On the basis of U.S. "}, "hash": "ad93cf611dd3deda89a1c7d2605b95d47ae16436017a4ce83b650974d19c04bc", "class_name": "RelatedNodeInfo"}}, "text": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Fir st Quar ter Results\n1/30/2020\nRevenues of $47.9 Billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $0.90 and Adjusted Diluted EPS of $1.76\nAdjusted Diluted EPS Guidance Range Raised to $7.55 to $7.80 for Fiscal 2020\nThe Board of Directors Increased the Quarterly Dividend Rate by 5% to $0.42 per share\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020 first\nquarter ended December 31, 2019, revenue increased 5.4 percent to $47.9 billion. ", "start_char_idx": 0, "end_char_idx": 644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22b9e2c7-576c-4dff-bfdd-fb6c75621b8b": {"__data__": {"id_": "22b9e2c7-576c-4dff-bfdd-fb6c75621b8b", "embedding": null, "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Fir st Quar ter Results\n1/30/2020\nRevenues of $47.9 Billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $0.90 and Adjusted Diluted EPS of $1.76\nAdjusted Diluted EPS Guidance Range Raised to $7.55 to $7.80 for Fiscal 2020\nThe Board of Directors Increased the Quarterly Dividend Rate by 5% to $0.42 per share\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020 first\nquarter ended December 31, 2019, revenue increased 5.4 percent to $47.9 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $0.90 for the December quarter of fiscal 2020, compared to $1.84\nin the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n \"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen. ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4192cde9b247c7ff5b90edee097a6793618c60f62297c3327437064401daf2f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c7921ac-edc5-4133-bba2-f4f6debdb32c", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Fir st Quar ter Results\n1/30/2020\nRevenues of $47.9 Billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $0.90 and Adjusted Diluted EPS of $1.76\nAdjusted Diluted EPS Guidance Range Raised to $7.55 to $7.80 for Fiscal 2020\nThe Board of Directors Increased the Quarterly Dividend Rate by 5% to $0.42 per share\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020 first\nquarter ended December 31, 2019, revenue increased 5.4 percent to $47.9 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $0.90 for the December quarter of fiscal 2020, compared to $1.84\nin the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n", "original_text": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Fir st Quar ter Results\n1/30/2020\nRevenues of $47.9 Billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $0.90 and Adjusted Diluted EPS of $1.76\nAdjusted Diluted EPS Guidance Range Raised to $7.55 to $7.80 for Fiscal 2020\nThe Board of Directors Increased the Quarterly Dividend Rate by 5% to $0.42 per share\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020 first\nquarter ended December 31, 2019, revenue increased 5.4 percent to $47.9 billion. ", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb6ffa2f97b38187a71abf23f4b22af0caae110e36243a00a2489d29389fd4b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5413af4a-22b9-4676-a8d5-f55728ed7129", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Fir st Quar ter Results\n1/30/2020\nRevenues of $47.9 Billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $0.90 and Adjusted Diluted EPS of $1.76\nAdjusted Diluted EPS Guidance Range Raised to $7.55 to $7.80 for Fiscal 2020\nThe Board of Directors Increased the Quarterly Dividend Rate by 5% to $0.42 per share\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020 first\nquarter ended December 31, 2019, revenue increased 5.4 percent to $47.9 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $0.90 for the December quarter of fiscal 2020, compared to $1.84\nin the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n \"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen.  \"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S. ", "original_text": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $0.90 for the December quarter of fiscal 2020, compared to $1.84\nin the prior year quarter. "}, "hash": "8691a4d8c53166db80a3f9df61ca3af9ebea1fb95af0a8f46dd3fba9dc5135b7", "class_name": "RelatedNodeInfo"}}, "text": "On the basis of U.S. ", "start_char_idx": 644, "end_char_idx": 665, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5413af4a-22b9-4676-a8d5-f55728ed7129": {"__data__": {"id_": "5413af4a-22b9-4676-a8d5-f55728ed7129", "embedding": null, "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Fir st Quar ter Results\n1/30/2020\nRevenues of $47.9 Billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $0.90 and Adjusted Diluted EPS of $1.76\nAdjusted Diluted EPS Guidance Range Raised to $7.55 to $7.80 for Fiscal 2020\nThe Board of Directors Increased the Quarterly Dividend Rate by 5% to $0.42 per share\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020 first\nquarter ended December 31, 2019, revenue increased 5.4 percent to $47.9 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $0.90 for the December quarter of fiscal 2020, compared to $1.84\nin the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n \"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen.  \"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S. ", "original_text": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $0.90 for the December quarter of fiscal 2020, compared to $1.84\nin the prior year quarter. ", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4192cde9b247c7ff5b90edee097a6793618c60f62297c3327437064401daf2f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22b9e2c7-576c-4dff-bfdd-fb6c75621b8b", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Fir st Quar ter Results\n1/30/2020\nRevenues of $47.9 Billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $0.90 and Adjusted Diluted EPS of $1.76\nAdjusted Diluted EPS Guidance Range Raised to $7.55 to $7.80 for Fiscal 2020\nThe Board of Directors Increased the Quarterly Dividend Rate by 5% to $0.42 per share\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020 first\nquarter ended December 31, 2019, revenue increased 5.4 percent to $47.9 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $0.90 for the December quarter of fiscal 2020, compared to $1.84\nin the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n \"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen. ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aec9629eb1662054cd1b46566b7ef632e2a936809b3584f4b751ed6d25c57702", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbf59b49-9c74-42eb-b446-2f14fa1a0cdf", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Fir st Quar ter Results\n1/30/2020\nRevenues of $47.9 Billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $0.90 and Adjusted Diluted EPS of $1.76\nAdjusted Diluted EPS Guidance Range Raised to $7.55 to $7.80 for Fiscal 2020\nThe Board of Directors Increased the Quarterly Dividend Rate by 5% to $0.42 per share\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020 first\nquarter ended December 31, 2019, revenue increased 5.4 percent to $47.9 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $0.90 for the December quarter of fiscal 2020, compared to $1.84\nin the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n \"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen.  \"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S.  market,\" said Mr. ", "original_text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n"}, "hash": "59ba34a0a19df666f4fcac1ad6d5292cdf40be2df0e360d10413c7a6225b4c1d", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $0.90 for the December quarter of fiscal 2020, compared to $1.84\nin the prior year quarter. ", "start_char_idx": 665, "end_char_idx": 843, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbf59b49-9c74-42eb-b446-2f14fa1a0cdf": {"__data__": {"id_": "dbf59b49-9c74-42eb-b446-2f14fa1a0cdf", "embedding": null, "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Fir st Quar ter Results\n1/30/2020\nRevenues of $47.9 Billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $0.90 and Adjusted Diluted EPS of $1.76\nAdjusted Diluted EPS Guidance Range Raised to $7.55 to $7.80 for Fiscal 2020\nThe Board of Directors Increased the Quarterly Dividend Rate by 5% to $0.42 per share\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020 first\nquarter ended December 31, 2019, revenue increased 5.4 percent to $47.9 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $0.90 for the December quarter of fiscal 2020, compared to $1.84\nin the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n \"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen.  \"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S.  market,\" said Mr. ", "original_text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4192cde9b247c7ff5b90edee097a6793618c60f62297c3327437064401daf2f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5413af4a-22b9-4676-a8d5-f55728ed7129", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Fir st Quar ter Results\n1/30/2020\nRevenues of $47.9 Billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $0.90 and Adjusted Diluted EPS of $1.76\nAdjusted Diluted EPS Guidance Range Raised to $7.55 to $7.80 for Fiscal 2020\nThe Board of Directors Increased the Quarterly Dividend Rate by 5% to $0.42 per share\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020 first\nquarter ended December 31, 2019, revenue increased 5.4 percent to $47.9 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $0.90 for the December quarter of fiscal 2020, compared to $1.84\nin the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n \"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen.  \"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S. ", "original_text": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $0.90 for the December quarter of fiscal 2020, compared to $1.84\nin the prior year quarter. ", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f8c49ba82d7b0337fd5ee54b65ce987cba0fdd86e792ab281bace7d24c2b366", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a4c3325-344d-4265-9eff-adbd2b83442a", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $0.90 for the December quarter of fiscal 2020, compared to $1.84\nin the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n \"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen.  \"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S.  market,\" said Mr.  Collis.\n", "original_text": "\"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen. "}, "hash": "71c8a786cac3d42610a5f376b3bf30a13c1774e5a60cbafdcd35f13c59066a1f", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n", "start_char_idx": 843, "end_char_idx": 991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a4c3325-344d-4265-9eff-adbd2b83442a": {"__data__": {"id_": "6a4c3325-344d-4265-9eff-adbd2b83442a", "embedding": null, "metadata": {"window": "On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $0.90 for the December quarter of fiscal 2020, compared to $1.84\nin the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n \"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen.  \"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S.  market,\" said Mr.  Collis.\n", "original_text": "\"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen. ", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4192cde9b247c7ff5b90edee097a6793618c60f62297c3327437064401daf2f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbf59b49-9c74-42eb-b446-2f14fa1a0cdf", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Fir st Quar ter Results\n1/30/2020\nRevenues of $47.9 Billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $0.90 and Adjusted Diluted EPS of $1.76\nAdjusted Diluted EPS Guidance Range Raised to $7.55 to $7.80 for Fiscal 2020\nThe Board of Directors Increased the Quarterly Dividend Rate by 5% to $0.42 per share\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020 first\nquarter ended December 31, 2019, revenue increased 5.4 percent to $47.9 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $0.90 for the December quarter of fiscal 2020, compared to $1.84\nin the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n \"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen.  \"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S.  market,\" said Mr. ", "original_text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80a2f1ad0d47353ff129071ec19273103a04dba5076741e0ed6ad45760caf908", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f0f71e1-f964-4192-995f-0f4dafeb8517", "node_type": "1", "metadata": {"window": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $0.90 for the December quarter of fiscal 2020, compared to $1.84\nin the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n \"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen.  \"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S.  market,\" said Mr.  Collis.\n In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business. ", "original_text": "\"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S. "}, "hash": "df7ca59520079e2abc4eeab04c9cf2bb7a6f9f738257921d00398747b1ce28c2", "class_name": "RelatedNodeInfo"}}, "text": "\"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen. ", "start_char_idx": 991, "end_char_idx": 1284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f0f71e1-f964-4192-995f-0f4dafeb8517": {"__data__": {"id_": "5f0f71e1-f964-4192-995f-0f4dafeb8517", "embedding": null, "metadata": {"window": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $0.90 for the December quarter of fiscal 2020, compared to $1.84\nin the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n \"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen.  \"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S.  market,\" said Mr.  Collis.\n In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business. ", "original_text": "\"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S. ", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4192cde9b247c7ff5b90edee097a6793618c60f62297c3327437064401daf2f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a4c3325-344d-4265-9eff-adbd2b83442a", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $0.90 for the December quarter of fiscal 2020, compared to $1.84\nin the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n \"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen.  \"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S.  market,\" said Mr.  Collis.\n", "original_text": "\"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen. ", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bf37f2d015f3c193cc6e07d06910a46d66f692bcc9d7364b7cc7dd116abe63d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df89fb75-4664-4f23-966a-ad1c04439526", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n \"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen.  \"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S.  market,\" said Mr.  Collis.\n In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business.  Additional details can be found in the section labeled\n\"PharMEDium Update\".\n", "original_text": "market,\" said Mr. "}, "hash": "693f0c1265c8d4cc30233ef561870c29d01e3210a28708aed34e65a373de3b78", "class_name": "RelatedNodeInfo"}}, "text": "\"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S. ", "start_char_idx": 1284, "end_char_idx": 1433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df89fb75-4664-4f23-966a-ad1c04439526": {"__data__": {"id_": "df89fb75-4664-4f23-966a-ad1c04439526", "embedding": null, "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n \"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen.  \"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S.  market,\" said Mr.  Collis.\n In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business.  Additional details can be found in the section labeled\n\"PharMEDium Update\".\n", "original_text": "market,\" said Mr. ", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4192cde9b247c7ff5b90edee097a6793618c60f62297c3327437064401daf2f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f0f71e1-f964-4192-995f-0f4dafeb8517", "node_type": "1", "metadata": {"window": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $0.90 for the December quarter of fiscal 2020, compared to $1.84\nin the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n \"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen.  \"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S.  market,\" said Mr.  Collis.\n In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business. ", "original_text": "\"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S. ", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21d92eceadcb9df313e673c332b9050f77eec3eca583bb81197e840c8bbca7d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bcd24d9-1dee-41fc-8abf-becee8eedf41", "node_type": "1", "metadata": {"window": "\"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen.  \"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S.  market,\" said Mr.  Collis.\n In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business.  Additional details can be found in the section labeled\n\"PharMEDium Update\".\n \"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\" ", "original_text": "Collis.\n"}, "hash": "0df5d14c99f96f5bf78e06b8043dffc60670d8984ad6044d24eb5b59b866c164", "class_name": "RelatedNodeInfo"}}, "text": "market,\" said Mr. ", "start_char_idx": 1433, "end_char_idx": 1451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bcd24d9-1dee-41fc-8abf-becee8eedf41": {"__data__": {"id_": "7bcd24d9-1dee-41fc-8abf-becee8eedf41", "embedding": null, "metadata": {"window": "\"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen.  \"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S.  market,\" said Mr.  Collis.\n In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business.  Additional details can be found in the section labeled\n\"PharMEDium Update\".\n \"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\" ", "original_text": "Collis.\n", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4192cde9b247c7ff5b90edee097a6793618c60f62297c3327437064401daf2f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df89fb75-4664-4f23-966a-ad1c04439526", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n \"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen.  \"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S.  market,\" said Mr.  Collis.\n In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business.  Additional details can be found in the section labeled\n\"PharMEDium Update\".\n", "original_text": "market,\" said Mr. ", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b1fdf36b457345807068767e3aac11afba0985b3b0aa7d1b7fa5fcfb5917f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "650f6f1c-4be8-484f-8c16-7eed75e4e07a", "node_type": "1", "metadata": {"window": "\"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S.  market,\" said Mr.  Collis.\n In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business.  Additional details can be found in the section labeled\n\"PharMEDium Update\".\n \"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\"  Mr. ", "original_text": "In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business. "}, "hash": "663a3edb6f2dd12a1ad44d69af1dc8f078c14de0b25deed4b37a64d1d4fee9ad", "class_name": "RelatedNodeInfo"}}, "text": "Collis.\n", "start_char_idx": 1451, "end_char_idx": 1459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "650f6f1c-4be8-484f-8c16-7eed75e4e07a": {"__data__": {"id_": "650f6f1c-4be8-484f-8c16-7eed75e4e07a", "embedding": null, "metadata": {"window": "\"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S.  market,\" said Mr.  Collis.\n In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business.  Additional details can be found in the section labeled\n\"PharMEDium Update\".\n \"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\"  Mr. ", "original_text": "In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business. ", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4192cde9b247c7ff5b90edee097a6793618c60f62297c3327437064401daf2f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bcd24d9-1dee-41fc-8abf-becee8eedf41", "node_type": "1", "metadata": {"window": "\"We delivered strong revenue and adjusted EPS growth in the first quarter of fiscal 2020, driven by both the Pharmaceutical\nDistribution and Global Commercialization Services & Animal Health groups,\" said Steven H. Collis, Chairman, President and Chief\nExecutive Officer of AmerisourceBergen.  \"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S.  market,\" said Mr.  Collis.\n In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business.  Additional details can be found in the section labeled\n\"PharMEDium Update\".\n \"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\" ", "original_text": "Collis.\n", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f0b111577cd2b22a4d32e8039066406a75118c38ad7856eedd7f127c2d8b9bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6953132-ca6d-4655-afdd-4948f4802fd6", "node_type": "1", "metadata": {"window": "market,\" said Mr.  Collis.\n In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business.  Additional details can be found in the section labeled\n\"PharMEDium Update\".\n \"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\"  Mr.  Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n", "original_text": "Additional details can be found in the section labeled\n\"PharMEDium Update\".\n"}, "hash": "eb73bae42839fb4749b16794d6003ce33fda700449ec045bcdd52d2355ea6bc7", "class_name": "RelatedNodeInfo"}}, "text": "In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business. ", "start_char_idx": 1459, "end_char_idx": 1655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6953132-ca6d-4655-afdd-4948f4802fd6": {"__data__": {"id_": "a6953132-ca6d-4655-afdd-4948f4802fd6", "embedding": null, "metadata": {"window": "market,\" said Mr.  Collis.\n In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business.  Additional details can be found in the section labeled\n\"PharMEDium Update\".\n \"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\"  Mr.  Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n", "original_text": "Additional details can be found in the section labeled\n\"PharMEDium Update\".\n", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4192cde9b247c7ff5b90edee097a6793618c60f62297c3327437064401daf2f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "650f6f1c-4be8-484f-8c16-7eed75e4e07a", "node_type": "1", "metadata": {"window": "\"Our results continue to demonstrate the strength of AmerisourceBergen's unique\npharmaceutical-centered strategy and compelling position in the U.S.  market,\" said Mr.  Collis.\n In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business.  Additional details can be found in the section labeled\n\"PharMEDium Update\".\n \"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\"  Mr. ", "original_text": "In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business. ", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff78ebf2abb7981cdd5617669e677e26bbc6f695174a32a8e0d8f653871ec861", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e11b6df-df35-4157-a52f-b4fd5b74314b", "node_type": "1", "metadata": {"window": "Collis.\n In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business.  Additional details can be found in the section labeled\n\"PharMEDium Update\".\n \"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\"  Mr.  Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share. ", "original_text": "\"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\" "}, "hash": "8d5b4845d01bf589215aba3e1a8791c305fa1ffa600a1d24a23cd43720d075d4", "class_name": "RelatedNodeInfo"}}, "text": "Additional details can be found in the section labeled\n\"PharMEDium Update\".\n", "start_char_idx": 1655, "end_char_idx": 1731, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e11b6df-df35-4157-a52f-b4fd5b74314b": {"__data__": {"id_": "0e11b6df-df35-4157-a52f-b4fd5b74314b", "embedding": null, "metadata": {"window": "Collis.\n In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business.  Additional details can be found in the section labeled\n\"PharMEDium Update\".\n \"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\"  Mr.  Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share. ", "original_text": "\"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\" ", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4192cde9b247c7ff5b90edee097a6793618c60f62297c3327437064401daf2f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6953132-ca6d-4655-afdd-4948f4802fd6", "node_type": "1", "metadata": {"window": "market,\" said Mr.  Collis.\n In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business.  Additional details can be found in the section labeled\n\"PharMEDium Update\".\n \"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\"  Mr.  Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n", "original_text": "Additional details can be found in the section labeled\n\"PharMEDium Update\".\n", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45625f4848bda38a4eceda6687877908119ab536bd141bf5e9805eb369ed9ce1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbf3184b-9333-4b5d-a715-5402ac4cbe4b", "node_type": "1", "metadata": {"window": "In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business.  Additional details can be found in the section labeled\n\"PharMEDium Update\".\n \"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\"  Mr.  Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share.  The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n", "original_text": "Mr. "}, "hash": "4c09746e24e2edcdbf2c2bad6b1d99b6ce005d3afae7a7ae9ceb25962e3d7a2d", "class_name": "RelatedNodeInfo"}}, "text": "\"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\" ", "start_char_idx": 1731, "end_char_idx": 1959, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbf3184b-9333-4b5d-a715-5402ac4cbe4b": {"__data__": {"id_": "dbf3184b-9333-4b5d-a715-5402ac4cbe4b", "embedding": null, "metadata": {"window": "In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business.  Additional details can be found in the section labeled\n\"PharMEDium Update\".\n \"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\"  Mr.  Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share.  The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n", "original_text": "Mr. ", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4192cde9b247c7ff5b90edee097a6793618c60f62297c3327437064401daf2f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e11b6df-df35-4157-a52f-b4fd5b74314b", "node_type": "1", "metadata": {"window": "Collis.\n In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business.  Additional details can be found in the section labeled\n\"PharMEDium Update\".\n \"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\"  Mr.  Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share. ", "original_text": "\"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\" ", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7931f29388f219b7653d9e8567403a3ff108c96d078932ed795a2e97ff7971f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db62eeb3-a078-464c-8f16-a113c169e830", "node_type": "1", "metadata": {"window": "Additional details can be found in the section labeled\n\"PharMEDium Update\".\n \"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\"  Mr.  Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share.  The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n \"As we move further into fiscal 2020, we remain confident that we will continue to execute our unique and differentiated business\nstrategy to deliver long-term growth for our shareholders,\" Mr. ", "original_text": "Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n"}, "hash": "3bf3d546567e962cd0ee669bc90c0737ffc86399ed63d712d5715669f602331c", "class_name": "RelatedNodeInfo"}}, "text": "Mr. ", "start_char_idx": 1447, "end_char_idx": 1451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db62eeb3-a078-464c-8f16-a113c169e830": {"__data__": {"id_": "db62eeb3-a078-464c-8f16-a113c169e830", "embedding": null, "metadata": {"window": "Additional details can be found in the section labeled\n\"PharMEDium Update\".\n \"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\"  Mr.  Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share.  The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n \"As we move further into fiscal 2020, we remain confident that we will continue to execute our unique and differentiated business\nstrategy to deliver long-term growth for our shareholders,\" Mr. ", "original_text": "Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4192cde9b247c7ff5b90edee097a6793618c60f62297c3327437064401daf2f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbf3184b-9333-4b5d-a715-5402ac4cbe4b", "node_type": "1", "metadata": {"window": "In late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will cease\nall commercial and administrative operations related to this business.  Additional details can be found in the section labeled\n\"PharMEDium Update\".\n \"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\"  Mr.  Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share.  The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n", "original_text": "Mr. ", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb1fcf1bb99132569d995b215299c4acaaced9a4203763e4077cc233a1f278eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25290bdd-dcfd-4730-ac0e-833d6599992d", "node_type": "1", "metadata": {"window": "\"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\"  Mr.  Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share.  The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n \"As we move further into fiscal 2020, we remain confident that we will continue to execute our unique and differentiated business\nstrategy to deliver long-term growth for our shareholders,\" Mr.  Collis said.\n", "original_text": "Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share. "}, "hash": "564cd9456809f0dc0c8a9be853e15ed4479f1f7458605750b3466a643646ef3e", "class_name": "RelatedNodeInfo"}}, "text": "Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n", "start_char_idx": 1963, "end_char_idx": 2149, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25290bdd-dcfd-4730-ac0e-833d6599992d": {"__data__": {"id_": "25290bdd-dcfd-4730-ac0e-833d6599992d", "embedding": null, "metadata": {"window": "\"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\"  Mr.  Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share.  The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n \"As we move further into fiscal 2020, we remain confident that we will continue to execute our unique and differentiated business\nstrategy to deliver long-term growth for our shareholders,\" Mr.  Collis said.\n", "original_text": "Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share. ", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4192cde9b247c7ff5b90edee097a6793618c60f62297c3327437064401daf2f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db62eeb3-a078-464c-8f16-a113c169e830", "node_type": "1", "metadata": {"window": "Additional details can be found in the section labeled\n\"PharMEDium Update\".\n \"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\"  Mr.  Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share.  The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n \"As we move further into fiscal 2020, we remain confident that we will continue to execute our unique and differentiated business\nstrategy to deliver long-term growth for our shareholders,\" Mr. ", "original_text": "Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb85a212979e71102235fbdaa76aa77be86866abe5ec521246d9cbaa5036b175", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79413521-8cc5-4f05-a815-ed34d9f8bfbd", "node_type": "1", "metadata": {"window": "Mr.  Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share.  The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n \"As we move further into fiscal 2020, we remain confident that we will continue to execute our unique and differentiated business\nstrategy to deliver long-term growth for our shareholders,\" Mr.  Collis said.\n First Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP \u00a0\u00a0Adjust ed (Non-GAAP)\nRevenue $47.9B $47.9B\n1", "original_text": "The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n"}, "hash": "3c96d9222f0855fee64922c3777d04ad0206995d7c096a9ad4acaeecc323ad02", "class_name": "RelatedNodeInfo"}}, "text": "Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share. ", "start_char_idx": 2149, "end_char_idx": 2337, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79413521-8cc5-4f05-a815-ed34d9f8bfbd": {"__data__": {"id_": "79413521-8cc5-4f05-a815-ed34d9f8bfbd", "embedding": null, "metadata": {"window": "Mr.  Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share.  The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n \"As we move further into fiscal 2020, we remain confident that we will continue to execute our unique and differentiated business\nstrategy to deliver long-term growth for our shareholders,\" Mr.  Collis said.\n First Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP \u00a0\u00a0Adjust ed (Non-GAAP)\nRevenue $47.9B $47.9B\n1", "original_text": "The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4192cde9b247c7ff5b90edee097a6793618c60f62297c3327437064401daf2f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25290bdd-dcfd-4730-ac0e-833d6599992d", "node_type": "1", "metadata": {"window": "\"After a comprehensive strategic and financial review of the PharMEDium business and continued operational challenges and\nfinancial burden, we have determined that the best path forward is to shut down the PharMEDium business.\"  Mr.  Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share.  The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n \"As we move further into fiscal 2020, we remain confident that we will continue to execute our unique and differentiated business\nstrategy to deliver long-term growth for our shareholders,\" Mr.  Collis said.\n", "original_text": "Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share. ", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51ed6cb65f3e89295b0686fa17d244d186a1d7b08a031b69433a02d938a2e5d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8479a757-f1f4-4e11-98d8-dfb2aa6a1901", "node_type": "1", "metadata": {"window": "Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share.  The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n \"As we move further into fiscal 2020, we remain confident that we will continue to execute our unique and differentiated business\nstrategy to deliver long-term growth for our shareholders,\" Mr.  Collis said.\n First Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP \u00a0\u00a0Adjust ed (Non-GAAP)\nRevenue $47.9B $47.9B\n1", "original_text": "\"As we move further into fiscal 2020, we remain confident that we will continue to execute our unique and differentiated business\nstrategy to deliver long-term growth for our shareholders,\" Mr. "}, "hash": "600dc4f3e8e482f18f919f5cfa2298ebe2d15c0ad528c8af085a5f54f8aed1ea", "class_name": "RelatedNodeInfo"}}, "text": "The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n", "start_char_idx": 2337, "end_char_idx": 2490, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8479a757-f1f4-4e11-98d8-dfb2aa6a1901": {"__data__": {"id_": "8479a757-f1f4-4e11-98d8-dfb2aa6a1901", "embedding": null, "metadata": {"window": "Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share.  The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n \"As we move further into fiscal 2020, we remain confident that we will continue to execute our unique and differentiated business\nstrategy to deliver long-term growth for our shareholders,\" Mr.  Collis said.\n First Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP \u00a0\u00a0Adjust ed (Non-GAAP)\nRevenue $47.9B $47.9B\n1", "original_text": "\"As we move further into fiscal 2020, we remain confident that we will continue to execute our unique and differentiated business\nstrategy to deliver long-term growth for our shareholders,\" Mr. ", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4192cde9b247c7ff5b90edee097a6793618c60f62297c3327437064401daf2f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79413521-8cc5-4f05-a815-ed34d9f8bfbd", "node_type": "1", "metadata": {"window": "Mr.  Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share.  The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n \"As we move further into fiscal 2020, we remain confident that we will continue to execute our unique and differentiated business\nstrategy to deliver long-term growth for our shareholders,\" Mr.  Collis said.\n First Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP \u00a0\u00a0Adjust ed (Non-GAAP)\nRevenue $47.9B $47.9B\n1", "original_text": "The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8f1dab7d4eea0550c4f78783e41fad2a0fafb28e6cb7c4c870e15942a8e188a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "526af04e-87a0-429c-8bb3-cab5c8167ae5", "node_type": "1", "metadata": {"window": "Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share.  The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n \"As we move further into fiscal 2020, we remain confident that we will continue to execute our unique and differentiated business\nstrategy to deliver long-term growth for our shareholders,\" Mr.  Collis said.\n First Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP \u00a0\u00a0Adjust ed (Non-GAAP)\nRevenue $47.9B $47.9B\n1", "original_text": "Collis said.\n"}, "hash": "5393711cea9f77b243ae3793e66c594f51b47d75a320cab3aeba51ea102a7c6b", "class_name": "RelatedNodeInfo"}}, "text": "\"As we move further into fiscal 2020, we remain confident that we will continue to execute our unique and differentiated business\nstrategy to deliver long-term growth for our shareholders,\" Mr. ", "start_char_idx": 2490, "end_char_idx": 2684, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "526af04e-87a0-429c-8bb3-cab5c8167ae5": {"__data__": {"id_": "526af04e-87a0-429c-8bb3-cab5c8167ae5", "embedding": null, "metadata": {"window": "Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share.  The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n \"As we move further into fiscal 2020, we remain confident that we will continue to execute our unique and differentiated business\nstrategy to deliver long-term growth for our shareholders,\" Mr.  Collis said.\n First Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP \u00a0\u00a0Adjust ed (Non-GAAP)\nRevenue $47.9B $47.9B\n1", "original_text": "Collis said.\n", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4192cde9b247c7ff5b90edee097a6793618c60f62297c3327437064401daf2f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8479a757-f1f4-4e11-98d8-dfb2aa6a1901", "node_type": "1", "metadata": {"window": "Collis continued,\n\"Our increased fiscal 2020 guidance reflects the ongoing strength of our business and the removal of PharMEDium's operating loss\nfor the remainder of the fiscal year.\"\n Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share.  The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n \"As we move further into fiscal 2020, we remain confident that we will continue to execute our unique and differentiated business\nstrategy to deliver long-term growth for our shareholders,\" Mr.  Collis said.\n First Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP \u00a0\u00a0Adjust ed (Non-GAAP)\nRevenue $47.9B $47.9B\n1", "original_text": "\"As we move further into fiscal 2020, we remain confident that we will continue to execute our unique and differentiated business\nstrategy to deliver long-term growth for our shareholders,\" Mr. ", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0b7470b80e8bcd3e636153ccafffc8b94beeaed7a9bd166b4dcc56e0be140105", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd27bca1-1151-490d-975b-a48a6f56c8d8", "node_type": "1", "metadata": {"window": "The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n \"As we move further into fiscal 2020, we remain confident that we will continue to execute our unique and differentiated business\nstrategy to deliver long-term growth for our shareholders,\" Mr.  Collis said.\n First Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP \u00a0\u00a0Adjust ed (Non-GAAP)\nRevenue $47.9B $47.9B\n1", "original_text": "First Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP \u00a0\u00a0Adjust ed (Non-GAAP)\nRevenue $47.9B $47.9B\n1"}, "hash": "6733bcbdafb7a6260a20d125f544b8ba41e3220d37dc9e2009a0df3f9bc415ec", "class_name": "RelatedNodeInfo"}}, "text": "Collis said.\n", "start_char_idx": 2684, "end_char_idx": 2697, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd27bca1-1151-490d-975b-a48a6f56c8d8": {"__data__": {"id_": "dd27bca1-1151-490d-975b-a48a6f56c8d8", "embedding": null, "metadata": {"window": "The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n \"As we move further into fiscal 2020, we remain confident that we will continue to execute our unique and differentiated business\nstrategy to deliver long-term growth for our shareholders,\" Mr.  Collis said.\n First Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP \u00a0\u00a0Adjust ed (Non-GAAP)\nRevenue $47.9B $47.9B\n1", "original_text": "First Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP \u00a0\u00a0Adjust ed (Non-GAAP)\nRevenue $47.9B $47.9B\n1", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4192cde9b247c7ff5b90edee097a6793618c60f62297c3327437064401daf2f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "526af04e-87a0-429c-8bb3-cab5c8167ae5", "node_type": "1", "metadata": {"window": "Today, the Company announced that the Board of Directors declared a quarterly dividend of $0.42 per common share, a 5%\nincrease in the quarterly dividend rate from $0.40 per common share.  The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n \"As we move further into fiscal 2020, we remain confident that we will continue to execute our unique and differentiated business\nstrategy to deliver long-term growth for our shareholders,\" Mr.  Collis said.\n First Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP \u00a0\u00a0Adjust ed (Non-GAAP)\nRevenue $47.9B $47.9B\n1", "original_text": "Collis said.\n", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "37abe92800cb8b68118f68e85047488c2b2934ee743959bee4275fac41bd15f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44f372a0-8695-4e66-892c-9dc9305b2ab5", "node_type": "1", "metadata": {"window": "Gross Pr ofit $1.2B $1.2B\nOperating Expenses $968M $748M\nOperating Income $263M $495M\nInterest Expense, Net $31M $31M\nEffectiv e Tax Rat e 18.7% 21.0%\nNet Income A ttributable t o ABC $188M $365M\nDilut ed Earnings P er Shar e $0.90 $1.76\nDilut ed Shar es Outstanding 208M 208M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n", "original_text": "Gross Pr ofit $1.2B $1.2B\nOperating Expenses $968M $748M\nOperating Income $263M $495M\nInterest Expense, Net $31M $31M\nEffectiv e Tax Rat e 18.7% 21.0%\nNet Income A ttributable t o ABC $188M $365M\nDilut ed Earnings P er Shar e $0.90 $1.76\nDilut ed Shar es Outstanding 208M 208M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. "}, "hash": "b94d3b66e27f89d48f637c97c13ef197558a085501b0334784dbc96dc414535a", "class_name": "RelatedNodeInfo"}}, "text": "First Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP \u00a0\u00a0Adjust ed (Non-GAAP)\nRevenue $47.9B $47.9B\n1", "start_char_idx": 2697, "end_char_idx": 2800, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44f372a0-8695-4e66-892c-9dc9305b2ab5": {"__data__": {"id_": "44f372a0-8695-4e66-892c-9dc9305b2ab5", "embedding": null, "metadata": {"window": "Gross Pr ofit $1.2B $1.2B\nOperating Expenses $968M $748M\nOperating Income $263M $495M\nInterest Expense, Net $31M $31M\nEffectiv e Tax Rat e 18.7% 21.0%\nNet Income A ttributable t o ABC $188M $365M\nDilut ed Earnings P er Shar e $0.90 $1.76\nDilut ed Shar es Outstanding 208M 208M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n", "original_text": "Gross Pr ofit $1.2B $1.2B\nOperating Expenses $968M $748M\nOperating Income $263M $495M\nInterest Expense, Net $31M $31M\nEffectiv e Tax Rat e 18.7% 21.0%\nNet Income A ttributable t o ABC $188M $365M\nDilut ed Earnings P er Shar e $0.90 $1.76\nDilut ed Shar es Outstanding 208M 208M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "650e795b3ca3dd95062f21a10fe595dd35b2dec0410016f9863741633c16830d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd27bca1-1151-490d-975b-a48a6f56c8d8", "node_type": "1", "metadata": {"window": "The quarterly dividend of $0.42 per common share will be\npayable March 2, 2020, to stockholders of record at the close of business on February 14, 2020.\n \"As we move further into fiscal 2020, we remain confident that we will continue to execute our unique and differentiated business\nstrategy to deliver long-term growth for our shareholders,\" Mr.  Collis said.\n First Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP \u00a0\u00a0Adjust ed (Non-GAAP)\nRevenue $47.9B $47.9B\n1", "original_text": "First Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP \u00a0\u00a0Adjust ed (Non-GAAP)\nRevenue $47.9B $47.9B\n1", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d73c92e551b64fd2f128f6948c8421a457326df5b04cf47e1ca704fdf5de0a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53091b22-d050-4b64-b486-448280843464", "node_type": "1", "metadata": {"window": "Gross Pr ofit $1.2B $1.2B\nOperating Expenses $968M $748M\nOperating Income $263M $495M\nInterest Expense, Net $31M $31M\nEffectiv e Tax Rat e 18.7% 21.0%\nNet Income A ttributable t o ABC $188M $365M\nDilut ed Earnings P er Shar e $0.90 $1.76\nDilut ed Shar es Outstanding 208M 208M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year. ", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. "}, "hash": "451391336bcf6e1ea209d365a24169598901dc23e35df814501eef92c308a326", "class_name": "RelatedNodeInfo"}}, "text": "Gross Pr ofit $1.2B $1.2B\nOperating Expenses $968M $748M\nOperating Income $263M $495M\nInterest Expense, Net $31M $31M\nEffectiv e Tax Rat e 18.7% 21.0%\nNet Income A ttributable t o ABC $188M $365M\nDilut ed Earnings P er Shar e $0.90 $1.76\nDilut ed Shar es Outstanding 208M 208M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "start_char_idx": 0, "end_char_idx": 398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53091b22-d050-4b64-b486-448280843464": {"__data__": {"id_": "53091b22-d050-4b64-b486-448280843464", "embedding": null, "metadata": {"window": "Gross Pr ofit $1.2B $1.2B\nOperating Expenses $968M $748M\nOperating Income $263M $495M\nInterest Expense, Net $31M $31M\nEffectiv e Tax Rat e 18.7% 21.0%\nNet Income A ttributable t o ABC $188M $365M\nDilut ed Earnings P er Shar e $0.90 $1.76\nDilut ed Shar es Outstanding 208M 208M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year. ", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "650e795b3ca3dd95062f21a10fe595dd35b2dec0410016f9863741633c16830d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44f372a0-8695-4e66-892c-9dc9305b2ab5", "node_type": "1", "metadata": {"window": "Gross Pr ofit $1.2B $1.2B\nOperating Expenses $968M $748M\nOperating Income $263M $495M\nInterest Expense, Net $31M $31M\nEffectiv e Tax Rat e 18.7% 21.0%\nNet Income A ttributable t o ABC $188M $365M\nDilut ed Earnings P er Shar e $0.90 $1.76\nDilut ed Shar es Outstanding 208M 208M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n", "original_text": "Gross Pr ofit $1.2B $1.2B\nOperating Expenses $968M $748M\nOperating Income $263M $495M\nInterest Expense, Net $31M $31M\nEffectiv e Tax Rat e 18.7% 21.0%\nNet Income A ttributable t o ABC $188M $365M\nDilut ed Earnings P er Shar e $0.90 $1.76\nDilut ed Shar es Outstanding 208M 208M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9b5ea62963afa6927d1dac3879b6d28ec573a8a955fd95ababa2b1306b678555", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e64faf6-545c-4a0c-8e9e-08d9883eb128", "node_type": "1", "metadata": {"window": "Gross Pr ofit $1.2B $1.2B\nOperating Expenses $968M $748M\nOperating Income $263M $495M\nInterest Expense, Net $31M $31M\nEffectiv e Tax Rat e 18.7% 21.0%\nNet Income A ttributable t o ABC $188M $365M\nDilut ed Earnings P er Shar e $0.90 $1.76\nDilut ed Shar es Outstanding 208M 208M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n"}, "hash": "074e6ae7fac666051a4a15ed014d00fe8e592287903842411ca29800e0d40523", "class_name": "RelatedNodeInfo"}}, "text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "start_char_idx": 398, "end_char_idx": 490, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e64faf6-545c-4a0c-8e9e-08d9883eb128": {"__data__": {"id_": "2e64faf6-545c-4a0c-8e9e-08d9883eb128", "embedding": null, "metadata": {"window": "Gross Pr ofit $1.2B $1.2B\nOperating Expenses $968M $748M\nOperating Income $263M $495M\nInterest Expense, Net $31M $31M\nEffectiv e Tax Rat e 18.7% 21.0%\nNet Income A ttributable t o ABC $188M $365M\nDilut ed Earnings P er Shar e $0.90 $1.76\nDilut ed Shar es Outstanding 208M 208M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "650e795b3ca3dd95062f21a10fe595dd35b2dec0410016f9863741633c16830d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53091b22-d050-4b64-b486-448280843464", "node_type": "1", "metadata": {"window": "Gross Pr ofit $1.2B $1.2B\nOperating Expenses $968M $748M\nOperating Income $263M $495M\nInterest Expense, Net $31M $31M\nEffectiv e Tax Rat e 18.7% 21.0%\nNet Income A ttributable t o ABC $188M $365M\nDilut ed Earnings P er Shar e $0.90 $1.76\nDilut ed Shar es Outstanding 208M 208M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year. ", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0b6c091ed7a93ac7a7455c284964d9ff7fc9a6bb3c658361154923eec649e5d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6113c6f8-65be-4057-9fe4-a22122b21d63", "node_type": "1", "metadata": {"window": "Gross Pr ofit $1.2B $1.2B\nOperating Expenses $968M $748M\nOperating Income $263M $495M\nInterest Expense, Net $31M $31M\nEffectiv e Tax Rat e 18.7% 21.0%\nNet Income A ttributable t o ABC $188M $365M\nDilut ed Earnings P er Shar e $0.90 $1.76\nDilut ed Shar es Outstanding 208M 208M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services.  Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n", "original_text": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n"}, "hash": "06f3e5ea9e827fcab307c5169ca6e066896a412e12c8deaa87079ae5258d3ac0", "class_name": "RelatedNodeInfo"}}, "text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n", "start_char_idx": 490, "end_char_idx": 710, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6113c6f8-65be-4057-9fe4-a22122b21d63": {"__data__": {"id_": "6113c6f8-65be-4057-9fe4-a22122b21d63", "embedding": null, "metadata": {"window": "Gross Pr ofit $1.2B $1.2B\nOperating Expenses $968M $748M\nOperating Income $263M $495M\nInterest Expense, Net $31M $31M\nEffectiv e Tax Rat e 18.7% 21.0%\nNet Income A ttributable t o ABC $188M $365M\nDilut ed Earnings P er Shar e $0.90 $1.76\nDilut ed Shar es Outstanding 208M 208M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services.  Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n", "original_text": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "650e795b3ca3dd95062f21a10fe595dd35b2dec0410016f9863741633c16830d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e64faf6-545c-4a0c-8e9e-08d9883eb128", "node_type": "1", "metadata": {"window": "Gross Pr ofit $1.2B $1.2B\nOperating Expenses $968M $748M\nOperating Income $263M $495M\nInterest Expense, Net $31M $31M\nEffectiv e Tax Rat e 18.7% 21.0%\nNet Income A ttributable t o ABC $188M $365M\nDilut ed Earnings P er Shar e $0.90 $1.76\nDilut ed Shar es Outstanding 208M 208M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6acb036d371cd490839e8ca88c07160f1c314b902e12c9945b8f9990d69b742d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23e30c4d-4353-4a16-b580-fecbfd9f3468", "node_type": "1", "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services.  Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year. ", "original_text": "Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year. "}, "hash": "2da7697bf589962109055023ab22d0c4a8dd1faf181fed45181a6ae4c9896eba", "class_name": "RelatedNodeInfo"}}, "text": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n", "start_char_idx": 710, "end_char_idx": 1021, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23e30c4d-4353-4a16-b580-fecbfd9f3468": {"__data__": {"id_": "23e30c4d-4353-4a16-b580-fecbfd9f3468", "embedding": null, "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services.  Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year. ", "original_text": "Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year. ", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "650e795b3ca3dd95062f21a10fe595dd35b2dec0410016f9863741633c16830d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6113c6f8-65be-4057-9fe4-a22122b21d63", "node_type": "1", "metadata": {"window": "Gross Pr ofit $1.2B $1.2B\nOperating Expenses $968M $748M\nOperating Income $263M $495M\nInterest Expense, Net $31M $31M\nEffectiv e Tax Rat e 18.7% 21.0%\nNet Income A ttributable t o ABC $188M $365M\nDilut ed Earnings P er Shar e $0.90 $1.76\nDilut ed Shar es Outstanding 208M 208M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services.  Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n", "original_text": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "044d601c97660d7ac62214d5d1b59b9a9c92f63b5bc29c32a0fc5b98a8271e59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac9e7c6b-76b9-4cba-ab66-93413020ee4e", "node_type": "1", "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services.  Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year.  The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense. ", "original_text": "Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services. "}, "hash": "dca093ec3a606748012a727d5495586fa9ac342eb89b9f52a4102e04d2be058e", "class_name": "RelatedNodeInfo"}}, "text": "Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year. ", "start_char_idx": 1021, "end_char_idx": 1180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac9e7c6b-76b9-4cba-ab66-93413020ee4e": {"__data__": {"id_": "ac9e7c6b-76b9-4cba-ab66-93413020ee4e", "embedding": null, "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services.  Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year.  The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense. ", "original_text": "Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services. ", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "650e795b3ca3dd95062f21a10fe595dd35b2dec0410016f9863741633c16830d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23e30c4d-4353-4a16-b580-fecbfd9f3468", "node_type": "1", "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services.  Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year. ", "original_text": "Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year. ", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdbbefe9c0e9ca65dd02cb877b7e81cf8200c3dcfc01d296413b6d1d36ac66e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55cc2121-bdc0-411c-bb4c-f31a75d4a71d", "node_type": "1", "metadata": {"window": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services.  Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year.  The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense.  Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n", "original_text": "Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n"}, "hash": "2792c7c7c45c3d4bf75d2d6fa0ffa64d664605e9a413146e6e94254bd86f2c4e", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services. ", "start_char_idx": 1180, "end_char_idx": 1619, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55cc2121-bdc0-411c-bb4c-f31a75d4a71d": {"__data__": {"id_": "55cc2121-bdc0-411c-bb4c-f31a75d4a71d", "embedding": null, "metadata": {"window": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services.  Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year.  The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense.  Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n", "original_text": "Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "650e795b3ca3dd95062f21a10fe595dd35b2dec0410016f9863741633c16830d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac9e7c6b-76b9-4cba-ab66-93413020ee4e", "node_type": "1", "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services.  Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year.  The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense. ", "original_text": "Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services. ", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "453e4b0617581365d4e15d9d8caa31c44231e06160c15868abf33fc35179163f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7211189-9530-4937-95f3-9ef4975fb93b", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services.  Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year.  The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense.  Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit. ", "original_text": "Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year. "}, "hash": "67c5721d581f010a000b2ae38f3ddb8dedf79c0f532af3c385101f8cab3cb16d", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n", "start_char_idx": 1619, "end_char_idx": 1736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7211189-9530-4937-95f3-9ef4975fb93b": {"__data__": {"id_": "a7211189-9530-4937-95f3-9ef4975fb93b", "embedding": null, "metadata": {"window": "Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services.  Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year.  The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense.  Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit. ", "original_text": "Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year. ", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "650e795b3ca3dd95062f21a10fe595dd35b2dec0410016f9863741633c16830d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55cc2121-bdc0-411c-bb4c-f31a75d4a71d", "node_type": "1", "metadata": {"window": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services.  Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year.  The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense.  Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n", "original_text": "Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a9832046f0394563dab23ade204a4b01479995adcedbd2a7c973c19653dba35b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e6f1486-ca85-4eea-94d6-87ee0a3e8f4a", "node_type": "1", "metadata": {"window": "Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services.  Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year.  The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense.  Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit.  Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n", "original_text": "The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense. "}, "hash": "d70e91f215b9a36548ff0c00b62cd259be55ddb2f572eb9a7b94a43875a09d78", "class_name": "RelatedNodeInfo"}}, "text": "Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year. ", "start_char_idx": 1736, "end_char_idx": 1898, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e6f1486-ca85-4eea-94d6-87ee0a3e8f4a": {"__data__": {"id_": "6e6f1486-ca85-4eea-94d6-87ee0a3e8f4a", "embedding": null, "metadata": {"window": "Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services.  Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year.  The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense.  Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit.  Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n", "original_text": "The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense. ", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "650e795b3ca3dd95062f21a10fe595dd35b2dec0410016f9863741633c16830d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7211189-9530-4937-95f3-9ef4975fb93b", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the fiscal 2020 first quarter was $1.2 billion, a 5.1 percent decrease compared to the same period\nin the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services.  Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year.  The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense.  Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit. ", "original_text": "Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year. ", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87bdbde32f24536ec8551d764e8c81763bb70e6fb149a620e16571841fef9ae0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a202ab79-2817-4344-9d2f-d334719d494b", "node_type": "1", "metadata": {"window": "Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year.  The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense.  Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit.  Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n", "original_text": "Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n"}, "hash": "e9eb168415a7e80108c05420eb26bcebe061d1533c8ee97c23f8920df951f204", "class_name": "RelatedNodeInfo"}}, "text": "The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense. ", "start_char_idx": 1898, "end_char_idx": 2168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a202ab79-2817-4344-9d2f-d334719d494b": {"__data__": {"id_": "a202ab79-2817-4344-9d2f-d334719d494b", "embedding": null, "metadata": {"window": "Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year.  The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense.  Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit.  Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n", "original_text": "Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "650e795b3ca3dd95062f21a10fe595dd35b2dec0410016f9863741633c16830d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e6f1486-ca85-4eea-94d6-87ee0a3e8f4a", "node_type": "1", "metadata": {"window": "Gross profit in the current year quarter was unfavorably impacted by lower gains from antitrust\nlitigation settlements, a LIFO expense in the current year quarter in comparison to a LIFO credit in the prior year quarter, and\nthe prior year reversal of a previously estimated assessment related to the New York State Opioid Stewardship Act, offset in\npart by the increases in gross profit in Other and Pharmaceutical Distribution Services.  Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year.  The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense.  Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit.  Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n", "original_text": "The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense. ", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "27c4fb6533e5a6246be7d45f757289369fbe8cc19f1a7cb64f4c46cc9c63e3d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0183999-bcdd-4cf2-9176-35ce31347879", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year.  The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense.  Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit.  Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020. ", "original_text": "Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit. "}, "hash": "e54e678a2c46e337c94ff34e51e3dd92e044642a8e73024e40d97e76591a3315", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n", "start_char_idx": 2168, "end_char_idx": 2339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0183999-bcdd-4cf2-9176-35ce31347879": {"__data__": {"id_": "b0183999-bcdd-4cf2-9176-35ce31347879", "embedding": null, "metadata": {"window": "Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year.  The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense.  Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit.  Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020. ", "original_text": "Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit. ", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "650e795b3ca3dd95062f21a10fe595dd35b2dec0410016f9863741633c16830d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a202ab79-2817-4344-9d2f-d334719d494b", "node_type": "1", "metadata": {"window": "Gross profit as a percentage of\nrevenue was 2.57 percent, a decrease of 29 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year.  The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense.  Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit.  Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n", "original_text": "Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53b78f92ce30a97dc6de2647ae32ce07b7c142d8658407b4a854fcb82fb86271", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98e32e69-caa4-4237-ad35-609446642b27", "node_type": "1", "metadata": {"window": "The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense.  Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit.  Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets. ", "original_text": "Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n"}, "hash": "329b706c1e14b58092788bc43b5e648d6b718883962db5c59134c196e42fcdcb", "class_name": "RelatedNodeInfo"}}, "text": "Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit. ", "start_char_idx": 2339, "end_char_idx": 2558, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98e32e69-caa4-4237-ad35-609446642b27": {"__data__": {"id_": "98e32e69-caa4-4237-ad35-609446642b27", "embedding": null, "metadata": {"window": "The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense.  Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit.  Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets. ", "original_text": "Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "650e795b3ca3dd95062f21a10fe595dd35b2dec0410016f9863741633c16830d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0183999-bcdd-4cf2-9176-35ce31347879", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the first quarter of fiscal 2020, operating expenses were $967.8 million, compared to $819.8 million in\nthe same period last fiscal year.  The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense.  Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit.  Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020. ", "original_text": "Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit. ", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "15b15897ecbe76d3b03e6e6417316be8fbdaa04cfb87512520538e6c63ce5f2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b06ac51-2c3e-4725-83e8-d590f46b7cae", "node_type": "1", "metadata": {"window": "Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit.  Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets.  The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n", "original_text": "Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n"}, "hash": "1ada7dadbe9d7291e73b208ea3b07b262400d797c520466bf3cebdb3d98782ad", "class_name": "RelatedNodeInfo"}}, "text": "Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n", "start_char_idx": 2558, "end_char_idx": 2730, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b06ac51-2c3e-4725-83e8-d590f46b7cae": {"__data__": {"id_": "8b06ac51-2c3e-4725-83e8-d590f46b7cae", "embedding": null, "metadata": {"window": "Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit.  Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets.  The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n", "original_text": "Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "650e795b3ca3dd95062f21a10fe595dd35b2dec0410016f9863741633c16830d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98e32e69-caa4-4237-ad35-609446642b27", "node_type": "1", "metadata": {"window": "The increase in operating expenses was primarily due to the $138.0 million impairment of\nPharMEDium's long-lived assets and an increase in distribution, selling and administrative expenses in the quarter, partially\noffset by lower depreciation and amortization expense.  Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit.  Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets. ", "original_text": "Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f7347ee1757db4d0e9792c50fea9249801a637537959ea844b9c4ae8512885a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bd46823-1830-47fb-baeb-fd4b1cde0166", "node_type": "1", "metadata": {"window": "Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit.  Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets.  The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n Diluted Earnings Per Share:  Diluted earnings per share was $0.90 in the first quarter of fiscal 2020 compared to $1.84 in the\nprevious fiscal year\u2019s first quarter. ", "original_text": "Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020. "}, "hash": "30105bc7b5a355437ce413fb26ee1dc46f800a72977325d4335d225b87fe9d74", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n", "start_char_idx": 2730, "end_char_idx": 3047, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bd46823-1830-47fb-baeb-fd4b1cde0166": {"__data__": {"id_": "1bd46823-1830-47fb-baeb-fd4b1cde0166", "embedding": null, "metadata": {"window": "Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit.  Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets.  The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n Diluted Earnings Per Share:  Diluted earnings per share was $0.90 in the first quarter of fiscal 2020 compared to $1.84 in the\nprevious fiscal year\u2019s first quarter. ", "original_text": "Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020. ", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "650e795b3ca3dd95062f21a10fe595dd35b2dec0410016f9863741633c16830d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b06ac51-2c3e-4725-83e8-d590f46b7cae", "node_type": "1", "metadata": {"window": "Operating expenses as a percentage of revenue in the fiscal 2020 first\nquarter was 2.02 percent, compared to 1.81 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit.  Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets.  The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n", "original_text": "Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd3bfbff15c930daf5049bf48b6ca45e896c89a822ccad7bfa96abe88f3ab7bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4e9efd4-614a-46a3-81ca-bc2d0dd2de55", "node_type": "1", "metadata": {"window": "Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets.  The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n Diluted Earnings Per Share:  Diluted earnings per share was $0.90 in the first quarter of fiscal 2020 compared to $1.84 in the\nprevious fiscal year\u2019s first quarter.  This decline was primarily due to a decrease in operating income.\n", "original_text": "The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets. "}, "hash": "0d438684b464efcc6b5d37fa2d0490cf19969f1198843875d6a71a950c8af534", "class_name": "RelatedNodeInfo"}}, "text": "Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020. ", "start_char_idx": 3047, "end_char_idx": 3146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4e9efd4-614a-46a3-81ca-bc2d0dd2de55": {"__data__": {"id_": "d4e9efd4-614a-46a3-81ca-bc2d0dd2de55", "embedding": null, "metadata": {"window": "Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets.  The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n Diluted Earnings Per Share:  Diluted earnings per share was $0.90 in the first quarter of fiscal 2020 compared to $1.84 in the\nprevious fiscal year\u2019s first quarter.  This decline was primarily due to a decrease in operating income.\n", "original_text": "The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets. ", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "650e795b3ca3dd95062f21a10fe595dd35b2dec0410016f9863741633c16830d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bd46823-1830-47fb-baeb-fd4b1cde0166", "node_type": "1", "metadata": {"window": "Operating Income:  In the fiscal 2020 first quarter, operating income declined to $263.4 million from $477.8 million in the prior\nyear quarter due to the increase in operating expenses and the decrease in gross profit.  Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets.  The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n Diluted Earnings Per Share:  Diluted earnings per share was $0.90 in the first quarter of fiscal 2020 compared to $1.84 in the\nprevious fiscal year\u2019s first quarter. ", "original_text": "Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020. ", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "343a5fada4dccc1827b6efd108198df8eb0523fb297275ff52003b496b291d67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "845e37ac-32ba-4be0-b1a5-786e41553a77", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets.  The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n Diluted Earnings Per Share:  Diluted earnings per share was $0.90 in the first quarter of fiscal 2020 compared to $1.84 in the\nprevious fiscal year\u2019s first quarter.  This decline was primarily due to a decrease in operating income.\n 2", "original_text": "The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n"}, "hash": "5acb3d396c67d519d49546986643bf6e6ac6110588913cd3cf8d30c1641ec1aa", "class_name": "RelatedNodeInfo"}}, "text": "The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets. ", "start_char_idx": 3146, "end_char_idx": 3275, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "845e37ac-32ba-4be0-b1a5-786e41553a77": {"__data__": {"id_": "845e37ac-32ba-4be0-b1a5-786e41553a77", "embedding": null, "metadata": {"window": "Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets.  The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n Diluted Earnings Per Share:  Diluted earnings per share was $0.90 in the first quarter of fiscal 2020 compared to $1.84 in the\nprevious fiscal year\u2019s first quarter.  This decline was primarily due to a decrease in operating income.\n 2", "original_text": "The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "650e795b3ca3dd95062f21a10fe595dd35b2dec0410016f9863741633c16830d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4e9efd4-614a-46a3-81ca-bc2d0dd2de55", "node_type": "1", "metadata": {"window": "Operating income as a percentage of\nrevenue was 0.55 percent in the first quarter of fiscal 2020, compared to 1.05 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets.  The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n Diluted Earnings Per Share:  Diluted earnings per share was $0.90 in the first quarter of fiscal 2020 compared to $1.84 in the\nprevious fiscal year\u2019s first quarter.  This decline was primarily due to a decrease in operating income.\n", "original_text": "The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets. ", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d36fd5fb1d142e7cc49a57a1c5134db78eebd7277618b2b7ca615c9db9468fbd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdfcf14e-f6d1-49c1-af53-06ac10b8eee3", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets.  The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n Diluted Earnings Per Share:  Diluted earnings per share was $0.90 in the first quarter of fiscal 2020 compared to $1.84 in the\nprevious fiscal year\u2019s first quarter.  This decline was primarily due to a decrease in operating income.\n 2", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $0.90 in the first quarter of fiscal 2020 compared to $1.84 in the\nprevious fiscal year\u2019s first quarter. "}, "hash": "e486571cbf421e97151889a9e23b6afa685677a10805cad70c0108ba893da295", "class_name": "RelatedNodeInfo"}}, "text": "The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n", "start_char_idx": 3275, "end_char_idx": 3398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdfcf14e-f6d1-49c1-af53-06ac10b8eee3": {"__data__": {"id_": "fdfcf14e-f6d1-49c1-af53-06ac10b8eee3", "embedding": null, "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets.  The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n Diluted Earnings Per Share:  Diluted earnings per share was $0.90 in the first quarter of fiscal 2020 compared to $1.84 in the\nprevious fiscal year\u2019s first quarter.  This decline was primarily due to a decrease in operating income.\n 2", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $0.90 in the first quarter of fiscal 2020 compared to $1.84 in the\nprevious fiscal year\u2019s first quarter. ", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "650e795b3ca3dd95062f21a10fe595dd35b2dec0410016f9863741633c16830d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "845e37ac-32ba-4be0-b1a5-786e41553a77", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the fiscal 2020 first quarter, net interest expense of $31.0 million was down 26.5 percent versus the\nprior year quarter due to certain finance leases now being accounted for as operating leases, resulting from the adoption of\nthe new lease accounting standard, and higher interest income.\n Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets.  The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n Diluted Earnings Per Share:  Diluted earnings per share was $0.90 in the first quarter of fiscal 2020 compared to $1.84 in the\nprevious fiscal year\u2019s first quarter.  This decline was primarily due to a decrease in operating income.\n 2", "original_text": "The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4f5eab452dfc313cde894b943097f25eb8e841b48f18e02465230efdd6cd34f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c4c5d93-ba08-40bd-956d-6aea53a72f22", "node_type": "1", "metadata": {"window": "The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets.  The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n Diluted Earnings Per Share:  Diluted earnings per share was $0.90 in the first quarter of fiscal 2020 compared to $1.84 in the\nprevious fiscal year\u2019s first quarter.  This decline was primarily due to a decrease in operating income.\n 2", "original_text": "This decline was primarily due to a decrease in operating income.\n"}, "hash": "b7af7af748847453024cfd32b23f6fb1e29cb853df0ba67a78f706cf7b0953e3", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Earnings Per Share:  Diluted earnings per share was $0.90 in the first quarter of fiscal 2020 compared to $1.84 in the\nprevious fiscal year\u2019s first quarter. ", "start_char_idx": 3398, "end_char_idx": 3563, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c4c5d93-ba08-40bd-956d-6aea53a72f22": {"__data__": {"id_": "0c4c5d93-ba08-40bd-956d-6aea53a72f22", "embedding": null, "metadata": {"window": "The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets.  The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n Diluted Earnings Per Share:  Diluted earnings per share was $0.90 in the first quarter of fiscal 2020 compared to $1.84 in the\nprevious fiscal year\u2019s first quarter.  This decline was primarily due to a decrease in operating income.\n 2", "original_text": "This decline was primarily due to a decrease in operating income.\n", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "650e795b3ca3dd95062f21a10fe595dd35b2dec0410016f9863741633c16830d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdfcf14e-f6d1-49c1-af53-06ac10b8eee3", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 18.7 percent for the first quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets.  The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n Diluted Earnings Per Share:  Diluted earnings per share was $0.90 in the first quarter of fiscal 2020 compared to $1.84 in the\nprevious fiscal year\u2019s first quarter.  This decline was primarily due to a decrease in operating income.\n 2", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $0.90 in the first quarter of fiscal 2020 compared to $1.84 in the\nprevious fiscal year\u2019s first quarter. ", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc4141bb940615d686d465c16f4845e3a3f80dfbb5cfedb11e3bf9d66af20c61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82d187db-0558-4e4a-8a92-afd3b64a5dfb", "node_type": "1", "metadata": {"window": "The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n Diluted Earnings Per Share:  Diluted earnings per share was $0.90 in the first quarter of fiscal 2020 compared to $1.84 in the\nprevious fiscal year\u2019s first quarter.  This decline was primarily due to a decrease in operating income.\n 2", "original_text": "2"}, "hash": "ca87b44c1d2d8c6e1b96e6e05dc413374bdcb6120a67ddb1272771cd9189c406", "class_name": "RelatedNodeInfo"}}, "text": "This decline was primarily due to a decrease in operating income.\n", "start_char_idx": 3563, "end_char_idx": 3629, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82d187db-0558-4e4a-8a92-afd3b64a5dfb": {"__data__": {"id_": "82d187db-0558-4e4a-8a92-afd3b64a5dfb", "embedding": null, "metadata": {"window": "The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n Diluted Earnings Per Share:  Diluted earnings per share was $0.90 in the first quarter of fiscal 2020 compared to $1.84 in the\nprevious fiscal year\u2019s first quarter.  This decline was primarily due to a decrease in operating income.\n 2", "original_text": "2", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "650e795b3ca3dd95062f21a10fe595dd35b2dec0410016f9863741633c16830d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c4c5d93-ba08-40bd-956d-6aea53a72f22", "node_type": "1", "metadata": {"window": "The effective tax rate in the\nquarter was primarily impacted by the $138.0 million impairment of PharMEDium's long-lived assets.  The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n Diluted Earnings Per Share:  Diluted earnings per share was $0.90 in the first quarter of fiscal 2020 compared to $1.84 in the\nprevious fiscal year\u2019s first quarter.  This decline was primarily due to a decrease in operating income.\n 2", "original_text": "This decline was primarily due to a decrease in operating income.\n", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "56baa1f99bce24c6a3964c2166b55e2794a4144e139b312825dfb2ecd6df2fe1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "804e7ca4-ebd0-45be-a150-c66b6ecb812e", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2020 were 207.5\nmillion, a 3.0 percent decline versus the prior fiscal year first quarter primarily due to share repurchases.\n PharMEDium Updat e\nIn late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will\ncease all commercial and administrative operations related to this business.  The decision to exit the PharMEDium business\nwas due to a number of factors including, but not limited to, ongoing operational, regulatory, and commercial challenges,\nsuch as PharMEDium's decision in January 2020 to suspend production at the compounding facility in New Jersey pending\nfacility upgrades related to the air handling and filtration systems.  In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2020 were 207.5\nmillion, a 3.0 percent decline versus the prior fiscal year first quarter primarily due to share repurchases.\n"}, "hash": "285fb94efb48865e6ae31eb47c632718791f33645c8f2bd1c5269c0cb85c2d67", "class_name": "RelatedNodeInfo"}}, "text": "2", "start_char_idx": 17, "end_char_idx": 18, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "804e7ca4-ebd0-45be-a150-c66b6ecb812e": {"__data__": {"id_": "804e7ca4-ebd0-45be-a150-c66b6ecb812e", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2020 were 207.5\nmillion, a 3.0 percent decline versus the prior fiscal year first quarter primarily due to share repurchases.\n PharMEDium Updat e\nIn late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will\ncease all commercial and administrative operations related to this business.  The decision to exit the PharMEDium business\nwas due to a number of factors including, but not limited to, ongoing operational, regulatory, and commercial challenges,\nsuch as PharMEDium's decision in January 2020 to suspend production at the compounding facility in New Jersey pending\nfacility upgrades related to the air handling and filtration systems.  In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2020 were 207.5\nmillion, a 3.0 percent decline versus the prior fiscal year first quarter primarily due to share repurchases.\n", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "723c9482-4103-4254-a210-9e3956cb44bf", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e5445d94d6d0aa9836b9d77a521b84843b563e02b0eecd17578e8d37d5ae8af", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82d187db-0558-4e4a-8a92-afd3b64a5dfb", "node_type": "1", "metadata": {"window": "The prior year's first\nquarter effective tax rate of 9.4 percent was favorably impacted by the 2017 Tax Cuts and Jobs Act.\n Diluted Earnings Per Share:  Diluted earnings per share was $0.90 in the first quarter of fiscal 2020 compared to $1.84 in the\nprevious fiscal year\u2019s first quarter.  This decline was primarily due to a decrease in operating income.\n 2", "original_text": "2", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8a2c23bb2cd4edf7ba3f878a520576d53578c89b897f044bde342413112fb31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16bb6b03-b80a-4fa0-ae3f-b546e71cdd82", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2020 were 207.5\nmillion, a 3.0 percent decline versus the prior fiscal year first quarter primarily due to share repurchases.\n PharMEDium Updat e\nIn late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will\ncease all commercial and administrative operations related to this business.  The decision to exit the PharMEDium business\nwas due to a number of factors including, but not limited to, ongoing operational, regulatory, and commercial challenges,\nsuch as PharMEDium's decision in January 2020 to suspend production at the compounding facility in New Jersey pending\nfacility upgrades related to the air handling and filtration systems.  In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020.  Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n", "original_text": "PharMEDium Updat e\nIn late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will\ncease all commercial and administrative operations related to this business. "}, "hash": "1ec879fb7387f1c6389406aefe6b6130687b4250412a6a8436b52adf58ba5081", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2020 were 207.5\nmillion, a 3.0 percent decline versus the prior fiscal year first quarter primarily due to share repurchases.\n", "start_char_idx": 0, "end_char_idx": 231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16bb6b03-b80a-4fa0-ae3f-b546e71cdd82": {"__data__": {"id_": "16bb6b03-b80a-4fa0-ae3f-b546e71cdd82", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2020 were 207.5\nmillion, a 3.0 percent decline versus the prior fiscal year first quarter primarily due to share repurchases.\n PharMEDium Updat e\nIn late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will\ncease all commercial and administrative operations related to this business.  The decision to exit the PharMEDium business\nwas due to a number of factors including, but not limited to, ongoing operational, regulatory, and commercial challenges,\nsuch as PharMEDium's decision in January 2020 to suspend production at the compounding facility in New Jersey pending\nfacility upgrades related to the air handling and filtration systems.  In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020.  Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n", "original_text": "PharMEDium Updat e\nIn late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will\ncease all commercial and administrative operations related to this business. ", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "723c9482-4103-4254-a210-9e3956cb44bf", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e5445d94d6d0aa9836b9d77a521b84843b563e02b0eecd17578e8d37d5ae8af", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "804e7ca4-ebd0-45be-a150-c66b6ecb812e", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2020 were 207.5\nmillion, a 3.0 percent decline versus the prior fiscal year first quarter primarily due to share repurchases.\n PharMEDium Updat e\nIn late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will\ncease all commercial and administrative operations related to this business.  The decision to exit the PharMEDium business\nwas due to a number of factors including, but not limited to, ongoing operational, regulatory, and commercial challenges,\nsuch as PharMEDium's decision in January 2020 to suspend production at the compounding facility in New Jersey pending\nfacility upgrades related to the air handling and filtration systems.  In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2020 were 207.5\nmillion, a 3.0 percent decline versus the prior fiscal year first quarter primarily due to share repurchases.\n", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e5c31ded5808c31bab80ec61880beb1ba63f0c9a1e836372260979a78c4f345", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8d2e1a0-52e8-40a5-b38e-fa1bd44a3600", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2020 were 207.5\nmillion, a 3.0 percent decline versus the prior fiscal year first quarter primarily due to share repurchases.\n PharMEDium Updat e\nIn late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will\ncease all commercial and administrative operations related to this business.  The decision to exit the PharMEDium business\nwas due to a number of factors including, but not limited to, ongoing operational, regulatory, and commercial challenges,\nsuch as PharMEDium's decision in January 2020 to suspend production at the compounding facility in New Jersey pending\nfacility upgrades related to the air handling and filtration systems.  In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020.  Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n", "original_text": "The decision to exit the PharMEDium business\nwas due to a number of factors including, but not limited to, ongoing operational, regulatory, and commercial challenges,\nsuch as PharMEDium's decision in January 2020 to suspend production at the compounding facility in New Jersey pending\nfacility upgrades related to the air handling and filtration systems. "}, "hash": "61e8b36fe97387cc27e0d6eb0909f13a93ddca1d92072c7a7c777c08f79abfdc", "class_name": "RelatedNodeInfo"}}, "text": "PharMEDium Updat e\nIn late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will\ncease all commercial and administrative operations related to this business. ", "start_char_idx": 231, "end_char_idx": 446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8d2e1a0-52e8-40a5-b38e-fa1bd44a3600": {"__data__": {"id_": "a8d2e1a0-52e8-40a5-b38e-fa1bd44a3600", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2020 were 207.5\nmillion, a 3.0 percent decline versus the prior fiscal year first quarter primarily due to share repurchases.\n PharMEDium Updat e\nIn late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will\ncease all commercial and administrative operations related to this business.  The decision to exit the PharMEDium business\nwas due to a number of factors including, but not limited to, ongoing operational, regulatory, and commercial challenges,\nsuch as PharMEDium's decision in January 2020 to suspend production at the compounding facility in New Jersey pending\nfacility upgrades related to the air handling and filtration systems.  In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020.  Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n", "original_text": "The decision to exit the PharMEDium business\nwas due to a number of factors including, but not limited to, ongoing operational, regulatory, and commercial challenges,\nsuch as PharMEDium's decision in January 2020 to suspend production at the compounding facility in New Jersey pending\nfacility upgrades related to the air handling and filtration systems. ", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "723c9482-4103-4254-a210-9e3956cb44bf", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e5445d94d6d0aa9836b9d77a521b84843b563e02b0eecd17578e8d37d5ae8af", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16bb6b03-b80a-4fa0-ae3f-b546e71cdd82", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2020 were 207.5\nmillion, a 3.0 percent decline versus the prior fiscal year first quarter primarily due to share repurchases.\n PharMEDium Updat e\nIn late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will\ncease all commercial and administrative operations related to this business.  The decision to exit the PharMEDium business\nwas due to a number of factors including, but not limited to, ongoing operational, regulatory, and commercial challenges,\nsuch as PharMEDium's decision in January 2020 to suspend production at the compounding facility in New Jersey pending\nfacility upgrades related to the air handling and filtration systems.  In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020.  Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n", "original_text": "PharMEDium Updat e\nIn late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will\ncease all commercial and administrative operations related to this business. ", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c704e54a6adbc8b7662df93e4cb5327e21f603cf16738134dd4c344fba835c51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fc90634-da50-41f1-8692-c568a6b0835b", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2020 were 207.5\nmillion, a 3.0 percent decline versus the prior fiscal year first quarter primarily due to share repurchases.\n PharMEDium Updat e\nIn late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will\ncease all commercial and administrative operations related to this business.  The decision to exit the PharMEDium business\nwas due to a number of factors including, but not limited to, ongoing operational, regulatory, and commercial challenges,\nsuch as PharMEDium's decision in January 2020 to suspend production at the compounding facility in New Jersey pending\nfacility upgrades related to the air handling and filtration systems.  In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020.  Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n", "original_text": "In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020. "}, "hash": "5032c2e81fec60dc36f303c1d471f001dbf1f73e71b17831df96f8cde22b10ac", "class_name": "RelatedNodeInfo"}}, "text": "The decision to exit the PharMEDium business\nwas due to a number of factors including, but not limited to, ongoing operational, regulatory, and commercial challenges,\nsuch as PharMEDium's decision in January 2020 to suspend production at the compounding facility in New Jersey pending\nfacility upgrades related to the air handling and filtration systems. ", "start_char_idx": 446, "end_char_idx": 801, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fc90634-da50-41f1-8692-c568a6b0835b": {"__data__": {"id_": "8fc90634-da50-41f1-8692-c568a6b0835b", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2020 were 207.5\nmillion, a 3.0 percent decline versus the prior fiscal year first quarter primarily due to share repurchases.\n PharMEDium Updat e\nIn late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will\ncease all commercial and administrative operations related to this business.  The decision to exit the PharMEDium business\nwas due to a number of factors including, but not limited to, ongoing operational, regulatory, and commercial challenges,\nsuch as PharMEDium's decision in January 2020 to suspend production at the compounding facility in New Jersey pending\nfacility upgrades related to the air handling and filtration systems.  In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020.  Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n", "original_text": "In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020. ", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "723c9482-4103-4254-a210-9e3956cb44bf", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e5445d94d6d0aa9836b9d77a521b84843b563e02b0eecd17578e8d37d5ae8af", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8d2e1a0-52e8-40a5-b38e-fa1bd44a3600", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2020 were 207.5\nmillion, a 3.0 percent decline versus the prior fiscal year first quarter primarily due to share repurchases.\n PharMEDium Updat e\nIn late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will\ncease all commercial and administrative operations related to this business.  The decision to exit the PharMEDium business\nwas due to a number of factors including, but not limited to, ongoing operational, regulatory, and commercial challenges,\nsuch as PharMEDium's decision in January 2020 to suspend production at the compounding facility in New Jersey pending\nfacility upgrades related to the air handling and filtration systems.  In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020.  Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n", "original_text": "The decision to exit the PharMEDium business\nwas due to a number of factors including, but not limited to, ongoing operational, regulatory, and commercial challenges,\nsuch as PharMEDium's decision in January 2020 to suspend production at the compounding facility in New Jersey pending\nfacility upgrades related to the air handling and filtration systems. ", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "58eb1537f1f1494def6d30fb814a00b941516256d60cbab5152bac7fd5562e5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0bdf68b0-4808-4b4b-a7a5-1fef3c950c8b", "node_type": "1", "metadata": {"window": "PharMEDium Updat e\nIn late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will\ncease all commercial and administrative operations related to this business.  The decision to exit the PharMEDium business\nwas due to a number of factors including, but not limited to, ongoing operational, regulatory, and commercial challenges,\nsuch as PharMEDium's decision in January 2020 to suspend production at the compounding facility in New Jersey pending\nfacility upgrades related to the air handling and filtration systems.  In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020.  Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n"}, "hash": "f2cc0cedd6ee53e1f40d2eaa14cd5606e0f7dda36f0c433c4aa084c50e78f1da", "class_name": "RelatedNodeInfo"}}, "text": "In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020. ", "start_char_idx": 801, "end_char_idx": 1141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0bdf68b0-4808-4b4b-a7a5-1fef3c950c8b": {"__data__": {"id_": "0bdf68b0-4808-4b4b-a7a5-1fef3c950c8b", "embedding": null, "metadata": {"window": "PharMEDium Updat e\nIn late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will\ncease all commercial and administrative operations related to this business.  The decision to exit the PharMEDium business\nwas due to a number of factors including, but not limited to, ongoing operational, regulatory, and commercial challenges,\nsuch as PharMEDium's decision in January 2020 to suspend production at the compounding facility in New Jersey pending\nfacility upgrades related to the air handling and filtration systems.  In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020.  Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "723c9482-4103-4254-a210-9e3956cb44bf", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e5445d94d6d0aa9836b9d77a521b84843b563e02b0eecd17578e8d37d5ae8af", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fc90634-da50-41f1-8692-c568a6b0835b", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2020 were 207.5\nmillion, a 3.0 percent decline versus the prior fiscal year first quarter primarily due to share repurchases.\n PharMEDium Updat e\nIn late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will\ncease all commercial and administrative operations related to this business.  The decision to exit the PharMEDium business\nwas due to a number of factors including, but not limited to, ongoing operational, regulatory, and commercial challenges,\nsuch as PharMEDium's decision in January 2020 to suspend production at the compounding facility in New Jersey pending\nfacility upgrades related to the air handling and filtration systems.  In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020.  Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n", "original_text": "In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020. ", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dde130b7dee0c4946fd15d792ef445cf65b25ce5a0280b8cbabdedee5fd7d3a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d46bc53-5592-41a7-9948-139202afb4b6", "node_type": "1", "metadata": {"window": "The decision to exit the PharMEDium business\nwas due to a number of factors including, but not limited to, ongoing operational, regulatory, and commercial challenges,\nsuch as PharMEDium's decision in January 2020 to suspend production at the compounding facility in New Jersey pending\nfacility upgrades related to the air handling and filtration systems.  In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020.  Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n", "original_text": "As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n"}, "hash": "fe7c9c612a68a5c534f67e70f051fd8370e36e8651802724127baa3be8ebd750", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n", "start_char_idx": 1141, "end_char_idx": 1400, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d46bc53-5592-41a7-9948-139202afb4b6": {"__data__": {"id_": "5d46bc53-5592-41a7-9948-139202afb4b6", "embedding": null, "metadata": {"window": "The decision to exit the PharMEDium business\nwas due to a number of factors including, but not limited to, ongoing operational, regulatory, and commercial challenges,\nsuch as PharMEDium's decision in January 2020 to suspend production at the compounding facility in New Jersey pending\nfacility upgrades related to the air handling and filtration systems.  In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020.  Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n", "original_text": "As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "723c9482-4103-4254-a210-9e3956cb44bf", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e5445d94d6d0aa9836b9d77a521b84843b563e02b0eecd17578e8d37d5ae8af", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0bdf68b0-4808-4b4b-a7a5-1fef3c950c8b", "node_type": "1", "metadata": {"window": "PharMEDium Updat e\nIn late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will\ncease all commercial and administrative operations related to this business.  The decision to exit the PharMEDium business\nwas due to a number of factors including, but not limited to, ongoing operational, regulatory, and commercial challenges,\nsuch as PharMEDium's decision in January 2020 to suspend production at the compounding facility in New Jersey pending\nfacility upgrades related to the air handling and filtration systems.  In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020.  Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e860f1194cc88b0c79c45b3b0018a9f01139bcd6d7f61337ff9a3804e84e6656", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa668d3a-12b7-442f-8384-0fa70eb747ad", "node_type": "1", "metadata": {"window": "In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020.  Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services. ", "original_text": "First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n"}, "hash": "a86b28e573eb2a0e53e2d4c3b7a5e4a40ecc7c5a891d3b9488cacb524b23792a", "class_name": "RelatedNodeInfo"}}, "text": "As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n", "start_char_idx": 1400, "end_char_idx": 1677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa668d3a-12b7-442f-8384-0fa70eb747ad": {"__data__": {"id_": "fa668d3a-12b7-442f-8384-0fa70eb747ad", "embedding": null, "metadata": {"window": "In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020.  Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services. ", "original_text": "First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "723c9482-4103-4254-a210-9e3956cb44bf", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e5445d94d6d0aa9836b9d77a521b84843b563e02b0eecd17578e8d37d5ae8af", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d46bc53-5592-41a7-9948-139202afb4b6", "node_type": "1", "metadata": {"window": "The decision to exit the PharMEDium business\nwas due to a number of factors including, but not limited to, ongoing operational, regulatory, and commercial challenges,\nsuch as PharMEDium's decision in January 2020 to suspend production at the compounding facility in New Jersey pending\nfacility upgrades related to the air handling and filtration systems.  In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020.  Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n", "original_text": "As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f42c61da73395cff34d6d46bbd1ce249ad3910158fb50e893b32ed9cd26f85d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28968693-b6a9-4c75-aee7-9e8ccaec02b3", "node_type": "1", "metadata": {"window": "Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services.  Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n", "original_text": "Revenue:  No adjustments were made to the GAAP presentation of revenue. "}, "hash": "8f2802861a8ab8ca721dcd89b841484f4107756dd3f82e97d4f61f3389dff761", "class_name": "RelatedNodeInfo"}}, "text": "First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n", "start_char_idx": 1677, "end_char_idx": 2076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28968693-b6a9-4c75-aee7-9e8ccaec02b3": {"__data__": {"id_": "28968693-b6a9-4c75-aee7-9e8ccaec02b3", "embedding": null, "metadata": {"window": "Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services.  Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n", "original_text": "Revenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "723c9482-4103-4254-a210-9e3956cb44bf", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e5445d94d6d0aa9836b9d77a521b84843b563e02b0eecd17578e8d37d5ae8af", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa668d3a-12b7-442f-8384-0fa70eb747ad", "node_type": "1", "metadata": {"window": "In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020.  Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services. ", "original_text": "First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb367b7bbbacecfcefd092306ecca6e68283a9f9b79c3b9500d1e50d9fda7580", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7e38d26-321d-4c64-9aeb-de63f6bc319a", "node_type": "1", "metadata": {"window": "As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services.  Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith. ", "original_text": "In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n"}, "hash": "9ea77e172f52a2b2001a5a9c9a5bfb8faa836d6ed75cf2fb1ba2b5fbff04ae86", "class_name": "RelatedNodeInfo"}}, "text": "Revenue:  No adjustments were made to the GAAP presentation of revenue. ", "start_char_idx": 2076, "end_char_idx": 2148, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7e38d26-321d-4c64-9aeb-de63f6bc319a": {"__data__": {"id_": "c7e38d26-321d-4c64-9aeb-de63f6bc319a", "embedding": null, "metadata": {"window": "As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services.  Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith. ", "original_text": "In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "723c9482-4103-4254-a210-9e3956cb44bf", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e5445d94d6d0aa9836b9d77a521b84843b563e02b0eecd17578e8d37d5ae8af", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28968693-b6a9-4c75-aee7-9e8ccaec02b3", "node_type": "1", "metadata": {"window": "Additionally, the Company will incur other costs, such as employee separation\ncosts, in connection with exiting the PharMEDium compounding business during the fiscal year ending September 30, 2020\nestimated to total approximately $80 million to $100 million.\n As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services.  Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n", "original_text": "Revenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e17d2736c9550fa297cc87458876d31ad1adac7b121c2f0a6e5428445392d160", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e269996-0e1c-49cc-a27c-21c02f3810c7", "node_type": "1", "metadata": {"window": "First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services.  Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services. "}, "hash": "9ae940a6fa38b549adf55c9a1336b2a92473f506a6d7e9fb78b6a66662236bf9", "class_name": "RelatedNodeInfo"}}, "text": "In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n", "start_char_idx": 2148, "end_char_idx": 2420, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e269996-0e1c-49cc-a27c-21c02f3810c7": {"__data__": {"id_": "8e269996-0e1c-49cc-a27c-21c02f3810c7", "embedding": null, "metadata": {"window": "First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services.  Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services. ", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "723c9482-4103-4254-a210-9e3956cb44bf", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e5445d94d6d0aa9836b9d77a521b84843b563e02b0eecd17578e8d37d5ae8af", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7e38d26-321d-4c64-9aeb-de63f6bc319a", "node_type": "1", "metadata": {"window": "As a result of the decision to exit the PharMEDium compounding business, the Company expects to claim an ordinary income\ntax deduction and estimates that it will realize a cash tax benefit in fiscal 2020 through fiscal 2022 totaling approximately\n$500 million to $600 million.\n First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services.  Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith. ", "original_text": "In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4995a7af7ae39665728be58e15f353999620639ea1d11734c51731ab10257171", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "972b0841-21da-454c-a2c8-6f2e70ddf685", "node_type": "1", "metadata": {"window": "Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services.  Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other. ", "original_text": "Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n"}, "hash": "396d6c89578c4c44aaa5f3fc6be17f3ca011094e115d1671b9e896e5b1cbb9ff", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services. ", "start_char_idx": 2420, "end_char_idx": 2680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "972b0841-21da-454c-a2c8-6f2e70ddf685": {"__data__": {"id_": "972b0841-21da-454c-a2c8-6f2e70ddf685", "embedding": null, "metadata": {"window": "Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services.  Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other. ", "original_text": "Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "723c9482-4103-4254-a210-9e3956cb44bf", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e5445d94d6d0aa9836b9d77a521b84843b563e02b0eecd17578e8d37d5ae8af", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e269996-0e1c-49cc-a27c-21c02f3810c7", "node_type": "1", "metadata": {"window": "First Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee\nseverance, litigation, and other; impairment of long-lived assets; and a one-time tax reform adjustment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services.  Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services. ", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d4de99814b318e6f429437d3ec2881c9e09b66edcc8bffe4707b57f2b434cb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d53fde0a-92c2-4e9f-9026-d10843577a60", "node_type": "1", "metadata": {"window": "In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services.  Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n", "original_text": "Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith. "}, "hash": "d591d35d7405f38e6dece75b795aa1ee1237b74e2dabe2c1ffa89bf2b4a9d5a1", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n", "start_char_idx": 2680, "end_char_idx": 2838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d53fde0a-92c2-4e9f-9026-d10843577a60": {"__data__": {"id_": "d53fde0a-92c2-4e9f-9026-d10843577a60", "embedding": null, "metadata": {"window": "In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services.  Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n", "original_text": "Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith. ", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "723c9482-4103-4254-a210-9e3956cb44bf", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e5445d94d6d0aa9836b9d77a521b84843b563e02b0eecd17578e8d37d5ae8af", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "972b0841-21da-454c-a2c8-6f2e70ddf685", "node_type": "1", "metadata": {"window": "Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services.  Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other. ", "original_text": "Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f63c84945e9d501f7b7662d1d15ca536b14601788fbcb3b33822893e601517e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dda2f501-6a41-4c7e-84c0-7653d3aecf92", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services.  Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n"}, "hash": "f56363315ca600b45aa8a9ccac4e651404ee38a9f90921c8cf3c10a7f9bb21da", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith. ", "start_char_idx": 2838, "end_char_idx": 3188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dda2f501-6a41-4c7e-84c0-7653d3aecf92": {"__data__": {"id_": "dda2f501-6a41-4c7e-84c0-7653d3aecf92", "embedding": null, "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services.  Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "723c9482-4103-4254-a210-9e3956cb44bf", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e5445d94d6d0aa9836b9d77a521b84843b563e02b0eecd17578e8d37d5ae8af", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d53fde0a-92c2-4e9f-9026-d10843577a60", "node_type": "1", "metadata": {"window": "In the first quarter of fiscal 2020, revenue was\n$47.9 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 5.2 percent increase in\nPharmaceutical Distribution Services revenue and a 10.5 percent increase in revenue within Other.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services.  Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n", "original_text": "Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith. ", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f9c351f6a9f3c331c73e9f8735edaea1b033ae6cb60d3052265f3e1031528e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae7c9e41-3248-4ed9-84c7-d0d53514afcd", "node_type": "1", "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n", "original_text": "Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other. "}, "hash": "1d2d3a2fb0f5f89418b4400fa9e6d99d4303da2a1e3d799b274d88e80687e995", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n", "start_char_idx": 3188, "end_char_idx": 3368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae7c9e41-3248-4ed9-84c7-d0d53514afcd": {"__data__": {"id_": "ae7c9e41-3248-4ed9-84c7-d0d53514afcd", "embedding": null, "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n", "original_text": "Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other. ", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "723c9482-4103-4254-a210-9e3956cb44bf", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e5445d94d6d0aa9836b9d77a521b84843b563e02b0eecd17578e8d37d5ae8af", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dda2f501-6a41-4c7e-84c0-7653d3aecf92", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 first quarter was $1.2 billion, which was up 3.3 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Other and Pharmaceutical\nDistribution Services.  Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3e62e17bb349e73ef5f8aefe1dfae36560f891d80ee2ff1e7e656a33ddaa4d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "926a7a82-479d-4cac-88f2-f75894627bac", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2020 and was 19.9\npercent in the previous fiscal year\u2019s first quarter. ", "original_text": "Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n"}, "hash": "72b5739bb758fa585099c8a80cb4fc0005ef44057cd34c7c0334b7f43986e7fc", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other. ", "start_char_idx": 3368, "end_char_idx": 3678, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "926a7a82-479d-4cac-88f2-f75894627bac": {"__data__": {"id_": "926a7a82-479d-4cac-88f2-f75894627bac", "embedding": null, "metadata": {"window": "Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2020 and was 19.9\npercent in the previous fiscal year\u2019s first quarter. ", "original_text": "Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "723c9482-4103-4254-a210-9e3956cb44bf", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e5445d94d6d0aa9836b9d77a521b84843b563e02b0eecd17578e8d37d5ae8af", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae7c9e41-3248-4ed9-84c7-d0d53514afcd", "node_type": "1", "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 2.60 percent in the fiscal 2020 first quarter, a\ndecrease of 5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n", "original_text": "Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other. ", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a80234caa2784a67162be8e435000499a075aa9b83a3916bc9943500540414c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "879206a6-8305-471c-8a12-9ac7d9e3f425", "node_type": "1", "metadata": {"window": "Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2020 and was 19.9\npercent in the previous fiscal year\u2019s first quarter.  The adjusted effective tax rate in the prior year quarter was favorably\nimpacted by a discrete state tax item.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. "}, "hash": "2d62bb0abe371b4b2c20ae3c20b86a4734e8e6788603cf7832561fd45c8d92c2", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n", "start_char_idx": 3678, "end_char_idx": 3858, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "879206a6-8305-471c-8a12-9ac7d9e3f425": {"__data__": {"id_": "879206a6-8305-471c-8a12-9ac7d9e3f425", "embedding": null, "metadata": {"window": "Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2020 and was 19.9\npercent in the previous fiscal year\u2019s first quarter.  The adjusted effective tax rate in the prior year quarter was favorably\nimpacted by a discrete state tax item.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "723c9482-4103-4254-a210-9e3956cb44bf", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e5445d94d6d0aa9836b9d77a521b84843b563e02b0eecd17578e8d37d5ae8af", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "926a7a82-479d-4cac-88f2-f75894627bac", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the first quarter of fiscal 2020, adjusted operating expenses were $747.9 million, an increase\nof 2.3 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to support\nrevenue growth, offset in part by operational synergies realized from the integration of H. D. Smith.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2020 and was 19.9\npercent in the previous fiscal year\u2019s first quarter. ", "original_text": "Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d60e74cd7ce8f314ce6110b9935c91204dcc92e942d5f134fd11555be53509c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28c7a494-95a7-4a4d-a3ac-3bad994755c2", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2020 and was 19.9\npercent in the previous fiscal year\u2019s first quarter.  The adjusted effective tax rate in the prior year quarter was favorably\nimpacted by a discrete state tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 10.0 percent to $1.76 in the first quarter of\n3", "original_text": "In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n"}, "hash": "5b0bba3892781198d8193401b3e781539e819757008b6ebf821374cdba1af71b", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "start_char_idx": 3858, "end_char_idx": 3957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28c7a494-95a7-4a4d-a3ac-3bad994755c2": {"__data__": {"id_": "28c7a494-95a7-4a4d-a3ac-3bad994755c2", "embedding": null, "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2020 and was 19.9\npercent in the previous fiscal year\u2019s first quarter.  The adjusted effective tax rate in the prior year quarter was favorably\nimpacted by a discrete state tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 10.0 percent to $1.76 in the first quarter of\n3", "original_text": "In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "723c9482-4103-4254-a210-9e3956cb44bf", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e5445d94d6d0aa9836b9d77a521b84843b563e02b0eecd17578e8d37d5ae8af", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "879206a6-8305-471c-8a12-9ac7d9e3f425", "node_type": "1", "metadata": {"window": "Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2020 first quarter was 1.56 percent, compared to 1.61 percent for the same\nperiod in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2020 and was 19.9\npercent in the previous fiscal year\u2019s first quarter.  The adjusted effective tax rate in the prior year quarter was favorably\nimpacted by a discrete state tax item.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "441264505068d873dc52bda79838b52cbaf0e39b272d46dc273cc1fd752661a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20349348-bcd5-4f56-8376-5f71d63c4a9a", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2020 and was 19.9\npercent in the previous fiscal year\u2019s first quarter.  The adjusted effective tax rate in the prior year quarter was favorably\nimpacted by a discrete state tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 10.0 percent to $1.76 in the first quarter of\n3", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2020 and was 19.9\npercent in the previous fiscal year\u2019s first quarter. "}, "hash": "ab452c83eaed1eb889b84a97e8037ead8451ca3d4779ff8b98c83026a00aa3b8", "class_name": "RelatedNodeInfo"}}, "text": "In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n", "start_char_idx": 3957, "end_char_idx": 4250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20349348-bcd5-4f56-8376-5f71d63c4a9a": {"__data__": {"id_": "20349348-bcd5-4f56-8376-5f71d63c4a9a", "embedding": null, "metadata": {"window": "Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2020 and was 19.9\npercent in the previous fiscal year\u2019s first quarter.  The adjusted effective tax rate in the prior year quarter was favorably\nimpacted by a discrete state tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 10.0 percent to $1.76 in the first quarter of\n3", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2020 and was 19.9\npercent in the previous fiscal year\u2019s first quarter. ", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "723c9482-4103-4254-a210-9e3956cb44bf", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e5445d94d6d0aa9836b9d77a521b84843b563e02b0eecd17578e8d37d5ae8af", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28c7a494-95a7-4a4d-a3ac-3bad994755c2", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2020 first quarter, adjusted operating income of $495.3 million increased 5.0 percent\nfrom the prior year period due to a 5.0 percent increase in operating income within Pharmaceutical Distribution Services and\na 5.6 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2020 and was 19.9\npercent in the previous fiscal year\u2019s first quarter.  The adjusted effective tax rate in the prior year quarter was favorably\nimpacted by a discrete state tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 10.0 percent to $1.76 in the first quarter of\n3", "original_text": "In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1a3dba7584ea9c7b00a62f45fdafa1dbf5284aefd160bf6894b27a096f782ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "357e0bd7-53a0-4764-af41-da7a73fad089", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2020 and was 19.9\npercent in the previous fiscal year\u2019s first quarter.  The adjusted effective tax rate in the prior year quarter was favorably\nimpacted by a discrete state tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 10.0 percent to $1.76 in the first quarter of\n3", "original_text": "The adjusted effective tax rate in the prior year quarter was favorably\nimpacted by a discrete state tax item.\n"}, "hash": "72ab46c401323827c7905f8a468dc9f6c207f007351d7768db37f86c5cc2f41b", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2020 and was 19.9\npercent in the previous fiscal year\u2019s first quarter. ", "start_char_idx": 4250, "end_char_idx": 4432, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "357e0bd7-53a0-4764-af41-da7a73fad089": {"__data__": {"id_": "357e0bd7-53a0-4764-af41-da7a73fad089", "embedding": null, "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2020 and was 19.9\npercent in the previous fiscal year\u2019s first quarter.  The adjusted effective tax rate in the prior year quarter was favorably\nimpacted by a discrete state tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 10.0 percent to $1.76 in the first quarter of\n3", "original_text": "The adjusted effective tax rate in the prior year quarter was favorably\nimpacted by a discrete state tax item.\n", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "723c9482-4103-4254-a210-9e3956cb44bf", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e5445d94d6d0aa9836b9d77a521b84843b563e02b0eecd17578e8d37d5ae8af", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20349348-bcd5-4f56-8376-5f71d63c4a9a", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of revenue decreased 1\nbasis point to 1.03 percent in the fiscal 2020 first quarter compared to the previous fiscal year\u2019s first quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2020 and was 19.9\npercent in the previous fiscal year\u2019s first quarter.  The adjusted effective tax rate in the prior year quarter was favorably\nimpacted by a discrete state tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 10.0 percent to $1.76 in the first quarter of\n3", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2020 and was 19.9\npercent in the previous fiscal year\u2019s first quarter. ", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e3f9a54007626712e26b74b2bcdf1b1baac766c767b8e9aeb5e85982e9970806", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c9ee8f4-243e-4ca2-8b10-99b49a0433a0", "node_type": "1", "metadata": {"window": "In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2020 and was 19.9\npercent in the previous fiscal year\u2019s first quarter.  The adjusted effective tax rate in the prior year quarter was favorably\nimpacted by a discrete state tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 10.0 percent to $1.76 in the first quarter of\n3", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 10.0 percent to $1.76 in the first quarter of\n3"}, "hash": "f72a4268bc488d741dc16880571d021334663bfe86b3c154ebe7b81079d39cb3", "class_name": "RelatedNodeInfo"}}, "text": "The adjusted effective tax rate in the prior year quarter was favorably\nimpacted by a discrete state tax item.\n", "start_char_idx": 4432, "end_char_idx": 4543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c9ee8f4-243e-4ca2-8b10-99b49a0433a0": {"__data__": {"id_": "8c9ee8f4-243e-4ca2-8b10-99b49a0433a0", "embedding": null, "metadata": {"window": "In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2020 and was 19.9\npercent in the previous fiscal year\u2019s first quarter.  The adjusted effective tax rate in the prior year quarter was favorably\nimpacted by a discrete state tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 10.0 percent to $1.76 in the first quarter of\n3", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 10.0 percent to $1.76 in the first quarter of\n3", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "723c9482-4103-4254-a210-9e3956cb44bf", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e5445d94d6d0aa9836b9d77a521b84843b563e02b0eecd17578e8d37d5ae8af", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "357e0bd7-53a0-4764-af41-da7a73fad089", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2020 and was 19.9\npercent in the previous fiscal year\u2019s first quarter.  The adjusted effective tax rate in the prior year quarter was favorably\nimpacted by a discrete state tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 10.0 percent to $1.76 in the first quarter of\n3", "original_text": "The adjusted effective tax rate in the prior year quarter was favorably\nimpacted by a discrete state tax item.\n", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebea9b5c4b12002a23f12247f21af2e8e71f5cddbb8406e34748a009c0e91cbf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1581e41-a4a4-41e6-a452-4e21fab22558", "node_type": "1", "metadata": {"window": "fiscal 2020 compared to $1.60 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income, a\nlower share count, and lower net interest expense.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2020 were 207.5 million, a 3.0 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation. ", "original_text": "fiscal 2020 compared to $1.60 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income, a\nlower share count, and lower net interest expense.\n"}, "hash": "811f80152d1638592f7f275e0263735c7587ff1305fd5f772879261db3e3a47f", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 10.0 percent to $1.76 in the first quarter of\n3", "start_char_idx": 4543, "end_char_idx": 4671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1581e41-a4a4-41e6-a452-4e21fab22558": {"__data__": {"id_": "c1581e41-a4a4-41e6-a452-4e21fab22558", "embedding": null, "metadata": {"window": "fiscal 2020 compared to $1.60 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income, a\nlower share count, and lower net interest expense.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2020 were 207.5 million, a 3.0 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation. ", "original_text": "fiscal 2020 compared to $1.60 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income, a\nlower share count, and lower net interest expense.\n", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "962783330a3bceab8c0fed642dcb2e9b819cf906481dee27c73e0f84e6ac397b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c9ee8f4-243e-4ca2-8b10-99b49a0433a0", "node_type": "1", "metadata": {"window": "In the fiscal 2020 first\nquarter, net interest expense of $31.0 million was down 26.5 percent versus the prior year quarter due to certain finance\nleases now being accounted for as operating leases, resulting from the adoption of the new lease accounting standard, and\nhigher interest income.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the first quarter of fiscal 2020 and was 19.9\npercent in the previous fiscal year\u2019s first quarter.  The adjusted effective tax rate in the prior year quarter was favorably\nimpacted by a discrete state tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 10.0 percent to $1.76 in the first quarter of\n3", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 10.0 percent to $1.76 in the first quarter of\n3", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "291edf236749626876c35537a6e533eb36567154c2a9ed2cc19e525d01dfffab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e4a22a4-b3c0-4e1d-a95a-b1f09824c204", "node_type": "1", "metadata": {"window": "fiscal 2020 compared to $1.60 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income, a\nlower share count, and lower net interest expense.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2020 were 207.5 million, a 3.0 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. "}, "hash": "0ddaeef2b06aaac8b8648b54923ee0014176c66f253a7a6582de2772b9594a61", "class_name": "RelatedNodeInfo"}}, "text": "fiscal 2020 compared to $1.60 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income, a\nlower share count, and lower net interest expense.\n", "start_char_idx": 0, "end_char_idx": 181, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e4a22a4-b3c0-4e1d-a95a-b1f09824c204": {"__data__": {"id_": "1e4a22a4-b3c0-4e1d-a95a-b1f09824c204", "embedding": null, "metadata": {"window": "fiscal 2020 compared to $1.60 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income, a\nlower share count, and lower net interest expense.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2020 were 207.5 million, a 3.0 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "962783330a3bceab8c0fed642dcb2e9b819cf906481dee27c73e0f84e6ac397b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1581e41-a4a4-41e6-a452-4e21fab22558", "node_type": "1", "metadata": {"window": "fiscal 2020 compared to $1.60 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income, a\nlower share count, and lower net interest expense.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2020 were 207.5 million, a 3.0 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation. ", "original_text": "fiscal 2020 compared to $1.60 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income, a\nlower share count, and lower net interest expense.\n", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe517ddd337af0bf4202051480967dc6636e56b8bb83a7ac5de3a7d3f4b1d206", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bece5fa0-8aa5-4104-b2c5-4b74f3122c67", "node_type": "1", "metadata": {"window": "fiscal 2020 compared to $1.60 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income, a\nlower share count, and lower net interest expense.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2020 were 207.5 million, a 3.0 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers. ", "original_text": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2020 were 207.5 million, a 3.0 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases.\n"}, "hash": "15654dece8d52a75994e9c678fd63227ac2bd410eb40f2ac2bbb955021c1238e", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "start_char_idx": 181, "end_char_idx": 291, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bece5fa0-8aa5-4104-b2c5-4b74f3122c67": {"__data__": {"id_": "bece5fa0-8aa5-4104-b2c5-4b74f3122c67", "embedding": null, "metadata": {"window": "fiscal 2020 compared to $1.60 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income, a\nlower share count, and lower net interest expense.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2020 were 207.5 million, a 3.0 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers. ", "original_text": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2020 were 207.5 million, a 3.0 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases.\n", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "962783330a3bceab8c0fed642dcb2e9b819cf906481dee27c73e0f84e6ac397b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e4a22a4-b3c0-4e1d-a95a-b1f09824c204", "node_type": "1", "metadata": {"window": "fiscal 2020 compared to $1.60 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income, a\nlower share count, and lower net interest expense.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2020 were 207.5 million, a 3.0 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "607376dee6dc68300d367e01133f5a6bc79c0dbd2c28142b6c630a49b6c841dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9658a6a2-6e12-4d63-90fc-f63a213e3a37", "node_type": "1", "metadata": {"window": "fiscal 2020 compared to $1.60 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income, a\nlower share count, and lower net interest expense.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2020 were 207.5 million, a 3.0 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers.  Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n", "original_text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation. "}, "hash": "2b624dcdfc33a393ff1ec2260dd37a465c4ab5847f6495737d950e80f6353014", "class_name": "RelatedNodeInfo"}}, "text": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2020 were 207.5 million, a 3.0 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases.\n", "start_char_idx": 291, "end_char_idx": 493, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9658a6a2-6e12-4d63-90fc-f63a213e3a37": {"__data__": {"id_": "9658a6a2-6e12-4d63-90fc-f63a213e3a37", "embedding": null, "metadata": {"window": "fiscal 2020 compared to $1.60 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income, a\nlower share count, and lower net interest expense.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2020 were 207.5 million, a 3.0 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers.  Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n", "original_text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation. ", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "962783330a3bceab8c0fed642dcb2e9b819cf906481dee27c73e0f84e6ac397b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bece5fa0-8aa5-4104-b2c5-4b74f3122c67", "node_type": "1", "metadata": {"window": "fiscal 2020 compared to $1.60 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income, a\nlower share count, and lower net interest expense.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2020 were 207.5 million, a 3.0 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers. ", "original_text": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2020 were 207.5 million, a 3.0 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases.\n", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "549708409cb44e335c56b1e2bbd3cddd3a63bec869f6665fe6d7211d7a1d3089", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cba2d70c-cdad-46b6-b026-063643080512", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2020 were 207.5 million, a 3.0 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers.  Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier. ", "original_text": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n"}, "hash": "9936dea45b283b608d3072f81cfd401880669e14238430c36d864babd34d40bf", "class_name": "RelatedNodeInfo"}}, "text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation. ", "start_char_idx": 493, "end_char_idx": 821, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cba2d70c-cdad-46b6-b026-063643080512": {"__data__": {"id_": "cba2d70c-cdad-46b6-b026-063643080512", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2020 were 207.5 million, a 3.0 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers.  Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier. ", "original_text": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "962783330a3bceab8c0fed642dcb2e9b819cf906481dee27c73e0f84e6ac397b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9658a6a2-6e12-4d63-90fc-f63a213e3a37", "node_type": "1", "metadata": {"window": "fiscal 2020 compared to $1.60 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income, a\nlower share count, and lower net interest expense.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2020 were 207.5 million, a 3.0 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers.  Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n", "original_text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation. ", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d50484dcf800771603de66528cbb31ae015360c611c4952ff859902390b3df7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f118632-66c9-4c3f-9cb9-075676311afd", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2020 were 207.5 million, a 3.0 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers.  Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier.  Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020. ", "original_text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers. "}, "hash": "df4e4a676301c02db161af96198f39ac061bd1fe7bb1cf7ff3730e14ec2e596b", "class_name": "RelatedNodeInfo"}}, "text": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "start_char_idx": 821, "end_char_idx": 1026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f118632-66c9-4c3f-9cb9-075676311afd": {"__data__": {"id_": "5f118632-66c9-4c3f-9cb9-075676311afd", "embedding": null, "metadata": {"window": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2020 were 207.5 million, a 3.0 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers.  Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier.  Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020. ", "original_text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers. ", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "962783330a3bceab8c0fed642dcb2e9b819cf906481dee27c73e0f84e6ac397b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cba2d70c-cdad-46b6-b026-063643080512", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2020 were 207.5 million, a 3.0 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers.  Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier. ", "original_text": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a49e118a7c9b252457f8bc9efc6485f2d412c9a14e433f884bf2592d73855292", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c109620-fea0-4c0a-b750-a718a980fb07", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers.  Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier.  Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020.  This increase was primarily due to the performance of ABCS and World Courier.\n", "original_text": "Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n"}, "hash": "9849d5695cb9742f930661ab8b63f8e2d72585b582e494e0497ff22ffc9010b1", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers. ", "start_char_idx": 1026, "end_char_idx": 1356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c109620-fea0-4c0a-b750-a718a980fb07": {"__data__": {"id_": "1c109620-fea0-4c0a-b750-a718a980fb07", "embedding": null, "metadata": {"window": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers.  Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier.  Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020.  This increase was primarily due to the performance of ABCS and World Courier.\n", "original_text": "Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "962783330a3bceab8c0fed642dcb2e9b819cf906481dee27c73e0f84e6ac397b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f118632-66c9-4c3f-9cb9-075676311afd", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2020 were 207.5 million, a 3.0 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers.  Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier.  Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020. ", "original_text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers. ", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ab8a368583bfb5716175f28173507ac8c5469f2dc26efde7c01a41c5ae21655", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57225f17-2276-46e5-8377-56fad3d48a5d", "node_type": "1", "metadata": {"window": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers.  Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier.  Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020.  This increase was primarily due to the performance of ABCS and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization. ", "original_text": "Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier. "}, "hash": "1cb3985451cc071d22420728f9e5fb30ba1063bb43bdf2961e502738b0ca16c4", "class_name": "RelatedNodeInfo"}}, "text": "Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n", "start_char_idx": 1356, "end_char_idx": 1595, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57225f17-2276-46e5-8377-56fad3d48a5d": {"__data__": {"id_": "57225f17-2276-46e5-8377-56fad3d48a5d", "embedding": null, "metadata": {"window": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers.  Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier.  Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020.  This increase was primarily due to the performance of ABCS and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization. ", "original_text": "Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier. ", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "962783330a3bceab8c0fed642dcb2e9b819cf906481dee27c73e0f84e6ac397b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c109620-fea0-4c0a-b750-a718a980fb07", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers.  Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier.  Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020.  This increase was primarily due to the performance of ABCS and World Courier.\n", "original_text": "Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79db6616a4dfe15eda4e510a1b4de465feeee88511a122636f804aee90f75b07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2473259-f2da-49e5-b83c-9d5397542fa6", "node_type": "1", "metadata": {"window": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers.  Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier.  Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020.  This increase was primarily due to the performance of ABCS and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization.  The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n", "original_text": "Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020. "}, "hash": "16c813de80e9ccf84206a9412acedb838b0de3371c77135c4e984c4e078d6991", "class_name": "RelatedNodeInfo"}}, "text": "Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier. ", "start_char_idx": 1595, "end_char_idx": 1810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2473259-f2da-49e5-b83c-9d5397542fa6": {"__data__": {"id_": "e2473259-f2da-49e5-b83c-9d5397542fa6", "embedding": null, "metadata": {"window": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers.  Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier.  Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020.  This increase was primarily due to the performance of ABCS and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization.  The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n", "original_text": "Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020. ", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "962783330a3bceab8c0fed642dcb2e9b819cf906481dee27c73e0f84e6ac397b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57225f17-2276-46e5-8377-56fad3d48a5d", "node_type": "1", "metadata": {"window": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers.  Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier.  Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020.  This increase was primarily due to the performance of ABCS and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization. ", "original_text": "Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier. ", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f489fe33d6a8bb177476cd6a87403002ead6b4e8e9d6107d324473ef90d0d845", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0289cfbf-8bc4-4188-9ee9-87b0bfbd3d4a", "node_type": "1", "metadata": {"window": "Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier.  Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020.  This increase was primarily due to the performance of ABCS and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization.  The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n", "original_text": "This increase was primarily due to the performance of ABCS and World Courier.\n"}, "hash": "b29502fcbeadb0379181cd0dff6ff62b684fea7174ca0247166786525987303f", "class_name": "RelatedNodeInfo"}}, "text": "Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020. ", "start_char_idx": 1810, "end_char_idx": 1913, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0289cfbf-8bc4-4188-9ee9-87b0bfbd3d4a": {"__data__": {"id_": "0289cfbf-8bc4-4188-9ee9-87b0bfbd3d4a", "embedding": null, "metadata": {"window": "Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier.  Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020.  This increase was primarily due to the performance of ABCS and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization.  The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n", "original_text": "This increase was primarily due to the performance of ABCS and World Courier.\n", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "962783330a3bceab8c0fed642dcb2e9b819cf906481dee27c73e0f84e6ac397b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2473259-f2da-49e5-b83c-9d5397542fa6", "node_type": "1", "metadata": {"window": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $46.0 billion, an increase of 5.2 percent compared to the same quarter in the prior\nfiscal year primarily due to continued strong specialty product sales and increased volume associated with the growth of some of its\nlargest customers.  Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier.  Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020.  This increase was primarily due to the performance of ABCS and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization.  The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n", "original_text": "Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020. ", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5955969818ea4c77edd290345d2e33857fdda423c32cf528d8c07613ad71ad48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7624d26e-0fcd-4a3f-bf3f-1552e31132ff", "node_type": "1", "metadata": {"window": "Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier.  Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020.  This increase was primarily due to the performance of ABCS and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization.  The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n", "original_text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization. "}, "hash": "a759386a9649c24e0f3e19626372a7918a5f95766819f6bf8d903d61ce369192", "class_name": "RelatedNodeInfo"}}, "text": "This increase was primarily due to the performance of ABCS and World Courier.\n", "start_char_idx": 1913, "end_char_idx": 1991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7624d26e-0fcd-4a3f-bf3f-1552e31132ff": {"__data__": {"id_": "7624d26e-0fcd-4a3f-bf3f-1552e31132ff", "embedding": null, "metadata": {"window": "Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier.  Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020.  This increase was primarily due to the performance of ABCS and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization.  The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n", "original_text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization. ", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "962783330a3bceab8c0fed642dcb2e9b819cf906481dee27c73e0f84e6ac397b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0289cfbf-8bc4-4188-9ee9-87b0bfbd3d4a", "node_type": "1", "metadata": {"window": "Segment operating income of $391.7 million in the first quarter of fiscal 2020 was up 5.0 percent compared to\nthe same period in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier.  Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020.  This increase was primarily due to the performance of ABCS and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization.  The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n", "original_text": "This increase was primarily due to the performance of ABCS and World Courier.\n", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a06550202e69f9ebcdd100ecd4d4308dc9bbabbeb8230d4b4f68b522c0ddfe27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22785523-de8f-4466-a78a-faf742f63007", "node_type": "1", "metadata": {"window": "Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020.  This increase was primarily due to the performance of ABCS and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization.  The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n", "original_text": "The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n"}, "hash": "89f90649c131ad84514d951615919cb65e800c9c43c8a00e730b4bc4012e51f9", "class_name": "RelatedNodeInfo"}}, "text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization. ", "start_char_idx": 1991, "end_char_idx": 2345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22785523-de8f-4466-a78a-faf742f63007": {"__data__": {"id_": "22785523-de8f-4466-a78a-faf742f63007", "embedding": null, "metadata": {"window": "Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020.  This increase was primarily due to the performance of ABCS and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization.  The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n", "original_text": "The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "962783330a3bceab8c0fed642dcb2e9b819cf906481dee27c73e0f84e6ac397b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7624d26e-0fcd-4a3f-bf3f-1552e31132ff", "node_type": "1", "metadata": {"window": "Other\nRevenue in Other was $1.8 billion in the first quarter of fiscal 2020, an increase of 10.5 percent compared to the same period in the\nprior fiscal year, primarily due to growth at MWI, ABCS and World Courier.  Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020.  This increase was primarily due to the performance of ABCS and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization.  The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n", "original_text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization. ", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c99ffebc7834062d9faccacc664f3fc9940d26c3132a611e234f75992887a4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bffd99ba-4de1-4e21-baf3-620fadda7bd0", "node_type": "1", "metadata": {"window": "This increase was primarily due to the performance of ABCS and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization.  The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n"}, "hash": "913d0d8056a5f057eecb86e149b13d26d2ea14667e23b8c30ad2a1e45d22739a", "class_name": "RelatedNodeInfo"}}, "text": "The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n", "start_char_idx": 2345, "end_char_idx": 2632, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bffd99ba-4de1-4e21-baf3-620fadda7bd0": {"__data__": {"id_": "bffd99ba-4de1-4e21-baf3-620fadda7bd0", "embedding": null, "metadata": {"window": "This increase was primarily due to the performance of ABCS and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization.  The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "962783330a3bceab8c0fed642dcb2e9b819cf906481dee27c73e0f84e6ac397b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22785523-de8f-4466-a78a-faf742f63007", "node_type": "1", "metadata": {"window": "Operating income in Other increased 5.6 percent to\n$104.5 million in the first quarter of fiscal 2020.  This increase was primarily due to the performance of ABCS and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization.  The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n", "original_text": "The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b4aa3ba6366957ce4d11ba9dfcd283b209fe765920fee11e9ba0466569bba5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bec5f817-0978-466d-bfe1-5ad077d1289d", "node_type": "1", "metadata": {"window": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization.  The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n"}, "hash": "7852119f99393ed345495a10d2c4b958cd894b11077b5c1d89cde8b5cff54285", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n", "start_char_idx": 2632, "end_char_idx": 2790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bec5f817-0978-466d-bfe1-5ad077d1289d": {"__data__": {"id_": "bec5f817-0978-466d-bfe1-5ad077d1289d", "embedding": null, "metadata": {"window": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization.  The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "962783330a3bceab8c0fed642dcb2e9b819cf906481dee27c73e0f84e6ac397b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bffd99ba-4de1-4e21-baf3-620fadda7bd0", "node_type": "1", "metadata": {"window": "This increase was primarily due to the performance of ABCS and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization.  The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af3b9ba795c8f70c35b505973c822e2071204b7464eaf50d6391db647686921c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a6c43ba-f101-42b9-a965-93fb3b45a841", "node_type": "1", "metadata": {"window": "The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\n4", "original_text": "The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n"}, "hash": "1d1b32ce1f929ebff0efdece66ebdccb66522144178a967568bd3f4de56ff2e8", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n", "start_char_idx": 2790, "end_char_idx": 3057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a6c43ba-f101-42b9-a965-93fb3b45a841": {"__data__": {"id_": "9a6c43ba-f101-42b9-a965-93fb3b45a841", "embedding": null, "metadata": {"window": "The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\n4", "original_text": "The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "962783330a3bceab8c0fed642dcb2e9b819cf906481dee27c73e0f84e6ac397b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bec5f817-0978-466d-bfe1-5ad077d1289d", "node_type": "1", "metadata": {"window": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen enhanced its logistics offering by integrating two of its businesses, World Courier, a global logistics\nprovider, and ICS, a third party logistics (3PL) provider, creating the first and only specialty logistics partner to deliver\ncomplete support from clinical trials through commercialization.  The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d1ccec43f5edcbdafb287021bfd6dd2c8b5ee59b52bd6f2c30c507874e51a81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49bad4e8-e24b-40e5-aee8-286a905775ae", "node_type": "1", "metadata": {"window": "AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\n4", "original_text": "Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. "}, "hash": "8bb334110fb9f0605f183edc6467cd9d8b5a8425369638d40f484c0de084b613", "class_name": "RelatedNodeInfo"}}, "text": "The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n", "start_char_idx": 3057, "end_char_idx": 3349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49bad4e8-e24b-40e5-aee8-286a905775ae": {"__data__": {"id_": "49bad4e8-e24b-40e5-aee8-286a905775ae", "embedding": null, "metadata": {"window": "AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\n4", "original_text": "Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "962783330a3bceab8c0fed642dcb2e9b819cf906481dee27c73e0f84e6ac397b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a6c43ba-f101-42b9-a965-93fb3b45a841", "node_type": "1", "metadata": {"window": "The integration offers enhanced global capabilities for\nmanufacturers navigating the complexities of their product\u2019s journey end-to-end, ultimately progressing the global growth of\nthe advanced therapy industry and enabling more patients to be treated with these life-changing products.\n AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\n4", "original_text": "The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e44d7a774a21bc91ec7839d7a1a5678a852bf96b0a4671d5379a252416d18bda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40d5c900-8b3d-4790-b23e-dba7249bd8e6", "node_type": "1", "metadata": {"window": "AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\n4", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n"}, "hash": "8b67bac52e6966d7436004b714ee1583aba3941363338aaf84f71490c829ebc8", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "start_char_idx": 3349, "end_char_idx": 3593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40d5c900-8b3d-4790-b23e-dba7249bd8e6": {"__data__": {"id_": "40d5c900-8b3d-4790-b23e-dba7249bd8e6", "embedding": null, "metadata": {"window": "AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\n4", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "962783330a3bceab8c0fed642dcb2e9b819cf906481dee27c73e0f84e6ac397b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49bad4e8-e24b-40e5-aee8-286a905775ae", "node_type": "1", "metadata": {"window": "AmerisourceBergen was named one of America\u2019s \u201cMost Responsible Companies\u201d by Newsweek  magazine and ranked 10 th in\nthe Health Care & Life Sciences category.\n AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\n4", "original_text": "Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6cf67836407f88b5416f2cc4a14e1775cdfc987a491cd7d84e075571266ac0c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "edea6586-b8ab-4f23-9aad-fa1fe0de13de", "node_type": "1", "metadata": {"window": "The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\n4", "original_text": "Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\n4"}, "hash": "f0dd5cede29d95a22338904f3bd1619b44cff30d61d38f50cf54160644f9fd9a", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "start_char_idx": 3593, "end_char_idx": 3725, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "edea6586-b8ab-4f23-9aad-fa1fe0de13de": {"__data__": {"id_": "edea6586-b8ab-4f23-9aad-fa1fe0de13de", "embedding": null, "metadata": {"window": "The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\n4", "original_text": "Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\n4", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "962783330a3bceab8c0fed642dcb2e9b819cf906481dee27c73e0f84e6ac397b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40d5c900-8b3d-4790-b23e-dba7249bd8e6", "node_type": "1", "metadata": {"window": "AmerisourceBergen received a perfect score of 100 on the 2019 Corporate Equality Index, the nation\u2019s premier benchmarking\nsurvey and report on corporate policies and practices related to LGBTQ workplace equality, administered by the Human\nRights Campaign Foundation.\n The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\n4", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b931695da468f4c7a052e0ebf24f25e7897abdbec3bf4ce524f6b34917e19b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efdd3fc6-f7c8-40d6-afc2-0d9d196fc1df", "node_type": "1", "metadata": {"window": "AmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s strong performance, opportunistic\nshare repurchases and the exit of our PharMEDium business.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $7.55 to $7.80, up from the previous range of $7.30 to $7.60.\n Additional expectations now include:\nAdjusted operating income growth in the mid-single digit percent range, up from the low-to mid-single percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range, up from\nthe low- to mid-single digit percent range;\nWeighted average diluted shares are now expected to be approximately 208 million, down from the previous expectation of\nbetween 209 million to 210 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n", "original_text": "AmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s strong performance, opportunistic\nshare repurchases and the exit of our PharMEDium business. "}, "hash": "0849642af093d0fc40c6926b7a207db08dbd345a9973fba3b6040a2add26b532", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\n4", "start_char_idx": 3725, "end_char_idx": 3790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efdd3fc6-f7c8-40d6-afc2-0d9d196fc1df": {"__data__": {"id_": "efdd3fc6-f7c8-40d6-afc2-0d9d196fc1df", "embedding": null, "metadata": {"window": "AmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s strong performance, opportunistic\nshare repurchases and the exit of our PharMEDium business.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $7.55 to $7.80, up from the previous range of $7.30 to $7.60.\n Additional expectations now include:\nAdjusted operating income growth in the mid-single digit percent range, up from the low-to mid-single percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range, up from\nthe low- to mid-single digit percent range;\nWeighted average diluted shares are now expected to be approximately 208 million, down from the previous expectation of\nbetween 209 million to 210 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n", "original_text": "AmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s strong performance, opportunistic\nshare repurchases and the exit of our PharMEDium business. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "edea6586-b8ab-4f23-9aad-fa1fe0de13de", "node_type": "1", "metadata": {"window": "The AmerisourceBergen Foundation announced a number of grants aimed at improving education and access to care in\nanimal health throughout 2020 and beyond, including new collaborations with the National FFA Foundation, the National\nDisaster Search Dog Foundation and K9 Partners for Patriots.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\n4", "original_text": "Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\n4", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee6c3d0ec6e7ced0c86336e2fc4b9e5e66c08a8d880fd5670e587bb7912a0bf7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8eed639c-85f9-4a02-8f70-08308819df7f", "node_type": "1", "metadata": {"window": "AmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s strong performance, opportunistic\nshare repurchases and the exit of our PharMEDium business.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $7.55 to $7.80, up from the previous range of $7.30 to $7.60.\n Additional expectations now include:\nAdjusted operating income growth in the mid-single digit percent range, up from the low-to mid-single percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range, up from\nthe low- to mid-single digit percent range;\nWeighted average diluted shares are now expected to be approximately 208 million, down from the previous expectation of\nbetween 209 million to 210 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "The Company now expects:\nAdjusted Diluted EPS to be in the range of $7.55 to $7.80, up from the previous range of $7.30 to $7.60.\n"}, "hash": "d69f43f0a9bcb4fa620c392bba2b62746b3370d70eef0c31ea073ff3233b2ddd", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s strong performance, opportunistic\nshare repurchases and the exit of our PharMEDium business. ", "start_char_idx": 0, "end_char_idx": 188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8eed639c-85f9-4a02-8f70-08308819df7f": {"__data__": {"id_": "8eed639c-85f9-4a02-8f70-08308819df7f", "embedding": null, "metadata": {"window": "AmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s strong performance, opportunistic\nshare repurchases and the exit of our PharMEDium business.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $7.55 to $7.80, up from the previous range of $7.30 to $7.60.\n Additional expectations now include:\nAdjusted operating income growth in the mid-single digit percent range, up from the low-to mid-single percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range, up from\nthe low- to mid-single digit percent range;\nWeighted average diluted shares are now expected to be approximately 208 million, down from the previous expectation of\nbetween 209 million to 210 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "The Company now expects:\nAdjusted Diluted EPS to be in the range of $7.55 to $7.80, up from the previous range of $7.30 to $7.60.\n", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efdd3fc6-f7c8-40d6-afc2-0d9d196fc1df", "node_type": "1", "metadata": {"window": "AmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s strong performance, opportunistic\nshare repurchases and the exit of our PharMEDium business.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $7.55 to $7.80, up from the previous range of $7.30 to $7.60.\n Additional expectations now include:\nAdjusted operating income growth in the mid-single digit percent range, up from the low-to mid-single percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range, up from\nthe low- to mid-single digit percent range;\nWeighted average diluted shares are now expected to be approximately 208 million, down from the previous expectation of\nbetween 209 million to 210 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n", "original_text": "AmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s strong performance, opportunistic\nshare repurchases and the exit of our PharMEDium business. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b929c2f31df3ecfc1e7c7a5f4d093e3a358c62f549e685468d10ba1b78f35469", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cd1bf29-5404-4fe9-a5c6-1e509c5a4da6", "node_type": "1", "metadata": {"window": "AmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s strong performance, opportunistic\nshare repurchases and the exit of our PharMEDium business.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $7.55 to $7.80, up from the previous range of $7.30 to $7.60.\n Additional expectations now include:\nAdjusted operating income growth in the mid-single digit percent range, up from the low-to mid-single percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range, up from\nthe low- to mid-single digit percent range;\nWeighted average diluted shares are now expected to be approximately 208 million, down from the previous expectation of\nbetween 209 million to 210 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 30, 2020. ", "original_text": "Additional expectations now include:\nAdjusted operating income growth in the mid-single digit percent range, up from the low-to mid-single percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range, up from\nthe low- to mid-single digit percent range;\nWeighted average diluted shares are now expected to be approximately 208 million, down from the previous expectation of\nbetween 209 million to 210 million for the fiscal year.\n"}, "hash": "db11973db2f60a39620abb8cd9888ce152e1c6ba4e91531ff231c09baecd74fb", "class_name": "RelatedNodeInfo"}}, "text": "The Company now expects:\nAdjusted Diluted EPS to be in the range of $7.55 to $7.80, up from the previous range of $7.30 to $7.60.\n", "start_char_idx": 188, "end_char_idx": 318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cd1bf29-5404-4fe9-a5c6-1e509c5a4da6": {"__data__": {"id_": "1cd1bf29-5404-4fe9-a5c6-1e509c5a4da6", "embedding": null, "metadata": {"window": "AmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s strong performance, opportunistic\nshare repurchases and the exit of our PharMEDium business.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $7.55 to $7.80, up from the previous range of $7.30 to $7.60.\n Additional expectations now include:\nAdjusted operating income growth in the mid-single digit percent range, up from the low-to mid-single percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range, up from\nthe low- to mid-single digit percent range;\nWeighted average diluted shares are now expected to be approximately 208 million, down from the previous expectation of\nbetween 209 million to 210 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 30, 2020. ", "original_text": "Additional expectations now include:\nAdjusted operating income growth in the mid-single digit percent range, up from the low-to mid-single percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range, up from\nthe low- to mid-single digit percent range;\nWeighted average diluted shares are now expected to be approximately 208 million, down from the previous expectation of\nbetween 209 million to 210 million for the fiscal year.\n", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8eed639c-85f9-4a02-8f70-08308819df7f", "node_type": "1", "metadata": {"window": "AmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s strong performance, opportunistic\nshare repurchases and the exit of our PharMEDium business.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $7.55 to $7.80, up from the previous range of $7.30 to $7.60.\n Additional expectations now include:\nAdjusted operating income growth in the mid-single digit percent range, up from the low-to mid-single percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range, up from\nthe low- to mid-single digit percent range;\nWeighted average diluted shares are now expected to be approximately 208 million, down from the previous expectation of\nbetween 209 million to 210 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "The Company now expects:\nAdjusted Diluted EPS to be in the range of $7.55 to $7.80, up from the previous range of $7.30 to $7.60.\n", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "614862d3629f1af257b54c93285bc391c0aa818d50e49cde8db10d14cad6ff39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e5d4320-1921-4d36-a183-9e395ef79add", "node_type": "1", "metadata": {"window": "AmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s strong performance, opportunistic\nshare repurchases and the exit of our PharMEDium business.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $7.55 to $7.80, up from the previous range of $7.30 to $7.60.\n Additional expectations now include:\nAdjusted operating income growth in the mid-single digit percent range, up from the low-to mid-single percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range, up from\nthe low- to mid-single digit percent range;\nWeighted average diluted shares are now expected to be approximately 208 million, down from the previous expectation of\nbetween 209 million to 210 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 30, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n"}, "hash": "8716baedcff001f456fe9ab891c9737651aa1c91684997a24bdcb7e049971590", "class_name": "RelatedNodeInfo"}}, "text": "Additional expectations now include:\nAdjusted operating income growth in the mid-single digit percent range, up from the low-to mid-single percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range, up from\nthe low- to mid-single digit percent range;\nWeighted average diluted shares are now expected to be approximately 208 million, down from the previous expectation of\nbetween 209 million to 210 million for the fiscal year.\n", "start_char_idx": 318, "end_char_idx": 808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e5d4320-1921-4d36-a183-9e395ef79add": {"__data__": {"id_": "9e5d4320-1921-4d36-a183-9e395ef79add", "embedding": null, "metadata": {"window": "AmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s strong performance, opportunistic\nshare repurchases and the exit of our PharMEDium business.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $7.55 to $7.80, up from the previous range of $7.30 to $7.60.\n Additional expectations now include:\nAdjusted operating income growth in the mid-single digit percent range, up from the low-to mid-single percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range, up from\nthe low- to mid-single digit percent range;\nWeighted average diluted shares are now expected to be approximately 208 million, down from the previous expectation of\nbetween 209 million to 210 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 30, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cd1bf29-5404-4fe9-a5c6-1e509c5a4da6", "node_type": "1", "metadata": {"window": "AmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s strong performance, opportunistic\nshare repurchases and the exit of our PharMEDium business.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $7.55 to $7.80, up from the previous range of $7.30 to $7.60.\n Additional expectations now include:\nAdjusted operating income growth in the mid-single digit percent range, up from the low-to mid-single percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range, up from\nthe low- to mid-single digit percent range;\nWeighted average diluted shares are now expected to be approximately 208 million, down from the previous expectation of\nbetween 209 million to 210 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 30, 2020. ", "original_text": "Additional expectations now include:\nAdjusted operating income growth in the mid-single digit percent range, up from the low-to mid-single percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range, up from\nthe low- to mid-single digit percent range;\nWeighted average diluted shares are now expected to be approximately 208 million, down from the previous expectation of\nbetween 209 million to 210 million for the fiscal year.\n", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4182c3984bb1c3b404897b718fab1fa06be551b10c16df51a351c1bf75450c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4bfb4de-f3fb-4433-9647-a2e08d70741e", "node_type": "1", "metadata": {"window": "The Company now expects:\nAdjusted Diluted EPS to be in the range of $7.55 to $7.80, up from the previous range of $7.30 to $7.60.\n Additional expectations now include:\nAdjusted operating income growth in the mid-single digit percent range, up from the low-to mid-single percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range, up from\nthe low- to mid-single digit percent range;\nWeighted average diluted shares are now expected to be approximately 208 million, down from the previous expectation of\nbetween 209 million to 210 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 30, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. "}, "hash": "24c9843610c8debd3912767c7287a2fb07ea4f761e10c2f89ec4dd64e58c651c", "class_name": "RelatedNodeInfo"}}, "text": "All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n", "start_char_idx": 808, "end_char_idx": 936, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4bfb4de-f3fb-4433-9647-a2e08d70741e": {"__data__": {"id_": "d4bfb4de-f3fb-4433-9647-a2e08d70741e", "embedding": null, "metadata": {"window": "The Company now expects:\nAdjusted Diluted EPS to be in the range of $7.55 to $7.80, up from the previous range of $7.30 to $7.60.\n Additional expectations now include:\nAdjusted operating income growth in the mid-single digit percent range, up from the low-to mid-single percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range, up from\nthe low- to mid-single digit percent range;\nWeighted average diluted shares are now expected to be approximately 208 million, down from the previous expectation of\nbetween 209 million to 210 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 30, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e5d4320-1921-4d36-a183-9e395ef79add", "node_type": "1", "metadata": {"window": "AmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s strong performance, opportunistic\nshare repurchases and the exit of our PharMEDium business.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $7.55 to $7.80, up from the previous range of $7.30 to $7.60.\n Additional expectations now include:\nAdjusted operating income growth in the mid-single digit percent range, up from the low-to mid-single percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range, up from\nthe low- to mid-single digit percent range;\nWeighted average diluted shares are now expected to be approximately 208 million, down from the previous expectation of\nbetween 209 million to 210 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 30, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad18d9c9d1ccc784f8adbf5d9f83eb8110b0e3b5ac0e30e694a6c6ee857d1c31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "817263f8-f92c-492a-8dc9-251982396838", "node_type": "1", "metadata": {"window": "Additional expectations now include:\nAdjusted operating income growth in the mid-single digit percent range, up from the low-to mid-single percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range, up from\nthe low- to mid-single digit percent range;\nWeighted average diluted shares are now expected to be approximately 208 million, down from the previous expectation of\nbetween 209 million to 210 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 30, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797. ", "original_text": "ET on January 30, 2020. "}, "hash": "5dbf88a3cbda0c77eac878538f641ee872202944014615644c4c2c1486606089", "class_name": "RelatedNodeInfo"}}, "text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "start_char_idx": 936, "end_char_idx": 1051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "817263f8-f92c-492a-8dc9-251982396838": {"__data__": {"id_": "817263f8-f92c-492a-8dc9-251982396838", "embedding": null, "metadata": {"window": "Additional expectations now include:\nAdjusted operating income growth in the mid-single digit percent range, up from the low-to mid-single percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range, up from\nthe low- to mid-single digit percent range;\nWeighted average diluted shares are now expected to be approximately 208 million, down from the previous expectation of\nbetween 209 million to 210 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 30, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797. ", "original_text": "ET on January 30, 2020. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4bfb4de-f3fb-4433-9647-a2e08d70741e", "node_type": "1", "metadata": {"window": "The Company now expects:\nAdjusted Diluted EPS to be in the range of $7.55 to $7.80, up from the previous range of $7.30 to $7.60.\n Additional expectations now include:\nAdjusted operating income growth in the mid-single digit percent range, up from the low-to mid-single percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range, up from\nthe low- to mid-single digit percent range;\nWeighted average diluted shares are now expected to be approximately 208 million, down from the previous expectation of\nbetween 209 million to 210 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 30, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f446441926517eeb8aed35221be2e8eab8341611ba071f8de2fc5af3b0a7f542", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7128346f-1b03-4a9c-91b5-697a2b5fa368", "node_type": "1", "metadata": {"window": "All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 30, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired. ", "original_text": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . "}, "hash": "7814d7d97d557611d157677373ef5b08e56645e9e7d836c0eec9a76a1931bf81", "class_name": "RelatedNodeInfo"}}, "text": "ET on January 30, 2020. ", "start_char_idx": 1051, "end_char_idx": 1075, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7128346f-1b03-4a9c-91b5-697a2b5fa368": {"__data__": {"id_": "7128346f-1b03-4a9c-91b5-697a2b5fa368", "embedding": null, "metadata": {"window": "All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 30, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired. ", "original_text": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "817263f8-f92c-492a-8dc9-251982396838", "node_type": "1", "metadata": {"window": "Additional expectations now include:\nAdjusted operating income growth in the mid-single digit percent range, up from the low-to mid-single percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range, up from\nthe low- to mid-single digit percent range;\nWeighted average diluted shares are now expected to be approximately 208 million, down from the previous expectation of\nbetween 209 million to 210 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 30, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797. ", "original_text": "ET on January 30, 2020. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50d60e1f4ddb0ea0953c46348e3b14ead6281bcc22530ee2da46626ba10d4198", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "327f8c5f-5a43-4173-8daa-a393f5a27dff", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 30, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533. "}, "hash": "933ecc39e746128342a519ce41ceb87d8777923c5ef5f31fedb58e0d2174cb05", "class_name": "RelatedNodeInfo"}}, "text": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "start_char_idx": 1075, "end_char_idx": 1192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "327f8c5f-5a43-4173-8daa-a393f5a27dff": {"__data__": {"id_": "327f8c5f-5a43-4173-8daa-a393f5a27dff", "embedding": null, "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 30, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7128346f-1b03-4a9c-91b5-697a2b5fa368", "node_type": "1", "metadata": {"window": "All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 30, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired. ", "original_text": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "376b5dd3d560616499949219e41745ddf5cc1af2a8fe3500a1a301c756944887", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25130bb8-745c-4ef3-98dc-4f91a69f6ccb", "node_type": "1", "metadata": {"window": "ET on January 30, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United States, dial (412) 317-0797. "}, "hash": "5e04be0d4f6cd5542a80e494b13a8baf1c2db3f637b67a0bcd1299f4b1720173", "class_name": "RelatedNodeInfo"}}, "text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533. ", "start_char_idx": 1192, "end_char_idx": 1431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25130bb8-745c-4ef3-98dc-4f91a69f6ccb": {"__data__": {"id_": "25130bb8-745c-4ef3-98dc-4f91a69f6ccb", "embedding": null, "metadata": {"window": "ET on January 30, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United States, dial (412) 317-0797. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "327f8c5f-5a43-4173-8daa-a393f5a27dff", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on January 30, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2c7e7e1f5d79a483f238ea7149b9802cc7e34891c5f9c1a1e2d5bde5f39cbc4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d632b23-468e-4b26-b031-e70475f2fbe2", "node_type": "1", "metadata": {"window": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "No access code is\nrequired. "}, "hash": "4151f2983941d060add63cbf6b22db2efca86bba5babf68e35f383106779913a", "class_name": "RelatedNodeInfo"}}, "text": "From outside the United States, dial (412) 317-0797. ", "start_char_idx": 1431, "end_char_idx": 1484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d632b23-468e-4b26-b031-e70475f2fbe2": {"__data__": {"id_": "5d632b23-468e-4b26-b031-e70475f2fbe2", "embedding": null, "metadata": {"window": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "No access code is\nrequired. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25130bb8-745c-4ef3-98dc-4f91a69f6ccb", "node_type": "1", "metadata": {"window": "ET on January 30, 2020.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United States, dial (412) 317-0797. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2a774b6a36df7655b384abf9ce24643beb4570201382a215174b248065cf0bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf370e98-773d-4cc5-b978-eff847d764e6", "node_type": "1", "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . "}, "hash": "6d82bb9a451bf4897bd5d821331e99a989c7d2cbec33e30b22924a7f007a8800", "class_name": "RelatedNodeInfo"}}, "text": "No access code is\nrequired. ", "start_char_idx": 1484, "end_char_idx": 1512, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf370e98-773d-4cc5-b978-eff847d764e6": {"__data__": {"id_": "bf370e98-773d-4cc5-b978-eff847d764e6", "embedding": null, "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d632b23-468e-4b26-b031-e70475f2fbe2", "node_type": "1", "metadata": {"window": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "No access code is\nrequired. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd9daf92d55e687a5ea42eca73dc3a4e90f5c4c371246f296ce9687dd3c5c915", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0448c0cd-c8b5-4f40-8e42-53b5ddce6cce", "node_type": "1", "metadata": {"window": "From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n"}, "hash": "b309f7f6e425ce1c550fecb1044235c6ddff75f4d76509ac5e75ca6223f4a3e0", "class_name": "RelatedNodeInfo"}}, "text": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "start_char_idx": 1512, "end_char_idx": 1609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0448c0cd-c8b5-4f40-8e42-53b5ddce6cce": {"__data__": {"id_": "0448c0cd-c8b5-4f40-8e42-53b5ddce6cce", "embedding": null, "metadata": {"window": "From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf370e98-773d-4cc5-b978-eff847d764e6", "node_type": "1", "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb606cac138e8b73093277f89fecba109a46a5e09d0e4015ec28f01bd9351420", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3db4352-d0e6-45b6-b366-3b1091202940", "node_type": "1", "metadata": {"window": "No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529. ", "original_text": "Replays of the call will be made available via telephone and webcast. "}, "hash": "a785338c29e966735e941039c52688d2834afbc610b23b145bbdf354a4b80e19", "class_name": "RelatedNodeInfo"}}, "text": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "start_char_idx": 1609, "end_char_idx": 1732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3db4352-d0e6-45b6-b366-3b1091202940": {"__data__": {"id_": "f3db4352-d0e6-45b6-b366-3b1091202940", "embedding": null, "metadata": {"window": "No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0448c0cd-c8b5-4f40-8e42-53b5ddce6cce", "node_type": "1", "metadata": {"window": "From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d59d3d694fcb19ca13b96e0a51a5cbe4e7fdbadea37a782025c4ca0d096162f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9eeaafd2-6d78-4501-9d7a-344f0fae2039", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. "}, "hash": "80b230657dea1b2f679665d2b0aff2710493136c1e1e423ccbded544c67949c2", "class_name": "RelatedNodeInfo"}}, "text": "Replays of the call will be made available via telephone and webcast. ", "start_char_idx": 1732, "end_char_idx": 1802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9eeaafd2-6d78-4501-9d7a-344f0fae2039": {"__data__": {"id_": "9eeaafd2-6d78-4501-9d7a-344f0fae2039", "embedding": null, "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3db4352-d0e6-45b6-b366-3b1091202940", "node_type": "1", "metadata": {"window": "No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "091e8537f48e2bc140f133b1e280a8cd2558a2117d7934bd8b81567467a13da6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59b2e735-7979-45b1-ba87-5177f2749af0", "node_type": "1", "metadata": {"window": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. "}, "hash": "0b885c158d26a5b360f201cea0d8affe463970880a02f11eaf905e31bf97d58c", "class_name": "RelatedNodeInfo"}}, "text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "start_char_idx": 1802, "end_char_idx": 1972, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59b2e735-7979-45b1-ba87-5177f2749af0": {"__data__": {"id_": "59b2e735-7979-45b1-ba87-5177f2749af0", "embedding": null, "metadata": {"window": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9eeaafd2-6d78-4501-9d7a-344f0fae2039", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2874f43427533df2d9e696033898eec644dccfeee172020a5dec52a2e63ebc77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81568d60-e603-47d7-a146-d6d7cde8e983", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10138176.\n", "original_text": "To access the telephone replay from within the U.S., dial (877) 344-7529. "}, "hash": "5b9945fd58f65e5a9001b301e430f5a8dc3672a6553ac731333282c737b350c2", "class_name": "RelatedNodeInfo"}}, "text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "start_char_idx": 1972, "end_char_idx": 2114, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81568d60-e603-47d7-a146-d6d7cde8e983": {"__data__": {"id_": "81568d60-e603-47d7-a146-d6d7cde8e983", "embedding": null, "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10138176.\n", "original_text": "To access the telephone replay from within the U.S., dial (877) 344-7529. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59b2e735-7979-45b1-ba87-5177f2749af0", "node_type": "1", "metadata": {"window": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2171fd85f7f840da4c259056fda6ab81342132764fb4957c5f4002cdafee16cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0eb21732-c70a-44de-ab95-9a68af724509", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10138176.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n", "original_text": "From Canada, dial (855) 669-9658. "}, "hash": "bca35d36acb6b09088a8f4ceb53fa7d3d6e26b11d95a138cf0477ff8633a64cf", "class_name": "RelatedNodeInfo"}}, "text": "To access the telephone replay from within the U.S., dial (877) 344-7529. ", "start_char_idx": 2114, "end_char_idx": 2188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0eb21732-c70a-44de-ab95-9a68af724509": {"__data__": {"id_": "0eb21732-c70a-44de-ab95-9a68af724509", "embedding": null, "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10138176.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n", "original_text": "From Canada, dial (855) 669-9658. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81568d60-e603-47d7-a146-d6d7cde8e983", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10138176.\n", "original_text": "To access the telephone replay from within the U.S., dial (877) 344-7529. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6332ccd68b5ed9cf2bd03818bed40049f23e29bb49a1fe29fa500ecc594d13ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b0dcbf3-25c2-41a7-97a3-9ed81a75e698", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10138176.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "From outside the\nUnited States and Canada, dial (412) 317-0088. "}, "hash": "bcf5b9605978b894b8a4b36b9d72bd076ededb5151a264507eeed176d7fb4352", "class_name": "RelatedNodeInfo"}}, "text": "From Canada, dial (855) 669-9658. ", "start_char_idx": 2188, "end_char_idx": 2222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b0dcbf3-25c2-41a7-97a3-9ed81a75e698": {"__data__": {"id_": "5b0dcbf3-25c2-41a7-97a3-9ed81a75e698", "embedding": null, "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10138176.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "From outside the\nUnited States and Canada, dial (412) 317-0088. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0eb21732-c70a-44de-ab95-9a68af724509", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10138176.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n", "original_text": "From Canada, dial (855) 669-9658. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b0b3fcec49ac2e3743a0b2fa82575544b841f8ddf3b1c9807fbb080aa49d6b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79a3b09f-b8ff-4e55-846b-8aabb1dd4ec9", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10138176.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n", "original_text": "The access code for the replay is 10138176.\n"}, "hash": "a1fd0ff0b65136cd478235753ec3e7bd1cae96e230f7f556570c513fe24222fb", "class_name": "RelatedNodeInfo"}}, "text": "From outside the\nUnited States and Canada, dial (412) 317-0088. ", "start_char_idx": 2222, "end_char_idx": 2286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79a3b09f-b8ff-4e55-846b-8aabb1dd4ec9": {"__data__": {"id_": "79a3b09f-b8ff-4e55-846b-8aabb1dd4ec9", "embedding": null, "metadata": {"window": "To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10138176.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n", "original_text": "The access code for the replay is 10138176.\n", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b0dcbf3-25c2-41a7-97a3-9ed81a75e698", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10138176.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "From outside the\nUnited States and Canada, dial (412) 317-0088. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "180afd8f99d4c13ac5df0d56e87a3d52f6d189922cd5d2054a5c09983d7f52be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f74f134c-7e51-49e1-84dd-5a1cb1370589", "node_type": "1", "metadata": {"window": "From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10138176.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n"}, "hash": "dc04f96d3e1f378f7aadacc8aa3372f668b01022a3452c2a5e41393c096d716b", "class_name": "RelatedNodeInfo"}}, "text": "The access code for the replay is 10138176.\n", "start_char_idx": 2286, "end_char_idx": 2330, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f74f134c-7e51-49e1-84dd-5a1cb1370589": {"__data__": {"id_": "f74f134c-7e51-49e1-84dd-5a1cb1370589", "embedding": null, "metadata": {"window": "From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10138176.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79a3b09f-b8ff-4e55-846b-8aabb1dd4ec9", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10138176.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n", "original_text": "The access code for the replay is 10138176.\n", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a160962f4c675a457e1b8141e88e33fd61de8af8ff4443e694ec7a7f79868458", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec2b42d8-d176-4042-9fed-c3bf8a0f5ca0", "node_type": "1", "metadata": {"window": "From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10138176.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n"}, "hash": "dded7996fb76eabff6866b27dcb681fc6334509b7832f56f81e4a9a706ea9772", "class_name": "RelatedNodeInfo"}}, "text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n", "start_char_idx": 2330, "end_char_idx": 2519, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec2b42d8-d176-4042-9fed-c3bf8a0f5ca0": {"__data__": {"id_": "ec2b42d8-d176-4042-9fed-c3bf8a0f5ca0", "embedding": null, "metadata": {"window": "From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10138176.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f74f134c-7e51-49e1-84dd-5a1cb1370589", "node_type": "1", "metadata": {"window": "From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10138176.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baa890934aa7e76f39e8b736b03910478f7648a65ff0a98e405c0c471f532651", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24caea4b-e095-48d7-a45c-0fd333e19d68", "node_type": "1", "metadata": {"window": "The access code for the replay is 10138176.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n"}, "hash": "fcae88c8e23365633c8249b14dfb6520bc3d1e18eff55cbbfbd58212beeefb58", "class_name": "RelatedNodeInfo"}}, "text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "start_char_idx": 2519, "end_char_idx": 2648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24caea4b-e095-48d7-a45c-0fd333e19d68": {"__data__": {"id_": "24caea4b-e095-48d7-a45c-0fd333e19d68", "embedding": null, "metadata": {"window": "The access code for the replay is 10138176.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec2b42d8-d176-4042-9fed-c3bf8a0f5ca0", "node_type": "1", "metadata": {"window": "From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10138176.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7b3937ea65771323c2df32e13c904732f3d0f61b735e683f42449b77d1fc994", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1a9cecf-6886-4cb1-b02d-d7a07e34d12a", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue. ", "original_text": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. "}, "hash": "9122b657dd63f14014840553fef37d51658b6024a31df7875672b98993fe16d6", "class_name": "RelatedNodeInfo"}}, "text": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n", "start_char_idx": 2648, "end_char_idx": 2801, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1a9cecf-6886-4cb1-b02d-d7a07e34d12a": {"__data__": {"id_": "c1a9cecf-6886-4cb1-b02d-d7a07e34d12a", "embedding": null, "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue. ", "original_text": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24caea4b-e095-48d7-a45c-0fd333e19d68", "node_type": "1", "metadata": {"window": "The access code for the replay is 10138176.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67758f81135f3945670d44613e765076385c7360a93afdf2fd96f7e7d616a6ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4919713e-763a-4e63-b4cd-b57a53f3f1b6", "node_type": "1", "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa. ", "original_text": "Global manufacturers depend on us for services that drive commercial success for their products.\n"}, "hash": "bd586078b4e7769262cab84e00182d725bef235a19cba68de89e066be1d6037e", "class_name": "RelatedNodeInfo"}}, "text": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "start_char_idx": 2801, "end_char_idx": 2951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4919713e-763a-4e63-b4cd-b57a53f3f1b6": {"__data__": {"id_": "4919713e-763a-4e63-b4cd-b57a53f3f1b6", "embedding": null, "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa. ", "original_text": "Global manufacturers depend on us for services that drive commercial success for their products.\n", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1a9cecf-6886-4cb1-b02d-d7a07e34d12a", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nBarclays Global Healthcare Conference, March 10-12, Miami.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue. ", "original_text": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "72f9c837028bd3386be2f407dda6bc7ef1e587872d910045a285be1a03dbae9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31d66fb0-24b4-44f9-9986-ada6856d49dd", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries. ", "original_text": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n"}, "hash": "aebc4c2cfb51b28ba3015cd4a38cf53c4b5aeee8a71e16e30724ee8c562851a1", "class_name": "RelatedNodeInfo"}}, "text": "Global manufacturers depend on us for services that drive commercial success for their products.\n", "start_char_idx": 2951, "end_char_idx": 3048, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31d66fb0-24b4-44f9-9986-ada6856d49dd": {"__data__": {"id_": "31d66fb0-24b4-44f9-9986-ada6856d49dd", "embedding": null, "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries. ", "original_text": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4919713e-763a-4e63-b4cd-b57a53f3f1b6", "node_type": "1", "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa. ", "original_text": "Global manufacturers depend on us for services that drive commercial success for their products.\n", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "078379d8f9825085779be0cf540a5ac814baffe053228a3690f428b76c5db5e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad1e36ab-0bae-4714-8687-acfc830601d3", "node_type": "1", "metadata": {"window": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue. "}, "hash": "0dcc30e6190a7f58768b4bc52bcd6f37b4cd49c3fb5dfc0f32a6fb7ecf07d241", "class_name": "RelatedNodeInfo"}}, "text": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n", "start_char_idx": 3048, "end_char_idx": 3173, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad1e36ab-0bae-4714-8687-acfc830601d3": {"__data__": {"id_": "ad1e36ab-0bae-4714-8687-acfc830601d3", "embedding": null, "metadata": {"window": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31d66fb0-24b4-44f9-9986-ada6856d49dd", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries. ", "original_text": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c39d76d52f20d901ce9d92e4ecffed9058b9bd980e6535a943d462e288b53bcf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79b34e17-380f-436c-825c-96a310e3f4ff", "node_type": "1", "metadata": {"window": "Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "original_text": "The company is\nheadquartered in Valley Forge, Pa. "}, "hash": "20c601e3802c4554bd00a32ab5196551c4ec1a81b3e4a189fe38db9668ae624e", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue. ", "start_char_idx": 3173, "end_char_idx": 3272, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79b34e17-380f-436c-825c-96a310e3f4ff": {"__data__": {"id_": "79b34e17-380f-436c-825c-96a310e3f4ff", "embedding": null, "metadata": {"window": "Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "original_text": "The company is\nheadquartered in Valley Forge, Pa. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad1e36ab-0bae-4714-8687-acfc830601d3", "node_type": "1", "metadata": {"window": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ed8fd86be39ff91c6141ef45b2033fb608f0931cbc241b4b99fef7d4d8b5ec1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64c220ca-d6b6-4b94-a469-94a252986bb9", "node_type": "1", "metadata": {"window": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "original_text": "and has a presence in 50+ countries. "}, "hash": "7de63fff4c2e10ea3a1c65b8fbf9e3411d5c1f54c5f829e284f49fbca5763125", "class_name": "RelatedNodeInfo"}}, "text": "The company is\nheadquartered in Valley Forge, Pa. ", "start_char_idx": 3272, "end_char_idx": 3322, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64c220ca-d6b6-4b94-a469-94a252986bb9": {"__data__": {"id_": "64c220ca-d6b6-4b94-a469-94a252986bb9", "embedding": null, "metadata": {"window": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "original_text": "and has a presence in 50+ countries. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79b34e17-380f-436c-825c-96a310e3f4ff", "node_type": "1", "metadata": {"window": "Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "original_text": "The company is\nheadquartered in Valley Forge, Pa. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "39eeff8a1de0f68ef8f52ba141e41012ae2c844be2ff383eca9c34cb944857d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29f3f899-4c91-4698-b2b9-ccd5ef394322", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "original_text": "Learn more at investor.amerisourcebergen.com .\n"}, "hash": "ec1190042b545918708efc0c08c7811f9804bc81ecd73b0e3c31c046a87d45ba", "class_name": "RelatedNodeInfo"}}, "text": "and has a presence in 50+ countries. ", "start_char_idx": 3322, "end_char_idx": 3359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29f3f899-4c91-4698-b2b9-ccd5ef394322": {"__data__": {"id_": "29f3f899-4c91-4698-b2b9-ccd5ef394322", "embedding": null, "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "original_text": "Learn more at investor.amerisourcebergen.com .\n", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64c220ca-d6b6-4b94-a469-94a252986bb9", "node_type": "1", "metadata": {"window": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "original_text": "and has a presence in 50+ countries. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67ba1a7b039f6cf844b2a7e86d7b87dac8da0ed3ba1eb189fa6fab46f4646583", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "157f87e1-6aaa-4c33-8d19-736b6efecb1b", "node_type": "1", "metadata": {"window": "The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5"}, "hash": "57d6e70cddc12cd16984b1ac74cbc219b1e153ac708f68800e659fdbfdd2d426", "class_name": "RelatedNodeInfo"}}, "text": "Learn more at investor.amerisourcebergen.com .\n", "start_char_idx": 3359, "end_char_idx": 3406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "157f87e1-6aaa-4c33-8d19-736b6efecb1b": {"__data__": {"id_": "157f87e1-6aaa-4c33-8d19-736b6efecb1b", "embedding": null, "metadata": {"window": "The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52547411-6af4-47ea-af2a-bb2cdd66e121", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ec3a5c9f898aa55d5565a915830865ea5f1190fb6cc19139f8502585295fc30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29f3f899-4c91-4698-b2b9-ccd5ef394322", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "original_text": "Learn more at investor.amerisourcebergen.com .\n", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8bca03f15185acbeeb2a2bae3ce185edcea817ee265d445e50473eea46623034", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bca6a7d-1cb0-4499-a58f-9d134ce2f69b", "node_type": "1", "metadata": {"window": "Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "original_text": "Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. "}, "hash": "ab7f5dacf3e8089cee72a12a3359b2b0aa4dc6478ee81d3efdee3a27715e31f4", "class_name": "RelatedNodeInfo"}}, "text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "start_char_idx": 3406, "end_char_idx": 3486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6bca6a7d-1cb0-4499-a58f-9d134ce2f69b": {"__data__": {"id_": "6bca6a7d-1cb0-4499-a58f-9d134ce2f69b", "embedding": null, "metadata": {"window": "Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "original_text": "Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70432d22-a097-4888-876b-20e363f3e3bc", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be4a4b0cfd6a2fef9b20e06da3a4e178c58a55504013013c05d86bba5da7a506", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "157f87e1-6aaa-4c33-8d19-736b6efecb1b", "node_type": "1", "metadata": {"window": "The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e5f7b2f5e9dd42a55e17092b3dbc73da7eebd07862c8d4c4666bedbfa60c3c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "027e9116-3467-4307-84ae-9094104f49aa", "node_type": "1", "metadata": {"window": "Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc. ", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. "}, "hash": "13365c41f78dbffdf469b48960a190491b21af8453e609eb10230171577409ac", "class_name": "RelatedNodeInfo"}}, "text": "Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "start_char_idx": 0, "end_char_idx": 211, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "027e9116-3467-4307-84ae-9094104f49aa": {"__data__": {"id_": "027e9116-3467-4307-84ae-9094104f49aa", "embedding": null, "metadata": {"window": "Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc. ", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70432d22-a097-4888-876b-20e363f3e3bc", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be4a4b0cfd6a2fef9b20e06da3a4e178c58a55504013013c05d86bba5da7a506", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bca6a7d-1cb0-4499-a58f-9d134ce2f69b", "node_type": "1", "metadata": {"window": "Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "original_text": "Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f484d4ee7e19a844d7dccb05f31c9e53cd36a84ffedc573917721a36cc418e78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30115299-6f57-4d9a-853c-a051a237979e", "node_type": "1", "metadata": {"window": "Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc.  and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S. ", "original_text": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. "}, "hash": "4a9d664d6815fe82f90f4c74fe8718cc6e8e64fc9db8ef82acf47f3284a9bec8", "class_name": "RelatedNodeInfo"}}, "text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "start_char_idx": 211, "end_char_idx": 561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30115299-6f57-4d9a-853c-a051a237979e": {"__data__": {"id_": "30115299-6f57-4d9a-853c-a051a237979e", "embedding": null, "metadata": {"window": "Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc.  and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S. ", "original_text": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70432d22-a097-4888-876b-20e363f3e3bc", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be4a4b0cfd6a2fef9b20e06da3a4e178c58a55504013013c05d86bba5da7a506", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "027e9116-3467-4307-84ae-9094104f49aa", "node_type": "1", "metadata": {"window": "Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc. ", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88a8784439ecb379d58e3676a91f81449d379e7583e8a5ddc1febf940eb6c378", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "364119f1-aaf5-4dd4-bdda-24be1e8011b1", "node_type": "1", "metadata": {"window": "Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc.  and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally. ", "original_text": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. "}, "hash": "a5616ba29db824ce66e304c440d3887415502a8ef9fc3bbafbd82806730a0207", "class_name": "RelatedNodeInfo"}}, "text": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "start_char_idx": 561, "end_char_idx": 723, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "364119f1-aaf5-4dd4-bdda-24be1e8011b1": {"__data__": {"id_": "364119f1-aaf5-4dd4-bdda-24be1e8011b1", "embedding": null, "metadata": {"window": "Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc.  and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally. ", "original_text": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70432d22-a097-4888-876b-20e363f3e3bc", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be4a4b0cfd6a2fef9b20e06da3a4e178c58a55504013013c05d86bba5da7a506", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30115299-6f57-4d9a-853c-a051a237979e", "node_type": "1", "metadata": {"window": "Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc.  and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S. ", "original_text": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1796df2121190137eeca52fc2d70f299274cba33811d3dab76ab2101f768cb01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82cb2082-b4f8-4e90-86bc-3ee22cb9c00e", "node_type": "1", "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc.  and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act. ", "original_text": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc. "}, "hash": "561b9cb3897348600512440fde0161e0e2fd169f6ed48a3aa9d32382f2b4dab4", "class_name": "RelatedNodeInfo"}}, "text": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "start_char_idx": 723, "end_char_idx": 922, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82cb2082-b4f8-4e90-86bc-3ee22cb9c00e": {"__data__": {"id_": "82cb2082-b4f8-4e90-86bc-3ee22cb9c00e", "embedding": null, "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc.  and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act. ", "original_text": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc. ", "page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70432d22-a097-4888-876b-20e363f3e3bc", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be4a4b0cfd6a2fef9b20e06da3a4e178c58a55504013013c05d86bba5da7a506", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "364119f1-aaf5-4dd4-bdda-24be1e8011b1", "node_type": "1", "metadata": {"window": "Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc.  and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally. ", "original_text": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74ab4427f3ff65e3c3e8ddaf2dcce2b213de090de432d8b0c2956ae69f111f05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9ec22f5-df95-4f1a-9334-ccd53be5f68d", "node_type": "1", "metadata": {"window": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc.  and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n", "original_text": "and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S. "}, "hash": "9bd3115ea3572a5ea20d5624697a03db4619449077cc4ec18c421e87c53c11dc", "class_name": "RelatedNodeInfo"}}, "text": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc. ", "start_char_idx": 922, "end_char_idx": 2894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9ec22f5-df95-4f1a-9334-ccd53be5f68d": {"__data__": {"id_": "e9ec22f5-df95-4f1a-9334-ccd53be5f68d", "embedding": null, "metadata": {"window": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc.  and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n", "original_text": "and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S. ", "page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70432d22-a097-4888-876b-20e363f3e3bc", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be4a4b0cfd6a2fef9b20e06da3a4e178c58a55504013013c05d86bba5da7a506", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82cb2082-b4f8-4e90-86bc-3ee22cb9c00e", "node_type": "1", "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc.  and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act. ", "original_text": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc. ", "page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d19adc125d02f6462357fd3cfb6759b29943ee1441a90f909a60b6ae8d9a0e19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3099ce00-86cb-4ac2-a684-72891ec36147", "node_type": "1", "metadata": {"window": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc.  and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n6", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally. "}, "hash": "85b5210fbe55fef73ff95692b45a29c121c79297587b3f52ed02f9732c2c56b6", "class_name": "RelatedNodeInfo"}}, "text": "and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S. ", "start_char_idx": 2894, "end_char_idx": 3524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3099ce00-86cb-4ac2-a684-72891ec36147": {"__data__": {"id_": "3099ce00-86cb-4ac2-a684-72891ec36147", "embedding": null, "metadata": {"window": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc.  and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n6", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally. ", "page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70432d22-a097-4888-876b-20e363f3e3bc", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be4a4b0cfd6a2fef9b20e06da3a4e178c58a55504013013c05d86bba5da7a506", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9ec22f5-df95-4f1a-9334-ccd53be5f68d", "node_type": "1", "metadata": {"window": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc.  and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n", "original_text": "and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S. ", "page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79285d975d746d7560327c818222f23d42a2a02492a94b45d8b066ebab92f992", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ec78619-3de1-42a2-9842-aa80eb62b280", "node_type": "1", "metadata": {"window": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc.  and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n6", "original_text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act. "}, "hash": "8d69380abf2730b5ffb33a6574df2761add15384b8b905b5a322a144f3933e8c", "class_name": "RelatedNodeInfo"}}, "text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally. ", "start_char_idx": 3524, "end_char_idx": 5083, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ec78619-3de1-42a2-9842-aa80eb62b280": {"__data__": {"id_": "4ec78619-3de1-42a2-9842-aa80eb62b280", "embedding": null, "metadata": {"window": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc.  and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n6", "original_text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act. ", "page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70432d22-a097-4888-876b-20e363f3e3bc", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be4a4b0cfd6a2fef9b20e06da3a4e178c58a55504013013c05d86bba5da7a506", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3099ce00-86cb-4ac2-a684-72891ec36147", "node_type": "1", "metadata": {"window": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc.  and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n6", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally. ", "page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c2887b4de055d6525acd1245473f853443d0801454bb33d4fdb5111960020a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5037ae06-a770-422c-9a33-3f2c2a8f674e", "node_type": "1", "metadata": {"window": "and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n6", "original_text": "The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n"}, "hash": "c82af06d1f01c2829416fc8adcf6737ee6692a311b7bf6542aa8990ed57a157f", "class_name": "RelatedNodeInfo"}}, "text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act. ", "start_char_idx": 5083, "end_char_idx": 5498, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5037ae06-a770-422c-9a33-3f2c2a8f674e": {"__data__": {"id_": "5037ae06-a770-422c-9a33-3f2c2a8f674e", "embedding": null, "metadata": {"window": "and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n6", "original_text": "The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n", "page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70432d22-a097-4888-876b-20e363f3e3bc", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be4a4b0cfd6a2fef9b20e06da3a4e178c58a55504013013c05d86bba5da7a506", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ec78619-3de1-42a2-9842-aa80eb62b280", "node_type": "1", "metadata": {"window": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\nsupply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between\nWalgreens Boots Alliance, Inc.  and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n6", "original_text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act. ", "page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "227eab67a5c7dc9b45dd15e20ea46a7765538969f95514fb39d88f87a729737c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e35924b7-507d-40d0-aa53-11240b0048bf", "node_type": "1", "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n6", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n6"}, "hash": "2cd561a5271cfd6cc24ab511bd445bca494d9fbd3ba654c45888e41fb57119aa", "class_name": "RelatedNodeInfo"}}, "text": "The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n", "start_char_idx": 5498, "end_char_idx": 5647, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e35924b7-507d-40d0-aa53-11240b0048bf": {"__data__": {"id_": "e35924b7-507d-40d0-aa53-11240b0048bf", "embedding": null, "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n6", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n6", "page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70432d22-a097-4888-876b-20e363f3e3bc", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be4a4b0cfd6a2fef9b20e06da3a4e178c58a55504013013c05d86bba5da7a506", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5037ae06-a770-422c-9a33-3f2c2a8f674e", "node_type": "1", "metadata": {"window": "and the Company, including principally with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect\nthe Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;\nregulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our\ncompounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-\ncompliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n6", "original_text": "The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n", "page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a22804be12281fcc6568ad9a3df688506b74d281f9968cf3867cdb23290d9023", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8d62f02-00db-4c3d-8f2a-a9faa7e0dd5e", "node_type": "1", "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0 \u00a0Three\nMonths Ended \n December 31,\n2019 \u00a0% of\nRevenue \u00a0Three\nMonths Ended \n December 31,\n2018 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a0$45,392,452 \u00a0\u00a0\u00a0 \u00a05.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a044,094,872 \u00a0\u00a0\u00a0 \u00a05.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,231,214 \u00a0\u00a02.57% \u00a01,297,580 \u00a0\u00a02.86% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0685,953 \u00a0\u00a01.43% \u00a0656,585 \u00a0\u00a01.45% \u00a04.5%\nDepreciation and amortization \u00a0104,515 \u00a0\u00a00.22% \u00a0122,500 \u00a0\u00a00.27% \u00a0(14.7)%\nEmployee severance, litigation, and other 2 \u00a039,309 \u00a0\u00a0\u00a0 \u00a040,672 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of long-lived assets 3 \u00a0138,000 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0967,777 \u00a0\u00a02.02% \u00a0819,757 \u00a0\u00a01.81% \u00a018.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0263,437 \u00a0\u00a00.55% \u00a0477,823 \u00a0\u00a01.05% \u00a0(44.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss \u00a02,842 \u00a0\u00a0\u00a0 \u00a03,097 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a031,007 \u00a0\u00a0\u00a0 \u00a042,170 \u00a0\u00a0\u00a0 \u00a0(26.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0229,588 \u00a0\u00a00.48% \u00a0432,556 \u00a0\u00a00.95% \u00a0(46.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a043,020 \u00a0\u00a0\u00a0 \u00a040,803 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "original_text": "(unaudited)\n\u00a0\n\u00a0 \u00a0Three\nMonths Ended \n December 31,\n2019 \u00a0% of\nRevenue \u00a0Three\nMonths Ended \n December 31,\n2018 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a0$45,392,452 \u00a0\u00a0\u00a0 \u00a05.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a044,094,872 \u00a0\u00a0\u00a0 \u00a05.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,231,214 \u00a0\u00a02.57% \u00a01,297,580 \u00a0\u00a02.86% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0685,953 \u00a0\u00a01.43% \u00a0656,585 \u00a0\u00a01.45% \u00a04.5%\nDepreciation and amortization \u00a0104,515 \u00a0\u00a00.22% \u00a0122,500 \u00a0\u00a00.27% \u00a0(14.7)%\nEmployee severance, litigation, and other 2 \u00a039,309 \u00a0\u00a0\u00a0 \u00a040,672 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of long-lived assets 3 \u00a0138,000 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0967,777 \u00a0\u00a02.02% \u00a0819,757 \u00a0\u00a01.81% \u00a018.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0263,437 \u00a0\u00a00.55% \u00a0477,823 \u00a0\u00a01.05% \u00a0(44.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss \u00a02,842 \u00a0\u00a0\u00a0 \u00a03,097 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a031,007 \u00a0\u00a0\u00a0 \u00a042,170 \u00a0\u00a0\u00a0 \u00a0(26.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0229,588 \u00a0\u00a00.48% \u00a0432,556 \u00a0\u00a00.95% \u00a0(46.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a043,020 \u00a0\u00a0\u00a0 \u00a040,803 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7"}, "hash": "b738457a8acaf6c0c3912d366d5c44e6b05d5a530869c60c0d5ce97454cab1a4", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n6", "start_char_idx": 5647, "end_char_idx": 5734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8d62f02-00db-4c3d-8f2a-a9faa7e0dd5e": {"__data__": {"id_": "f8d62f02-00db-4c3d-8f2a-a9faa7e0dd5e", "embedding": null, "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0 \u00a0Three\nMonths Ended \n December 31,\n2019 \u00a0% of\nRevenue \u00a0Three\nMonths Ended \n December 31,\n2018 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a0$45,392,452 \u00a0\u00a0\u00a0 \u00a05.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a044,094,872 \u00a0\u00a0\u00a0 \u00a05.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,231,214 \u00a0\u00a02.57% \u00a01,297,580 \u00a0\u00a02.86% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0685,953 \u00a0\u00a01.43% \u00a0656,585 \u00a0\u00a01.45% \u00a04.5%\nDepreciation and amortization \u00a0104,515 \u00a0\u00a00.22% \u00a0122,500 \u00a0\u00a00.27% \u00a0(14.7)%\nEmployee severance, litigation, and other 2 \u00a039,309 \u00a0\u00a0\u00a0 \u00a040,672 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of long-lived assets 3 \u00a0138,000 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0967,777 \u00a0\u00a02.02% \u00a0819,757 \u00a0\u00a01.81% \u00a018.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0263,437 \u00a0\u00a00.55% \u00a0477,823 \u00a0\u00a01.05% \u00a0(44.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss \u00a02,842 \u00a0\u00a0\u00a0 \u00a03,097 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a031,007 \u00a0\u00a0\u00a0 \u00a042,170 \u00a0\u00a0\u00a0 \u00a0(26.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0229,588 \u00a0\u00a00.48% \u00a0432,556 \u00a0\u00a00.95% \u00a0(46.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a043,020 \u00a0\u00a0\u00a0 \u00a040,803 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "original_text": "(unaudited)\n\u00a0\n\u00a0 \u00a0Three\nMonths Ended \n December 31,\n2019 \u00a0% of\nRevenue \u00a0Three\nMonths Ended \n December 31,\n2018 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a0$45,392,452 \u00a0\u00a0\u00a0 \u00a05.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a044,094,872 \u00a0\u00a0\u00a0 \u00a05.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,231,214 \u00a0\u00a02.57% \u00a01,297,580 \u00a0\u00a02.86% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0685,953 \u00a0\u00a01.43% \u00a0656,585 \u00a0\u00a01.45% \u00a04.5%\nDepreciation and amortization \u00a0104,515 \u00a0\u00a00.22% \u00a0122,500 \u00a0\u00a00.27% \u00a0(14.7)%\nEmployee severance, litigation, and other 2 \u00a039,309 \u00a0\u00a0\u00a0 \u00a040,672 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of long-lived assets 3 \u00a0138,000 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0967,777 \u00a0\u00a02.02% \u00a0819,757 \u00a0\u00a01.81% \u00a018.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0263,437 \u00a0\u00a00.55% \u00a0477,823 \u00a0\u00a01.05% \u00a0(44.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss \u00a02,842 \u00a0\u00a0\u00a0 \u00a03,097 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a031,007 \u00a0\u00a0\u00a0 \u00a042,170 \u00a0\u00a0\u00a0 \u00a0(26.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0229,588 \u00a0\u00a00.48% \u00a0432,556 \u00a0\u00a00.95% \u00a0(46.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a043,020 \u00a0\u00a0\u00a0 \u00a040,803 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "page_label": "7", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "754d642f-1f12-4807-bfdf-d35f9acfa49a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e604af213a6f7c568a04a1b1c88e54d076df62c9b3f6d28af71fcd101dd7c43a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e35924b7-507d-40d0-aa53-11240b0048bf", "node_type": "1", "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier\nmix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data\nprivacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the\nCompany\u2019s operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any\nadditional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete\ndivestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past\npractices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and\nabroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's\nbusiness generally.  Certain additional factors that management believes could cause actual outcomes and results to differ materially\nfrom those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on\nForm 10-K for the fiscal year ended September 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company\npursuant to the Securities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking\nstatements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n6", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n6", "page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d11c0e91b3850cac37524307e6d20dff8f48d14327bb480cb38a9b97daf6e763", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61fce454-f2af-4931-a6f8-54bab198d2bc", "node_type": "1", "metadata": {"window": "Net income \u00a0186,568 \u00a0\u00a00.39% \u00a0391,753 \u00a0\u00a00.86% \u00a0(52.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interest \u00a01,072 \u00a0\u00a0\u00a0 \u00a01,899 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$187,640\u00a0\n\u00a00.39% \u00a0$393,652\u00a0\n\u00a00.87% \u00a0(52.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0$1.86 \u00a0\u00a0\u00a0 \u00a0(51.1)%\nDiluted \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0$1.84 \u00a0\u00a0\u00a0 \u00a0(51.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0212,054 \u00a0\u00a0\u00a0 \u00a0(2.9)%\nDiluted \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0213,969 \u00a0\u00a0\u00a0 \u00a0(3.0)%\n_____________________________________\n1Includes a $13.3 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $7.1 million of\nPharMEDium remediation costs in the three months ended December 31, 2019.  Includes an $87.3 million gain from antitrust\nlitigation settlements, a $22.0 million reversal of a prior period assessment relating to the New York State Opioid Stewardship\nAct, $17.9 million of PharMEDium remediation costs, and a $3.0 million LIFO credit in the three months ended December 31,\n2018.\n\u00a0\n 2Includes $0.8 million of employee severance, $24.7 million of litigation and opioid-related costs related to legal fees in\nconnection with opioid lawsuits and investigations, and $13.8 million of other costs in connection with acquisition-related deal\nand integration costs, business transformation efforts, and other restructuring initiatives in the three months ended December\n31, 2019.  Includes $4.8 million of employee severance, $14.5 million of litigation costs related to opioid lawsuits and\ninvestigations, and $21.4 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2018.\n\u00a0\n", "original_text": "Net income \u00a0186,568 \u00a0\u00a00.39% \u00a0391,753 \u00a0\u00a00.86% \u00a0(52.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interest \u00a01,072 \u00a0\u00a0\u00a0 \u00a01,899 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$187,640\u00a0\n\u00a00.39% \u00a0$393,652\u00a0\n\u00a00.87% \u00a0(52.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0$1.86 \u00a0\u00a0\u00a0 \u00a0(51.1)%\nDiluted \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0$1.84 \u00a0\u00a0\u00a0 \u00a0(51.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0212,054 \u00a0\u00a0\u00a0 \u00a0(2.9)%\nDiluted \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0213,969 \u00a0\u00a0\u00a0 \u00a0(3.0)%\n_____________________________________\n1Includes a $13.3 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $7.1 million of\nPharMEDium remediation costs in the three months ended December 31, 2019. "}, "hash": "66dda84e23fd4739bf2306e45d9a645fbc679d5e8653142c74b74656aad0b992", "class_name": "RelatedNodeInfo"}}, "text": "(unaudited)\n\u00a0\n\u00a0 \u00a0Three\nMonths Ended \n December 31,\n2019 \u00a0% of\nRevenue \u00a0Three\nMonths Ended \n December 31,\n2018 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a0$45,392,452 \u00a0\u00a0\u00a0 \u00a05.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a044,094,872 \u00a0\u00a0\u00a0 \u00a05.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,231,214 \u00a0\u00a02.57% \u00a01,297,580 \u00a0\u00a02.86% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0685,953 \u00a0\u00a01.43% \u00a0656,585 \u00a0\u00a01.45% \u00a04.5%\nDepreciation and amortization \u00a0104,515 \u00a0\u00a00.22% \u00a0122,500 \u00a0\u00a00.27% \u00a0(14.7)%\nEmployee severance, litigation, and other 2 \u00a039,309 \u00a0\u00a0\u00a0 \u00a040,672 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of long-lived assets 3 \u00a0138,000 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0967,777 \u00a0\u00a02.02% \u00a0819,757 \u00a0\u00a01.81% \u00a018.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0263,437 \u00a0\u00a00.55% \u00a0477,823 \u00a0\u00a01.05% \u00a0(44.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss \u00a02,842 \u00a0\u00a0\u00a0 \u00a03,097 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a031,007 \u00a0\u00a0\u00a0 \u00a042,170 \u00a0\u00a0\u00a0 \u00a0(26.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0229,588 \u00a0\u00a00.48% \u00a0432,556 \u00a0\u00a00.95% \u00a0(46.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a043,020 \u00a0\u00a0\u00a0 \u00a040,803 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "start_char_idx": 0, "end_char_idx": 1088, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61fce454-f2af-4931-a6f8-54bab198d2bc": {"__data__": {"id_": "61fce454-f2af-4931-a6f8-54bab198d2bc", "embedding": null, "metadata": {"window": "Net income \u00a0186,568 \u00a0\u00a00.39% \u00a0391,753 \u00a0\u00a00.86% \u00a0(52.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interest \u00a01,072 \u00a0\u00a0\u00a0 \u00a01,899 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$187,640\u00a0\n\u00a00.39% \u00a0$393,652\u00a0\n\u00a00.87% \u00a0(52.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0$1.86 \u00a0\u00a0\u00a0 \u00a0(51.1)%\nDiluted \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0$1.84 \u00a0\u00a0\u00a0 \u00a0(51.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0212,054 \u00a0\u00a0\u00a0 \u00a0(2.9)%\nDiluted \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0213,969 \u00a0\u00a0\u00a0 \u00a0(3.0)%\n_____________________________________\n1Includes a $13.3 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $7.1 million of\nPharMEDium remediation costs in the three months ended December 31, 2019.  Includes an $87.3 million gain from antitrust\nlitigation settlements, a $22.0 million reversal of a prior period assessment relating to the New York State Opioid Stewardship\nAct, $17.9 million of PharMEDium remediation costs, and a $3.0 million LIFO credit in the three months ended December 31,\n2018.\n\u00a0\n 2Includes $0.8 million of employee severance, $24.7 million of litigation and opioid-related costs related to legal fees in\nconnection with opioid lawsuits and investigations, and $13.8 million of other costs in connection with acquisition-related deal\nand integration costs, business transformation efforts, and other restructuring initiatives in the three months ended December\n31, 2019.  Includes $4.8 million of employee severance, $14.5 million of litigation costs related to opioid lawsuits and\ninvestigations, and $21.4 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2018.\n\u00a0\n", "original_text": "Net income \u00a0186,568 \u00a0\u00a00.39% \u00a0391,753 \u00a0\u00a00.86% \u00a0(52.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interest \u00a01,072 \u00a0\u00a0\u00a0 \u00a01,899 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$187,640\u00a0\n\u00a00.39% \u00a0$393,652\u00a0\n\u00a00.87% \u00a0(52.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0$1.86 \u00a0\u00a0\u00a0 \u00a0(51.1)%\nDiluted \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0$1.84 \u00a0\u00a0\u00a0 \u00a0(51.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0212,054 \u00a0\u00a0\u00a0 \u00a0(2.9)%\nDiluted \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0213,969 \u00a0\u00a0\u00a0 \u00a0(3.0)%\n_____________________________________\n1Includes a $13.3 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $7.1 million of\nPharMEDium remediation costs in the three months ended December 31, 2019. ", "page_label": "8", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff4ec43f-3185-4206-9869-12e51438f08a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8da477ff6ea90a80edabe166457b1ca0a4dd3cbd7a755218a12c6735d2724ae5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8d62f02-00db-4c3d-8f2a-a9faa7e0dd5e", "node_type": "1", "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0 \u00a0Three\nMonths Ended \n December 31,\n2019 \u00a0% of\nRevenue \u00a0Three\nMonths Ended \n December 31,\n2018 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a0$45,392,452 \u00a0\u00a0\u00a0 \u00a05.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a044,094,872 \u00a0\u00a0\u00a0 \u00a05.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,231,214 \u00a0\u00a02.57% \u00a01,297,580 \u00a0\u00a02.86% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0685,953 \u00a0\u00a01.43% \u00a0656,585 \u00a0\u00a01.45% \u00a04.5%\nDepreciation and amortization \u00a0104,515 \u00a0\u00a00.22% \u00a0122,500 \u00a0\u00a00.27% \u00a0(14.7)%\nEmployee severance, litigation, and other 2 \u00a039,309 \u00a0\u00a0\u00a0 \u00a040,672 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of long-lived assets 3 \u00a0138,000 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0967,777 \u00a0\u00a02.02% \u00a0819,757 \u00a0\u00a01.81% \u00a018.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0263,437 \u00a0\u00a00.55% \u00a0477,823 \u00a0\u00a01.05% \u00a0(44.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss \u00a02,842 \u00a0\u00a0\u00a0 \u00a03,097 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a031,007 \u00a0\u00a0\u00a0 \u00a042,170 \u00a0\u00a0\u00a0 \u00a0(26.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0229,588 \u00a0\u00a00.48% \u00a0432,556 \u00a0\u00a00.95% \u00a0(46.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a043,020 \u00a0\u00a0\u00a0 \u00a040,803 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "original_text": "(unaudited)\n\u00a0\n\u00a0 \u00a0Three\nMonths Ended \n December 31,\n2019 \u00a0% of\nRevenue \u00a0Three\nMonths Ended \n December 31,\n2018 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a0$45,392,452 \u00a0\u00a0\u00a0 \u00a05.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a044,094,872 \u00a0\u00a0\u00a0 \u00a05.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,231,214 \u00a0\u00a02.57% \u00a01,297,580 \u00a0\u00a02.86% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0685,953 \u00a0\u00a01.43% \u00a0656,585 \u00a0\u00a01.45% \u00a04.5%\nDepreciation and amortization \u00a0104,515 \u00a0\u00a00.22% \u00a0122,500 \u00a0\u00a00.27% \u00a0(14.7)%\nEmployee severance, litigation, and other 2 \u00a039,309 \u00a0\u00a0\u00a0 \u00a040,672 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of long-lived assets 3 \u00a0138,000 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0967,777 \u00a0\u00a02.02% \u00a0819,757 \u00a0\u00a01.81% \u00a018.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0263,437 \u00a0\u00a00.55% \u00a0477,823 \u00a0\u00a01.05% \u00a0(44.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss \u00a02,842 \u00a0\u00a0\u00a0 \u00a03,097 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a031,007 \u00a0\u00a0\u00a0 \u00a042,170 \u00a0\u00a0\u00a0 \u00a0(26.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0229,588 \u00a0\u00a00.48% \u00a0432,556 \u00a0\u00a00.95% \u00a0(46.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a043,020 \u00a0\u00a0\u00a0 \u00a040,803 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "page_label": "7", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "653bed13dc2c7675163cca611709e5cf92c782f27c14e347a6abf0fe3d1098f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fda072e-32a8-4219-a6c7-ee2d70501069", "node_type": "1", "metadata": {"window": "Net income \u00a0186,568 \u00a0\u00a00.39% \u00a0391,753 \u00a0\u00a00.86% \u00a0(52.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interest \u00a01,072 \u00a0\u00a0\u00a0 \u00a01,899 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$187,640\u00a0\n\u00a00.39% \u00a0$393,652\u00a0\n\u00a00.87% \u00a0(52.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0$1.86 \u00a0\u00a0\u00a0 \u00a0(51.1)%\nDiluted \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0$1.84 \u00a0\u00a0\u00a0 \u00a0(51.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0212,054 \u00a0\u00a0\u00a0 \u00a0(2.9)%\nDiluted \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0213,969 \u00a0\u00a0\u00a0 \u00a0(3.0)%\n_____________________________________\n1Includes a $13.3 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $7.1 million of\nPharMEDium remediation costs in the three months ended December 31, 2019.  Includes an $87.3 million gain from antitrust\nlitigation settlements, a $22.0 million reversal of a prior period assessment relating to the New York State Opioid Stewardship\nAct, $17.9 million of PharMEDium remediation costs, and a $3.0 million LIFO credit in the three months ended December 31,\n2018.\n\u00a0\n 2Includes $0.8 million of employee severance, $24.7 million of litigation and opioid-related costs related to legal fees in\nconnection with opioid lawsuits and investigations, and $13.8 million of other costs in connection with acquisition-related deal\nand integration costs, business transformation efforts, and other restructuring initiatives in the three months ended December\n31, 2019.  Includes $4.8 million of employee severance, $14.5 million of litigation costs related to opioid lawsuits and\ninvestigations, and $21.4 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2018.\n\u00a0\n 3Impairment of finite-lived intangible assets, property and equipment, and right-of-use assets relating to PharMEDium in the\nthree months ended December 31, 2019.\n", "original_text": "Includes an $87.3 million gain from antitrust\nlitigation settlements, a $22.0 million reversal of a prior period assessment relating to the New York State Opioid Stewardship\nAct, $17.9 million of PharMEDium remediation costs, and a $3.0 million LIFO credit in the three months ended December 31,\n2018.\n\u00a0\n"}, "hash": "f5614e7a793a4b9fdd873b193430548f98674d4dac60037b84b3e750f2f29bdc", "class_name": "RelatedNodeInfo"}}, "text": "Net income \u00a0186,568 \u00a0\u00a00.39% \u00a0391,753 \u00a0\u00a00.86% \u00a0(52.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interest \u00a01,072 \u00a0\u00a0\u00a0 \u00a01,899 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$187,640\u00a0\n\u00a00.39% \u00a0$393,652\u00a0\n\u00a00.87% \u00a0(52.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0$1.86 \u00a0\u00a0\u00a0 \u00a0(51.1)%\nDiluted \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0$1.84 \u00a0\u00a0\u00a0 \u00a0(51.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0212,054 \u00a0\u00a0\u00a0 \u00a0(2.9)%\nDiluted \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0213,969 \u00a0\u00a0\u00a0 \u00a0(3.0)%\n_____________________________________\n1Includes a $13.3 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $7.1 million of\nPharMEDium remediation costs in the three months ended December 31, 2019. ", "start_char_idx": 0, "end_char_idx": 782, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fda072e-32a8-4219-a6c7-ee2d70501069": {"__data__": {"id_": "3fda072e-32a8-4219-a6c7-ee2d70501069", "embedding": null, "metadata": {"window": "Net income \u00a0186,568 \u00a0\u00a00.39% \u00a0391,753 \u00a0\u00a00.86% \u00a0(52.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interest \u00a01,072 \u00a0\u00a0\u00a0 \u00a01,899 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$187,640\u00a0\n\u00a00.39% \u00a0$393,652\u00a0\n\u00a00.87% \u00a0(52.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0$1.86 \u00a0\u00a0\u00a0 \u00a0(51.1)%\nDiluted \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0$1.84 \u00a0\u00a0\u00a0 \u00a0(51.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0212,054 \u00a0\u00a0\u00a0 \u00a0(2.9)%\nDiluted \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0213,969 \u00a0\u00a0\u00a0 \u00a0(3.0)%\n_____________________________________\n1Includes a $13.3 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $7.1 million of\nPharMEDium remediation costs in the three months ended December 31, 2019.  Includes an $87.3 million gain from antitrust\nlitigation settlements, a $22.0 million reversal of a prior period assessment relating to the New York State Opioid Stewardship\nAct, $17.9 million of PharMEDium remediation costs, and a $3.0 million LIFO credit in the three months ended December 31,\n2018.\n\u00a0\n 2Includes $0.8 million of employee severance, $24.7 million of litigation and opioid-related costs related to legal fees in\nconnection with opioid lawsuits and investigations, and $13.8 million of other costs in connection with acquisition-related deal\nand integration costs, business transformation efforts, and other restructuring initiatives in the three months ended December\n31, 2019.  Includes $4.8 million of employee severance, $14.5 million of litigation costs related to opioid lawsuits and\ninvestigations, and $21.4 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2018.\n\u00a0\n 3Impairment of finite-lived intangible assets, property and equipment, and right-of-use assets relating to PharMEDium in the\nthree months ended December 31, 2019.\n", "original_text": "Includes an $87.3 million gain from antitrust\nlitigation settlements, a $22.0 million reversal of a prior period assessment relating to the New York State Opioid Stewardship\nAct, $17.9 million of PharMEDium remediation costs, and a $3.0 million LIFO credit in the three months ended December 31,\n2018.\n\u00a0\n", "page_label": "8", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff4ec43f-3185-4206-9869-12e51438f08a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8da477ff6ea90a80edabe166457b1ca0a4dd3cbd7a755218a12c6735d2724ae5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61fce454-f2af-4931-a6f8-54bab198d2bc", "node_type": "1", "metadata": {"window": "Net income \u00a0186,568 \u00a0\u00a00.39% \u00a0391,753 \u00a0\u00a00.86% \u00a0(52.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interest \u00a01,072 \u00a0\u00a0\u00a0 \u00a01,899 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$187,640\u00a0\n\u00a00.39% \u00a0$393,652\u00a0\n\u00a00.87% \u00a0(52.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0$1.86 \u00a0\u00a0\u00a0 \u00a0(51.1)%\nDiluted \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0$1.84 \u00a0\u00a0\u00a0 \u00a0(51.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0212,054 \u00a0\u00a0\u00a0 \u00a0(2.9)%\nDiluted \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0213,969 \u00a0\u00a0\u00a0 \u00a0(3.0)%\n_____________________________________\n1Includes a $13.3 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $7.1 million of\nPharMEDium remediation costs in the three months ended December 31, 2019.  Includes an $87.3 million gain from antitrust\nlitigation settlements, a $22.0 million reversal of a prior period assessment relating to the New York State Opioid Stewardship\nAct, $17.9 million of PharMEDium remediation costs, and a $3.0 million LIFO credit in the three months ended December 31,\n2018.\n\u00a0\n 2Includes $0.8 million of employee severance, $24.7 million of litigation and opioid-related costs related to legal fees in\nconnection with opioid lawsuits and investigations, and $13.8 million of other costs in connection with acquisition-related deal\nand integration costs, business transformation efforts, and other restructuring initiatives in the three months ended December\n31, 2019.  Includes $4.8 million of employee severance, $14.5 million of litigation costs related to opioid lawsuits and\ninvestigations, and $21.4 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2018.\n\u00a0\n", "original_text": "Net income \u00a0186,568 \u00a0\u00a00.39% \u00a0391,753 \u00a0\u00a00.86% \u00a0(52.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interest \u00a01,072 \u00a0\u00a0\u00a0 \u00a01,899 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$187,640\u00a0\n\u00a00.39% \u00a0$393,652\u00a0\n\u00a00.87% \u00a0(52.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0$1.86 \u00a0\u00a0\u00a0 \u00a0(51.1)%\nDiluted \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0$1.84 \u00a0\u00a0\u00a0 \u00a0(51.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0212,054 \u00a0\u00a0\u00a0 \u00a0(2.9)%\nDiluted \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0213,969 \u00a0\u00a0\u00a0 \u00a0(3.0)%\n_____________________________________\n1Includes a $13.3 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $7.1 million of\nPharMEDium remediation costs in the three months ended December 31, 2019. ", "page_label": "8", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93d2da29b74e7736a0b90eb6212b6fefa34cb8d8e17efdf47d284f6258f362fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02dc72fd-dd72-4f35-9a57-a50dee70a689", "node_type": "1", "metadata": {"window": "Net income \u00a0186,568 \u00a0\u00a00.39% \u00a0391,753 \u00a0\u00a00.86% \u00a0(52.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interest \u00a01,072 \u00a0\u00a0\u00a0 \u00a01,899 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$187,640\u00a0\n\u00a00.39% \u00a0$393,652\u00a0\n\u00a00.87% \u00a0(52.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0$1.86 \u00a0\u00a0\u00a0 \u00a0(51.1)%\nDiluted \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0$1.84 \u00a0\u00a0\u00a0 \u00a0(51.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0212,054 \u00a0\u00a0\u00a0 \u00a0(2.9)%\nDiluted \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0213,969 \u00a0\u00a0\u00a0 \u00a0(3.0)%\n_____________________________________\n1Includes a $13.3 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $7.1 million of\nPharMEDium remediation costs in the three months ended December 31, 2019.  Includes an $87.3 million gain from antitrust\nlitigation settlements, a $22.0 million reversal of a prior period assessment relating to the New York State Opioid Stewardship\nAct, $17.9 million of PharMEDium remediation costs, and a $3.0 million LIFO credit in the three months ended December 31,\n2018.\n\u00a0\n 2Includes $0.8 million of employee severance, $24.7 million of litigation and opioid-related costs related to legal fees in\nconnection with opioid lawsuits and investigations, and $13.8 million of other costs in connection with acquisition-related deal\nand integration costs, business transformation efforts, and other restructuring initiatives in the three months ended December\n31, 2019.  Includes $4.8 million of employee severance, $14.5 million of litigation costs related to opioid lawsuits and\ninvestigations, and $21.4 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2018.\n\u00a0\n 3Impairment of finite-lived intangible assets, property and equipment, and right-of-use assets relating to PharMEDium in the\nthree months ended December 31, 2019.\n AMERISOURCEBERGEN CORPORATION\n8", "original_text": "2Includes $0.8 million of employee severance, $24.7 million of litigation and opioid-related costs related to legal fees in\nconnection with opioid lawsuits and investigations, and $13.8 million of other costs in connection with acquisition-related deal\nand integration costs, business transformation efforts, and other restructuring initiatives in the three months ended December\n31, 2019. "}, "hash": "2391f639009cb9a26052ab2ecffa5e5a75d68daaf0ef030493ef98a7a419bab4", "class_name": "RelatedNodeInfo"}}, "text": "Includes an $87.3 million gain from antitrust\nlitigation settlements, a $22.0 million reversal of a prior period assessment relating to the New York State Opioid Stewardship\nAct, $17.9 million of PharMEDium remediation costs, and a $3.0 million LIFO credit in the three months ended December 31,\n2018.\n\u00a0\n", "start_char_idx": 782, "end_char_idx": 1086, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02dc72fd-dd72-4f35-9a57-a50dee70a689": {"__data__": {"id_": "02dc72fd-dd72-4f35-9a57-a50dee70a689", "embedding": null, "metadata": {"window": "Net income \u00a0186,568 \u00a0\u00a00.39% \u00a0391,753 \u00a0\u00a00.86% \u00a0(52.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interest \u00a01,072 \u00a0\u00a0\u00a0 \u00a01,899 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$187,640\u00a0\n\u00a00.39% \u00a0$393,652\u00a0\n\u00a00.87% \u00a0(52.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0$1.86 \u00a0\u00a0\u00a0 \u00a0(51.1)%\nDiluted \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0$1.84 \u00a0\u00a0\u00a0 \u00a0(51.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0212,054 \u00a0\u00a0\u00a0 \u00a0(2.9)%\nDiluted \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0213,969 \u00a0\u00a0\u00a0 \u00a0(3.0)%\n_____________________________________\n1Includes a $13.3 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $7.1 million of\nPharMEDium remediation costs in the three months ended December 31, 2019.  Includes an $87.3 million gain from antitrust\nlitigation settlements, a $22.0 million reversal of a prior period assessment relating to the New York State Opioid Stewardship\nAct, $17.9 million of PharMEDium remediation costs, and a $3.0 million LIFO credit in the three months ended December 31,\n2018.\n\u00a0\n 2Includes $0.8 million of employee severance, $24.7 million of litigation and opioid-related costs related to legal fees in\nconnection with opioid lawsuits and investigations, and $13.8 million of other costs in connection with acquisition-related deal\nand integration costs, business transformation efforts, and other restructuring initiatives in the three months ended December\n31, 2019.  Includes $4.8 million of employee severance, $14.5 million of litigation costs related to opioid lawsuits and\ninvestigations, and $21.4 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2018.\n\u00a0\n 3Impairment of finite-lived intangible assets, property and equipment, and right-of-use assets relating to PharMEDium in the\nthree months ended December 31, 2019.\n AMERISOURCEBERGEN CORPORATION\n8", "original_text": "2Includes $0.8 million of employee severance, $24.7 million of litigation and opioid-related costs related to legal fees in\nconnection with opioid lawsuits and investigations, and $13.8 million of other costs in connection with acquisition-related deal\nand integration costs, business transformation efforts, and other restructuring initiatives in the three months ended December\n31, 2019. ", "page_label": "8", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff4ec43f-3185-4206-9869-12e51438f08a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8da477ff6ea90a80edabe166457b1ca0a4dd3cbd7a755218a12c6735d2724ae5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fda072e-32a8-4219-a6c7-ee2d70501069", "node_type": "1", "metadata": {"window": "Net income \u00a0186,568 \u00a0\u00a00.39% \u00a0391,753 \u00a0\u00a00.86% \u00a0(52.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interest \u00a01,072 \u00a0\u00a0\u00a0 \u00a01,899 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$187,640\u00a0\n\u00a00.39% \u00a0$393,652\u00a0\n\u00a00.87% \u00a0(52.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0$1.86 \u00a0\u00a0\u00a0 \u00a0(51.1)%\nDiluted \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0$1.84 \u00a0\u00a0\u00a0 \u00a0(51.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0212,054 \u00a0\u00a0\u00a0 \u00a0(2.9)%\nDiluted \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0213,969 \u00a0\u00a0\u00a0 \u00a0(3.0)%\n_____________________________________\n1Includes a $13.3 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $7.1 million of\nPharMEDium remediation costs in the three months ended December 31, 2019.  Includes an $87.3 million gain from antitrust\nlitigation settlements, a $22.0 million reversal of a prior period assessment relating to the New York State Opioid Stewardship\nAct, $17.9 million of PharMEDium remediation costs, and a $3.0 million LIFO credit in the three months ended December 31,\n2018.\n\u00a0\n 2Includes $0.8 million of employee severance, $24.7 million of litigation and opioid-related costs related to legal fees in\nconnection with opioid lawsuits and investigations, and $13.8 million of other costs in connection with acquisition-related deal\nand integration costs, business transformation efforts, and other restructuring initiatives in the three months ended December\n31, 2019.  Includes $4.8 million of employee severance, $14.5 million of litigation costs related to opioid lawsuits and\ninvestigations, and $21.4 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2018.\n\u00a0\n 3Impairment of finite-lived intangible assets, property and equipment, and right-of-use assets relating to PharMEDium in the\nthree months ended December 31, 2019.\n", "original_text": "Includes an $87.3 million gain from antitrust\nlitigation settlements, a $22.0 million reversal of a prior period assessment relating to the New York State Opioid Stewardship\nAct, $17.9 million of PharMEDium remediation costs, and a $3.0 million LIFO credit in the three months ended December 31,\n2018.\n\u00a0\n", "page_label": "8", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0734454c217636958d40a47ad2062f828929ee1b069f76db6cf4ae3620b963b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e729fc0a-6007-4624-b3e6-50eb00127b17", "node_type": "1", "metadata": {"window": "Net income \u00a0186,568 \u00a0\u00a00.39% \u00a0391,753 \u00a0\u00a00.86% \u00a0(52.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interest \u00a01,072 \u00a0\u00a0\u00a0 \u00a01,899 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$187,640\u00a0\n\u00a00.39% \u00a0$393,652\u00a0\n\u00a00.87% \u00a0(52.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0$1.86 \u00a0\u00a0\u00a0 \u00a0(51.1)%\nDiluted \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0$1.84 \u00a0\u00a0\u00a0 \u00a0(51.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0212,054 \u00a0\u00a0\u00a0 \u00a0(2.9)%\nDiluted \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0213,969 \u00a0\u00a0\u00a0 \u00a0(3.0)%\n_____________________________________\n1Includes a $13.3 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $7.1 million of\nPharMEDium remediation costs in the three months ended December 31, 2019.  Includes an $87.3 million gain from antitrust\nlitigation settlements, a $22.0 million reversal of a prior period assessment relating to the New York State Opioid Stewardship\nAct, $17.9 million of PharMEDium remediation costs, and a $3.0 million LIFO credit in the three months ended December 31,\n2018.\n\u00a0\n 2Includes $0.8 million of employee severance, $24.7 million of litigation and opioid-related costs related to legal fees in\nconnection with opioid lawsuits and investigations, and $13.8 million of other costs in connection with acquisition-related deal\nand integration costs, business transformation efforts, and other restructuring initiatives in the three months ended December\n31, 2019.  Includes $4.8 million of employee severance, $14.5 million of litigation costs related to opioid lawsuits and\ninvestigations, and $21.4 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2018.\n\u00a0\n 3Impairment of finite-lived intangible assets, property and equipment, and right-of-use assets relating to PharMEDium in the\nthree months ended December 31, 2019.\n AMERISOURCEBERGEN CORPORATION\n8", "original_text": "Includes $4.8 million of employee severance, $14.5 million of litigation costs related to opioid lawsuits and\ninvestigations, and $21.4 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2018.\n\u00a0\n"}, "hash": "10fccbd5c4c41a1f53827c633b3d09d775b195e65d92254de6bbec7c2afa8081", "class_name": "RelatedNodeInfo"}}, "text": "2Includes $0.8 million of employee severance, $24.7 million of litigation and opioid-related costs related to legal fees in\nconnection with opioid lawsuits and investigations, and $13.8 million of other costs in connection with acquisition-related deal\nand integration costs, business transformation efforts, and other restructuring initiatives in the three months ended December\n31, 2019. ", "start_char_idx": 1086, "end_char_idx": 1476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e729fc0a-6007-4624-b3e6-50eb00127b17": {"__data__": {"id_": "e729fc0a-6007-4624-b3e6-50eb00127b17", "embedding": null, "metadata": {"window": "Net income \u00a0186,568 \u00a0\u00a00.39% \u00a0391,753 \u00a0\u00a00.86% \u00a0(52.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interest \u00a01,072 \u00a0\u00a0\u00a0 \u00a01,899 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$187,640\u00a0\n\u00a00.39% \u00a0$393,652\u00a0\n\u00a00.87% \u00a0(52.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0$1.86 \u00a0\u00a0\u00a0 \u00a0(51.1)%\nDiluted \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0$1.84 \u00a0\u00a0\u00a0 \u00a0(51.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0212,054 \u00a0\u00a0\u00a0 \u00a0(2.9)%\nDiluted \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0213,969 \u00a0\u00a0\u00a0 \u00a0(3.0)%\n_____________________________________\n1Includes a $13.3 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $7.1 million of\nPharMEDium remediation costs in the three months ended December 31, 2019.  Includes an $87.3 million gain from antitrust\nlitigation settlements, a $22.0 million reversal of a prior period assessment relating to the New York State Opioid Stewardship\nAct, $17.9 million of PharMEDium remediation costs, and a $3.0 million LIFO credit in the three months ended December 31,\n2018.\n\u00a0\n 2Includes $0.8 million of employee severance, $24.7 million of litigation and opioid-related costs related to legal fees in\nconnection with opioid lawsuits and investigations, and $13.8 million of other costs in connection with acquisition-related deal\nand integration costs, business transformation efforts, and other restructuring initiatives in the three months ended December\n31, 2019.  Includes $4.8 million of employee severance, $14.5 million of litigation costs related to opioid lawsuits and\ninvestigations, and $21.4 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2018.\n\u00a0\n 3Impairment of finite-lived intangible assets, property and equipment, and right-of-use assets relating to PharMEDium in the\nthree months ended December 31, 2019.\n AMERISOURCEBERGEN CORPORATION\n8", "original_text": "Includes $4.8 million of employee severance, $14.5 million of litigation costs related to opioid lawsuits and\ninvestigations, and $21.4 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2018.\n\u00a0\n", "page_label": "8", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff4ec43f-3185-4206-9869-12e51438f08a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8da477ff6ea90a80edabe166457b1ca0a4dd3cbd7a755218a12c6735d2724ae5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02dc72fd-dd72-4f35-9a57-a50dee70a689", "node_type": "1", "metadata": {"window": "Net income \u00a0186,568 \u00a0\u00a00.39% \u00a0391,753 \u00a0\u00a00.86% \u00a0(52.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interest \u00a01,072 \u00a0\u00a0\u00a0 \u00a01,899 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$187,640\u00a0\n\u00a00.39% \u00a0$393,652\u00a0\n\u00a00.87% \u00a0(52.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0$1.86 \u00a0\u00a0\u00a0 \u00a0(51.1)%\nDiluted \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0$1.84 \u00a0\u00a0\u00a0 \u00a0(51.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0212,054 \u00a0\u00a0\u00a0 \u00a0(2.9)%\nDiluted \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0213,969 \u00a0\u00a0\u00a0 \u00a0(3.0)%\n_____________________________________\n1Includes a $13.3 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $7.1 million of\nPharMEDium remediation costs in the three months ended December 31, 2019.  Includes an $87.3 million gain from antitrust\nlitigation settlements, a $22.0 million reversal of a prior period assessment relating to the New York State Opioid Stewardship\nAct, $17.9 million of PharMEDium remediation costs, and a $3.0 million LIFO credit in the three months ended December 31,\n2018.\n\u00a0\n 2Includes $0.8 million of employee severance, $24.7 million of litigation and opioid-related costs related to legal fees in\nconnection with opioid lawsuits and investigations, and $13.8 million of other costs in connection with acquisition-related deal\nand integration costs, business transformation efforts, and other restructuring initiatives in the three months ended December\n31, 2019.  Includes $4.8 million of employee severance, $14.5 million of litigation costs related to opioid lawsuits and\ninvestigations, and $21.4 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2018.\n\u00a0\n 3Impairment of finite-lived intangible assets, property and equipment, and right-of-use assets relating to PharMEDium in the\nthree months ended December 31, 2019.\n AMERISOURCEBERGEN CORPORATION\n8", "original_text": "2Includes $0.8 million of employee severance, $24.7 million of litigation and opioid-related costs related to legal fees in\nconnection with opioid lawsuits and investigations, and $13.8 million of other costs in connection with acquisition-related deal\nand integration costs, business transformation efforts, and other restructuring initiatives in the three months ended December\n31, 2019. ", "page_label": "8", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b4ad6ffc5774181be288b9a083eb18fc0bd77c7f05d8548a8a9c1f9dab1c0e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16926dcc-ae2c-484e-bf58-ff52cabc2fee", "node_type": "1", "metadata": {"window": "Includes an $87.3 million gain from antitrust\nlitigation settlements, a $22.0 million reversal of a prior period assessment relating to the New York State Opioid Stewardship\nAct, $17.9 million of PharMEDium remediation costs, and a $3.0 million LIFO credit in the three months ended December 31,\n2018.\n\u00a0\n 2Includes $0.8 million of employee severance, $24.7 million of litigation and opioid-related costs related to legal fees in\nconnection with opioid lawsuits and investigations, and $13.8 million of other costs in connection with acquisition-related deal\nand integration costs, business transformation efforts, and other restructuring initiatives in the three months ended December\n31, 2019.  Includes $4.8 million of employee severance, $14.5 million of litigation costs related to opioid lawsuits and\ninvestigations, and $21.4 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2018.\n\u00a0\n 3Impairment of finite-lived intangible assets, property and equipment, and right-of-use assets relating to PharMEDium in the\nthree months ended December 31, 2019.\n AMERISOURCEBERGEN CORPORATION\n8", "original_text": "3Impairment of finite-lived intangible assets, property and equipment, and right-of-use assets relating to PharMEDium in the\nthree months ended December 31, 2019.\n"}, "hash": "4a513fcd7a00efb2ad8f486455e3a61340ef93e5c447a89970cf6ef17e3049c3", "class_name": "RelatedNodeInfo"}}, "text": "Includes $4.8 million of employee severance, $14.5 million of litigation costs related to opioid lawsuits and\ninvestigations, and $21.4 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2018.\n\u00a0\n", "start_char_idx": 1476, "end_char_idx": 1818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16926dcc-ae2c-484e-bf58-ff52cabc2fee": {"__data__": {"id_": "16926dcc-ae2c-484e-bf58-ff52cabc2fee", "embedding": null, "metadata": {"window": "Includes an $87.3 million gain from antitrust\nlitigation settlements, a $22.0 million reversal of a prior period assessment relating to the New York State Opioid Stewardship\nAct, $17.9 million of PharMEDium remediation costs, and a $3.0 million LIFO credit in the three months ended December 31,\n2018.\n\u00a0\n 2Includes $0.8 million of employee severance, $24.7 million of litigation and opioid-related costs related to legal fees in\nconnection with opioid lawsuits and investigations, and $13.8 million of other costs in connection with acquisition-related deal\nand integration costs, business transformation efforts, and other restructuring initiatives in the three months ended December\n31, 2019.  Includes $4.8 million of employee severance, $14.5 million of litigation costs related to opioid lawsuits and\ninvestigations, and $21.4 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2018.\n\u00a0\n 3Impairment of finite-lived intangible assets, property and equipment, and right-of-use assets relating to PharMEDium in the\nthree months ended December 31, 2019.\n AMERISOURCEBERGEN CORPORATION\n8", "original_text": "3Impairment of finite-lived intangible assets, property and equipment, and right-of-use assets relating to PharMEDium in the\nthree months ended December 31, 2019.\n", "page_label": "8", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff4ec43f-3185-4206-9869-12e51438f08a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8da477ff6ea90a80edabe166457b1ca0a4dd3cbd7a755218a12c6735d2724ae5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e729fc0a-6007-4624-b3e6-50eb00127b17", "node_type": "1", "metadata": {"window": "Net income \u00a0186,568 \u00a0\u00a00.39% \u00a0391,753 \u00a0\u00a00.86% \u00a0(52.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interest \u00a01,072 \u00a0\u00a0\u00a0 \u00a01,899 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$187,640\u00a0\n\u00a00.39% \u00a0$393,652\u00a0\n\u00a00.87% \u00a0(52.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0$1.86 \u00a0\u00a0\u00a0 \u00a0(51.1)%\nDiluted \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0$1.84 \u00a0\u00a0\u00a0 \u00a0(51.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0212,054 \u00a0\u00a0\u00a0 \u00a0(2.9)%\nDiluted \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0213,969 \u00a0\u00a0\u00a0 \u00a0(3.0)%\n_____________________________________\n1Includes a $13.3 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $7.1 million of\nPharMEDium remediation costs in the three months ended December 31, 2019.  Includes an $87.3 million gain from antitrust\nlitigation settlements, a $22.0 million reversal of a prior period assessment relating to the New York State Opioid Stewardship\nAct, $17.9 million of PharMEDium remediation costs, and a $3.0 million LIFO credit in the three months ended December 31,\n2018.\n\u00a0\n 2Includes $0.8 million of employee severance, $24.7 million of litigation and opioid-related costs related to legal fees in\nconnection with opioid lawsuits and investigations, and $13.8 million of other costs in connection with acquisition-related deal\nand integration costs, business transformation efforts, and other restructuring initiatives in the three months ended December\n31, 2019.  Includes $4.8 million of employee severance, $14.5 million of litigation costs related to opioid lawsuits and\ninvestigations, and $21.4 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2018.\n\u00a0\n 3Impairment of finite-lived intangible assets, property and equipment, and right-of-use assets relating to PharMEDium in the\nthree months ended December 31, 2019.\n AMERISOURCEBERGEN CORPORATION\n8", "original_text": "Includes $4.8 million of employee severance, $14.5 million of litigation costs related to opioid lawsuits and\ninvestigations, and $21.4 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2018.\n\u00a0\n", "page_label": "8", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2f3d2181937bf8060c47340f693346be86a1e87c8fe6044c1e4736c7913aab9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6eac4261-997d-4778-82bb-bd8ae883340e", "node_type": "1", "metadata": {"window": "2Includes $0.8 million of employee severance, $24.7 million of litigation and opioid-related costs related to legal fees in\nconnection with opioid lawsuits and investigations, and $13.8 million of other costs in connection with acquisition-related deal\nand integration costs, business transformation efforts, and other restructuring initiatives in the three months ended December\n31, 2019.  Includes $4.8 million of employee severance, $14.5 million of litigation costs related to opioid lawsuits and\ninvestigations, and $21.4 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2018.\n\u00a0\n 3Impairment of finite-lived intangible assets, property and equipment, and right-of-use assets relating to PharMEDium in the\nthree months ended December 31, 2019.\n AMERISOURCEBERGEN CORPORATION\n8", "original_text": "AMERISOURCEBERGEN CORPORATION\n8"}, "hash": "933b38c02f250825301af28111f3e19ee641108dddf87c89dddcda904043bc5a", "class_name": "RelatedNodeInfo"}}, "text": "3Impairment of finite-lived intangible assets, property and equipment, and right-of-use assets relating to PharMEDium in the\nthree months ended December 31, 2019.\n", "start_char_idx": 1818, "end_char_idx": 1981, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6eac4261-997d-4778-82bb-bd8ae883340e": {"__data__": {"id_": "6eac4261-997d-4778-82bb-bd8ae883340e", "embedding": null, "metadata": {"window": "2Includes $0.8 million of employee severance, $24.7 million of litigation and opioid-related costs related to legal fees in\nconnection with opioid lawsuits and investigations, and $13.8 million of other costs in connection with acquisition-related deal\nand integration costs, business transformation efforts, and other restructuring initiatives in the three months ended December\n31, 2019.  Includes $4.8 million of employee severance, $14.5 million of litigation costs related to opioid lawsuits and\ninvestigations, and $21.4 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2018.\n\u00a0\n 3Impairment of finite-lived intangible assets, property and equipment, and right-of-use assets relating to PharMEDium in the\nthree months ended December 31, 2019.\n AMERISOURCEBERGEN CORPORATION\n8", "original_text": "AMERISOURCEBERGEN CORPORATION\n8", "page_label": "8", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff4ec43f-3185-4206-9869-12e51438f08a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8da477ff6ea90a80edabe166457b1ca0a4dd3cbd7a755218a12c6735d2724ae5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16926dcc-ae2c-484e-bf58-ff52cabc2fee", "node_type": "1", "metadata": {"window": "Includes an $87.3 million gain from antitrust\nlitigation settlements, a $22.0 million reversal of a prior period assessment relating to the New York State Opioid Stewardship\nAct, $17.9 million of PharMEDium remediation costs, and a $3.0 million LIFO credit in the three months ended December 31,\n2018.\n\u00a0\n 2Includes $0.8 million of employee severance, $24.7 million of litigation and opioid-related costs related to legal fees in\nconnection with opioid lawsuits and investigations, and $13.8 million of other costs in connection with acquisition-related deal\nand integration costs, business transformation efforts, and other restructuring initiatives in the three months ended December\n31, 2019.  Includes $4.8 million of employee severance, $14.5 million of litigation costs related to opioid lawsuits and\ninvestigations, and $21.4 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2018.\n\u00a0\n 3Impairment of finite-lived intangible assets, property and equipment, and right-of-use assets relating to PharMEDium in the\nthree months ended December 31, 2019.\n AMERISOURCEBERGEN CORPORATION\n8", "original_text": "3Impairment of finite-lived intangible assets, property and equipment, and right-of-use assets relating to PharMEDium in the\nthree months ended December 31, 2019.\n", "page_label": "8", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2152c16eb878a3612945d7e19b94191d2e17caff357c6dc4a524e80b2f2b7ece", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5236aa6-5de0-4bdf-ae4f-765bb25e39de", "node_type": "1", "metadata": {"window": "GAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,231,214 \u00a0\u00a0$967,777 \u00a0\u00a0$263,437 \u00a0\u00a0$229,588 \u00a0\u00a0$43,020 \u00a0\u00a0$1,072 \u00a0\u00a0$187,640 \u00a0\u00a0$0.90 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,492 )\u00a0\u2014\u00a0\n\u00a0(8,492 )\u00a0(8,492 )\u00a0(1,974 )\u00a0\u2014\u00a0\n\u00a0(6,518 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a013,281 \u00a0\u00a0\u2014 \u00a0\u00a013,281 \u00a0\u00a013,281 \u00a0\u00a03,087 \u00a0\u00a0\u2014 \u00a0\u00a010,194 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a07,135\u00a0\n\u00a0(9,030 )\u00a016,165\u00a0\n\u00a016,165\u00a0\n\u00a03,757\u00a0\n\u00a0\u2014\u00a0\n\u00a012,408\u00a0\n\u00a00.06\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(33,566 )\u00a033,566\u00a0\n\u00a033,566\u00a0\n\u00a07,801\u00a0\n\u00a0(436 )\u00a025,329\u00a0\n\u00a00.12\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(39,309 )\u00a039,309\u00a0\n\u00a039,309\u00a0\n\u00a09,136\u00a0\n\u00a0\u2014\u00a0\n\u00a030,173\u00a0\n\u00a00.15\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nlong-lived\nassets \u00a0\u2014\u00a0\n\u00a0(138,000 )\u00a0138,000\u00a0\n\u00a0138,000\u00a0\n\u00a032,071\u00a0\n\u00a0\u2014\u00a0\n\u00a0105,929\u00a0\n\u00a00.51\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "original_text": "GAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,231,214 \u00a0\u00a0$967,777 \u00a0\u00a0$263,437 \u00a0\u00a0$229,588 \u00a0\u00a0$43,020 \u00a0\u00a0$1,072 \u00a0\u00a0$187,640 \u00a0\u00a0$0.90 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,492 )\u00a0\u2014\u00a0\n\u00a0(8,492 )\u00a0(8,492 )\u00a0(1,974 )\u00a0\u2014\u00a0\n\u00a0(6,518 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a013,281 \u00a0\u00a0\u2014 \u00a0\u00a013,281 \u00a0\u00a013,281 \u00a0\u00a03,087 \u00a0\u00a0\u2014 \u00a0\u00a010,194 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a07,135\u00a0\n\u00a0(9,030 )\u00a016,165\u00a0\n\u00a016,165\u00a0\n\u00a03,757\u00a0\n\u00a0\u2014\u00a0\n\u00a012,408\u00a0\n\u00a00.06\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(33,566 )\u00a033,566\u00a0\n\u00a033,566\u00a0\n\u00a07,801\u00a0\n\u00a0(436 )\u00a025,329\u00a0\n\u00a00.12\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(39,309 )\u00a039,309\u00a0\n\u00a039,309\u00a0\n\u00a09,136\u00a0\n\u00a0\u2014\u00a0\n\u00a030,173\u00a0\n\u00a00.15\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nlong-lived\nassets \u00a0\u2014\u00a0\n\u00a0(138,000 )\u00a0138,000\u00a0\n\u00a0138,000\u00a0\n\u00a032,071\u00a0\n\u00a0\u2014\u00a0\n\u00a0105,929\u00a0\n\u00a00.51\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9"}, "hash": "1ba2c5a3f7f616b3ecd4128371f9bd71d25a794325d380fdb367b5197323b475", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\n8", "start_char_idx": 1981, "end_char_idx": 2012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5236aa6-5de0-4bdf-ae4f-765bb25e39de": {"__data__": {"id_": "d5236aa6-5de0-4bdf-ae4f-765bb25e39de", "embedding": null, "metadata": {"window": "GAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,231,214 \u00a0\u00a0$967,777 \u00a0\u00a0$263,437 \u00a0\u00a0$229,588 \u00a0\u00a0$43,020 \u00a0\u00a0$1,072 \u00a0\u00a0$187,640 \u00a0\u00a0$0.90 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,492 )\u00a0\u2014\u00a0\n\u00a0(8,492 )\u00a0(8,492 )\u00a0(1,974 )\u00a0\u2014\u00a0\n\u00a0(6,518 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a013,281 \u00a0\u00a0\u2014 \u00a0\u00a013,281 \u00a0\u00a013,281 \u00a0\u00a03,087 \u00a0\u00a0\u2014 \u00a0\u00a010,194 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a07,135\u00a0\n\u00a0(9,030 )\u00a016,165\u00a0\n\u00a016,165\u00a0\n\u00a03,757\u00a0\n\u00a0\u2014\u00a0\n\u00a012,408\u00a0\n\u00a00.06\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(33,566 )\u00a033,566\u00a0\n\u00a033,566\u00a0\n\u00a07,801\u00a0\n\u00a0(436 )\u00a025,329\u00a0\n\u00a00.12\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(39,309 )\u00a039,309\u00a0\n\u00a039,309\u00a0\n\u00a09,136\u00a0\n\u00a0\u2014\u00a0\n\u00a030,173\u00a0\n\u00a00.15\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nlong-lived\nassets \u00a0\u2014\u00a0\n\u00a0(138,000 )\u00a0138,000\u00a0\n\u00a0138,000\u00a0\n\u00a032,071\u00a0\n\u00a0\u2014\u00a0\n\u00a0105,929\u00a0\n\u00a00.51\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "original_text": "GAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,231,214 \u00a0\u00a0$967,777 \u00a0\u00a0$263,437 \u00a0\u00a0$229,588 \u00a0\u00a0$43,020 \u00a0\u00a0$1,072 \u00a0\u00a0$187,640 \u00a0\u00a0$0.90 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,492 )\u00a0\u2014\u00a0\n\u00a0(8,492 )\u00a0(8,492 )\u00a0(1,974 )\u00a0\u2014\u00a0\n\u00a0(6,518 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a013,281 \u00a0\u00a0\u2014 \u00a0\u00a013,281 \u00a0\u00a013,281 \u00a0\u00a03,087 \u00a0\u00a0\u2014 \u00a0\u00a010,194 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a07,135\u00a0\n\u00a0(9,030 )\u00a016,165\u00a0\n\u00a016,165\u00a0\n\u00a03,757\u00a0\n\u00a0\u2014\u00a0\n\u00a012,408\u00a0\n\u00a00.06\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(33,566 )\u00a033,566\u00a0\n\u00a033,566\u00a0\n\u00a07,801\u00a0\n\u00a0(436 )\u00a025,329\u00a0\n\u00a00.12\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(39,309 )\u00a039,309\u00a0\n\u00a039,309\u00a0\n\u00a09,136\u00a0\n\u00a0\u2014\u00a0\n\u00a030,173\u00a0\n\u00a00.15\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nlong-lived\nassets \u00a0\u2014\u00a0\n\u00a0(138,000 )\u00a0138,000\u00a0\n\u00a0138,000\u00a0\n\u00a032,071\u00a0\n\u00a0\u2014\u00a0\n\u00a0105,929\u00a0\n\u00a00.51\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "page_label": "9", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "695df1ff-c27d-4015-ab41-0b563338101c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fd4b0843261886c812ceae835d9822ea264d29a9f2f8c71c8c001487b4dacaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6eac4261-997d-4778-82bb-bd8ae883340e", "node_type": "1", "metadata": {"window": "2Includes $0.8 million of employee severance, $24.7 million of litigation and opioid-related costs related to legal fees in\nconnection with opioid lawsuits and investigations, and $13.8 million of other costs in connection with acquisition-related deal\nand integration costs, business transformation efforts, and other restructuring initiatives in the three months ended December\n31, 2019.  Includes $4.8 million of employee severance, $14.5 million of litigation costs related to opioid lawsuits and\ninvestigations, and $21.4 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2018.\n\u00a0\n 3Impairment of finite-lived intangible assets, property and equipment, and right-of-use assets relating to PharMEDium in the\nthree months ended December 31, 2019.\n AMERISOURCEBERGEN CORPORATION\n8", "original_text": "AMERISOURCEBERGEN CORPORATION\n8", "page_label": "8", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df44d233bd970edc8f71a31062aa07890c6afaf6daf0ffab2788344eb3598514", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e0cca3e-44d0-4be8-9cb2-4c954589d5e9", "node_type": "1", "metadata": {"window": "Adjusted Non-\nGAAP \u00a0$1,243,138\u00a0\n\u00a0$747,872\u00a0\n\u00a0$495,266\u00a0\n\u00a0$461,417\u00a0\n\u00a0$96,898\u00a0\n\u00a0$636\u00a0\n\u00a0$365,155\u00a0\n\u00a0$1.76\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nperiod \u00a03.3 %\u00a02.3 %\u00a05.0 %\u00a08.2 %\u00a014.1 %\u00a0\u00a0 \u00a06.4 %\u00a010.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.57% \u00a02.60%\nOperating expenses \u00a02.02% \u00a01.56%\nOperating income \u00a00.55% \u00a01.03%\n_____________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2018 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,297,580 \u00a0\u00a0$819,757 \u00a0\u00a0$477,823 \u00a0\u00a0$432,556 \u00a0\u00a0$40,803 \u00a0\u00a0$1,899 \u00a0\u00a0$393,652 \u00a0\u00a0$1.84 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from antitrust \u00a0 \u00a0\n10", "original_text": "Adjusted Non-\nGAAP \u00a0$1,243,138\u00a0\n\u00a0$747,872\u00a0\n\u00a0$495,266\u00a0\n\u00a0$461,417\u00a0\n\u00a0$96,898\u00a0\n\u00a0$636\u00a0\n\u00a0$365,155\u00a0\n\u00a0$1.76\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n"}, "hash": "7eb761b89ad4facf67ffbf558e56614c025c7eb644de7ce0720130d761993662", "class_name": "RelatedNodeInfo"}}, "text": "GAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,231,214 \u00a0\u00a0$967,777 \u00a0\u00a0$263,437 \u00a0\u00a0$229,588 \u00a0\u00a0$43,020 \u00a0\u00a0$1,072 \u00a0\u00a0$187,640 \u00a0\u00a0$0.90 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,492 )\u00a0\u2014\u00a0\n\u00a0(8,492 )\u00a0(8,492 )\u00a0(1,974 )\u00a0\u2014\u00a0\n\u00a0(6,518 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a013,281 \u00a0\u00a0\u2014 \u00a0\u00a013,281 \u00a0\u00a013,281 \u00a0\u00a03,087 \u00a0\u00a0\u2014 \u00a0\u00a010,194 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a07,135\u00a0\n\u00a0(9,030 )\u00a016,165\u00a0\n\u00a016,165\u00a0\n\u00a03,757\u00a0\n\u00a0\u2014\u00a0\n\u00a012,408\u00a0\n\u00a00.06\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(33,566 )\u00a033,566\u00a0\n\u00a033,566\u00a0\n\u00a07,801\u00a0\n\u00a0(436 )\u00a025,329\u00a0\n\u00a00.12\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(39,309 )\u00a039,309\u00a0\n\u00a039,309\u00a0\n\u00a09,136\u00a0\n\u00a0\u2014\u00a0\n\u00a030,173\u00a0\n\u00a00.15\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nlong-lived\nassets \u00a0\u2014\u00a0\n\u00a0(138,000 )\u00a0138,000\u00a0\n\u00a0138,000\u00a0\n\u00a032,071\u00a0\n\u00a0\u2014\u00a0\n\u00a0105,929\u00a0\n\u00a00.51\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "start_char_idx": 0, "end_char_idx": 1235, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e0cca3e-44d0-4be8-9cb2-4c954589d5e9": {"__data__": {"id_": "9e0cca3e-44d0-4be8-9cb2-4c954589d5e9", "embedding": null, "metadata": {"window": "Adjusted Non-\nGAAP \u00a0$1,243,138\u00a0\n\u00a0$747,872\u00a0\n\u00a0$495,266\u00a0\n\u00a0$461,417\u00a0\n\u00a0$96,898\u00a0\n\u00a0$636\u00a0\n\u00a0$365,155\u00a0\n\u00a0$1.76\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nperiod \u00a03.3 %\u00a02.3 %\u00a05.0 %\u00a08.2 %\u00a014.1 %\u00a0\u00a0 \u00a06.4 %\u00a010.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.57% \u00a02.60%\nOperating expenses \u00a02.02% \u00a01.56%\nOperating income \u00a00.55% \u00a01.03%\n_____________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2018 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,297,580 \u00a0\u00a0$819,757 \u00a0\u00a0$477,823 \u00a0\u00a0$432,556 \u00a0\u00a0$40,803 \u00a0\u00a0$1,899 \u00a0\u00a0$393,652 \u00a0\u00a0$1.84 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from antitrust \u00a0 \u00a0\n10", "original_text": "Adjusted Non-\nGAAP \u00a0$1,243,138\u00a0\n\u00a0$747,872\u00a0\n\u00a0$495,266\u00a0\n\u00a0$461,417\u00a0\n\u00a0$96,898\u00a0\n\u00a0$636\u00a0\n\u00a0$365,155\u00a0\n\u00a0$1.76\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "page_label": "10", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e84d20e8-2fad-4c78-a41a-fe1d76b8982b", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f693186efaeac7baf726056e14a3a6b017d7690f2ae25d80a957c5a022b3677", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5236aa6-5de0-4bdf-ae4f-765bb25e39de", "node_type": "1", "metadata": {"window": "GAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,231,214 \u00a0\u00a0$967,777 \u00a0\u00a0$263,437 \u00a0\u00a0$229,588 \u00a0\u00a0$43,020 \u00a0\u00a0$1,072 \u00a0\u00a0$187,640 \u00a0\u00a0$0.90 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,492 )\u00a0\u2014\u00a0\n\u00a0(8,492 )\u00a0(8,492 )\u00a0(1,974 )\u00a0\u2014\u00a0\n\u00a0(6,518 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a013,281 \u00a0\u00a0\u2014 \u00a0\u00a013,281 \u00a0\u00a013,281 \u00a0\u00a03,087 \u00a0\u00a0\u2014 \u00a0\u00a010,194 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a07,135\u00a0\n\u00a0(9,030 )\u00a016,165\u00a0\n\u00a016,165\u00a0\n\u00a03,757\u00a0\n\u00a0\u2014\u00a0\n\u00a012,408\u00a0\n\u00a00.06\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(33,566 )\u00a033,566\u00a0\n\u00a033,566\u00a0\n\u00a07,801\u00a0\n\u00a0(436 )\u00a025,329\u00a0\n\u00a00.12\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(39,309 )\u00a039,309\u00a0\n\u00a039,309\u00a0\n\u00a09,136\u00a0\n\u00a0\u2014\u00a0\n\u00a030,173\u00a0\n\u00a00.15\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nlong-lived\nassets \u00a0\u2014\u00a0\n\u00a0(138,000 )\u00a0138,000\u00a0\n\u00a0138,000\u00a0\n\u00a032,071\u00a0\n\u00a0\u2014\u00a0\n\u00a0105,929\u00a0\n\u00a00.51\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "original_text": "GAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,231,214 \u00a0\u00a0$967,777 \u00a0\u00a0$263,437 \u00a0\u00a0$229,588 \u00a0\u00a0$43,020 \u00a0\u00a0$1,072 \u00a0\u00a0$187,640 \u00a0\u00a0$0.90 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,492 )\u00a0\u2014\u00a0\n\u00a0(8,492 )\u00a0(8,492 )\u00a0(1,974 )\u00a0\u2014\u00a0\n\u00a0(6,518 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a013,281 \u00a0\u00a0\u2014 \u00a0\u00a013,281 \u00a0\u00a013,281 \u00a0\u00a03,087 \u00a0\u00a0\u2014 \u00a0\u00a010,194 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a07,135\u00a0\n\u00a0(9,030 )\u00a016,165\u00a0\n\u00a016,165\u00a0\n\u00a03,757\u00a0\n\u00a0\u2014\u00a0\n\u00a012,408\u00a0\n\u00a00.06\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(33,566 )\u00a033,566\u00a0\n\u00a033,566\u00a0\n\u00a07,801\u00a0\n\u00a0(436 )\u00a025,329\u00a0\n\u00a00.12\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(39,309 )\u00a039,309\u00a0\n\u00a039,309\u00a0\n\u00a09,136\u00a0\n\u00a0\u2014\u00a0\n\u00a030,173\u00a0\n\u00a00.15\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nlong-lived\nassets \u00a0\u2014\u00a0\n\u00a0(138,000 )\u00a0138,000\u00a0\n\u00a0138,000\u00a0\n\u00a032,071\u00a0\n\u00a0\u2014\u00a0\n\u00a0105,929\u00a0\n\u00a00.51\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "page_label": "9", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ab6387f477fff2e9551df124cd01cdb6e91ca0e87d718f5664365aec9dad9ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89ce199f-0986-4ea7-8a8d-4a761321bc78", "node_type": "1", "metadata": {"window": "Adjusted Non-\nGAAP \u00a0$1,243,138\u00a0\n\u00a0$747,872\u00a0\n\u00a0$495,266\u00a0\n\u00a0$461,417\u00a0\n\u00a0$96,898\u00a0\n\u00a0$636\u00a0\n\u00a0$365,155\u00a0\n\u00a0$1.76\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nperiod \u00a03.3 %\u00a02.3 %\u00a05.0 %\u00a08.2 %\u00a014.1 %\u00a0\u00a0 \u00a06.4 %\u00a010.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.57% \u00a02.60%\nOperating expenses \u00a02.02% \u00a01.56%\nOperating income \u00a00.55% \u00a01.03%\n_____________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2018 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,297,580 \u00a0\u00a0$819,757 \u00a0\u00a0$477,823 \u00a0\u00a0$432,556 \u00a0\u00a0$40,803 \u00a0\u00a0$1,899 \u00a0\u00a0$393,652 \u00a0\u00a0$1.84 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from antitrust \u00a0 \u00a0\n10", "original_text": "prior year\nperiod \u00a03.3 %\u00a02.3 %\u00a05.0 %\u00a08.2 %\u00a014.1 %\u00a0\u00a0 \u00a06.4 %\u00a010.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.57% \u00a02.60%\nOperating expenses \u00a02.02% \u00a01.56%\nOperating income \u00a00.55% \u00a01.03%\n_____________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "f87181a5069fbf5301e5caac747e4ac64e9d32973937eb54f0ad4b6752cfd41c", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Non-\nGAAP \u00a0$1,243,138\u00a0\n\u00a0$747,872\u00a0\n\u00a0$495,266\u00a0\n\u00a0$461,417\u00a0\n\u00a0$96,898\u00a0\n\u00a0$636\u00a0\n\u00a0$365,155\u00a0\n\u00a0$1.76\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "start_char_idx": 0, "end_char_idx": 163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89ce199f-0986-4ea7-8a8d-4a761321bc78": {"__data__": {"id_": "89ce199f-0986-4ea7-8a8d-4a761321bc78", "embedding": null, "metadata": {"window": "Adjusted Non-\nGAAP \u00a0$1,243,138\u00a0\n\u00a0$747,872\u00a0\n\u00a0$495,266\u00a0\n\u00a0$461,417\u00a0\n\u00a0$96,898\u00a0\n\u00a0$636\u00a0\n\u00a0$365,155\u00a0\n\u00a0$1.76\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nperiod \u00a03.3 %\u00a02.3 %\u00a05.0 %\u00a08.2 %\u00a014.1 %\u00a0\u00a0 \u00a06.4 %\u00a010.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.57% \u00a02.60%\nOperating expenses \u00a02.02% \u00a01.56%\nOperating income \u00a00.55% \u00a01.03%\n_____________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2018 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,297,580 \u00a0\u00a0$819,757 \u00a0\u00a0$477,823 \u00a0\u00a0$432,556 \u00a0\u00a0$40,803 \u00a0\u00a0$1,899 \u00a0\u00a0$393,652 \u00a0\u00a0$1.84 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from antitrust \u00a0 \u00a0\n10", "original_text": "prior year\nperiod \u00a03.3 %\u00a02.3 %\u00a05.0 %\u00a08.2 %\u00a014.1 %\u00a0\u00a0 \u00a06.4 %\u00a010.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.57% \u00a02.60%\nOperating expenses \u00a02.02% \u00a01.56%\nOperating income \u00a00.55% \u00a01.03%\n_____________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "10", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e84d20e8-2fad-4c78-a41a-fe1d76b8982b", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f693186efaeac7baf726056e14a3a6b017d7690f2ae25d80a957c5a022b3677", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e0cca3e-44d0-4be8-9cb2-4c954589d5e9", "node_type": "1", "metadata": {"window": "Adjusted Non-\nGAAP \u00a0$1,243,138\u00a0\n\u00a0$747,872\u00a0\n\u00a0$495,266\u00a0\n\u00a0$461,417\u00a0\n\u00a0$96,898\u00a0\n\u00a0$636\u00a0\n\u00a0$365,155\u00a0\n\u00a0$1.76\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nperiod \u00a03.3 %\u00a02.3 %\u00a05.0 %\u00a08.2 %\u00a014.1 %\u00a0\u00a0 \u00a06.4 %\u00a010.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.57% \u00a02.60%\nOperating expenses \u00a02.02% \u00a01.56%\nOperating income \u00a00.55% \u00a01.03%\n_____________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2018 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,297,580 \u00a0\u00a0$819,757 \u00a0\u00a0$477,823 \u00a0\u00a0$432,556 \u00a0\u00a0$40,803 \u00a0\u00a0$1,899 \u00a0\u00a0$393,652 \u00a0\u00a0$1.84 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from antitrust \u00a0 \u00a0\n10", "original_text": "Adjusted Non-\nGAAP \u00a0$1,243,138\u00a0\n\u00a0$747,872\u00a0\n\u00a0$495,266\u00a0\n\u00a0$461,417\u00a0\n\u00a0$96,898\u00a0\n\u00a0$636\u00a0\n\u00a0$365,155\u00a0\n\u00a0$1.76\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "page_label": "10", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b91a8d182e0597dfd03b8a21f178632990d6d590f84028c1acc65ee3db53ead", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99dfbb03-be4e-476e-bb86-f58c24d06615", "node_type": "1", "metadata": {"window": "Adjusted Non-\nGAAP \u00a0$1,243,138\u00a0\n\u00a0$747,872\u00a0\n\u00a0$495,266\u00a0\n\u00a0$461,417\u00a0\n\u00a0$96,898\u00a0\n\u00a0$636\u00a0\n\u00a0$365,155\u00a0\n\u00a0$1.76\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nperiod \u00a03.3 %\u00a02.3 %\u00a05.0 %\u00a08.2 %\u00a014.1 %\u00a0\u00a0 \u00a06.4 %\u00a010.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.57% \u00a02.60%\nOperating expenses \u00a02.02% \u00a01.56%\nOperating income \u00a00.55% \u00a01.03%\n_____________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2018 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,297,580 \u00a0\u00a0$819,757 \u00a0\u00a0$477,823 \u00a0\u00a0$432,556 \u00a0\u00a0$40,803 \u00a0\u00a0$1,899 \u00a0\u00a0$393,652 \u00a0\u00a0$1.84 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from antitrust \u00a0 \u00a0\n10", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2018 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,297,580 \u00a0\u00a0$819,757 \u00a0\u00a0$477,823 \u00a0\u00a0$432,556 \u00a0\u00a0$40,803 \u00a0\u00a0$1,899 \u00a0\u00a0$393,652 \u00a0\u00a0$1.84 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from antitrust \u00a0 \u00a0\n10"}, "hash": "462d277253a2663bf700ea5daa62e084eb6f95e54e4f8f8e962836a244394a38", "class_name": "RelatedNodeInfo"}}, "text": "prior year\nperiod \u00a03.3 %\u00a02.3 %\u00a05.0 %\u00a08.2 %\u00a014.1 %\u00a0\u00a0 \u00a06.4 %\u00a010.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.57% \u00a02.60%\nOperating expenses \u00a02.02% \u00a01.56%\nOperating income \u00a00.55% \u00a01.03%\n_____________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 163, "end_char_idx": 589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99dfbb03-be4e-476e-bb86-f58c24d06615": {"__data__": {"id_": "99dfbb03-be4e-476e-bb86-f58c24d06615", "embedding": null, "metadata": {"window": "Adjusted Non-\nGAAP \u00a0$1,243,138\u00a0\n\u00a0$747,872\u00a0\n\u00a0$495,266\u00a0\n\u00a0$461,417\u00a0\n\u00a0$96,898\u00a0\n\u00a0$636\u00a0\n\u00a0$365,155\u00a0\n\u00a0$1.76\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nperiod \u00a03.3 %\u00a02.3 %\u00a05.0 %\u00a08.2 %\u00a014.1 %\u00a0\u00a0 \u00a06.4 %\u00a010.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.57% \u00a02.60%\nOperating expenses \u00a02.02% \u00a01.56%\nOperating income \u00a00.55% \u00a01.03%\n_____________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2018 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,297,580 \u00a0\u00a0$819,757 \u00a0\u00a0$477,823 \u00a0\u00a0$432,556 \u00a0\u00a0$40,803 \u00a0\u00a0$1,899 \u00a0\u00a0$393,652 \u00a0\u00a0$1.84 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from antitrust \u00a0 \u00a0\n10", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2018 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,297,580 \u00a0\u00a0$819,757 \u00a0\u00a0$477,823 \u00a0\u00a0$432,556 \u00a0\u00a0$40,803 \u00a0\u00a0$1,899 \u00a0\u00a0$393,652 \u00a0\u00a0$1.84 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from antitrust \u00a0 \u00a0\n10", "page_label": "10", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e84d20e8-2fad-4c78-a41a-fe1d76b8982b", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f693186efaeac7baf726056e14a3a6b017d7690f2ae25d80a957c5a022b3677", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89ce199f-0986-4ea7-8a8d-4a761321bc78", "node_type": "1", "metadata": {"window": "Adjusted Non-\nGAAP \u00a0$1,243,138\u00a0\n\u00a0$747,872\u00a0\n\u00a0$495,266\u00a0\n\u00a0$461,417\u00a0\n\u00a0$96,898\u00a0\n\u00a0$636\u00a0\n\u00a0$365,155\u00a0\n\u00a0$1.76\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nperiod \u00a03.3 %\u00a02.3 %\u00a05.0 %\u00a08.2 %\u00a014.1 %\u00a0\u00a0 \u00a06.4 %\u00a010.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.57% \u00a02.60%\nOperating expenses \u00a02.02% \u00a01.56%\nOperating income \u00a00.55% \u00a01.03%\n_____________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2018 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,297,580 \u00a0\u00a0$819,757 \u00a0\u00a0$477,823 \u00a0\u00a0$432,556 \u00a0\u00a0$40,803 \u00a0\u00a0$1,899 \u00a0\u00a0$393,652 \u00a0\u00a0$1.84 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from antitrust \u00a0 \u00a0\n10", "original_text": "prior year\nperiod \u00a03.3 %\u00a02.3 %\u00a05.0 %\u00a08.2 %\u00a014.1 %\u00a0\u00a0 \u00a06.4 %\u00a010.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.57% \u00a02.60%\nOperating expenses \u00a02.02% \u00a01.56%\nOperating income \u00a00.55% \u00a01.03%\n_____________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "10", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3cdf1ac19af04c9fccbcfc6fe2cb777459f3ee4e46ca50c1c79423b861f4159", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71aeb2c3-6bc5-4093-8f1e-71f119ed5b3e", "node_type": "1", "metadata": {"window": "litigation\nsettlements \u00a0(87,279 )\u00a0\u2014 \u00a0(87,279 )\u00a0(87,279 )\u00a0(18,470 )\u00a0\u2014 \u00a0(68,809 )\u00a0(0.32 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(3,029 )\u00a0\u2014 \u00a0\u00a0(3,029 )\u00a0(3,029 )\u00a0(641 )\u00a0\u2014 \u00a0\u00a0(2,388 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation costs \u00a017,911\u00a0\n\u00a0(2,584 )\u00a020,495\u00a0\n\u00a020,495\u00a0\n\u00a04,337\u00a0\n\u00a0\u2014\u00a0\n\u00a016,158\u00a0\n\u00a00.08\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York State\nOpioid Stewardship\nAct \u00a0(22,000 )\u00a0\u2014\u00a0\n\u00a0(22,000 )\u00a0(22,000 )\u00a0(4,656 )\u00a0\u2014\u00a0\n\u00a0(17,344 )\u00a0(0.08 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(45,152 )\u00a045,152\u00a0\n\u00a045,152\u00a0\n\u00a09,555\u00a0\n\u00a0(506 )\u00a035,091\u00a0\n\u00a00.16\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(40,672 )\u00a040,672\u00a0\n\u00a040,672\u00a0\n\u00a016,980\u00a0\n\u00a0\u2014\u00a0\n\u00a023,692\u00a0\n\u00a00.11\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax Reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,203,183\u00a0\n\u00a0$731,349\u00a0\n\u00a0$471,834\u00a0\n\u00a0$426,567\u00a0\n\u00a0$84,905\u00a0\n\u00a0$1,393\u00a0\n\u00a0$343,055\u00a0\n\u00a0$1.60\u00a0\n2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.86% \u00a02.65%\nOperating expenses \u00a01.81% \u00a01.61%\nOperating income \u00a01.05% \u00a01.04%\n_____________________________________\n11", "original_text": "litigation\nsettlements \u00a0(87,279 )\u00a0\u2014 \u00a0(87,279 )\u00a0(87,279 )\u00a0(18,470 )\u00a0\u2014 \u00a0(68,809 )\u00a0(0.32 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(3,029 )\u00a0\u2014 \u00a0\u00a0(3,029 )\u00a0(3,029 )\u00a0(641 )\u00a0\u2014 \u00a0\u00a0(2,388 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation costs \u00a017,911\u00a0\n\u00a0(2,584 )\u00a020,495\u00a0\n\u00a020,495\u00a0\n\u00a04,337\u00a0\n\u00a0\u2014\u00a0\n\u00a016,158\u00a0\n\u00a00.08\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York State\nOpioid Stewardship\nAct \u00a0(22,000 )\u00a0\u2014\u00a0\n\u00a0(22,000 )\u00a0(22,000 )\u00a0(4,656 )\u00a0\u2014\u00a0\n\u00a0(17,344 )\u00a0(0.08 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(45,152 )\u00a045,152\u00a0\n\u00a045,152\u00a0\n\u00a09,555\u00a0\n\u00a0(506 )\u00a035,091\u00a0\n\u00a00.16\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(40,672 )\u00a040,672\u00a0\n\u00a040,672\u00a0\n\u00a016,980\u00a0\n\u00a0\u2014\u00a0\n\u00a023,692\u00a0\n\u00a00.11\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax Reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,203,183\u00a0\n\u00a0$731,349\u00a0\n\u00a0$471,834\u00a0\n\u00a0$426,567\u00a0\n\u00a0$84,905\u00a0\n\u00a0$1,393\u00a0\n\u00a0$343,055\u00a0\n\u00a0$1.60\u00a0\n2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.86% \u00a02.65%\nOperating expenses \u00a01.81% \u00a01.61%\nOperating income \u00a01.05% \u00a01.04%\n_____________________________________\n11"}, "hash": "8da32bd9a981cbb81d8f017ca9c13fa2bace940cd227cf8f047f8de6376a5c85", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2018 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,297,580 \u00a0\u00a0$819,757 \u00a0\u00a0$477,823 \u00a0\u00a0$432,556 \u00a0\u00a0$40,803 \u00a0\u00a0$1,899 \u00a0\u00a0$393,652 \u00a0\u00a0$1.84 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from antitrust \u00a0 \u00a0\n10", "start_char_idx": 589, "end_char_idx": 1117, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71aeb2c3-6bc5-4093-8f1e-71f119ed5b3e": {"__data__": {"id_": "71aeb2c3-6bc5-4093-8f1e-71f119ed5b3e", "embedding": null, "metadata": {"window": "litigation\nsettlements \u00a0(87,279 )\u00a0\u2014 \u00a0(87,279 )\u00a0(87,279 )\u00a0(18,470 )\u00a0\u2014 \u00a0(68,809 )\u00a0(0.32 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(3,029 )\u00a0\u2014 \u00a0\u00a0(3,029 )\u00a0(3,029 )\u00a0(641 )\u00a0\u2014 \u00a0\u00a0(2,388 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation costs \u00a017,911\u00a0\n\u00a0(2,584 )\u00a020,495\u00a0\n\u00a020,495\u00a0\n\u00a04,337\u00a0\n\u00a0\u2014\u00a0\n\u00a016,158\u00a0\n\u00a00.08\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York State\nOpioid Stewardship\nAct \u00a0(22,000 )\u00a0\u2014\u00a0\n\u00a0(22,000 )\u00a0(22,000 )\u00a0(4,656 )\u00a0\u2014\u00a0\n\u00a0(17,344 )\u00a0(0.08 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(45,152 )\u00a045,152\u00a0\n\u00a045,152\u00a0\n\u00a09,555\u00a0\n\u00a0(506 )\u00a035,091\u00a0\n\u00a00.16\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(40,672 )\u00a040,672\u00a0\n\u00a040,672\u00a0\n\u00a016,980\u00a0\n\u00a0\u2014\u00a0\n\u00a023,692\u00a0\n\u00a00.11\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax Reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,203,183\u00a0\n\u00a0$731,349\u00a0\n\u00a0$471,834\u00a0\n\u00a0$426,567\u00a0\n\u00a0$84,905\u00a0\n\u00a0$1,393\u00a0\n\u00a0$343,055\u00a0\n\u00a0$1.60\u00a0\n2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.86% \u00a02.65%\nOperating expenses \u00a01.81% \u00a01.61%\nOperating income \u00a01.05% \u00a01.04%\n_____________________________________\n11", "original_text": "litigation\nsettlements \u00a0(87,279 )\u00a0\u2014 \u00a0(87,279 )\u00a0(87,279 )\u00a0(18,470 )\u00a0\u2014 \u00a0(68,809 )\u00a0(0.32 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(3,029 )\u00a0\u2014 \u00a0\u00a0(3,029 )\u00a0(3,029 )\u00a0(641 )\u00a0\u2014 \u00a0\u00a0(2,388 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation costs \u00a017,911\u00a0\n\u00a0(2,584 )\u00a020,495\u00a0\n\u00a020,495\u00a0\n\u00a04,337\u00a0\n\u00a0\u2014\u00a0\n\u00a016,158\u00a0\n\u00a00.08\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York State\nOpioid Stewardship\nAct \u00a0(22,000 )\u00a0\u2014\u00a0\n\u00a0(22,000 )\u00a0(22,000 )\u00a0(4,656 )\u00a0\u2014\u00a0\n\u00a0(17,344 )\u00a0(0.08 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(45,152 )\u00a045,152\u00a0\n\u00a045,152\u00a0\n\u00a09,555\u00a0\n\u00a0(506 )\u00a035,091\u00a0\n\u00a00.16\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(40,672 )\u00a040,672\u00a0\n\u00a040,672\u00a0\n\u00a016,980\u00a0\n\u00a0\u2014\u00a0\n\u00a023,692\u00a0\n\u00a00.11\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax Reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,203,183\u00a0\n\u00a0$731,349\u00a0\n\u00a0$471,834\u00a0\n\u00a0$426,567\u00a0\n\u00a0$84,905\u00a0\n\u00a0$1,393\u00a0\n\u00a0$343,055\u00a0\n\u00a0$1.60\u00a0\n2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.86% \u00a02.65%\nOperating expenses \u00a01.81% \u00a01.61%\nOperating income \u00a01.05% \u00a01.04%\n_____________________________________\n11", "page_label": "11", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c3df90e-4a1d-4aea-a05d-533e0e763894", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c6b8e18270e62cad31a0d823b52b5f088dd7fc16d0eb9cabb973458950f2460", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99dfbb03-be4e-476e-bb86-f58c24d06615", "node_type": "1", "metadata": {"window": "Adjusted Non-\nGAAP \u00a0$1,243,138\u00a0\n\u00a0$747,872\u00a0\n\u00a0$495,266\u00a0\n\u00a0$461,417\u00a0\n\u00a0$96,898\u00a0\n\u00a0$636\u00a0\n\u00a0$365,155\u00a0\n\u00a0$1.76\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nperiod \u00a03.3 %\u00a02.3 %\u00a05.0 %\u00a08.2 %\u00a014.1 %\u00a0\u00a0 \u00a06.4 %\u00a010.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.57% \u00a02.60%\nOperating expenses \u00a02.02% \u00a01.56%\nOperating income \u00a00.55% \u00a01.03%\n_____________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2018 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,297,580 \u00a0\u00a0$819,757 \u00a0\u00a0$477,823 \u00a0\u00a0$432,556 \u00a0\u00a0$40,803 \u00a0\u00a0$1,899 \u00a0\u00a0$393,652 \u00a0\u00a0$1.84 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from antitrust \u00a0 \u00a0\n10", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2018 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,297,580 \u00a0\u00a0$819,757 \u00a0\u00a0$477,823 \u00a0\u00a0$432,556 \u00a0\u00a0$40,803 \u00a0\u00a0$1,899 \u00a0\u00a0$393,652 \u00a0\u00a0$1.84 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from antitrust \u00a0 \u00a0\n10", "page_label": "10", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a3ab3be0d26bca819891d7582d1aba7e4a2150773e058bc117c6358d4b3e250", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0503464-0b9c-4d38-adac-853e803938a5", "node_type": "1", "metadata": {"window": "1Amount represents the final measurement period adjustment to the one-time transition tax on historical foreign earnings and\nprofits through December 31, 2017.\n\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$46,036,828 \u00a0\u00a0$43,744,381 \u00a0\u00a05.2%\nOther \u00a01,846,984 \u00a0\u00a01,670,938 \u00a0\u00a010.5%\nIntersegment eliminations \u00a0(19,070 )\u00a0(22,867 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,864,742 \u00a0\u00a0$45,392,452 \u00a0\u00a05.4%\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$391,694 \u00a0\u00a0\u00a0$373,207 \u00a0\u00a0\u00a05.0%\nOther \u00a0104,479 \u00a0\u00a0\u00a098,934 \u00a0\u00a0\u00a05.6%\nIntersegment eliminations \u00a0(907 )\u00a0\u00a0(307 )\u00a0\u00a0\u00a0\n12", "original_text": "1Amount represents the final measurement period adjustment to the one-time transition tax on historical foreign earnings and\nprofits through December 31, 2017.\n\u00a0\n"}, "hash": "8f1cb74c402a5a8761cb291fe2b6c629189df2f57f1417bb2a474bec74c8e178", "class_name": "RelatedNodeInfo"}}, "text": "litigation\nsettlements \u00a0(87,279 )\u00a0\u2014 \u00a0(87,279 )\u00a0(87,279 )\u00a0(18,470 )\u00a0\u2014 \u00a0(68,809 )\u00a0(0.32 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(3,029 )\u00a0\u2014 \u00a0\u00a0(3,029 )\u00a0(3,029 )\u00a0(641 )\u00a0\u2014 \u00a0\u00a0(2,388 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation costs \u00a017,911\u00a0\n\u00a0(2,584 )\u00a020,495\u00a0\n\u00a020,495\u00a0\n\u00a04,337\u00a0\n\u00a0\u2014\u00a0\n\u00a016,158\u00a0\n\u00a00.08\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York State\nOpioid Stewardship\nAct \u00a0(22,000 )\u00a0\u2014\u00a0\n\u00a0(22,000 )\u00a0(22,000 )\u00a0(4,656 )\u00a0\u2014\u00a0\n\u00a0(17,344 )\u00a0(0.08 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(45,152 )\u00a045,152\u00a0\n\u00a045,152\u00a0\n\u00a09,555\u00a0\n\u00a0(506 )\u00a035,091\u00a0\n\u00a00.16\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(40,672 )\u00a040,672\u00a0\n\u00a040,672\u00a0\n\u00a016,980\u00a0\n\u00a0\u2014\u00a0\n\u00a023,692\u00a0\n\u00a00.11\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax Reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,203,183\u00a0\n\u00a0$731,349\u00a0\n\u00a0$471,834\u00a0\n\u00a0$426,567\u00a0\n\u00a0$84,905\u00a0\n\u00a0$1,393\u00a0\n\u00a0$343,055\u00a0\n\u00a0$1.60\u00a0\n2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.86% \u00a02.65%\nOperating expenses \u00a01.81% \u00a01.61%\nOperating income \u00a01.05% \u00a01.04%\n_____________________________________\n11", "start_char_idx": 0, "end_char_idx": 1122, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0503464-0b9c-4d38-adac-853e803938a5": {"__data__": {"id_": "e0503464-0b9c-4d38-adac-853e803938a5", "embedding": null, "metadata": {"window": "1Amount represents the final measurement period adjustment to the one-time transition tax on historical foreign earnings and\nprofits through December 31, 2017.\n\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$46,036,828 \u00a0\u00a0$43,744,381 \u00a0\u00a05.2%\nOther \u00a01,846,984 \u00a0\u00a01,670,938 \u00a0\u00a010.5%\nIntersegment eliminations \u00a0(19,070 )\u00a0(22,867 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,864,742 \u00a0\u00a0$45,392,452 \u00a0\u00a05.4%\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$391,694 \u00a0\u00a0\u00a0$373,207 \u00a0\u00a0\u00a05.0%\nOther \u00a0104,479 \u00a0\u00a0\u00a098,934 \u00a0\u00a0\u00a05.6%\nIntersegment eliminations \u00a0(907 )\u00a0\u00a0(307 )\u00a0\u00a0\u00a0\n12", "original_text": "1Amount represents the final measurement period adjustment to the one-time transition tax on historical foreign earnings and\nprofits through December 31, 2017.\n\u00a0\n", "page_label": "12", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ce185f9-5529-409e-9658-656939bce4c8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a0c3ec2d5bee103f4dafb05f5b8df8c699237bc98daa3d7de678709dc2ff6f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71aeb2c3-6bc5-4093-8f1e-71f119ed5b3e", "node_type": "1", "metadata": {"window": "litigation\nsettlements \u00a0(87,279 )\u00a0\u2014 \u00a0(87,279 )\u00a0(87,279 )\u00a0(18,470 )\u00a0\u2014 \u00a0(68,809 )\u00a0(0.32 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(3,029 )\u00a0\u2014 \u00a0\u00a0(3,029 )\u00a0(3,029 )\u00a0(641 )\u00a0\u2014 \u00a0\u00a0(2,388 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation costs \u00a017,911\u00a0\n\u00a0(2,584 )\u00a020,495\u00a0\n\u00a020,495\u00a0\n\u00a04,337\u00a0\n\u00a0\u2014\u00a0\n\u00a016,158\u00a0\n\u00a00.08\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York State\nOpioid Stewardship\nAct \u00a0(22,000 )\u00a0\u2014\u00a0\n\u00a0(22,000 )\u00a0(22,000 )\u00a0(4,656 )\u00a0\u2014\u00a0\n\u00a0(17,344 )\u00a0(0.08 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(45,152 )\u00a045,152\u00a0\n\u00a045,152\u00a0\n\u00a09,555\u00a0\n\u00a0(506 )\u00a035,091\u00a0\n\u00a00.16\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(40,672 )\u00a040,672\u00a0\n\u00a040,672\u00a0\n\u00a016,980\u00a0\n\u00a0\u2014\u00a0\n\u00a023,692\u00a0\n\u00a00.11\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax Reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,203,183\u00a0\n\u00a0$731,349\u00a0\n\u00a0$471,834\u00a0\n\u00a0$426,567\u00a0\n\u00a0$84,905\u00a0\n\u00a0$1,393\u00a0\n\u00a0$343,055\u00a0\n\u00a0$1.60\u00a0\n2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.86% \u00a02.65%\nOperating expenses \u00a01.81% \u00a01.61%\nOperating income \u00a01.05% \u00a01.04%\n_____________________________________\n11", "original_text": "litigation\nsettlements \u00a0(87,279 )\u00a0\u2014 \u00a0(87,279 )\u00a0(87,279 )\u00a0(18,470 )\u00a0\u2014 \u00a0(68,809 )\u00a0(0.32 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(3,029 )\u00a0\u2014 \u00a0\u00a0(3,029 )\u00a0(3,029 )\u00a0(641 )\u00a0\u2014 \u00a0\u00a0(2,388 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation costs \u00a017,911\u00a0\n\u00a0(2,584 )\u00a020,495\u00a0\n\u00a020,495\u00a0\n\u00a04,337\u00a0\n\u00a0\u2014\u00a0\n\u00a016,158\u00a0\n\u00a00.08\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York State\nOpioid Stewardship\nAct \u00a0(22,000 )\u00a0\u2014\u00a0\n\u00a0(22,000 )\u00a0(22,000 )\u00a0(4,656 )\u00a0\u2014\u00a0\n\u00a0(17,344 )\u00a0(0.08 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(45,152 )\u00a045,152\u00a0\n\u00a045,152\u00a0\n\u00a09,555\u00a0\n\u00a0(506 )\u00a035,091\u00a0\n\u00a00.16\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(40,672 )\u00a040,672\u00a0\n\u00a040,672\u00a0\n\u00a016,980\u00a0\n\u00a0\u2014\u00a0\n\u00a023,692\u00a0\n\u00a00.11\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax Reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,203,183\u00a0\n\u00a0$731,349\u00a0\n\u00a0$471,834\u00a0\n\u00a0$426,567\u00a0\n\u00a0$84,905\u00a0\n\u00a0$1,393\u00a0\n\u00a0$343,055\u00a0\n\u00a0$1.60\u00a0\n2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.86% \u00a02.65%\nOperating expenses \u00a01.81% \u00a01.61%\nOperating income \u00a01.05% \u00a01.04%\n_____________________________________\n11", "page_label": "11", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09ff7f39ecf03306e7ee78a800c2e43809ca9b4ab5f5079c489db420849464a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab2ff440-c747-4404-aa24-ecafcb625ef7", "node_type": "1", "metadata": {"window": "1Amount represents the final measurement period adjustment to the one-time transition tax on historical foreign earnings and\nprofits through December 31, 2017.\n\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$46,036,828 \u00a0\u00a0$43,744,381 \u00a0\u00a05.2%\nOther \u00a01,846,984 \u00a0\u00a01,670,938 \u00a0\u00a010.5%\nIntersegment eliminations \u00a0(19,070 )\u00a0(22,867 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,864,742 \u00a0\u00a0$45,392,452 \u00a0\u00a05.4%\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$391,694 \u00a0\u00a0\u00a0$373,207 \u00a0\u00a0\u00a05.0%\nOther \u00a0104,479 \u00a0\u00a0\u00a098,934 \u00a0\u00a0\u00a05.6%\nIntersegment eliminations \u00a0(907 )\u00a0\u00a0(307 )\u00a0\u00a0\u00a0\n12", "original_text": "2The sum of the components does not equal the total due to rounding.\n\u00a0\n"}, "hash": "5b535249a74a2a0cb3dd9c27b9e84826918817c2c5f8898c83dd2a632af3fd7c", "class_name": "RelatedNodeInfo"}}, "text": "1Amount represents the final measurement period adjustment to the one-time transition tax on historical foreign earnings and\nprofits through December 31, 2017.\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab2ff440-c747-4404-aa24-ecafcb625ef7": {"__data__": {"id_": "ab2ff440-c747-4404-aa24-ecafcb625ef7", "embedding": null, "metadata": {"window": "1Amount represents the final measurement period adjustment to the one-time transition tax on historical foreign earnings and\nprofits through December 31, 2017.\n\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$46,036,828 \u00a0\u00a0$43,744,381 \u00a0\u00a05.2%\nOther \u00a01,846,984 \u00a0\u00a01,670,938 \u00a0\u00a010.5%\nIntersegment eliminations \u00a0(19,070 )\u00a0(22,867 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,864,742 \u00a0\u00a0$45,392,452 \u00a0\u00a05.4%\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$391,694 \u00a0\u00a0\u00a0$373,207 \u00a0\u00a0\u00a05.0%\nOther \u00a0104,479 \u00a0\u00a0\u00a098,934 \u00a0\u00a0\u00a05.6%\nIntersegment eliminations \u00a0(907 )\u00a0\u00a0(307 )\u00a0\u00a0\u00a0\n12", "original_text": "2The sum of the components does not equal the total due to rounding.\n\u00a0\n", "page_label": "12", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ce185f9-5529-409e-9658-656939bce4c8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a0c3ec2d5bee103f4dafb05f5b8df8c699237bc98daa3d7de678709dc2ff6f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0503464-0b9c-4d38-adac-853e803938a5", "node_type": "1", "metadata": {"window": "1Amount represents the final measurement period adjustment to the one-time transition tax on historical foreign earnings and\nprofits through December 31, 2017.\n\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$46,036,828 \u00a0\u00a0$43,744,381 \u00a0\u00a05.2%\nOther \u00a01,846,984 \u00a0\u00a01,670,938 \u00a0\u00a010.5%\nIntersegment eliminations \u00a0(19,070 )\u00a0(22,867 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,864,742 \u00a0\u00a0$45,392,452 \u00a0\u00a05.4%\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$391,694 \u00a0\u00a0\u00a0$373,207 \u00a0\u00a0\u00a05.0%\nOther \u00a0104,479 \u00a0\u00a0\u00a098,934 \u00a0\u00a0\u00a05.6%\nIntersegment eliminations \u00a0(907 )\u00a0\u00a0(307 )\u00a0\u00a0\u00a0\n12", "original_text": "1Amount represents the final measurement period adjustment to the one-time transition tax on historical foreign earnings and\nprofits through December 31, 2017.\n\u00a0\n", "page_label": "12", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f0facffe84dc0f2e06355dc5e71f486523b0ef6dafe0a30a3ff921521ca9ee9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb6ae795-f11e-49f3-9bce-0fb4b394454d", "node_type": "1", "metadata": {"window": "1Amount represents the final measurement period adjustment to the one-time transition tax on historical foreign earnings and\nprofits through December 31, 2017.\n\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$46,036,828 \u00a0\u00a0$43,744,381 \u00a0\u00a05.2%\nOther \u00a01,846,984 \u00a0\u00a01,670,938 \u00a0\u00a010.5%\nIntersegment eliminations \u00a0(19,070 )\u00a0(22,867 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,864,742 \u00a0\u00a0$45,392,452 \u00a0\u00a05.4%\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$391,694 \u00a0\u00a0\u00a0$373,207 \u00a0\u00a0\u00a05.0%\nOther \u00a0104,479 \u00a0\u00a0\u00a098,934 \u00a0\u00a0\u00a05.6%\nIntersegment eliminations \u00a0(907 )\u00a0\u00a0(307 )\u00a0\u00a0\u00a0\n12", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n"}, "hash": "6b874dcb2c9f807017eeabe82849f3275c6e5dfb0613a6d487da9f9c1d74e2be", "class_name": "RelatedNodeInfo"}}, "text": "2The sum of the components does not equal the total due to rounding.\n\u00a0\n", "start_char_idx": 162, "end_char_idx": 233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb6ae795-f11e-49f3-9bce-0fb4b394454d": {"__data__": {"id_": "eb6ae795-f11e-49f3-9bce-0fb4b394454d", "embedding": null, "metadata": {"window": "1Amount represents the final measurement period adjustment to the one-time transition tax on historical foreign earnings and\nprofits through December 31, 2017.\n\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$46,036,828 \u00a0\u00a0$43,744,381 \u00a0\u00a05.2%\nOther \u00a01,846,984 \u00a0\u00a01,670,938 \u00a0\u00a010.5%\nIntersegment eliminations \u00a0(19,070 )\u00a0(22,867 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,864,742 \u00a0\u00a0$45,392,452 \u00a0\u00a05.4%\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$391,694 \u00a0\u00a0\u00a0$373,207 \u00a0\u00a0\u00a05.0%\nOther \u00a0104,479 \u00a0\u00a0\u00a098,934 \u00a0\u00a0\u00a05.6%\nIntersegment eliminations \u00a0(907 )\u00a0\u00a0(307 )\u00a0\u00a0\u00a0\n12", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "page_label": "12", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ce185f9-5529-409e-9658-656939bce4c8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a0c3ec2d5bee103f4dafb05f5b8df8c699237bc98daa3d7de678709dc2ff6f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab2ff440-c747-4404-aa24-ecafcb625ef7", "node_type": "1", "metadata": {"window": "1Amount represents the final measurement period adjustment to the one-time transition tax on historical foreign earnings and\nprofits through December 31, 2017.\n\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$46,036,828 \u00a0\u00a0$43,744,381 \u00a0\u00a05.2%\nOther \u00a01,846,984 \u00a0\u00a01,670,938 \u00a0\u00a010.5%\nIntersegment eliminations \u00a0(19,070 )\u00a0(22,867 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,864,742 \u00a0\u00a0$45,392,452 \u00a0\u00a05.4%\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$391,694 \u00a0\u00a0\u00a0$373,207 \u00a0\u00a0\u00a05.0%\nOther \u00a0104,479 \u00a0\u00a0\u00a098,934 \u00a0\u00a0\u00a05.6%\nIntersegment eliminations \u00a0(907 )\u00a0\u00a0(307 )\u00a0\u00a0\u00a0\n12", "original_text": "2The sum of the components does not equal the total due to rounding.\n\u00a0\n", "page_label": "12", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6144e49aaaae73b8dcc2476fcd36330af3d18f52443da764d99d39b6397888c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6856a033-1be7-4fd1-8212-c1b72d6bd9d8", "node_type": "1", "metadata": {"window": "1Amount represents the final measurement period adjustment to the one-time transition tax on historical foreign earnings and\nprofits through December 31, 2017.\n\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$46,036,828 \u00a0\u00a0$43,744,381 \u00a0\u00a05.2%\nOther \u00a01,846,984 \u00a0\u00a01,670,938 \u00a0\u00a010.5%\nIntersegment eliminations \u00a0(19,070 )\u00a0(22,867 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,864,742 \u00a0\u00a0$45,392,452 \u00a0\u00a05.4%\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$391,694 \u00a0\u00a0\u00a0$373,207 \u00a0\u00a0\u00a05.0%\nOther \u00a0104,479 \u00a0\u00a0\u00a098,934 \u00a0\u00a0\u00a05.6%\nIntersegment eliminations \u00a0(907 )\u00a0\u00a0(307 )\u00a0\u00a0\u00a0\n12", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$46,036,828 \u00a0\u00a0$43,744,381 \u00a0\u00a05.2%\nOther \u00a01,846,984 \u00a0\u00a01,670,938 \u00a0\u00a010.5%\nIntersegment eliminations \u00a0(19,070 )\u00a0(22,867 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,864,742 \u00a0\u00a0$45,392,452 \u00a0\u00a05.4%\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$391,694 \u00a0\u00a0\u00a0$373,207 \u00a0\u00a0\u00a05.0%\nOther \u00a0104,479 \u00a0\u00a0\u00a098,934 \u00a0\u00a0\u00a05.6%\nIntersegment eliminations \u00a0(907 )\u00a0\u00a0(307 )\u00a0\u00a0\u00a0\n12"}, "hash": "97b2046915f67953ffff2c5de43ec083af4cf8d71030ebb2b019253a3d394795", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "start_char_idx": 233, "end_char_idx": 412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6856a033-1be7-4fd1-8212-c1b72d6bd9d8": {"__data__": {"id_": "6856a033-1be7-4fd1-8212-c1b72d6bd9d8", "embedding": null, "metadata": {"window": "1Amount represents the final measurement period adjustment to the one-time transition tax on historical foreign earnings and\nprofits through December 31, 2017.\n\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$46,036,828 \u00a0\u00a0$43,744,381 \u00a0\u00a05.2%\nOther \u00a01,846,984 \u00a0\u00a01,670,938 \u00a0\u00a010.5%\nIntersegment eliminations \u00a0(19,070 )\u00a0(22,867 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,864,742 \u00a0\u00a0$45,392,452 \u00a0\u00a05.4%\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$391,694 \u00a0\u00a0\u00a0$373,207 \u00a0\u00a0\u00a05.0%\nOther \u00a0104,479 \u00a0\u00a0\u00a098,934 \u00a0\u00a0\u00a05.6%\nIntersegment eliminations \u00a0(907 )\u00a0\u00a0(307 )\u00a0\u00a0\u00a0\n12", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$46,036,828 \u00a0\u00a0$43,744,381 \u00a0\u00a05.2%\nOther \u00a01,846,984 \u00a0\u00a01,670,938 \u00a0\u00a010.5%\nIntersegment eliminations \u00a0(19,070 )\u00a0(22,867 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,864,742 \u00a0\u00a0$45,392,452 \u00a0\u00a05.4%\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$391,694 \u00a0\u00a0\u00a0$373,207 \u00a0\u00a0\u00a05.0%\nOther \u00a0104,479 \u00a0\u00a0\u00a098,934 \u00a0\u00a0\u00a05.6%\nIntersegment eliminations \u00a0(907 )\u00a0\u00a0(307 )\u00a0\u00a0\u00a0\n12", "page_label": "12", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ce185f9-5529-409e-9658-656939bce4c8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a0c3ec2d5bee103f4dafb05f5b8df8c699237bc98daa3d7de678709dc2ff6f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb6ae795-f11e-49f3-9bce-0fb4b394454d", "node_type": "1", "metadata": {"window": "1Amount represents the final measurement period adjustment to the one-time transition tax on historical foreign earnings and\nprofits through December 31, 2017.\n\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$46,036,828 \u00a0\u00a0$43,744,381 \u00a0\u00a05.2%\nOther \u00a01,846,984 \u00a0\u00a01,670,938 \u00a0\u00a010.5%\nIntersegment eliminations \u00a0(19,070 )\u00a0(22,867 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,864,742 \u00a0\u00a0$45,392,452 \u00a0\u00a05.4%\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$391,694 \u00a0\u00a0\u00a0$373,207 \u00a0\u00a0\u00a05.0%\nOther \u00a0104,479 \u00a0\u00a0\u00a098,934 \u00a0\u00a0\u00a05.6%\nIntersegment eliminations \u00a0(907 )\u00a0\u00a0(307 )\u00a0\u00a0\u00a0\n12", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n", "page_label": "12", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41b21b6238453c663809f6aa56b2a56ab0aebdba914404cc1c7b7b1659ce26a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29b6fa4b-ee96-4c21-ab0c-fc1101ca5fc9", "node_type": "1", "metadata": {"window": "Total segment operating income \u00a0495,266 \u00a0\u00a0\u00a0471,834 \u00a0\u00a0\u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,492 \u00a0\u00a0\u00a087,279 \u00a0\u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(13,281 )\u00a0\u00a03,029 \u00a0\u00a0\u00a0\u00a0\nPharMEDium remediation costs \u00a0(16,165 )\u00a0\u00a0(20,495 )\u00a0\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a0\u00a022,000 \u00a0\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(33,566 )\u00a0\u00a0(45,152 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(39,309 )\u00a0\u00a0(40,672 )\u00a0\u00a0\u00a0\nImpairment of long-lived assets \u00a0(138,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u00a0\nOperating income \u00a0$263,437 \u00a0\u00a0\u00a0$477,823 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a01.94% \u00a0\u00a02.01% \u00a0\u00a0\u00a0\nOperating expenses \u00a01.09% \u00a0\u00a01.16% \u00a0\u00a0\u00a0\nOperating income \u00a00.85% \u00a0\u00a00.85% \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a019.01% \u00a0\u00a019.45% \u00a0\u00a0\u00a0\nOperating expenses \u00a013.35% \u00a0\u00a013.53% \u00a0\u00a0\u00a0\nOperating income \u00a05.66% \u00a0\u00a05.92% \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a02.57% \u00a0\u00a02.86% \u00a0\u00a0\u00a0\nOperating expenses \u00a02.02% \u00a0\u00a01.81% \u00a0\u00a0\u00a0\nOperating income \u00a00.55% \u00a0\u00a01.05% \u00a0\u00a0\u00a0\n13", "original_text": "Total segment operating income \u00a0495,266 \u00a0\u00a0\u00a0471,834 \u00a0\u00a0\u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,492 \u00a0\u00a0\u00a087,279 \u00a0\u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(13,281 )\u00a0\u00a03,029 \u00a0\u00a0\u00a0\u00a0\nPharMEDium remediation costs \u00a0(16,165 )\u00a0\u00a0(20,495 )\u00a0\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a0\u00a022,000 \u00a0\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(33,566 )\u00a0\u00a0(45,152 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(39,309 )\u00a0\u00a0(40,672 )\u00a0\u00a0\u00a0\nImpairment of long-lived assets \u00a0(138,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u00a0\nOperating income \u00a0$263,437 \u00a0\u00a0\u00a0$477,823 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a01.94% \u00a0\u00a02.01% \u00a0\u00a0\u00a0\nOperating expenses \u00a01.09% \u00a0\u00a01.16% \u00a0\u00a0\u00a0\nOperating income \u00a00.85% \u00a0\u00a00.85% \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a019.01% \u00a0\u00a019.45% \u00a0\u00a0\u00a0\nOperating expenses \u00a013.35% \u00a0\u00a013.53% \u00a0\u00a0\u00a0\nOperating income \u00a05.66% \u00a0\u00a05.92% \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a02.57% \u00a0\u00a02.86% \u00a0\u00a0\u00a0\nOperating expenses \u00a02.02% \u00a0\u00a01.81% \u00a0\u00a0\u00a0\nOperating income \u00a00.55% \u00a0\u00a01.05% \u00a0\u00a0\u00a0\n13"}, "hash": "807c77c53742ecd4f56c7b3613a6552da63a44c8328a0d160f0f81470202da53", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$46,036,828 \u00a0\u00a0$43,744,381 \u00a0\u00a05.2%\nOther \u00a01,846,984 \u00a0\u00a01,670,938 \u00a0\u00a010.5%\nIntersegment eliminations \u00a0(19,070 )\u00a0(22,867 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,864,742 \u00a0\u00a0$45,392,452 \u00a0\u00a05.4%\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$391,694 \u00a0\u00a0\u00a0$373,207 \u00a0\u00a0\u00a05.0%\nOther \u00a0104,479 \u00a0\u00a0\u00a098,934 \u00a0\u00a0\u00a05.6%\nIntersegment eliminations \u00a0(907 )\u00a0\u00a0(307 )\u00a0\u00a0\u00a0\n12", "start_char_idx": 412, "end_char_idx": 1003, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29b6fa4b-ee96-4c21-ab0c-fc1101ca5fc9": {"__data__": {"id_": "29b6fa4b-ee96-4c21-ab0c-fc1101ca5fc9", "embedding": null, "metadata": {"window": "Total segment operating income \u00a0495,266 \u00a0\u00a0\u00a0471,834 \u00a0\u00a0\u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,492 \u00a0\u00a0\u00a087,279 \u00a0\u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(13,281 )\u00a0\u00a03,029 \u00a0\u00a0\u00a0\u00a0\nPharMEDium remediation costs \u00a0(16,165 )\u00a0\u00a0(20,495 )\u00a0\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a0\u00a022,000 \u00a0\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(33,566 )\u00a0\u00a0(45,152 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(39,309 )\u00a0\u00a0(40,672 )\u00a0\u00a0\u00a0\nImpairment of long-lived assets \u00a0(138,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u00a0\nOperating income \u00a0$263,437 \u00a0\u00a0\u00a0$477,823 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a01.94% \u00a0\u00a02.01% \u00a0\u00a0\u00a0\nOperating expenses \u00a01.09% \u00a0\u00a01.16% \u00a0\u00a0\u00a0\nOperating income \u00a00.85% \u00a0\u00a00.85% \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a019.01% \u00a0\u00a019.45% \u00a0\u00a0\u00a0\nOperating expenses \u00a013.35% \u00a0\u00a013.53% \u00a0\u00a0\u00a0\nOperating income \u00a05.66% \u00a0\u00a05.92% \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a02.57% \u00a0\u00a02.86% \u00a0\u00a0\u00a0\nOperating expenses \u00a02.02% \u00a0\u00a01.81% \u00a0\u00a0\u00a0\nOperating income \u00a00.55% \u00a0\u00a01.05% \u00a0\u00a0\u00a0\n13", "original_text": "Total segment operating income \u00a0495,266 \u00a0\u00a0\u00a0471,834 \u00a0\u00a0\u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,492 \u00a0\u00a0\u00a087,279 \u00a0\u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(13,281 )\u00a0\u00a03,029 \u00a0\u00a0\u00a0\u00a0\nPharMEDium remediation costs \u00a0(16,165 )\u00a0\u00a0(20,495 )\u00a0\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a0\u00a022,000 \u00a0\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(33,566 )\u00a0\u00a0(45,152 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(39,309 )\u00a0\u00a0(40,672 )\u00a0\u00a0\u00a0\nImpairment of long-lived assets \u00a0(138,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u00a0\nOperating income \u00a0$263,437 \u00a0\u00a0\u00a0$477,823 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a01.94% \u00a0\u00a02.01% \u00a0\u00a0\u00a0\nOperating expenses \u00a01.09% \u00a0\u00a01.16% \u00a0\u00a0\u00a0\nOperating income \u00a00.85% \u00a0\u00a00.85% \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a019.01% \u00a0\u00a019.45% \u00a0\u00a0\u00a0\nOperating expenses \u00a013.35% \u00a0\u00a013.53% \u00a0\u00a0\u00a0\nOperating income \u00a05.66% \u00a0\u00a05.92% \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a02.57% \u00a0\u00a02.86% \u00a0\u00a0\u00a0\nOperating expenses \u00a02.02% \u00a0\u00a01.81% \u00a0\u00a0\u00a0\nOperating income \u00a00.55% \u00a0\u00a01.05% \u00a0\u00a0\u00a0\n13", "page_label": "13", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "039396cb-7fcb-40f4-8be7-eed53f885066", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48c326cf04b75239cee38b841d69b65c7da74040db54ef3fdff0196c30052e92", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6856a033-1be7-4fd1-8212-c1b72d6bd9d8", "node_type": "1", "metadata": {"window": "1Amount represents the final measurement period adjustment to the one-time transition tax on historical foreign earnings and\nprofits through December 31, 2017.\n\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$46,036,828 \u00a0\u00a0$43,744,381 \u00a0\u00a05.2%\nOther \u00a01,846,984 \u00a0\u00a01,670,938 \u00a0\u00a010.5%\nIntersegment eliminations \u00a0(19,070 )\u00a0(22,867 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,864,742 \u00a0\u00a0$45,392,452 \u00a0\u00a05.4%\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$391,694 \u00a0\u00a0\u00a0$373,207 \u00a0\u00a0\u00a05.0%\nOther \u00a0104,479 \u00a0\u00a0\u00a098,934 \u00a0\u00a0\u00a05.6%\nIntersegment eliminations \u00a0(907 )\u00a0\u00a0(307 )\u00a0\u00a0\u00a0\n12", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$46,036,828 \u00a0\u00a0$43,744,381 \u00a0\u00a05.2%\nOther \u00a01,846,984 \u00a0\u00a01,670,938 \u00a0\u00a010.5%\nIntersegment eliminations \u00a0(19,070 )\u00a0(22,867 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,864,742 \u00a0\u00a0$45,392,452 \u00a0\u00a05.4%\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$391,694 \u00a0\u00a0\u00a0$373,207 \u00a0\u00a0\u00a05.0%\nOther \u00a0104,479 \u00a0\u00a0\u00a098,934 \u00a0\u00a0\u00a05.6%\nIntersegment eliminations \u00a0(907 )\u00a0\u00a0(307 )\u00a0\u00a0\u00a0\n12", "page_label": "12", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f1180cd5638940f320444026b3bd5adb5387f2737d95a48597826e015e483f8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3c1c099-dfc9-4b28-85f8-8ed1304d2484", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAdjusted gross profit \u00a02.60% \u00a0\u00a02.65% \u00a0\u00a0\u00a0\nAdjusted operating expenses \u00a01.56% \u00a0\u00a01.61% \u00a0\u00a0\u00a0\nAdjusted operating income \u00a01.03% \u00a0\u00a01.04% \u00a0\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2019 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,232,604 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 12,568,816 \u00a0\u00a012,386,879 \u00a0\nInventories 11,686,466 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,277,714 \u00a0\u00a01,147,483 \u00a0\nPrepaid expenses and other 189,216 \u00a0\u00a0163,244 \u00a0\nTotal current assets 28,954,816 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,442,383 \u00a0\u00a01,770,516 \u00a0\n14", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAdjusted gross profit \u00a02.60% \u00a0\u00a02.65% \u00a0\u00a0\u00a0\nAdjusted operating expenses \u00a01.56% \u00a0\u00a01.61% \u00a0\u00a0\u00a0\nAdjusted operating income \u00a01.03% \u00a0\u00a01.04% \u00a0\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "417b9c8c49432fd69d6febb77ebb2c72dc2400cfea070b68b17f5eca6cbc846e", "class_name": "RelatedNodeInfo"}}, "text": "Total segment operating income \u00a0495,266 \u00a0\u00a0\u00a0471,834 \u00a0\u00a0\u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,492 \u00a0\u00a0\u00a087,279 \u00a0\u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(13,281 )\u00a0\u00a03,029 \u00a0\u00a0\u00a0\u00a0\nPharMEDium remediation costs \u00a0(16,165 )\u00a0\u00a0(20,495 )\u00a0\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a0\u00a022,000 \u00a0\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(33,566 )\u00a0\u00a0(45,152 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(39,309 )\u00a0\u00a0(40,672 )\u00a0\u00a0\u00a0\nImpairment of long-lived assets \u00a0(138,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u00a0\nOperating income \u00a0$263,437 \u00a0\u00a0\u00a0$477,823 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a01.94% \u00a0\u00a02.01% \u00a0\u00a0\u00a0\nOperating expenses \u00a01.09% \u00a0\u00a01.16% \u00a0\u00a0\u00a0\nOperating income \u00a00.85% \u00a0\u00a00.85% \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a019.01% \u00a0\u00a019.45% \u00a0\u00a0\u00a0\nOperating expenses \u00a013.35% \u00a0\u00a013.53% \u00a0\u00a0\u00a0\nOperating income \u00a05.66% \u00a0\u00a05.92% \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a02.57% \u00a0\u00a02.86% \u00a0\u00a0\u00a0\nOperating expenses \u00a02.02% \u00a0\u00a01.81% \u00a0\u00a0\u00a0\nOperating income \u00a00.55% \u00a0\u00a01.05% \u00a0\u00a0\u00a0\n13", "start_char_idx": 0, "end_char_idx": 1049, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3c1c099-dfc9-4b28-85f8-8ed1304d2484": {"__data__": {"id_": "a3c1c099-dfc9-4b28-85f8-8ed1304d2484", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAdjusted gross profit \u00a02.60% \u00a0\u00a02.65% \u00a0\u00a0\u00a0\nAdjusted operating expenses \u00a01.56% \u00a0\u00a01.61% \u00a0\u00a0\u00a0\nAdjusted operating income \u00a01.03% \u00a0\u00a01.04% \u00a0\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2019 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,232,604 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 12,568,816 \u00a0\u00a012,386,879 \u00a0\nInventories 11,686,466 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,277,714 \u00a0\u00a01,147,483 \u00a0\nPrepaid expenses and other 189,216 \u00a0\u00a0163,244 \u00a0\nTotal current assets 28,954,816 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,442,383 \u00a0\u00a01,770,516 \u00a0\n14", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAdjusted gross profit \u00a02.60% \u00a0\u00a02.65% \u00a0\u00a0\u00a0\nAdjusted operating expenses \u00a01.56% \u00a0\u00a01.61% \u00a0\u00a0\u00a0\nAdjusted operating income \u00a01.03% \u00a0\u00a01.04% \u00a0\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "14", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8feaf2ba-529e-4c33-bab2-6c2c10f75ca1", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a0d79fc37a509043c868e1dbf21590e66df87ecfabf4d8788f5ed1bd823d1b7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29b6fa4b-ee96-4c21-ab0c-fc1101ca5fc9", "node_type": "1", "metadata": {"window": "Total segment operating income \u00a0495,266 \u00a0\u00a0\u00a0471,834 \u00a0\u00a0\u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,492 \u00a0\u00a0\u00a087,279 \u00a0\u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(13,281 )\u00a0\u00a03,029 \u00a0\u00a0\u00a0\u00a0\nPharMEDium remediation costs \u00a0(16,165 )\u00a0\u00a0(20,495 )\u00a0\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a0\u00a022,000 \u00a0\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(33,566 )\u00a0\u00a0(45,152 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(39,309 )\u00a0\u00a0(40,672 )\u00a0\u00a0\u00a0\nImpairment of long-lived assets \u00a0(138,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u00a0\nOperating income \u00a0$263,437 \u00a0\u00a0\u00a0$477,823 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a01.94% \u00a0\u00a02.01% \u00a0\u00a0\u00a0\nOperating expenses \u00a01.09% \u00a0\u00a01.16% \u00a0\u00a0\u00a0\nOperating income \u00a00.85% \u00a0\u00a00.85% \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a019.01% \u00a0\u00a019.45% \u00a0\u00a0\u00a0\nOperating expenses \u00a013.35% \u00a0\u00a013.53% \u00a0\u00a0\u00a0\nOperating income \u00a05.66% \u00a0\u00a05.92% \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a02.57% \u00a0\u00a02.86% \u00a0\u00a0\u00a0\nOperating expenses \u00a02.02% \u00a0\u00a01.81% \u00a0\u00a0\u00a0\nOperating income \u00a00.55% \u00a0\u00a01.05% \u00a0\u00a0\u00a0\n13", "original_text": "Total segment operating income \u00a0495,266 \u00a0\u00a0\u00a0471,834 \u00a0\u00a0\u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,492 \u00a0\u00a0\u00a087,279 \u00a0\u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(13,281 )\u00a0\u00a03,029 \u00a0\u00a0\u00a0\u00a0\nPharMEDium remediation costs \u00a0(16,165 )\u00a0\u00a0(20,495 )\u00a0\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a0\u00a022,000 \u00a0\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(33,566 )\u00a0\u00a0(45,152 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(39,309 )\u00a0\u00a0(40,672 )\u00a0\u00a0\u00a0\nImpairment of long-lived assets \u00a0(138,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u00a0\nOperating income \u00a0$263,437 \u00a0\u00a0\u00a0$477,823 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a01.94% \u00a0\u00a02.01% \u00a0\u00a0\u00a0\nOperating expenses \u00a01.09% \u00a0\u00a01.16% \u00a0\u00a0\u00a0\nOperating income \u00a00.85% \u00a0\u00a00.85% \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a019.01% \u00a0\u00a019.45% \u00a0\u00a0\u00a0\nOperating expenses \u00a013.35% \u00a0\u00a013.53% \u00a0\u00a0\u00a0\nOperating income \u00a05.66% \u00a0\u00a05.92% \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a02.57% \u00a0\u00a02.86% \u00a0\u00a0\u00a0\nOperating expenses \u00a02.02% \u00a0\u00a01.81% \u00a0\u00a0\u00a0\nOperating income \u00a00.55% \u00a0\u00a01.05% \u00a0\u00a0\u00a0\n13", "page_label": "13", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "501bab0bb5083d6a840c736bd3d466cd5b4216cc32ce2417e10907f050f967af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4c06b65-1eaa-4add-a657-9371d2543139", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAdjusted gross profit \u00a02.60% \u00a0\u00a02.65% \u00a0\u00a0\u00a0\nAdjusted operating expenses \u00a01.56% \u00a0\u00a01.61% \u00a0\u00a0\u00a0\nAdjusted operating income \u00a01.03% \u00a0\u00a01.04% \u00a0\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2019 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,232,604 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 12,568,816 \u00a0\u00a012,386,879 \u00a0\nInventories 11,686,466 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,277,714 \u00a0\u00a01,147,483 \u00a0\nPrepaid expenses and other 189,216 \u00a0\u00a0163,244 \u00a0\nTotal current assets 28,954,816 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,442,383 \u00a0\u00a01,770,516 \u00a0\n14", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2019 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,232,604 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 12,568,816 \u00a0\u00a012,386,879 \u00a0\nInventories 11,686,466 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,277,714 \u00a0\u00a01,147,483 \u00a0\nPrepaid expenses and other 189,216 \u00a0\u00a0163,244 \u00a0\nTotal current assets 28,954,816 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,442,383 \u00a0\u00a01,770,516 \u00a0\n14"}, "hash": "b133ac8a4d2384ef97f7b4192487a4f0358bdcc14c17adda9554076304fae868", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAdjusted gross profit \u00a02.60% \u00a0\u00a02.65% \u00a0\u00a0\u00a0\nAdjusted operating expenses \u00a01.56% \u00a0\u00a01.61% \u00a0\u00a0\u00a0\nAdjusted operating income \u00a01.03% \u00a0\u00a01.04% \u00a0\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 0, "end_char_idx": 375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4c06b65-1eaa-4add-a657-9371d2543139": {"__data__": {"id_": "e4c06b65-1eaa-4add-a657-9371d2543139", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAdjusted gross profit \u00a02.60% \u00a0\u00a02.65% \u00a0\u00a0\u00a0\nAdjusted operating expenses \u00a01.56% \u00a0\u00a01.61% \u00a0\u00a0\u00a0\nAdjusted operating income \u00a01.03% \u00a0\u00a01.04% \u00a0\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2019 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,232,604 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 12,568,816 \u00a0\u00a012,386,879 \u00a0\nInventories 11,686,466 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,277,714 \u00a0\u00a01,147,483 \u00a0\nPrepaid expenses and other 189,216 \u00a0\u00a0163,244 \u00a0\nTotal current assets 28,954,816 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,442,383 \u00a0\u00a01,770,516 \u00a0\n14", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2019 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,232,604 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 12,568,816 \u00a0\u00a012,386,879 \u00a0\nInventories 11,686,466 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,277,714 \u00a0\u00a01,147,483 \u00a0\nPrepaid expenses and other 189,216 \u00a0\u00a0163,244 \u00a0\nTotal current assets 28,954,816 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,442,383 \u00a0\u00a01,770,516 \u00a0\n14", "page_label": "14", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8feaf2ba-529e-4c33-bab2-6c2c10f75ca1", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a0d79fc37a509043c868e1dbf21590e66df87ecfabf4d8788f5ed1bd823d1b7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3c1c099-dfc9-4b28-85f8-8ed1304d2484", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAdjusted gross profit \u00a02.60% \u00a0\u00a02.65% \u00a0\u00a0\u00a0\nAdjusted operating expenses \u00a01.56% \u00a0\u00a01.61% \u00a0\u00a0\u00a0\nAdjusted operating income \u00a01.03% \u00a0\u00a01.04% \u00a0\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2019 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,232,604 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 12,568,816 \u00a0\u00a012,386,879 \u00a0\nInventories 11,686,466 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,277,714 \u00a0\u00a01,147,483 \u00a0\nPrepaid expenses and other 189,216 \u00a0\u00a0163,244 \u00a0\nTotal current assets 28,954,816 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,442,383 \u00a0\u00a01,770,516 \u00a0\n14", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAdjusted gross profit \u00a02.60% \u00a0\u00a02.65% \u00a0\u00a0\u00a0\nAdjusted operating expenses \u00a01.56% \u00a0\u00a01.61% \u00a0\u00a0\u00a0\nAdjusted operating income \u00a01.03% \u00a0\u00a01.04% \u00a0\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "14", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f67b47660e078bf7305fd27842707491d647aa3d35cdeb4e9cf1331f762cab7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3f9ae9a-8c3a-485b-9d27-c96a9080f261", "node_type": "1", "metadata": {"window": "Goodwill and other intangible assets 8,846,162 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 773,377 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $40,016,738 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $29,181,860 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 916,107 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 532,489 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 30,630,456 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,636,114 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 289,047 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,895,453 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 496,587 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,069,081 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity\n$40,016,738\u00a0\n\u00a0$39,171,980\u00a0\n\u00a0\n\u00a0\nAMERISOURCEBERGEN CORPORATION\n15", "original_text": "Goodwill and other intangible assets 8,846,162 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 773,377 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $40,016,738 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $29,181,860 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 916,107 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 532,489 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 30,630,456 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,636,114 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 289,047 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,895,453 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 496,587 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,069,081 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity\n$40,016,738\u00a0\n\u00a0$39,171,980\u00a0\n\u00a0\n\u00a0\nAMERISOURCEBERGEN CORPORATION\n15"}, "hash": "94560ede07cfb822df21ced5dfdd2beaff0129ba4cd525494a00c60492e022a5", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2019 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,232,604 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 12,568,816 \u00a0\u00a012,386,879 \u00a0\nInventories 11,686,466 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,277,714 \u00a0\u00a01,147,483 \u00a0\nPrepaid expenses and other 189,216 \u00a0\u00a0163,244 \u00a0\nTotal current assets 28,954,816 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,442,383 \u00a0\u00a01,770,516 \u00a0\n14", "start_char_idx": 375, "end_char_idx": 896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3f9ae9a-8c3a-485b-9d27-c96a9080f261": {"__data__": {"id_": "c3f9ae9a-8c3a-485b-9d27-c96a9080f261", "embedding": null, "metadata": {"window": "Goodwill and other intangible assets 8,846,162 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 773,377 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $40,016,738 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $29,181,860 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 916,107 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 532,489 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 30,630,456 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,636,114 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 289,047 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,895,453 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 496,587 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,069,081 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity\n$40,016,738\u00a0\n\u00a0$39,171,980\u00a0\n\u00a0\n\u00a0\nAMERISOURCEBERGEN CORPORATION\n15", "original_text": "Goodwill and other intangible assets 8,846,162 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 773,377 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $40,016,738 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $29,181,860 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 916,107 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 532,489 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 30,630,456 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,636,114 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 289,047 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,895,453 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 496,587 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,069,081 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity\n$40,016,738\u00a0\n\u00a0$39,171,980\u00a0\n\u00a0\n\u00a0\nAMERISOURCEBERGEN CORPORATION\n15", "page_label": "15", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8b533cdf-8511-46fb-942d-8ee9c9cb5db2", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c2ae87aac4ea5e9aa1ca1bb022f9dbd36790d115f89e0697515b878c3ea9ce6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4c06b65-1eaa-4add-a657-9371d2543139", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAdjusted gross profit \u00a02.60% \u00a0\u00a02.65% \u00a0\u00a0\u00a0\nAdjusted operating expenses \u00a01.56% \u00a0\u00a01.61% \u00a0\u00a0\u00a0\nAdjusted operating income \u00a01.03% \u00a0\u00a01.04% \u00a0\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2019 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,232,604 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 12,568,816 \u00a0\u00a012,386,879 \u00a0\nInventories 11,686,466 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,277,714 \u00a0\u00a01,147,483 \u00a0\nPrepaid expenses and other 189,216 \u00a0\u00a0163,244 \u00a0\nTotal current assets 28,954,816 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,442,383 \u00a0\u00a01,770,516 \u00a0\n14", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2019 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,232,604 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 12,568,816 \u00a0\u00a012,386,879 \u00a0\nInventories 11,686,466 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,277,714 \u00a0\u00a01,147,483 \u00a0\nPrepaid expenses and other 189,216 \u00a0\u00a0163,244 \u00a0\nTotal current assets 28,954,816 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,442,383 \u00a0\u00a01,770,516 \u00a0\n14", "page_label": "14", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2769e33abb4b10fbe29ba9ead0ff985bead0ea277768a8ea4e6b9281faaffea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab8690a5-4c61-4bea-b4ab-6f0bef00826e", "node_type": "1", "metadata": {"window": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\n\u00a0 \u00a02019 \u00a02018\nOperating Activities: \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0$186,568 \u00a0\u00a0$391,753 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1\u00a0341,020 \u00a0\u00a0206,905 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0\u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(307,204 )\u00a0(658,890 )\nInventories \u00a0(630,980 )\u00a0(898,775 )\nAccounts payable \u00a0787,037 \u00a0\u00a01,498,643 \u00a0\nOther \u00a0(233,631 )\u00a0(60,668 )\nNet cash provided by operating activities \u00a0142,810 \u00a0\u00a0478,968 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0\u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(67,305 )\u00a0(79,233 )\nCost of acquired companies, net of cash acquired \u00a0\u2014 \u00a0\u00a0(52,398 )\nOther \u00a04,966 \u00a0\u00a04,013 \u00a0\nNet cash used in investing activities \u00a0(62,339 )\u00a0(127,618 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0\u00a0 \u00a0\u00a0\nNet (repayments) borrowings \u00a0(13,981 )\u00a08,442 \u00a0\nPurchases of common stock 2 \u00a0(135,128 )\u00a0(239,008 )\nExercises of stock options \u00a020,113 \u00a0\u00a022,400 \u00a0\nCash dividends on common stock \u00a0(83,088 )\u00a0(85,535 )\n16", "original_text": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\n\u00a0 \u00a02019 \u00a02018\nOperating Activities: \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0$186,568 \u00a0\u00a0$391,753 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1\u00a0341,020 \u00a0\u00a0206,905 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0\u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(307,204 )\u00a0(658,890 )\nInventories \u00a0(630,980 )\u00a0(898,775 )\nAccounts payable \u00a0787,037 \u00a0\u00a01,498,643 \u00a0\nOther \u00a0(233,631 )\u00a0(60,668 )\nNet cash provided by operating activities \u00a0142,810 \u00a0\u00a0478,968 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0\u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(67,305 )\u00a0(79,233 )\nCost of acquired companies, net of cash acquired \u00a0\u2014 \u00a0\u00a0(52,398 )\nOther \u00a04,966 \u00a0\u00a04,013 \u00a0\nNet cash used in investing activities \u00a0(62,339 )\u00a0(127,618 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0\u00a0 \u00a0\u00a0\nNet (repayments) borrowings \u00a0(13,981 )\u00a08,442 \u00a0\nPurchases of common stock 2 \u00a0(135,128 )\u00a0(239,008 )\nExercises of stock options \u00a020,113 \u00a0\u00a022,400 \u00a0\nCash dividends on common stock \u00a0(83,088 )\u00a0(85,535 )\n16"}, "hash": "86dd1ab28e458f024d4bc1888eb6dd47877cf5a00d871f5045237c628699b551", "class_name": "RelatedNodeInfo"}}, "text": "Goodwill and other intangible assets 8,846,162 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 773,377 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $40,016,738 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $29,181,860 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 916,107 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 532,489 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 30,630,456 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,636,114 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 289,047 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,895,453 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 496,587 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,069,081 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity\n$40,016,738\u00a0\n\u00a0$39,171,980\u00a0\n\u00a0\n\u00a0\nAMERISOURCEBERGEN CORPORATION\n15", "start_char_idx": 0, "end_char_idx": 746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab8690a5-4c61-4bea-b4ab-6f0bef00826e": {"__data__": {"id_": "ab8690a5-4c61-4bea-b4ab-6f0bef00826e", "embedding": null, "metadata": {"window": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\n\u00a0 \u00a02019 \u00a02018\nOperating Activities: \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0$186,568 \u00a0\u00a0$391,753 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1\u00a0341,020 \u00a0\u00a0206,905 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0\u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(307,204 )\u00a0(658,890 )\nInventories \u00a0(630,980 )\u00a0(898,775 )\nAccounts payable \u00a0787,037 \u00a0\u00a01,498,643 \u00a0\nOther \u00a0(233,631 )\u00a0(60,668 )\nNet cash provided by operating activities \u00a0142,810 \u00a0\u00a0478,968 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0\u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(67,305 )\u00a0(79,233 )\nCost of acquired companies, net of cash acquired \u00a0\u2014 \u00a0\u00a0(52,398 )\nOther \u00a04,966 \u00a0\u00a04,013 \u00a0\nNet cash used in investing activities \u00a0(62,339 )\u00a0(127,618 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0\u00a0 \u00a0\u00a0\nNet (repayments) borrowings \u00a0(13,981 )\u00a08,442 \u00a0\nPurchases of common stock 2 \u00a0(135,128 )\u00a0(239,008 )\nExercises of stock options \u00a020,113 \u00a0\u00a022,400 \u00a0\nCash dividends on common stock \u00a0(83,088 )\u00a0(85,535 )\n16", "original_text": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\n\u00a0 \u00a02019 \u00a02018\nOperating Activities: \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0$186,568 \u00a0\u00a0$391,753 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1\u00a0341,020 \u00a0\u00a0206,905 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0\u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(307,204 )\u00a0(658,890 )\nInventories \u00a0(630,980 )\u00a0(898,775 )\nAccounts payable \u00a0787,037 \u00a0\u00a01,498,643 \u00a0\nOther \u00a0(233,631 )\u00a0(60,668 )\nNet cash provided by operating activities \u00a0142,810 \u00a0\u00a0478,968 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0\u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(67,305 )\u00a0(79,233 )\nCost of acquired companies, net of cash acquired \u00a0\u2014 \u00a0\u00a0(52,398 )\nOther \u00a04,966 \u00a0\u00a04,013 \u00a0\nNet cash used in investing activities \u00a0(62,339 )\u00a0(127,618 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0\u00a0 \u00a0\u00a0\nNet (repayments) borrowings \u00a0(13,981 )\u00a08,442 \u00a0\nPurchases of common stock 2 \u00a0(135,128 )\u00a0(239,008 )\nExercises of stock options \u00a020,113 \u00a0\u00a022,400 \u00a0\nCash dividends on common stock \u00a0(83,088 )\u00a0(85,535 )\n16", "page_label": "16", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f31e967-4279-40dd-a1a0-717238a4e3a2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0e16a134e06e494cdfc6eb172118a408891e5294cf39c3edda63b425817f3db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3f9ae9a-8c3a-485b-9d27-c96a9080f261", "node_type": "1", "metadata": {"window": "Goodwill and other intangible assets 8,846,162 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 773,377 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $40,016,738 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $29,181,860 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 916,107 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 532,489 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 30,630,456 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,636,114 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 289,047 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,895,453 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 496,587 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,069,081 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity\n$40,016,738\u00a0\n\u00a0$39,171,980\u00a0\n\u00a0\n\u00a0\nAMERISOURCEBERGEN CORPORATION\n15", "original_text": "Goodwill and other intangible assets 8,846,162 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 773,377 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $40,016,738 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $29,181,860 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 916,107 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 532,489 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 30,630,456 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,636,114 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 289,047 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,895,453 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 496,587 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,069,081 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity\n$40,016,738\u00a0\n\u00a0$39,171,980\u00a0\n\u00a0\n\u00a0\nAMERISOURCEBERGEN CORPORATION\n15", "page_label": "15", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bf2e0fec7cbe085993035b9e2dfcdeed12c23afc1f20a35845e004c8bb6cf3df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7914144c-42f1-47a2-ac09-dc31d1075ccc", "node_type": "1", "metadata": {"window": "Other \u00a0(9,977 )\u00a0(10,009 )\nNet cash used in financing activities \u00a0(222,061 )\u00a0(303,710 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents \u00a0(141,590 )\u00a047,640 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period \u00a03,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period \u00a0$3,232,604 \u00a0\u00a0$2,540,156 \u00a0\n_____________________________________\n1Includes a LIFO expense of $13.3 million and an impairment of long-lived assets of $138.0 million in the three months ended\nDecember 31, 2019.  Includes a LIFO credit of $3.0 million in the three months ended December 31, 2018.\n\u00a0\n 2Purchases of common stock in the three months ended December 31, 2019 includes $14.8 million of September 2019\npurchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases that cash settled in January\n2020.  Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n", "original_text": "Other \u00a0(9,977 )\u00a0(10,009 )\nNet cash used in financing activities \u00a0(222,061 )\u00a0(303,710 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents \u00a0(141,590 )\u00a047,640 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period \u00a03,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period \u00a0$3,232,604 \u00a0\u00a0$2,540,156 \u00a0\n_____________________________________\n1Includes a LIFO expense of $13.3 million and an impairment of long-lived assets of $138.0 million in the three months ended\nDecember 31, 2019. "}, "hash": "731df4206bcd14e0eb9072f44e4374367c26a93f8bcb7d6f07bc96388209c3f1", "class_name": "RelatedNodeInfo"}}, "text": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\n\u00a0 \u00a02019 \u00a02018\nOperating Activities: \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0$186,568 \u00a0\u00a0$391,753 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1\u00a0341,020 \u00a0\u00a0206,905 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0\u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(307,204 )\u00a0(658,890 )\nInventories \u00a0(630,980 )\u00a0(898,775 )\nAccounts payable \u00a0787,037 \u00a0\u00a01,498,643 \u00a0\nOther \u00a0(233,631 )\u00a0(60,668 )\nNet cash provided by operating activities \u00a0142,810 \u00a0\u00a0478,968 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0\u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(67,305 )\u00a0(79,233 )\nCost of acquired companies, net of cash acquired \u00a0\u2014 \u00a0\u00a0(52,398 )\nOther \u00a04,966 \u00a0\u00a04,013 \u00a0\nNet cash used in investing activities \u00a0(62,339 )\u00a0(127,618 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0\u00a0 \u00a0\u00a0\nNet (repayments) borrowings \u00a0(13,981 )\u00a08,442 \u00a0\nPurchases of common stock 2 \u00a0(135,128 )\u00a0(239,008 )\nExercises of stock options \u00a020,113 \u00a0\u00a022,400 \u00a0\nCash dividends on common stock \u00a0(83,088 )\u00a0(85,535 )\n16", "start_char_idx": 0, "end_char_idx": 1049, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7914144c-42f1-47a2-ac09-dc31d1075ccc": {"__data__": {"id_": "7914144c-42f1-47a2-ac09-dc31d1075ccc", "embedding": null, "metadata": {"window": "Other \u00a0(9,977 )\u00a0(10,009 )\nNet cash used in financing activities \u00a0(222,061 )\u00a0(303,710 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents \u00a0(141,590 )\u00a047,640 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period \u00a03,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period \u00a0$3,232,604 \u00a0\u00a0$2,540,156 \u00a0\n_____________________________________\n1Includes a LIFO expense of $13.3 million and an impairment of long-lived assets of $138.0 million in the three months ended\nDecember 31, 2019.  Includes a LIFO credit of $3.0 million in the three months ended December 31, 2018.\n\u00a0\n 2Purchases of common stock in the three months ended December 31, 2019 includes $14.8 million of September 2019\npurchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases that cash settled in January\n2020.  Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n", "original_text": "Other \u00a0(9,977 )\u00a0(10,009 )\nNet cash used in financing activities \u00a0(222,061 )\u00a0(303,710 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents \u00a0(141,590 )\u00a047,640 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period \u00a03,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period \u00a0$3,232,604 \u00a0\u00a0$2,540,156 \u00a0\n_____________________________________\n1Includes a LIFO expense of $13.3 million and an impairment of long-lived assets of $138.0 million in the three months ended\nDecember 31, 2019. ", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebd46aeb95e5ead98f80a472906c3a0f7e609645fa7a5f1fab62a4a95568ef89", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab8690a5-4c61-4bea-b4ab-6f0bef00826e", "node_type": "1", "metadata": {"window": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\n\u00a0 \u00a02019 \u00a02018\nOperating Activities: \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0$186,568 \u00a0\u00a0$391,753 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1\u00a0341,020 \u00a0\u00a0206,905 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0\u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(307,204 )\u00a0(658,890 )\nInventories \u00a0(630,980 )\u00a0(898,775 )\nAccounts payable \u00a0787,037 \u00a0\u00a01,498,643 \u00a0\nOther \u00a0(233,631 )\u00a0(60,668 )\nNet cash provided by operating activities \u00a0142,810 \u00a0\u00a0478,968 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0\u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(67,305 )\u00a0(79,233 )\nCost of acquired companies, net of cash acquired \u00a0\u2014 \u00a0\u00a0(52,398 )\nOther \u00a04,966 \u00a0\u00a04,013 \u00a0\nNet cash used in investing activities \u00a0(62,339 )\u00a0(127,618 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0\u00a0 \u00a0\u00a0\nNet (repayments) borrowings \u00a0(13,981 )\u00a08,442 \u00a0\nPurchases of common stock 2 \u00a0(135,128 )\u00a0(239,008 )\nExercises of stock options \u00a020,113 \u00a0\u00a022,400 \u00a0\nCash dividends on common stock \u00a0(83,088 )\u00a0(85,535 )\n16", "original_text": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\n\u00a0 \u00a02019 \u00a02018\nOperating Activities: \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0$186,568 \u00a0\u00a0$391,753 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1\u00a0341,020 \u00a0\u00a0206,905 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0\u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(307,204 )\u00a0(658,890 )\nInventories \u00a0(630,980 )\u00a0(898,775 )\nAccounts payable \u00a0787,037 \u00a0\u00a01,498,643 \u00a0\nOther \u00a0(233,631 )\u00a0(60,668 )\nNet cash provided by operating activities \u00a0142,810 \u00a0\u00a0478,968 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0\u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(67,305 )\u00a0(79,233 )\nCost of acquired companies, net of cash acquired \u00a0\u2014 \u00a0\u00a0(52,398 )\nOther \u00a04,966 \u00a0\u00a04,013 \u00a0\nNet cash used in investing activities \u00a0(62,339 )\u00a0(127,618 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0\u00a0 \u00a0\u00a0\nNet (repayments) borrowings \u00a0(13,981 )\u00a08,442 \u00a0\nPurchases of common stock 2 \u00a0(135,128 )\u00a0(239,008 )\nExercises of stock options \u00a020,113 \u00a0\u00a022,400 \u00a0\nCash dividends on common stock \u00a0(83,088 )\u00a0(85,535 )\n16", "page_label": "16", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0242e9386fc7b1296a17f5e1970c1e99addbab77a237be0f40e1d4a9e3080429", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80e630cf-e520-400c-8abc-1cf63a21d9e2", "node_type": "1", "metadata": {"window": "Other \u00a0(9,977 )\u00a0(10,009 )\nNet cash used in financing activities \u00a0(222,061 )\u00a0(303,710 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents \u00a0(141,590 )\u00a047,640 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period \u00a03,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period \u00a0$3,232,604 \u00a0\u00a0$2,540,156 \u00a0\n_____________________________________\n1Includes a LIFO expense of $13.3 million and an impairment of long-lived assets of $138.0 million in the three months ended\nDecember 31, 2019.  Includes a LIFO credit of $3.0 million in the three months ended December 31, 2018.\n\u00a0\n 2Purchases of common stock in the three months ended December 31, 2019 includes $14.8 million of September 2019\npurchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases that cash settled in January\n2020.  Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "original_text": "Includes a LIFO credit of $3.0 million in the three months ended December 31, 2018.\n\u00a0\n"}, "hash": "bd1bd042b551ca8e2763f0a1fa0add76eb40a616034e7b3eeebab8a6cd5e3cd2", "class_name": "RelatedNodeInfo"}}, "text": "Other \u00a0(9,977 )\u00a0(10,009 )\nNet cash used in financing activities \u00a0(222,061 )\u00a0(303,710 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents \u00a0(141,590 )\u00a047,640 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period \u00a03,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period \u00a0$3,232,604 \u00a0\u00a0$2,540,156 \u00a0\n_____________________________________\n1Includes a LIFO expense of $13.3 million and an impairment of long-lived assets of $138.0 million in the three months ended\nDecember 31, 2019. ", "start_char_idx": 0, "end_char_idx": 507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80e630cf-e520-400c-8abc-1cf63a21d9e2": {"__data__": {"id_": "80e630cf-e520-400c-8abc-1cf63a21d9e2", "embedding": null, "metadata": {"window": "Other \u00a0(9,977 )\u00a0(10,009 )\nNet cash used in financing activities \u00a0(222,061 )\u00a0(303,710 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents \u00a0(141,590 )\u00a047,640 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period \u00a03,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period \u00a0$3,232,604 \u00a0\u00a0$2,540,156 \u00a0\n_____________________________________\n1Includes a LIFO expense of $13.3 million and an impairment of long-lived assets of $138.0 million in the three months ended\nDecember 31, 2019.  Includes a LIFO credit of $3.0 million in the three months ended December 31, 2018.\n\u00a0\n 2Purchases of common stock in the three months ended December 31, 2019 includes $14.8 million of September 2019\npurchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases that cash settled in January\n2020.  Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "original_text": "Includes a LIFO credit of $3.0 million in the three months ended December 31, 2018.\n\u00a0\n", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebd46aeb95e5ead98f80a472906c3a0f7e609645fa7a5f1fab62a4a95568ef89", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7914144c-42f1-47a2-ac09-dc31d1075ccc", "node_type": "1", "metadata": {"window": "Other \u00a0(9,977 )\u00a0(10,009 )\nNet cash used in financing activities \u00a0(222,061 )\u00a0(303,710 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents \u00a0(141,590 )\u00a047,640 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period \u00a03,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period \u00a0$3,232,604 \u00a0\u00a0$2,540,156 \u00a0\n_____________________________________\n1Includes a LIFO expense of $13.3 million and an impairment of long-lived assets of $138.0 million in the three months ended\nDecember 31, 2019.  Includes a LIFO credit of $3.0 million in the three months ended December 31, 2018.\n\u00a0\n 2Purchases of common stock in the three months ended December 31, 2019 includes $14.8 million of September 2019\npurchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases that cash settled in January\n2020.  Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n", "original_text": "Other \u00a0(9,977 )\u00a0(10,009 )\nNet cash used in financing activities \u00a0(222,061 )\u00a0(303,710 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents \u00a0(141,590 )\u00a047,640 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period \u00a03,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period \u00a0$3,232,604 \u00a0\u00a0$2,540,156 \u00a0\n_____________________________________\n1Includes a LIFO expense of $13.3 million and an impairment of long-lived assets of $138.0 million in the three months ended\nDecember 31, 2019. ", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9aec40c16fa9f4dcfea6eb57d652eb34f4fbf5dbb279216c24c98b6da1d91ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7427053f-65af-46f2-85df-80b58211589c", "node_type": "1", "metadata": {"window": "Other \u00a0(9,977 )\u00a0(10,009 )\nNet cash used in financing activities \u00a0(222,061 )\u00a0(303,710 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents \u00a0(141,590 )\u00a047,640 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period \u00a03,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period \u00a0$3,232,604 \u00a0\u00a0$2,540,156 \u00a0\n_____________________________________\n1Includes a LIFO expense of $13.3 million and an impairment of long-lived assets of $138.0 million in the three months ended\nDecember 31, 2019.  Includes a LIFO credit of $3.0 million in the three months ended December 31, 2018.\n\u00a0\n 2Purchases of common stock in the three months ended December 31, 2019 includes $14.8 million of September 2019\npurchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases that cash settled in January\n2020.  Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "2Purchases of common stock in the three months ended December 31, 2019 includes $14.8 million of September 2019\npurchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases that cash settled in January\n2020. "}, "hash": "289719a15ee62696c559b122dbec7db8c20d4d8f4d1ff979ff72fadaedb10f56", "class_name": "RelatedNodeInfo"}}, "text": "Includes a LIFO credit of $3.0 million in the three months ended December 31, 2018.\n\u00a0\n", "start_char_idx": 507, "end_char_idx": 593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7427053f-65af-46f2-85df-80b58211589c": {"__data__": {"id_": "7427053f-65af-46f2-85df-80b58211589c", "embedding": null, "metadata": {"window": "Other \u00a0(9,977 )\u00a0(10,009 )\nNet cash used in financing activities \u00a0(222,061 )\u00a0(303,710 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents \u00a0(141,590 )\u00a047,640 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period \u00a03,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period \u00a0$3,232,604 \u00a0\u00a0$2,540,156 \u00a0\n_____________________________________\n1Includes a LIFO expense of $13.3 million and an impairment of long-lived assets of $138.0 million in the three months ended\nDecember 31, 2019.  Includes a LIFO credit of $3.0 million in the three months ended December 31, 2018.\n\u00a0\n 2Purchases of common stock in the three months ended December 31, 2019 includes $14.8 million of September 2019\npurchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases that cash settled in January\n2020.  Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "2Purchases of common stock in the three months ended December 31, 2019 includes $14.8 million of September 2019\npurchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases that cash settled in January\n2020. ", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebd46aeb95e5ead98f80a472906c3a0f7e609645fa7a5f1fab62a4a95568ef89", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80e630cf-e520-400c-8abc-1cf63a21d9e2", "node_type": "1", "metadata": {"window": "Other \u00a0(9,977 )\u00a0(10,009 )\nNet cash used in financing activities \u00a0(222,061 )\u00a0(303,710 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents \u00a0(141,590 )\u00a047,640 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period \u00a03,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period \u00a0$3,232,604 \u00a0\u00a0$2,540,156 \u00a0\n_____________________________________\n1Includes a LIFO expense of $13.3 million and an impairment of long-lived assets of $138.0 million in the three months ended\nDecember 31, 2019.  Includes a LIFO credit of $3.0 million in the three months ended December 31, 2018.\n\u00a0\n 2Purchases of common stock in the three months ended December 31, 2019 includes $14.8 million of September 2019\npurchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases that cash settled in January\n2020.  Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "original_text": "Includes a LIFO credit of $3.0 million in the three months ended December 31, 2018.\n\u00a0\n", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b59cf0684aebfd0cb0e5347f718b62e716bb44267af2e22b236b1658022dfa0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70c2deec-b132-4931-8392-4ace4758a43f", "node_type": "1", "metadata": {"window": "Other \u00a0(9,977 )\u00a0(10,009 )\nNet cash used in financing activities \u00a0(222,061 )\u00a0(303,710 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents \u00a0(141,590 )\u00a047,640 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period \u00a03,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period \u00a0$3,232,604 \u00a0\u00a0$2,540,156 \u00a0\n_____________________________________\n1Includes a LIFO expense of $13.3 million and an impairment of long-lived assets of $138.0 million in the three months ended\nDecember 31, 2019.  Includes a LIFO credit of $3.0 million in the three months ended December 31, 2018.\n\u00a0\n 2Purchases of common stock in the three months ended December 31, 2019 includes $14.8 million of September 2019\npurchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases that cash settled in January\n2020.  Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n"}, "hash": "66f67d1bd0e2636dd211f4c120c3a603c656b2f2424032cf5ae1e39c20f49322", "class_name": "RelatedNodeInfo"}}, "text": "2Purchases of common stock in the three months ended December 31, 2019 includes $14.8 million of September 2019\npurchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases that cash settled in January\n2020. ", "start_char_idx": 593, "end_char_idx": 837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70c2deec-b132-4931-8392-4ace4758a43f": {"__data__": {"id_": "70c2deec-b132-4931-8392-4ace4758a43f", "embedding": null, "metadata": {"window": "Other \u00a0(9,977 )\u00a0(10,009 )\nNet cash used in financing activities \u00a0(222,061 )\u00a0(303,710 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents \u00a0(141,590 )\u00a047,640 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period \u00a03,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period \u00a0$3,232,604 \u00a0\u00a0$2,540,156 \u00a0\n_____________________________________\n1Includes a LIFO expense of $13.3 million and an impairment of long-lived assets of $138.0 million in the three months ended\nDecember 31, 2019.  Includes a LIFO credit of $3.0 million in the three months ended December 31, 2018.\n\u00a0\n 2Purchases of common stock in the three months ended December 31, 2019 includes $14.8 million of September 2019\npurchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases that cash settled in January\n2020.  Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebd46aeb95e5ead98f80a472906c3a0f7e609645fa7a5f1fab62a4a95568ef89", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7427053f-65af-46f2-85df-80b58211589c", "node_type": "1", "metadata": {"window": "Other \u00a0(9,977 )\u00a0(10,009 )\nNet cash used in financing activities \u00a0(222,061 )\u00a0(303,710 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents \u00a0(141,590 )\u00a047,640 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period \u00a03,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period \u00a0$3,232,604 \u00a0\u00a0$2,540,156 \u00a0\n_____________________________________\n1Includes a LIFO expense of $13.3 million and an impairment of long-lived assets of $138.0 million in the three months ended\nDecember 31, 2019.  Includes a LIFO credit of $3.0 million in the three months ended December 31, 2018.\n\u00a0\n 2Purchases of common stock in the three months ended December 31, 2019 includes $14.8 million of September 2019\npurchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases that cash settled in January\n2020.  Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "2Purchases of common stock in the three months ended December 31, 2019 includes $14.8 million of September 2019\npurchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases that cash settled in January\n2020. ", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0185dd8737470f638130147330f0901a377f238fd4dfea4ad97e4b81505159e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64c66de7-fd54-4c4b-ac15-4ede7845e255", "node_type": "1", "metadata": {"window": "Includes a LIFO credit of $3.0 million in the three months ended December 31, 2018.\n\u00a0\n 2Purchases of common stock in the three months ended December 31, 2019 includes $14.8 million of September 2019\npurchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases that cash settled in January\n2020.  Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. "}, "hash": "ae6fc519c9fb04d5d84006c86d5ac4360f3117306fdee07e796f109a3e6993f6", "class_name": "RelatedNodeInfo"}}, "text": "Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n", "start_char_idx": 837, "end_char_idx": 1081, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64c66de7-fd54-4c4b-ac15-4ede7845e255": {"__data__": {"id_": "64c66de7-fd54-4c4b-ac15-4ede7845e255", "embedding": null, "metadata": {"window": "Includes a LIFO credit of $3.0 million in the three months ended December 31, 2018.\n\u00a0\n 2Purchases of common stock in the three months ended December 31, 2019 includes $14.8 million of September 2019\npurchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases that cash settled in January\n2020.  Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebd46aeb95e5ead98f80a472906c3a0f7e609645fa7a5f1fab62a4a95568ef89", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70c2deec-b132-4931-8392-4ace4758a43f", "node_type": "1", "metadata": {"window": "Other \u00a0(9,977 )\u00a0(10,009 )\nNet cash used in financing activities \u00a0(222,061 )\u00a0(303,710 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents \u00a0(141,590 )\u00a047,640 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period \u00a03,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period \u00a0$3,232,604 \u00a0\u00a0$2,540,156 \u00a0\n_____________________________________\n1Includes a LIFO expense of $13.3 million and an impairment of long-lived assets of $138.0 million in the three months ended\nDecember 31, 2019.  Includes a LIFO credit of $3.0 million in the three months ended December 31, 2018.\n\u00a0\n 2Purchases of common stock in the three months ended December 31, 2019 includes $14.8 million of September 2019\npurchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases that cash settled in January\n2020.  Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b7cf3a7ed38c7ef55fb51c78e2f952e4746c3795a9713600374dfb17389c5d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "166d1592-de26-485d-b6fb-c13ce3a75709", "node_type": "1", "metadata": {"window": "2Purchases of common stock in the three months ended December 31, 2019 includes $14.8 million of September 2019\npurchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases that cash settled in January\n2020.  Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. "}, "hash": "690427a546614e8d97d19d81a8dcfed42ffb7e04185630937ad5f53e9597b118", "class_name": "RelatedNodeInfo"}}, "text": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "start_char_idx": 1081, "end_char_idx": 1219, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "166d1592-de26-485d-b6fb-c13ce3a75709": {"__data__": {"id_": "166d1592-de26-485d-b6fb-c13ce3a75709", "embedding": null, "metadata": {"window": "2Purchases of common stock in the three months ended December 31, 2019 includes $14.8 million of September 2019\npurchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases that cash settled in January\n2020.  Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebd46aeb95e5ead98f80a472906c3a0f7e609645fa7a5f1fab62a4a95568ef89", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64c66de7-fd54-4c4b-ac15-4ede7845e255", "node_type": "1", "metadata": {"window": "Includes a LIFO credit of $3.0 million in the three months ended December 31, 2018.\n\u00a0\n 2Purchases of common stock in the three months ended December 31, 2019 includes $14.8 million of September 2019\npurchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases that cash settled in January\n2020.  Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2aa3e7063d38c49cf7e8c6ca264a95ea4f1d9f92a039bfba14f6081254a32379", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "191532cf-ca29-4141-9fa5-a28e5726bd97", "node_type": "1", "metadata": {"window": "Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. "}, "hash": "12bc19a799f4566e86d624a49e92212dd084591a7a1c59b6896a9eddc7b98312", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "start_char_idx": 1219, "end_char_idx": 1334, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "191532cf-ca29-4141-9fa5-a28e5726bd97": {"__data__": {"id_": "191532cf-ca29-4141-9fa5-a28e5726bd97", "embedding": null, "metadata": {"window": "Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebd46aeb95e5ead98f80a472906c3a0f7e609645fa7a5f1fab62a4a95568ef89", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "166d1592-de26-485d-b6fb-c13ce3a75709", "node_type": "1", "metadata": {"window": "2Purchases of common stock in the three months ended December 31, 2019 includes $14.8 million of September 2019\npurchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases that cash settled in January\n2020.  Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f23ae8a5738a0f867dcc1e0c3109f42d4223c9af7983315997526a6d73b2a78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb961eb5-ac6e-46cc-9e8b-f4cbece5f08b", "node_type": "1", "metadata": {"window": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n"}, "hash": "d7f41ea6e423d600cac2fbc4858ef319d95447153d4c26be00f5ad76552c02d8", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "start_char_idx": 1334, "end_char_idx": 1474, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb961eb5-ac6e-46cc-9e8b-f4cbece5f08b": {"__data__": {"id_": "eb961eb5-ac6e-46cc-9e8b-f4cbece5f08b", "embedding": null, "metadata": {"window": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebd46aeb95e5ead98f80a472906c3a0f7e609645fa7a5f1fab62a4a95568ef89", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "191532cf-ca29-4141-9fa5-a28e5726bd97", "node_type": "1", "metadata": {"window": "Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4cc3e056059c2e0bf20af3fb3bc658134a84ceb2d505078dba098cf9cfb01dd1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71747ed3-a2e4-4d85-9067-390ee1c36501", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act. ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. "}, "hash": "5b3476486ffe53a61e550489571e409022a8acd6bd63706365cc301bbfd56e06", "class_name": "RelatedNodeInfo"}}, "text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "start_char_idx": 1474, "end_char_idx": 1593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71747ed3-a2e4-4d85-9067-390ee1c36501": {"__data__": {"id_": "71747ed3-a2e4-4d85-9067-390ee1c36501", "embedding": null, "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act. ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebd46aeb95e5ead98f80a472906c3a0f7e609645fa7a5f1fab62a4a95568ef89", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb961eb5-ac6e-46cc-9e8b-f4cbece5f08b", "node_type": "1", "metadata": {"window": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0fd6bb323f95a5ab011acd783abaf8d450aa925cf0d3b9ab1c72026334e954b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "262082c9-3478-4c6f-a6aa-131eec9ed05f", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act.  Gain from antitrust litigation settlements and LIFO expense (credit) are\nexcluded because the Company cannot control the amounts recognized or timing of these items. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. "}, "hash": "fceab225b580e6358b065c03b0bd9819eaaa28b7e71c77bdff058e5d7b3732d6", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "start_char_idx": 1593, "end_char_idx": 1812, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "262082c9-3478-4c6f-a6aa-131eec9ed05f": {"__data__": {"id_": "262082c9-3478-4c6f-a6aa-131eec9ed05f", "embedding": null, "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act.  Gain from antitrust litigation settlements and LIFO expense (credit) are\nexcluded because the Company cannot control the amounts recognized or timing of these items. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebd46aeb95e5ead98f80a472906c3a0f7e609645fa7a5f1fab62a4a95568ef89", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71747ed3-a2e4-4d85-9067-390ee1c36501", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act. ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b1d540884b722f33ebcd3a2aba4f7959204700022129f099e2e6f2fc1ca10b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a632129f-4138-47aa-8a48-e6d1cae8a1eb", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act.  Gain from antitrust litigation settlements and LIFO expense (credit) are\nexcluded because the Company cannot control the amounts recognized or timing of these items.  PharMEDium remediation\ncosts are excluded because they are unpredictable expenses. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. "}, "hash": "9baade804ae23f8ad7d4441604678680f275f4e689e1d2c725f5c5763704cd0b", "class_name": "RelatedNodeInfo"}}, "text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "start_char_idx": 1812, "end_char_idx": 1994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a632129f-4138-47aa-8a48-e6d1cae8a1eb": {"__data__": {"id_": "a632129f-4138-47aa-8a48-e6d1cae8a1eb", "embedding": null, "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act.  Gain from antitrust litigation settlements and LIFO expense (credit) are\nexcluded because the Company cannot control the amounts recognized or timing of these items.  PharMEDium remediation\ncosts are excluded because they are unpredictable expenses. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebd46aeb95e5ead98f80a472906c3a0f7e609645fa7a5f1fab62a4a95568ef89", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "262082c9-3478-4c6f-a6aa-131eec9ed05f", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act.  Gain from antitrust litigation settlements and LIFO expense (credit) are\nexcluded because the Company cannot control the amounts recognized or timing of these items. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9bd93c75f205f5383f897c244f7e43538901cbfcb7dcc5f99d88b004bfe90855", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9072523-6e39-41eb-ac3f-0abe25eb19e5", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act.  Gain from antitrust litigation settlements and LIFO expense (credit) are\nexcluded because the Company cannot control the amounts recognized or timing of these items.  PharMEDium remediation\ncosts are excluded because they are unpredictable expenses.  The (credit) related to the New York State Opioid Stewardship\n17", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act. "}, "hash": "741bc0995fea92d30124fd2bbebe38766f7dce538709f481d874a53c3a16810f", "class_name": "RelatedNodeInfo"}}, "text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "start_char_idx": 1994, "end_char_idx": 2275, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9072523-6e39-41eb-ac3f-0abe25eb19e5": {"__data__": {"id_": "a9072523-6e39-41eb-ac3f-0abe25eb19e5", "embedding": null, "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act.  Gain from antitrust litigation settlements and LIFO expense (credit) are\nexcluded because the Company cannot control the amounts recognized or timing of these items.  PharMEDium remediation\ncosts are excluded because they are unpredictable expenses.  The (credit) related to the New York State Opioid Stewardship\n17", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act. ", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebd46aeb95e5ead98f80a472906c3a0f7e609645fa7a5f1fab62a4a95568ef89", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a632129f-4138-47aa-8a48-e6d1cae8a1eb", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act.  Gain from antitrust litigation settlements and LIFO expense (credit) are\nexcluded because the Company cannot control the amounts recognized or timing of these items.  PharMEDium remediation\ncosts are excluded because they are unpredictable expenses. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "69b4938e9c6de4c556a5eac4d2b7819d13c5f50e0a4db08226b5247a75664f77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8df7fa5-974c-4da5-a611-d197779cde55", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act.  Gain from antitrust litigation settlements and LIFO expense (credit) are\nexcluded because the Company cannot control the amounts recognized or timing of these items.  PharMEDium remediation\ncosts are excluded because they are unpredictable expenses.  The (credit) related to the New York State Opioid Stewardship\n17", "original_text": "Gain from antitrust litigation settlements and LIFO expense (credit) are\nexcluded because the Company cannot control the amounts recognized or timing of these items. "}, "hash": "15d3784985cafdd15c97b505bcf0a9c6c3c7c2d639335907c5105eb3213d656c", "class_name": "RelatedNodeInfo"}}, "text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act. ", "start_char_idx": 2275, "end_char_idx": 2673, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8df7fa5-974c-4da5-a611-d197779cde55": {"__data__": {"id_": "a8df7fa5-974c-4da5-a611-d197779cde55", "embedding": null, "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act.  Gain from antitrust litigation settlements and LIFO expense (credit) are\nexcluded because the Company cannot control the amounts recognized or timing of these items.  PharMEDium remediation\ncosts are excluded because they are unpredictable expenses.  The (credit) related to the New York State Opioid Stewardship\n17", "original_text": "Gain from antitrust litigation settlements and LIFO expense (credit) are\nexcluded because the Company cannot control the amounts recognized or timing of these items. ", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebd46aeb95e5ead98f80a472906c3a0f7e609645fa7a5f1fab62a4a95568ef89", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9072523-6e39-41eb-ac3f-0abe25eb19e5", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act.  Gain from antitrust litigation settlements and LIFO expense (credit) are\nexcluded because the Company cannot control the amounts recognized or timing of these items.  PharMEDium remediation\ncosts are excluded because they are unpredictable expenses.  The (credit) related to the New York State Opioid Stewardship\n17", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act. ", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61e46215b6e1d53271c411b7f342bcb67d3b605ac4a29b4f9ea6d89eaad497c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c61be182-120e-4d8a-a862-4ecf8bbddaa3", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act.  Gain from antitrust litigation settlements and LIFO expense (credit) are\nexcluded because the Company cannot control the amounts recognized or timing of these items.  PharMEDium remediation\ncosts are excluded because they are unpredictable expenses.  The (credit) related to the New York State Opioid Stewardship\n17", "original_text": "PharMEDium remediation\ncosts are excluded because they are unpredictable expenses. "}, "hash": "936706c887549e1d493262511a1f5ed469ac5560571ce7626d809597c07ac88a", "class_name": "RelatedNodeInfo"}}, "text": "Gain from antitrust litigation settlements and LIFO expense (credit) are\nexcluded because the Company cannot control the amounts recognized or timing of these items. ", "start_char_idx": 2673, "end_char_idx": 2839, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c61be182-120e-4d8a-a862-4ecf8bbddaa3": {"__data__": {"id_": "c61be182-120e-4d8a-a862-4ecf8bbddaa3", "embedding": null, "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act.  Gain from antitrust litigation settlements and LIFO expense (credit) are\nexcluded because the Company cannot control the amounts recognized or timing of these items.  PharMEDium remediation\ncosts are excluded because they are unpredictable expenses.  The (credit) related to the New York State Opioid Stewardship\n17", "original_text": "PharMEDium remediation\ncosts are excluded because they are unpredictable expenses. ", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebd46aeb95e5ead98f80a472906c3a0f7e609645fa7a5f1fab62a4a95568ef89", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8df7fa5-974c-4da5-a611-d197779cde55", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act.  Gain from antitrust litigation settlements and LIFO expense (credit) are\nexcluded because the Company cannot control the amounts recognized or timing of these items.  PharMEDium remediation\ncosts are excluded because they are unpredictable expenses.  The (credit) related to the New York State Opioid Stewardship\n17", "original_text": "Gain from antitrust litigation settlements and LIFO expense (credit) are\nexcluded because the Company cannot control the amounts recognized or timing of these items. ", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "880029cb2d86032a2cf79aefd28cbda8ef1de3cf8b0e4f58697d16053accbb43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "254ee87e-01a1-4f01-aa50-6273ff7f9be1", "node_type": "1", "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act.  Gain from antitrust litigation settlements and LIFO expense (credit) are\nexcluded because the Company cannot control the amounts recognized or timing of these items.  PharMEDium remediation\ncosts are excluded because they are unpredictable expenses.  The (credit) related to the New York State Opioid Stewardship\n17", "original_text": "The (credit) related to the New York State Opioid Stewardship\n17"}, "hash": "7035b27ba46966465e35944667252057ad5c0647d7e678b66c0c29afcdaea724", "class_name": "RelatedNodeInfo"}}, "text": "PharMEDium remediation\ncosts are excluded because they are unpredictable expenses. ", "start_char_idx": 2839, "end_char_idx": 2922, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "254ee87e-01a1-4f01-aa50-6273ff7f9be1": {"__data__": {"id_": "254ee87e-01a1-4f01-aa50-6273ff7f9be1", "embedding": null, "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act.  Gain from antitrust litigation settlements and LIFO expense (credit) are\nexcluded because the Company cannot control the amounts recognized or timing of these items.  PharMEDium remediation\ncosts are excluded because they are unpredictable expenses.  The (credit) related to the New York State Opioid Stewardship\n17", "original_text": "The (credit) related to the New York State Opioid Stewardship\n17", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebd46aeb95e5ead98f80a472906c3a0f7e609645fa7a5f1fab62a4a95568ef89", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c61be182-120e-4d8a-a862-4ecf8bbddaa3", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act.  Gain from antitrust litigation settlements and LIFO expense (credit) are\nexcluded because the Company cannot control the amounts recognized or timing of these items.  PharMEDium remediation\ncosts are excluded because they are unpredictable expenses.  The (credit) related to the New York State Opioid Stewardship\n17", "original_text": "PharMEDium remediation\ncosts are excluded because they are unpredictable expenses. ", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fac4eed0bf8d3b234b2bd4d71efff69f9428fbf4819edd1cd9cf7b90d880592", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "451e207d-fda7-4e4c-80c7-be237e88bdd4", "node_type": "1", "metadata": {"window": "Act is excluded because it is unusual, non-recurring and non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket. ", "original_text": "Act is excluded because it is unusual, non-recurring and non-cash. "}, "hash": "13c02cead53a6fde248362617f8fb448405d36ed321fbf3ac320d8036190154d", "class_name": "RelatedNodeInfo"}}, "text": "The (credit) related to the New York State Opioid Stewardship\n17", "start_char_idx": 2922, "end_char_idx": 2986, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "451e207d-fda7-4e4c-80c7-be237e88bdd4": {"__data__": {"id_": "451e207d-fda7-4e4c-80c7-be237e88bdd4", "embedding": null, "metadata": {"window": "Act is excluded because it is unusual, non-recurring and non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket. ", "original_text": "Act is excluded because it is unusual, non-recurring and non-cash. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "254ee87e-01a1-4f01-aa50-6273ff7f9be1", "node_type": "1", "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, and the (credit)\nrelated to the New York State Opioid Stewardship Act.  Gain from antitrust litigation settlements and LIFO expense (credit) are\nexcluded because the Company cannot control the amounts recognized or timing of these items.  PharMEDium remediation\ncosts are excluded because they are unpredictable expenses.  The (credit) related to the New York State Opioid Stewardship\n17", "original_text": "The (credit) related to the New York State Opioid Stewardship\n17", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7710ef1443fa24e9fd0f74c713bceba81b1632c258a84a3b68ef5d3e65f7060d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63dd53ad-dd51-4a81-9cf9-93753f7c30f4", "node_type": "1", "metadata": {"window": "Act is excluded because it is unusual, non-recurring and non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S. ", "original_text": "Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue. "}, "hash": "40f38bff91d1948b96ca9b502a72c1e91a71952c433c93aed297f16a08f756db", "class_name": "RelatedNodeInfo"}}, "text": "Act is excluded because it is unusual, non-recurring and non-cash. ", "start_char_idx": 0, "end_char_idx": 67, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63dd53ad-dd51-4a81-9cf9-93753f7c30f4": {"__data__": {"id_": "63dd53ad-dd51-4a81-9cf9-93753f7c30f4", "embedding": null, "metadata": {"window": "Act is excluded because it is unusual, non-recurring and non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S. ", "original_text": "Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "451e207d-fda7-4e4c-80c7-be237e88bdd4", "node_type": "1", "metadata": {"window": "Act is excluded because it is unusual, non-recurring and non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket. ", "original_text": "Act is excluded because it is unusual, non-recurring and non-cash. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e637a7d5981147f99a5b7aabe10e82451bcd5e2baeab33ebce5bfdef0e4dfd2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fdcfcf6-27d3-4801-b172-6ee2eab36980", "node_type": "1", "metadata": {"window": "Act is excluded because it is unusual, non-recurring and non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections. ", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. "}, "hash": "495462d8878243bbeee4e426a192330c633b893141d5f22167a55a93e690dd6f", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue. ", "start_char_idx": 67, "end_char_idx": 152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fdcfcf6-27d3-4801-b172-6ee2eab36980": {"__data__": {"id_": "3fdcfcf6-27d3-4801-b172-6ee2eab36980", "embedding": null, "metadata": {"window": "Act is excluded because it is unusual, non-recurring and non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections. ", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63dd53ad-dd51-4a81-9cf9-93753f7c30f4", "node_type": "1", "metadata": {"window": "Act is excluded because it is unusual, non-recurring and non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S. ", "original_text": "Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b7c41fa543879878204f5b00e39b8b7149b108be9ac578f2103f057ada6742d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "427e59db-da42-4a54-9225-18e913ff5740", "node_type": "1", "metadata": {"window": "Act is excluded because it is unusual, non-recurring and non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences. ", "original_text": "The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket. "}, "hash": "6eafffd102d80a25c20336d6d3ab4e4dd7363f080ef87c4972a0d2e2ef393b9d", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. ", "start_char_idx": 152, "end_char_idx": 309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "427e59db-da42-4a54-9225-18e913ff5740": {"__data__": {"id_": "427e59db-da42-4a54-9225-18e913ff5740", "embedding": null, "metadata": {"window": "Act is excluded because it is unusual, non-recurring and non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences. ", "original_text": "The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fdcfcf6-27d3-4801-b172-6ee2eab36980", "node_type": "1", "metadata": {"window": "Act is excluded because it is unusual, non-recurring and non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections. ", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7fd5c82034c87ef0731ca28caa2e6a5d5673350ca43833b59b9937ecb6e96d4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdcffc1a-cfe6-4d22-83f7-5db2f6575c3b", "node_type": "1", "metadata": {"window": "Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state. ", "original_text": "The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S. "}, "hash": "2508877a4f12f56b7eafc1c12b1064b66a50d37c3db3159d0f9b4c725e5a0992", "class_name": "RelatedNodeInfo"}}, "text": "The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket. ", "start_char_idx": 309, "end_char_idx": 609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdcffc1a-cfe6-4d22-83f7-5db2f6575c3b": {"__data__": {"id_": "fdcffc1a-cfe6-4d22-83f7-5db2f6575c3b", "embedding": null, "metadata": {"window": "Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state. ", "original_text": "The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "427e59db-da42-4a54-9225-18e913ff5740", "node_type": "1", "metadata": {"window": "Act is excluded because it is unusual, non-recurring and non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences. ", "original_text": "The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a6e24af42b356d2442f6773cc4bd9bc8c9395224f45e887ef67560013de5240", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "381a411f-a503-4460-8c7e-447e7163fc3f", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state.  In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S. ", "original_text": "Food and Drug Administration inspections. "}, "hash": "20182ab3bb53cb94fd061765677f5424bd7c3c76e39b5c5361f7572d05417171", "class_name": "RelatedNodeInfo"}}, "text": "The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S. ", "start_char_idx": 609, "end_char_idx": 733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "381a411f-a503-4460-8c7e-447e7163fc3f": {"__data__": {"id_": "381a411f-a503-4460-8c7e-447e7163fc3f", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state.  In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S. ", "original_text": "Food and Drug Administration inspections. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdcffc1a-cfe6-4d22-83f7-5db2f6575c3b", "node_type": "1", "metadata": {"window": "Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state. ", "original_text": "The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28f41280b396c88c4beff606a1eab4b74709d3251f13f31bddc218bb2bd2a61e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d63de384-f341-46f9-aa95-2a25ac03f46c", "node_type": "1", "metadata": {"window": "The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state.  In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S.  District Court for the Southern District of New York.\n", "original_text": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences. "}, "hash": "45dabc654e80eaeb9f075eb3c8059f2f29bd6f1900ba59f6b2e9eab3b343c739", "class_name": "RelatedNodeInfo"}}, "text": "Food and Drug Administration inspections. ", "start_char_idx": 733, "end_char_idx": 775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d63de384-f341-46f9-aa95-2a25ac03f46c": {"__data__": {"id_": "d63de384-f341-46f9-aa95-2a25ac03f46c", "embedding": null, "metadata": {"window": "The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state.  In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S.  District Court for the Southern District of New York.\n", "original_text": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "381a411f-a503-4460-8c7e-447e7163fc3f", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state.  In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S. ", "original_text": "Food and Drug Administration inspections. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b3085c9edcf6fe8e4ded6b3af9cadbddae357736f45a4fab238562a7d9fd00b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca2b85ef-8a30-43df-b64f-3eecc124b63f", "node_type": "1", "metadata": {"window": "The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state.  In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S.  District Court for the Southern District of New York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets. ", "original_text": "The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state. "}, "hash": "99e9418907236abbae4ef9c1b2738be05ad79d083b3f2d5b88f72f0583c6814d", "class_name": "RelatedNodeInfo"}}, "text": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences. ", "start_char_idx": 775, "end_char_idx": 957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca2b85ef-8a30-43df-b64f-3eecc124b63f": {"__data__": {"id_": "ca2b85ef-8a30-43df-b64f-3eecc124b63f", "embedding": null, "metadata": {"window": "The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state.  In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S.  District Court for the Southern District of New York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets. ", "original_text": "The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d63de384-f341-46f9-aa95-2a25ac03f46c", "node_type": "1", "metadata": {"window": "The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state.  In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S.  District Court for the Southern District of New York.\n", "original_text": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "058866ff0d547101710a40ac66a6b343157117c929c2eb255fbd6ed422dbf997", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d756f18-e20a-4b3e-a820-5e1c40553c49", "node_type": "1", "metadata": {"window": "Food and Drug Administration inspections.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state.  In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S.  District Court for the Southern District of New York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue. ", "original_text": "In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S. "}, "hash": "e27447433c2a700f18528c453e31fab83c5c6ad10d0b09a204b5cd06a9c6955f", "class_name": "RelatedNodeInfo"}}, "text": "The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state. ", "start_char_idx": 957, "end_char_idx": 1236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d756f18-e20a-4b3e-a820-5e1c40553c49": {"__data__": {"id_": "5d756f18-e20a-4b3e-a820-5e1c40553c49", "embedding": null, "metadata": {"window": "Food and Drug Administration inspections.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state.  In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S.  District Court for the Southern District of New York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue. ", "original_text": "In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca2b85ef-8a30-43df-b64f-3eecc124b63f", "node_type": "1", "metadata": {"window": "The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state.  In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S.  District Court for the Southern District of New York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets. ", "original_text": "The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "567236662d41c4166e5a0216fcf82defcb39503365233c3daa18b023da329bb2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "801e04b2-fd16-4ec3-89df-ee7a07c37ea6", "node_type": "1", "metadata": {"window": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state.  In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S.  District Court for the Southern District of New York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies. ", "original_text": "District Court for the Southern District of New York.\n"}, "hash": "633dc9e56778131b560e52e08f433a4161d44f723cb4bf0a9cb44b8d2244a752", "class_name": "RelatedNodeInfo"}}, "text": "In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S. ", "start_char_idx": 1236, "end_char_idx": 1335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "801e04b2-fd16-4ec3-89df-ee7a07c37ea6": {"__data__": {"id_": "801e04b2-fd16-4ec3-89df-ee7a07c37ea6", "embedding": null, "metadata": {"window": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state.  In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S.  District Court for the Southern District of New York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies. ", "original_text": "District Court for the Southern District of New York.\n", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d756f18-e20a-4b3e-a820-5e1c40553c49", "node_type": "1", "metadata": {"window": "Food and Drug Administration inspections.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state.  In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S.  District Court for the Southern District of New York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue. ", "original_text": "In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57b242de2b208d1b9ca51b4ed52e77c72f5fc1ed3414a202485546dd71931cc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "855b9474-f9e9-4984-9295-fa40be786b10", "node_type": "1", "metadata": {"window": "The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state.  In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S.  District Court for the Southern District of New York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets. "}, "hash": "31f0d37121c7198220fa3415221131e62d9ef6ced929a0f82e8ba6fc85217ba3", "class_name": "RelatedNodeInfo"}}, "text": "District Court for the Southern District of New York.\n", "start_char_idx": 1335, "end_char_idx": 1389, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "855b9474-f9e9-4984-9295-fa40be786b10": {"__data__": {"id_": "855b9474-f9e9-4984-9295-fa40be786b10", "embedding": null, "metadata": {"window": "The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state.  In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S.  District Court for the Southern District of New York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "801e04b2-fd16-4ec3-89df-ee7a07c37ea6", "node_type": "1", "metadata": {"window": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state.  In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S.  District Court for the Southern District of New York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies. ", "original_text": "District Court for the Southern District of New York.\n", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65d79b31e17d8230a6d589480de1e8e17e8ab624ce3d946c4ef2b2006e4ac01c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fc5d713-1d66-4331-983e-b99a9ea90174", "node_type": "1", "metadata": {"window": "In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S.  District Court for the Southern District of New York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n", "original_text": "Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue. "}, "hash": "3f099d999708c0ce0ced893c2803f9273b57db2e1f52db7d08cf58d46564bbef", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets. ", "start_char_idx": 1389, "end_char_idx": 1694, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fc5d713-1d66-4331-983e-b99a9ea90174": {"__data__": {"id_": "2fc5d713-1d66-4331-983e-b99a9ea90174", "embedding": null, "metadata": {"window": "In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S.  District Court for the Southern District of New York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n", "original_text": "Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "855b9474-f9e9-4984-9295-fa40be786b10", "node_type": "1", "metadata": {"window": "The New\nYork State Opioid Stewardship Act, which went into effect on July 1, 2018, established an annual $100 million fund and\nrequires manufacturers, distributors, and importers to ratably share the assessment based upon opioids sold or distributed to\nor within New York state.  In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S.  District Court for the Southern District of New York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0fec0dd1b2596f65a9059a421411ae5dcebccd132a946b3b3d3006893be2cd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76cb6819-68f2-442b-aef7-710d5d260740", "node_type": "1", "metadata": {"window": "District Court for the Southern District of New York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies. "}, "hash": "10134c2b5ce1e7c59cd5cb80e4ab5390e09404d0df6a84a4c08c9a5707bd21b8", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue. ", "start_char_idx": 1694, "end_char_idx": 1790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76cb6819-68f2-442b-aef7-710d5d260740": {"__data__": {"id_": "76cb6819-68f2-442b-aef7-710d5d260740", "embedding": null, "metadata": {"window": "District Court for the Southern District of New York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fc5d713-1d66-4331-983e-b99a9ea90174", "node_type": "1", "metadata": {"window": "In December 2018, the New York State Opioid Stewardship Act was ruled unconstitutional by the\nU.S.  District Court for the Southern District of New York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n", "original_text": "Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f47328a3cb31ee37d55eb5d83f03e165889c3271096f00236f97a75616137258", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e52513c-ec50-4123-b4f4-a4a9229674c9", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring. "}, "hash": "1c915ac590133306306bfb1d3d905e0f9b9e423145511015a8712c2e70046796", "class_name": "RelatedNodeInfo"}}, "text": "Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies. ", "start_char_idx": 1790, "end_char_idx": 1952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e52513c-ec50-4123-b4f4-a4a9229674c9": {"__data__": {"id_": "1e52513c-ec50-4123-b4f4-a4a9229674c9", "embedding": null, "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76cb6819-68f2-442b-aef7-710d5d260740", "node_type": "1", "metadata": {"window": "District Court for the Southern District of New York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "117b2ba66f7fc5f380c5c0b9ae15b0a6c04ee4b91e5b24e14dfa92bd820bae7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "741e2f26-8d88-4523-9c6d-ee91eb8cac19", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n"}, "hash": "c85d0bd0f0f95442d944ff7a9f211e108dabc6417638aa16fbeb354adae403db", "class_name": "RelatedNodeInfo"}}, "text": "We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring. ", "start_char_idx": 1952, "end_char_idx": 2064, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "741e2f26-8d88-4523-9c6d-ee91eb8cac19": {"__data__": {"id_": "741e2f26-8d88-4523-9c6d-ee91eb8cac19", "embedding": null, "metadata": {"window": "Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e52513c-ec50-4123-b4f4-a4a9229674c9", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, and impairment of long-lived assets.  Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b3dc49aca1832173875d2acbce97da0464b0a68da9254e91173c9f6af1d64de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14985a43-3b15-43d4-b104-5662abb43f94", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. "}, "hash": "479185eee0d36f94cd9898b756ec63c41d8c637a55f689e03461ba5b1035e564", "class_name": "RelatedNodeInfo"}}, "text": "We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n", "start_char_idx": 2064, "end_char_idx": 2397, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14985a43-3b15-43d4-b104-5662abb43f94": {"__data__": {"id_": "14985a43-3b15-43d4-b104-5662abb43f94", "embedding": null, "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "741e2f26-8d88-4523-9c6d-ee91eb8cac19", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of\nadjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2356db16d8afcb5b69390472d4d66b1e15a858ee9faed145fe56d7d63bbe86a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50a8d02f-cf28-480e-8037-e2ceb1d546de", "node_type": "1", "metadata": {"window": "We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n"}, "hash": "1d637b506c9d2a3987f55151955f334d5424e476662d3205a7493d792b476875", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "start_char_idx": 2397, "end_char_idx": 2646, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50a8d02f-cf28-480e-8037-e2ceb1d546de": {"__data__": {"id_": "50a8d02f-cf28-480e-8037-e2ceb1d546de", "embedding": null, "metadata": {"window": "We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14985a43-3b15-43d4-b104-5662abb43f94", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-\ncash item and does not reflect the operating performance of the acquired companies.  We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "debb5d1134fbe8b5d7a67683e94347c18a6e434d2ac1a47ac86ae20d86146e83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f589c643-4ede-4b63-a749-ccfd5dca919f", "node_type": "1", "metadata": {"window": "We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n"}, "hash": "baa3dd2bbbe8ebabe4029d77423ff8e21d446256797b7256fd93f217210b82bf", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "start_char_idx": 2646, "end_char_idx": 2739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f589c643-4ede-4b63-a749-ccfd5dca919f": {"__data__": {"id_": "f589c643-4ede-4b63-a749-ccfd5dca919f", "embedding": null, "metadata": {"window": "We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50a8d02f-cf28-480e-8037-e2ceb1d546de", "node_type": "1", "metadata": {"window": "We exclude employee severance\namounts that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c374d92ce4130fd462afb0b0b5bb749cff82c342248786a05f2ea8bd44f20739", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72fe4108-4802-4d0a-a7f7-e984cdf25ea1", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. "}, "hash": "019342fc2af6c5c58626e8d3d368dfc25b5fdd824a30b1663980c05c608f941e", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "start_char_idx": 2739, "end_char_idx": 2986, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72fe4108-4802-4d0a-a7f7-e984cdf25ea1": {"__data__": {"id_": "72fe4108-4802-4d0a-a7f7-e984cdf25ea1", "embedding": null, "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f589c643-4ede-4b63-a749-ccfd5dca919f", "node_type": "1", "metadata": {"window": "We exclude the amount of litigation\nsettlements and other expenses, as well as PharMEDium remediation costs and the impairment of long-lived assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "776e37913b739e8234148a868d0ec6f77eec9693b247fce0cac1d87057de0e15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0255fc9-f72e-405b-bfab-35d6082e957d", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n"}, "hash": "42da323549d66873cb6270b1e3d80d56588f3b0e44a65993ca0dc8a98404bcf6", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "start_char_idx": 2986, "end_char_idx": 3191, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0255fc9-f72e-405b-bfab-35d6082e957d": {"__data__": {"id_": "d0255fc9-f72e-405b-bfab-35d6082e957d", "embedding": null, "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72fe4108-4802-4d0a-a7f7-e984cdf25ea1", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a8df74c5e86babe94c71afc126703557a156ab66ee926c9fed8dac701da1e52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c120f3b5-cbce-4cca-8493-71fbb4ae2eca", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n In addition, the final U.S. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. "}, "hash": "3871afdae7d96dae22e8026e617290b5be3a65d0fff0f293b5003f732d936bf2", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n", "start_char_idx": 3191, "end_char_idx": 3357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c120f3b5-cbce-4cca-8493-71fbb4ae2eca": {"__data__": {"id_": "c120f3b5-cbce-4cca-8493-71fbb4ae2eca", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n In addition, the final U.S. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0255fc9-f72e-405b-bfab-35d6082e957d", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "792cb81cb572863b355dbf84499dc4548b24244bf263810f3173c3bcd9368481", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17aba320-251d-49d2-8508-deb2ff9b42a1", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n In addition, the final U.S.  tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n"}, "hash": "084b6df406d3dcecfa4cfb778e9836e438125264a7a5ac1413977be917c64f29", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "start_char_idx": 3357, "end_char_idx": 3554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17aba320-251d-49d2-8508-deb2ff9b42a1": {"__data__": {"id_": "17aba320-251d-49d2-8508-deb2ff9b42a1", "embedding": null, "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n In addition, the final U.S.  tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c120f3b5-cbce-4cca-8493-71fbb4ae2eca", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n In addition, the final U.S. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6d994d639bbcff723d92fa03a4a3130bf504a67071711667d8cc129981f1b5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "936c1b93-e96e-4dda-b4ae-9500b45bf21b", "node_type": "1", "metadata": {"window": "Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n In addition, the final U.S.  tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n"}, "hash": "8e965ea61fcf342b2e52bcd0dbf8b947d0796ae426526fcb0c1e807189be99ad", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "start_char_idx": 3554, "end_char_idx": 3826, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "936c1b93-e96e-4dda-b4ae-9500b45bf21b": {"__data__": {"id_": "936c1b93-e96e-4dda-b4ae-9500b45bf21b", "embedding": null, "metadata": {"window": "Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n In addition, the final U.S.  tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17aba320-251d-49d2-8508-deb2ff9b42a1", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n In addition, the final U.S.  tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e6d0e61b3763ce088ec2aec230b129a2cd8fa29a9adc61456a5c7902a537c3bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1264105b-65d5-44c2-9eb9-f9770e35a63a", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n In addition, the final U.S.  tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization. ", "original_text": "In addition, the final U.S. "}, "hash": "af55a30e88274086f184c89cbdfc9d3258e841e49b8ae58866cfaebe8f42c7d6", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "start_char_idx": 3826, "end_char_idx": 4064, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1264105b-65d5-44c2-9eb9-f9770e35a63a": {"__data__": {"id_": "1264105b-65d5-44c2-9eb9-f9770e35a63a", "embedding": null, "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n In addition, the final U.S.  tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization. ", "original_text": "In addition, the final U.S. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "936c1b93-e96e-4dda-b4ae-9500b45bf21b", "node_type": "1", "metadata": {"window": "Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\nrate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n In addition, the final U.S.  tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c19652e606d7a64bcd2a4c94af8112e7d6f84c8060a71b325ebe5246fcd0cd96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce43ab2d-dcd8-4f9e-beac-4e9e76ae5efb", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n In addition, the final U.S.  tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n", "original_text": "tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018. "}, "hash": "f4c8fe3c3ff46c472a55d801546c63012d0fb565c3e843be67b3d97941c942e1", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the final U.S. ", "start_char_idx": 4064, "end_char_idx": 4092, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce43ab2d-dcd8-4f9e-beac-4e9e76ae5efb": {"__data__": {"id_": "ce43ab2d-dcd8-4f9e-beac-4e9e76ae5efb", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n In addition, the final U.S.  tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n", "original_text": "tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1264105b-65d5-44c2-9eb9-f9770e35a63a", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n In addition, the final U.S.  tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization. ", "original_text": "In addition, the final U.S. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb4fedd4854b057cda46a87f2e59817eb593410ee0e00bd92d7b51c60e78a983", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ca8296b-6739-40fc-8495-dd11ebf2ebd3", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n In addition, the final U.S.  tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n"}, "hash": "690448ae629114af7e9a6791e3e7b6c187c4e913a79a3ab420af98c84acd74f8", "class_name": "RelatedNodeInfo"}}, "text": "tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018. ", "start_char_idx": 4092, "end_char_idx": 4349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ca8296b-6739-40fc-8495-dd11ebf2ebd3": {"__data__": {"id_": "7ca8296b-6739-40fc-8495-dd11ebf2ebd3", "embedding": null, "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n In addition, the final U.S.  tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce43ab2d-dcd8-4f9e-beac-4e9e76ae5efb", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n In addition, the final U.S.  tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n", "original_text": "tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "85812d129c41ce03f239ed056fcb0d0c7fa01f3d10628961167aac5833138b47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80e658e9-a765-4735-82fd-eee4a0b6239c", "node_type": "1", "metadata": {"window": "In addition, the final U.S.  tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization. "}, "hash": "7ed753ed1e9a305dffccab54534b3d81447dbdf1acaee7176de0ee48b22128d8", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 4349, "end_char_idx": 4593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80e658e9-a765-4735-82fd-eee4a0b6239c": {"__data__": {"id_": "80e658e9-a765-4735-82fd-eee4a0b6239c", "embedding": null, "metadata": {"window": "In addition, the final U.S.  tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ca8296b-6739-40fc-8495-dd11ebf2ebd3", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n In addition, the final U.S.  tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00dab9c78a6a47ae42c757abdd5b7babc416637da8f3859b9dcd1e3ad8ee5ad7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f75ead6-c032-4e14-a00d-98c7346287ba", "node_type": "1", "metadata": {"window": "tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n 18", "original_text": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n"}, "hash": "aa30b05bd4a54cd6274bbcd9f76f834680e42f8b7098ac49a9e37af1610dc9e2", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization. ", "start_char_idx": 4593, "end_char_idx": 4805, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f75ead6-c032-4e14-a00d-98c7346287ba": {"__data__": {"id_": "5f75ead6-c032-4e14-a00d-98c7346287ba", "embedding": null, "metadata": {"window": "tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n 18", "original_text": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80e658e9-a765-4735-82fd-eee4a0b6239c", "node_type": "1", "metadata": {"window": "In addition, the final U.S.  tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f129af4ada1113a7d3482c4b0bbc57d45b9788aeac6462c58153601da3cf16a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "246f56c9-6bcf-4add-9ea0-be401b1b4579", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n 18", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. "}, "hash": "e9eea0ad224f38682acde81b47a4ba5582f108077bef9814f90268a4c177ea49", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n", "start_char_idx": 4805, "end_char_idx": 4968, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "246f56c9-6bcf-4add-9ea0-be401b1b4579": {"__data__": {"id_": "246f56c9-6bcf-4add-9ea0-be401b1b4579", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n 18", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f75ead6-c032-4e14-a00d-98c7346287ba", "node_type": "1", "metadata": {"window": "tax reform measurement period adjustment to the one-time transition tax liability on historical\nforeign earnings and profits through December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the\nthree months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n 18", "original_text": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4da6cdce0c6f53462af5d534150feb5d93f51c6726cc5f93d12d53abdeab33b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c70cd78e-2927-4f1b-a43f-b3c8311bace9", "node_type": "1", "metadata": {"window": "Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n 18", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n"}, "hash": "4cba5766287ccda11c60a59c5b18819e0514da853b5df696cc92bee63dd8512d", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "start_char_idx": 4968, "end_char_idx": 5137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c70cd78e-2927-4f1b-a43f-b3c8311bace9": {"__data__": {"id_": "c70cd78e-2927-4f1b-a43f-b3c8311bace9", "embedding": null, "metadata": {"window": "Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n 18", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "246f56c9-6bcf-4add-9ea0-be401b1b4579", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as\na supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.\n Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n 18", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6889b70609086b70a0f64bc99f8ef921028c53220eb2b7533b982d35f8cb2917", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a2ea091-3ebc-43c8-b236-a68dece1c9e5", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n 18", "original_text": "18"}, "hash": "a03f67d1fb3693ca65fbc502ed8cb8d756e5fc2f237c53df5571d701ef81fe41", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 5137, "end_char_idx": 5382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a2ea091-3ebc-43c8-b236-a68dece1c9e5": {"__data__": {"id_": "9a2ea091-3ebc-43c8-b236-a68dece1c9e5", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n 18", "original_text": "18", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5a086f163c35588ea7644ec3b411aa1ae0d2a15512aadac6c34da11a5f015e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c70cd78e-2927-4f1b-a43f-b3c8311bace9", "node_type": "1", "metadata": {"window": "Adjusted net loss attributable to noncontrolling interest: Adjusted net loss attributable to noncontrolling interest excludes the\nnon-controlling interest portion of acquisition-related intangibles amortization.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n 18", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3c7478dc80fd6ab83e2f251fcd2ca32fb304094341078abc64e1e4e4818bdd4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ce563d7-bc10-47bb-a9d1-ac44943c4a67", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; the (credit) related\nto the New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation,\nand other; and impairment of long-lived assets; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe three months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; the (credit) related\nto the New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation,\nand other; and impairment of long-lived assets; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items. "}, "hash": "75ce2824e331f4c3913fc76a24541233f37d41c5e418648620bf2070c444b599", "class_name": "RelatedNodeInfo"}}, "text": "18", "start_char_idx": 1036, "end_char_idx": 1038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ce563d7-bc10-47bb-a9d1-ac44943c4a67": {"__data__": {"id_": "7ce563d7-bc10-47bb-a9d1-ac44943c4a67", "embedding": null, "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; the (credit) related\nto the New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation,\nand other; and impairment of long-lived assets; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe three months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; the (credit) related\nto the New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation,\nand other; and impairment of long-lived assets; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items. ", "page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83178449-8605-45a3-a4c3-38c42742cd0b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1dbf84b3f0af0e948f1983bf219426169a35d1ae7735b9165000ab87e0469e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a2ea091-3ebc-43c8-b236-a68dece1c9e5", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n 18", "original_text": "18", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e8d643da94d22c1eb0e9adef82015508aa0591a5a42bcf52daf3333e9bc461", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef58a4cc-378b-485d-91ce-bb682e2af7b9", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; the (credit) related\nto the New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation,\nand other; and impairment of long-lived assets; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe three months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance. ", "original_text": "In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe three months ended December 31, 2018. "}, "hash": "071c6a01d12e7ed508d58d6dcac4a3fd097e692f59c6f497823169073a9218c6", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; the (credit) related\nto the New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation,\nand other; and impairment of long-lived assets; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items. ", "start_char_idx": 0, "end_char_idx": 521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef58a4cc-378b-485d-91ce-bb682e2af7b9": {"__data__": {"id_": "ef58a4cc-378b-485d-91ce-bb682e2af7b9", "embedding": null, "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; the (credit) related\nto the New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation,\nand other; and impairment of long-lived assets; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe three months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance. ", "original_text": "In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe three months ended December 31, 2018. ", "page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83178449-8605-45a3-a4c3-38c42742cd0b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1dbf84b3f0af0e948f1983bf219426169a35d1ae7735b9165000ab87e0469e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ce563d7-bc10-47bb-a9d1-ac44943c4a67", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; the (credit) related\nto the New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation,\nand other; and impairment of long-lived assets; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe three months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; the (credit) related\nto the New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation,\nand other; and impairment of long-lived assets; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items. ", "page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "acb8f3a198b6d68a9fa119cbe343186876369a4d67fc72efb45fc3496856bc92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99238e0b-cafa-41f0-91c5-371bd7069d7a", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; the (credit) related\nto the New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation,\nand other; and impairment of long-lived assets; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe three months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n"}, "hash": "ad430b95689d3c6f12dc6ac88658a60c3267cf570c919c5ebe3f9db688e21d35", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe three months ended December 31, 2018. ", "start_char_idx": 521, "end_char_idx": 668, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99238e0b-cafa-41f0-91c5-371bd7069d7a": {"__data__": {"id_": "99238e0b-cafa-41f0-91c5-371bd7069d7a", "embedding": null, "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; the (credit) related\nto the New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation,\nand other; and impairment of long-lived assets; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe three months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n", "page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83178449-8605-45a3-a4c3-38c42742cd0b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1dbf84b3f0af0e948f1983bf219426169a35d1ae7735b9165000ab87e0469e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef58a4cc-378b-485d-91ce-bb682e2af7b9", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; the (credit) related\nto the New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation,\nand other; and impairment of long-lived assets; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe three months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance. ", "original_text": "In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe three months ended December 31, 2018. ", "page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f93e6b023a72b5a70bcc858a682f408270b3c33f49ce24b1a499cb1665267792", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d24d640-e7f7-40cd-8886-a511172725e4", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; the (credit) related\nto the New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation,\nand other; and impairment of long-lived assets; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe three months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million. ", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. "}, "hash": "318399f5ffb8016c5c609f7b97d03d2b3ef5f0b9f2bdd4f506e7dfbb238e338c", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n", "start_char_idx": 668, "end_char_idx": 1022, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d24d640-e7f7-40cd-8886-a511172725e4": {"__data__": {"id_": "5d24d640-e7f7-40cd-8886-a511172725e4", "embedding": null, "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; the (credit) related\nto the New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation,\nand other; and impairment of long-lived assets; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe three months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million. ", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83178449-8605-45a3-a4c3-38c42742cd0b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1dbf84b3f0af0e948f1983bf219426169a35d1ae7735b9165000ab87e0469e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99238e0b-cafa-41f0-91c5-371bd7069d7a", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; the (credit) related\nto the New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation,\nand other; and impairment of long-lived assets; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe three months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n", "page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1a9846d69bbb25ea5cc124450bc42fbac45cbb0aa60d648f88194fc606ee525", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe72c292-0947-413d-8c7d-b6465f9e78c3", "node_type": "1", "metadata": {"window": "In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe three months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated. ", "original_text": "In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance. "}, "hash": "a3887e40ac01f01ad9389084fc6550e52f90b7c3d88c9a56b9c1d988843d60bd", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "start_char_idx": 1022, "end_char_idx": 1473, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe72c292-0947-413d-8c7d-b6465f9e78c3": {"__data__": {"id_": "fe72c292-0947-413d-8c7d-b6465f9e78c3", "embedding": null, "metadata": {"window": "In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe three months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated. ", "original_text": "In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance. ", "page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83178449-8605-45a3-a4c3-38c42742cd0b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1dbf84b3f0af0e948f1983bf219426169a35d1ae7735b9165000ab87e0469e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d24d640-e7f7-40cd-8886-a511172725e4", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; the (credit) related\nto the New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation,\nand other; and impairment of long-lived assets; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe three months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million. ", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87de7086f59486ea88a346e1637e202a74d2497212a591f9341f0844020878c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbb7679c-b0c9-4328-9728-e50fbfb3a6d9", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. "}, "hash": "22ea1cf23fd5947bf4e306fa2c95a9d33441c7c9e8c56fc01953a5acf82415ec", "class_name": "RelatedNodeInfo"}}, "text": "In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance. ", "start_char_idx": 1473, "end_char_idx": 1553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbb7679c-b0c9-4328-9728-e50fbfb3a6d9": {"__data__": {"id_": "fbb7679c-b0c9-4328-9728-e50fbfb3a6d9", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83178449-8605-45a3-a4c3-38c42742cd0b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1dbf84b3f0af0e948f1983bf219426169a35d1ae7735b9165000ab87e0469e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe72c292-0947-413d-8c7d-b6465f9e78c3", "node_type": "1", "metadata": {"window": "In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe three months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated. ", "original_text": "In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance. ", "page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9fc5baae1d87945409df5885d31e3debf28feecabe35b199141789eee8f5ada5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21177c0e-b4b2-48c9-9e42-04014d734312", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n", "original_text": "For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million. "}, "hash": "00c2f80a6f54cc5e97a8014499a8372c0c74a7e73e9f31e587eb4b9a5934ebdc", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "start_char_idx": 1553, "end_char_idx": 1839, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21177c0e-b4b2-48c9-9e42-04014d734312": {"__data__": {"id_": "21177c0e-b4b2-48c9-9e42-04014d734312", "embedding": null, "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n", "original_text": "For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million. ", "page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83178449-8605-45a3-a4c3-38c42742cd0b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1dbf84b3f0af0e948f1983bf219426169a35d1ae7735b9165000ab87e0469e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbb7679c-b0c9-4328-9728-e50fbfb3a6d9", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38b95475dc3ac044b36922c545a670a5abea67b6a1059e61d53f93749d91918b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2df0a1b2-4b61-44c1-97b6-b5f63d15affe", "node_type": "1", "metadata": {"window": "In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200130005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated. "}, "hash": "e410bc4c5d1802929dd392681775799a783df9d59c4fb715af9deb022934ecf6", "class_name": "RelatedNodeInfo"}}, "text": "For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million. ", "start_char_idx": 1839, "end_char_idx": 2218, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2df0a1b2-4b61-44c1-97b6-b5f63d15affe": {"__data__": {"id_": "2df0a1b2-4b61-44c1-97b6-b5f63d15affe", "embedding": null, "metadata": {"window": "In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200130005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated. ", "page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83178449-8605-45a3-a4c3-38c42742cd0b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1dbf84b3f0af0e948f1983bf219426169a35d1ae7735b9165000ab87e0469e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21177c0e-b4b2-48c9-9e42-04014d734312", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n", "original_text": "For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million. ", "page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e5330c5fa1924c28f34e97f92297b0e4aac2879efec94a3919f7580af1fd8ba8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a216014-c47b-470e-9ee4-d41557f94f92", "node_type": "1", "metadata": {"window": "For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200130005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated. "}, "hash": "7004f0a8398aff564ecb6479c277debd321678997e1a9ca176eaf27fdc8c3244", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated. ", "start_char_idx": 2218, "end_char_idx": 2454, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a216014-c47b-470e-9ee4-d41557f94f92": {"__data__": {"id_": "0a216014-c47b-470e-9ee4-d41557f94f92", "embedding": null, "metadata": {"window": "For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200130005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated. ", "page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83178449-8605-45a3-a4c3-38c42742cd0b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1dbf84b3f0af0e948f1983bf219426169a35d1ae7735b9165000ab87e0469e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2df0a1b2-4b61-44c1-97b6-b5f63d15affe", "node_type": "1", "metadata": {"window": "In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200130005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated. ", "page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3fd29ee97905e1bda163cc080598d9255f8280a4aade7bcd4be113f2ec70fcb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7184336b-0d3c-4398-9656-f8b5c89952f1", "node_type": "1", "metadata": {"window": "For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200130005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "original_text": "Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n"}, "hash": "f0acb40653c72a3d0d526a7c23042a28c2418592837b6f561c40080502ee8192", "class_name": "RelatedNodeInfo"}}, "text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated. ", "start_char_idx": 2454, "end_char_idx": 2770, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7184336b-0d3c-4398-9656-f8b5c89952f1": {"__data__": {"id_": "7184336b-0d3c-4398-9656-f8b5c89952f1", "embedding": null, "metadata": {"window": "For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200130005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "original_text": "Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n", "page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83178449-8605-45a3-a4c3-38c42742cd0b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1dbf84b3f0af0e948f1983bf219426169a35d1ae7735b9165000ab87e0469e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a216014-c47b-470e-9ee4-d41557f94f92", "node_type": "1", "metadata": {"window": "For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200130005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated. ", "page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aee51fad3e435d7eb7622f28b2b7e6823b63b73328f84f7ef5e8ecb059bedac3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de8a79d3-2e44-4c2f-89b1-0ce602a4fa0c", "node_type": "1", "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200130005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "original_text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20200130005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19"}, "hash": "5f82b01863707549bc007b05f508cfb47421565da9adede74457063849d9cb09", "class_name": "RelatedNodeInfo"}}, "text": "Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n", "start_char_idx": 2770, "end_char_idx": 2865, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de8a79d3-2e44-4c2f-89b1-0ce602a4fa0c": {"__data__": {"id_": "de8a79d3-2e44-4c2f-89b1-0ce602a4fa0c", "embedding": null, "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200130005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "original_text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20200130005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83178449-8605-45a3-a4c3-38c42742cd0b", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1dbf84b3f0af0e948f1983bf219426169a35d1ae7735b9165000ab87e0469e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7184336b-0d3c-4398-9656-f8b5c89952f1", "node_type": "1", "metadata": {"window": "For the three months ended December 31, 2019 adjusted free cash flow of $133.7\nmillion consisted of net cash provided by operating activities of $142.8 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $67.3 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200130005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "original_text": "Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n", "page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9b5c65ffb4ed1a670bdab1ca6cf964b7cdfbcf2194fd4f66918cc240217e0d8", "class_name": "RelatedNodeInfo"}}, "text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20200130005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "start_char_idx": 2865, "end_char_idx": 3115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"2c7921ac-edc5-4133-bba2-f4f6debdb32c": {"doc_hash": "cb6ffa2f97b38187a71abf23f4b22af0caae110e36243a00a2489d29389fd4b8", "ref_doc_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17"}, "22b9e2c7-576c-4dff-bfdd-fb6c75621b8b": {"doc_hash": "aec9629eb1662054cd1b46566b7ef632e2a936809b3584f4b751ed6d25c57702", "ref_doc_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17"}, "5413af4a-22b9-4676-a8d5-f55728ed7129": {"doc_hash": "5f8c49ba82d7b0337fd5ee54b65ce987cba0fdd86e792ab281bace7d24c2b366", "ref_doc_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17"}, "dbf59b49-9c74-42eb-b446-2f14fa1a0cdf": {"doc_hash": "80a2f1ad0d47353ff129071ec19273103a04dba5076741e0ed6ad45760caf908", "ref_doc_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17"}, "6a4c3325-344d-4265-9eff-adbd2b83442a": {"doc_hash": "bf37f2d015f3c193cc6e07d06910a46d66f692bcc9d7364b7cc7dd116abe63d2", "ref_doc_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17"}, "5f0f71e1-f964-4192-995f-0f4dafeb8517": {"doc_hash": "21d92eceadcb9df313e673c332b9050f77eec3eca583bb81197e840c8bbca7d5", "ref_doc_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17"}, "df89fb75-4664-4f23-966a-ad1c04439526": {"doc_hash": "24b1fdf36b457345807068767e3aac11afba0985b3b0aa7d1b7fa5fcfb5917f8", "ref_doc_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17"}, "7bcd24d9-1dee-41fc-8abf-becee8eedf41": {"doc_hash": "4f0b111577cd2b22a4d32e8039066406a75118c38ad7856eedd7f127c2d8b9bb", "ref_doc_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17"}, "650f6f1c-4be8-484f-8c16-7eed75e4e07a": {"doc_hash": "ff78ebf2abb7981cdd5617669e677e26bbc6f695174a32a8e0d8f653871ec861", "ref_doc_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17"}, "a6953132-ca6d-4655-afdd-4948f4802fd6": {"doc_hash": "45625f4848bda38a4eceda6687877908119ab536bd141bf5e9805eb369ed9ce1", "ref_doc_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17"}, "0e11b6df-df35-4157-a52f-b4fd5b74314b": {"doc_hash": "7931f29388f219b7653d9e8567403a3ff108c96d078932ed795a2e97ff7971f6", "ref_doc_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17"}, "dbf3184b-9333-4b5d-a715-5402ac4cbe4b": {"doc_hash": "bb1fcf1bb99132569d995b215299c4acaaced9a4203763e4077cc233a1f278eb", "ref_doc_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17"}, "db62eeb3-a078-464c-8f16-a113c169e830": {"doc_hash": "fb85a212979e71102235fbdaa76aa77be86866abe5ec521246d9cbaa5036b175", "ref_doc_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17"}, "25290bdd-dcfd-4730-ac0e-833d6599992d": {"doc_hash": "51ed6cb65f3e89295b0686fa17d244d186a1d7b08a031b69433a02d938a2e5d0", "ref_doc_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17"}, "79413521-8cc5-4f05-a815-ed34d9f8bfbd": {"doc_hash": "f8f1dab7d4eea0550c4f78783e41fad2a0fafb28e6cb7c4c870e15942a8e188a", "ref_doc_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17"}, "8479a757-f1f4-4e11-98d8-dfb2aa6a1901": {"doc_hash": "0b7470b80e8bcd3e636153ccafffc8b94beeaed7a9bd166b4dcc56e0be140105", "ref_doc_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17"}, "526af04e-87a0-429c-8bb3-cab5c8167ae5": {"doc_hash": "37abe92800cb8b68118f68e85047488c2b2934ee743959bee4275fac41bd15f3", "ref_doc_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17"}, "dd27bca1-1151-490d-975b-a48a6f56c8d8": {"doc_hash": "5d73c92e551b64fd2f128f6948c8421a457326df5b04cf47e1ca704fdf5de0a4", "ref_doc_id": "c2d4ecd8-80af-4811-aeb7-84c417570b17"}, "44f372a0-8695-4e66-892c-9dc9305b2ab5": {"doc_hash": "9b5ea62963afa6927d1dac3879b6d28ec573a8a955fd95ababa2b1306b678555", "ref_doc_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1"}, "53091b22-d050-4b64-b486-448280843464": {"doc_hash": "0b6c091ed7a93ac7a7455c284964d9ff7fc9a6bb3c658361154923eec649e5d0", "ref_doc_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1"}, "2e64faf6-545c-4a0c-8e9e-08d9883eb128": {"doc_hash": "6acb036d371cd490839e8ca88c07160f1c314b902e12c9945b8f9990d69b742d", "ref_doc_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1"}, "6113c6f8-65be-4057-9fe4-a22122b21d63": {"doc_hash": "044d601c97660d7ac62214d5d1b59b9a9c92f63b5bc29c32a0fc5b98a8271e59", "ref_doc_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1"}, "23e30c4d-4353-4a16-b580-fecbfd9f3468": {"doc_hash": "fdbbefe9c0e9ca65dd02cb877b7e81cf8200c3dcfc01d296413b6d1d36ac66e4", "ref_doc_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1"}, "ac9e7c6b-76b9-4cba-ab66-93413020ee4e": {"doc_hash": "453e4b0617581365d4e15d9d8caa31c44231e06160c15868abf33fc35179163f", "ref_doc_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1"}, "55cc2121-bdc0-411c-bb4c-f31a75d4a71d": {"doc_hash": "a9832046f0394563dab23ade204a4b01479995adcedbd2a7c973c19653dba35b", "ref_doc_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1"}, "a7211189-9530-4937-95f3-9ef4975fb93b": {"doc_hash": "87bdbde32f24536ec8551d764e8c81763bb70e6fb149a620e16571841fef9ae0", "ref_doc_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1"}, "6e6f1486-ca85-4eea-94d6-87ee0a3e8f4a": {"doc_hash": "27c4fb6533e5a6246be7d45f757289369fbe8cc19f1a7cb64f4c46cc9c63e3d2", "ref_doc_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1"}, "a202ab79-2817-4344-9d2f-d334719d494b": {"doc_hash": "53b78f92ce30a97dc6de2647ae32ce07b7c142d8658407b4a854fcb82fb86271", "ref_doc_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1"}, "b0183999-bcdd-4cf2-9176-35ce31347879": {"doc_hash": "15b15897ecbe76d3b03e6e6417316be8fbdaa04cfb87512520538e6c63ce5f2e", "ref_doc_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1"}, "98e32e69-caa4-4237-ad35-609446642b27": {"doc_hash": "3f7347ee1757db4d0e9792c50fea9249801a637537959ea844b9c4ae8512885a", "ref_doc_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1"}, "8b06ac51-2c3e-4725-83e8-d590f46b7cae": {"doc_hash": "cd3bfbff15c930daf5049bf48b6ca45e896c89a822ccad7bfa96abe88f3ab7bb", "ref_doc_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1"}, "1bd46823-1830-47fb-baeb-fd4b1cde0166": {"doc_hash": "343a5fada4dccc1827b6efd108198df8eb0523fb297275ff52003b496b291d67", "ref_doc_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1"}, "d4e9efd4-614a-46a3-81ca-bc2d0dd2de55": {"doc_hash": "d36fd5fb1d142e7cc49a57a1c5134db78eebd7277618b2b7ca615c9db9468fbd", "ref_doc_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1"}, "845e37ac-32ba-4be0-b1a5-786e41553a77": {"doc_hash": "c4f5eab452dfc313cde894b943097f25eb8e841b48f18e02465230efdd6cd34f", "ref_doc_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1"}, "fdfcf14e-f6d1-49c1-af53-06ac10b8eee3": {"doc_hash": "dc4141bb940615d686d465c16f4845e3a3f80dfbb5cfedb11e3bf9d66af20c61", "ref_doc_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1"}, "0c4c5d93-ba08-40bd-956d-6aea53a72f22": {"doc_hash": "56baa1f99bce24c6a3964c2166b55e2794a4144e139b312825dfb2ecd6df2fe1", "ref_doc_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1"}, "82d187db-0558-4e4a-8a92-afd3b64a5dfb": {"doc_hash": "f8a2c23bb2cd4edf7ba3f878a520576d53578c89b897f044bde342413112fb31", "ref_doc_id": "a3bf5850-52b8-4bdc-a178-03658af66ae1"}, "804e7ca4-ebd0-45be-a150-c66b6ecb812e": {"doc_hash": "1e5c31ded5808c31bab80ec61880beb1ba63f0c9a1e836372260979a78c4f345", "ref_doc_id": "723c9482-4103-4254-a210-9e3956cb44bf"}, "16bb6b03-b80a-4fa0-ae3f-b546e71cdd82": {"doc_hash": "c704e54a6adbc8b7662df93e4cb5327e21f603cf16738134dd4c344fba835c51", "ref_doc_id": "723c9482-4103-4254-a210-9e3956cb44bf"}, "a8d2e1a0-52e8-40a5-b38e-fa1bd44a3600": {"doc_hash": "58eb1537f1f1494def6d30fb814a00b941516256d60cbab5152bac7fd5562e5c", "ref_doc_id": "723c9482-4103-4254-a210-9e3956cb44bf"}, "8fc90634-da50-41f1-8692-c568a6b0835b": {"doc_hash": "dde130b7dee0c4946fd15d792ef445cf65b25ce5a0280b8cbabdedee5fd7d3a4", "ref_doc_id": "723c9482-4103-4254-a210-9e3956cb44bf"}, "0bdf68b0-4808-4b4b-a7a5-1fef3c950c8b": {"doc_hash": "e860f1194cc88b0c79c45b3b0018a9f01139bcd6d7f61337ff9a3804e84e6656", "ref_doc_id": "723c9482-4103-4254-a210-9e3956cb44bf"}, "5d46bc53-5592-41a7-9948-139202afb4b6": {"doc_hash": "f42c61da73395cff34d6d46bbd1ce249ad3910158fb50e893b32ed9cd26f85d5", "ref_doc_id": "723c9482-4103-4254-a210-9e3956cb44bf"}, "fa668d3a-12b7-442f-8384-0fa70eb747ad": {"doc_hash": "eb367b7bbbacecfcefd092306ecca6e68283a9f9b79c3b9500d1e50d9fda7580", "ref_doc_id": "723c9482-4103-4254-a210-9e3956cb44bf"}, "28968693-b6a9-4c75-aee7-9e8ccaec02b3": {"doc_hash": "e17d2736c9550fa297cc87458876d31ad1adac7b121c2f0a6e5428445392d160", "ref_doc_id": "723c9482-4103-4254-a210-9e3956cb44bf"}, "c7e38d26-321d-4c64-9aeb-de63f6bc319a": {"doc_hash": "4995a7af7ae39665728be58e15f353999620639ea1d11734c51731ab10257171", "ref_doc_id": "723c9482-4103-4254-a210-9e3956cb44bf"}, "8e269996-0e1c-49cc-a27c-21c02f3810c7": {"doc_hash": "3d4de99814b318e6f429437d3ec2881c9e09b66edcc8bffe4707b57f2b434cb1", "ref_doc_id": "723c9482-4103-4254-a210-9e3956cb44bf"}, "972b0841-21da-454c-a2c8-6f2e70ddf685": {"doc_hash": "2f63c84945e9d501f7b7662d1d15ca536b14601788fbcb3b33822893e601517e", "ref_doc_id": "723c9482-4103-4254-a210-9e3956cb44bf"}, "d53fde0a-92c2-4e9f-9026-d10843577a60": {"doc_hash": "5f9c351f6a9f3c331c73e9f8735edaea1b033ae6cb60d3052265f3e1031528e2", "ref_doc_id": "723c9482-4103-4254-a210-9e3956cb44bf"}, "dda2f501-6a41-4c7e-84c0-7653d3aecf92": {"doc_hash": "a3e62e17bb349e73ef5f8aefe1dfae36560f891d80ee2ff1e7e656a33ddaa4d7", "ref_doc_id": "723c9482-4103-4254-a210-9e3956cb44bf"}, "ae7c9e41-3248-4ed9-84c7-d0d53514afcd": {"doc_hash": "3a80234caa2784a67162be8e435000499a075aa9b83a3916bc9943500540414c", "ref_doc_id": "723c9482-4103-4254-a210-9e3956cb44bf"}, "926a7a82-479d-4cac-88f2-f75894627bac": {"doc_hash": "d60e74cd7ce8f314ce6110b9935c91204dcc92e942d5f134fd11555be53509c7", "ref_doc_id": "723c9482-4103-4254-a210-9e3956cb44bf"}, "879206a6-8305-471c-8a12-9ac7d9e3f425": {"doc_hash": "441264505068d873dc52bda79838b52cbaf0e39b272d46dc273cc1fd752661a4", "ref_doc_id": "723c9482-4103-4254-a210-9e3956cb44bf"}, "28c7a494-95a7-4a4d-a3ac-3bad994755c2": {"doc_hash": "b1a3dba7584ea9c7b00a62f45fdafa1dbf5284aefd160bf6894b27a096f782ac", "ref_doc_id": "723c9482-4103-4254-a210-9e3956cb44bf"}, "20349348-bcd5-4f56-8376-5f71d63c4a9a": {"doc_hash": "e3f9a54007626712e26b74b2bcdf1b1baac766c767b8e9aeb5e85982e9970806", "ref_doc_id": "723c9482-4103-4254-a210-9e3956cb44bf"}, "357e0bd7-53a0-4764-af41-da7a73fad089": {"doc_hash": "ebea9b5c4b12002a23f12247f21af2e8e71f5cddbb8406e34748a009c0e91cbf", "ref_doc_id": "723c9482-4103-4254-a210-9e3956cb44bf"}, "8c9ee8f4-243e-4ca2-8b10-99b49a0433a0": {"doc_hash": "291edf236749626876c35537a6e533eb36567154c2a9ed2cc19e525d01dfffab", "ref_doc_id": "723c9482-4103-4254-a210-9e3956cb44bf"}, "c1581e41-a4a4-41e6-a452-4e21fab22558": {"doc_hash": "fe517ddd337af0bf4202051480967dc6636e56b8bb83a7ac5de3a7d3f4b1d206", "ref_doc_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9"}, "1e4a22a4-b3c0-4e1d-a95a-b1f09824c204": {"doc_hash": "607376dee6dc68300d367e01133f5a6bc79c0dbd2c28142b6c630a49b6c841dc", "ref_doc_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9"}, "bece5fa0-8aa5-4104-b2c5-4b74f3122c67": {"doc_hash": "549708409cb44e335c56b1e2bbd3cddd3a63bec869f6665fe6d7211d7a1d3089", "ref_doc_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9"}, "9658a6a2-6e12-4d63-90fc-f63a213e3a37": {"doc_hash": "5d50484dcf800771603de66528cbb31ae015360c611c4952ff859902390b3df7", "ref_doc_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9"}, "cba2d70c-cdad-46b6-b026-063643080512": {"doc_hash": "a49e118a7c9b252457f8bc9efc6485f2d412c9a14e433f884bf2592d73855292", "ref_doc_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9"}, "5f118632-66c9-4c3f-9cb9-075676311afd": {"doc_hash": "5ab8a368583bfb5716175f28173507ac8c5469f2dc26efde7c01a41c5ae21655", "ref_doc_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9"}, "1c109620-fea0-4c0a-b750-a718a980fb07": {"doc_hash": "79db6616a4dfe15eda4e510a1b4de465feeee88511a122636f804aee90f75b07", "ref_doc_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9"}, "57225f17-2276-46e5-8377-56fad3d48a5d": {"doc_hash": "f489fe33d6a8bb177476cd6a87403002ead6b4e8e9d6107d324473ef90d0d845", "ref_doc_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9"}, "e2473259-f2da-49e5-b83c-9d5397542fa6": {"doc_hash": "5955969818ea4c77edd290345d2e33857fdda423c32cf528d8c07613ad71ad48", "ref_doc_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9"}, "0289cfbf-8bc4-4188-9ee9-87b0bfbd3d4a": {"doc_hash": "a06550202e69f9ebcdd100ecd4d4308dc9bbabbeb8230d4b4f68b522c0ddfe27", "ref_doc_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9"}, "7624d26e-0fcd-4a3f-bf3f-1552e31132ff": {"doc_hash": "2c99ffebc7834062d9faccacc664f3fc9940d26c3132a611e234f75992887a4f", "ref_doc_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9"}, "22785523-de8f-4466-a78a-faf742f63007": {"doc_hash": "6b4aa3ba6366957ce4d11ba9dfcd283b209fe765920fee11e9ba0466569bba5e", "ref_doc_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9"}, "bffd99ba-4de1-4e21-baf3-620fadda7bd0": {"doc_hash": "af3b9ba795c8f70c35b505973c822e2071204b7464eaf50d6391db647686921c", "ref_doc_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9"}, "bec5f817-0978-466d-bfe1-5ad077d1289d": {"doc_hash": "7d1ccec43f5edcbdafb287021bfd6dd2c8b5ee59b52bd6f2c30c507874e51a81", "ref_doc_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9"}, "9a6c43ba-f101-42b9-a965-93fb3b45a841": {"doc_hash": "e44d7a774a21bc91ec7839d7a1a5678a852bf96b0a4671d5379a252416d18bda", "ref_doc_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9"}, "49bad4e8-e24b-40e5-aee8-286a905775ae": {"doc_hash": "6cf67836407f88b5416f2cc4a14e1775cdfc987a491cd7d84e075571266ac0c9", "ref_doc_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9"}, "40d5c900-8b3d-4790-b23e-dba7249bd8e6": {"doc_hash": "6b931695da468f4c7a052e0ebf24f25e7897abdbec3bf4ce524f6b34917e19b8", "ref_doc_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9"}, "edea6586-b8ab-4f23-9aad-fa1fe0de13de": {"doc_hash": "ee6c3d0ec6e7ced0c86336e2fc4b9e5e66c08a8d880fd5670e587bb7912a0bf7", "ref_doc_id": "184fa4e1-1db9-4e77-8864-26dc435d74b9"}, "efdd3fc6-f7c8-40d6-afc2-0d9d196fc1df": {"doc_hash": "b929c2f31df3ecfc1e7c7a5f4d093e3a358c62f549e685468d10ba1b78f35469", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "8eed639c-85f9-4a02-8f70-08308819df7f": {"doc_hash": "614862d3629f1af257b54c93285bc391c0aa818d50e49cde8db10d14cad6ff39", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "1cd1bf29-5404-4fe9-a5c6-1e509c5a4da6": {"doc_hash": "d4182c3984bb1c3b404897b718fab1fa06be551b10c16df51a351c1bf75450c2", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "9e5d4320-1921-4d36-a183-9e395ef79add": {"doc_hash": "ad18d9c9d1ccc784f8adbf5d9f83eb8110b0e3b5ac0e30e694a6c6ee857d1c31", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "d4bfb4de-f3fb-4433-9647-a2e08d70741e": {"doc_hash": "f446441926517eeb8aed35221be2e8eab8341611ba071f8de2fc5af3b0a7f542", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "817263f8-f92c-492a-8dc9-251982396838": {"doc_hash": "50d60e1f4ddb0ea0953c46348e3b14ead6281bcc22530ee2da46626ba10d4198", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "7128346f-1b03-4a9c-91b5-697a2b5fa368": {"doc_hash": "376b5dd3d560616499949219e41745ddf5cc1af2a8fe3500a1a301c756944887", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "327f8c5f-5a43-4173-8daa-a393f5a27dff": {"doc_hash": "e2c7e7e1f5d79a483f238ea7149b9802cc7e34891c5f9c1a1e2d5bde5f39cbc4", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "25130bb8-745c-4ef3-98dc-4f91a69f6ccb": {"doc_hash": "e2a774b6a36df7655b384abf9ce24643beb4570201382a215174b248065cf0bd", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "5d632b23-468e-4b26-b031-e70475f2fbe2": {"doc_hash": "dd9daf92d55e687a5ea42eca73dc3a4e90f5c4c371246f296ce9687dd3c5c915", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "bf370e98-773d-4cc5-b978-eff847d764e6": {"doc_hash": "cb606cac138e8b73093277f89fecba109a46a5e09d0e4015ec28f01bd9351420", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "0448c0cd-c8b5-4f40-8e42-53b5ddce6cce": {"doc_hash": "d59d3d694fcb19ca13b96e0a51a5cbe4e7fdbadea37a782025c4ca0d096162f0", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "f3db4352-d0e6-45b6-b366-3b1091202940": {"doc_hash": "091e8537f48e2bc140f133b1e280a8cd2558a2117d7934bd8b81567467a13da6", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "9eeaafd2-6d78-4501-9d7a-344f0fae2039": {"doc_hash": "2874f43427533df2d9e696033898eec644dccfeee172020a5dec52a2e63ebc77", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "59b2e735-7979-45b1-ba87-5177f2749af0": {"doc_hash": "2171fd85f7f840da4c259056fda6ab81342132764fb4957c5f4002cdafee16cb", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "81568d60-e603-47d7-a146-d6d7cde8e983": {"doc_hash": "6332ccd68b5ed9cf2bd03818bed40049f23e29bb49a1fe29fa500ecc594d13ee", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "0eb21732-c70a-44de-ab95-9a68af724509": {"doc_hash": "8b0b3fcec49ac2e3743a0b2fa82575544b841f8ddf3b1c9807fbb080aa49d6b6", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "5b0dcbf3-25c2-41a7-97a3-9ed81a75e698": {"doc_hash": "180afd8f99d4c13ac5df0d56e87a3d52f6d189922cd5d2054a5c09983d7f52be", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "79a3b09f-b8ff-4e55-846b-8aabb1dd4ec9": {"doc_hash": "a160962f4c675a457e1b8141e88e33fd61de8af8ff4443e694ec7a7f79868458", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "f74f134c-7e51-49e1-84dd-5a1cb1370589": {"doc_hash": "baa890934aa7e76f39e8b736b03910478f7648a65ff0a98e405c0c471f532651", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "ec2b42d8-d176-4042-9fed-c3bf8a0f5ca0": {"doc_hash": "e7b3937ea65771323c2df32e13c904732f3d0f61b735e683f42449b77d1fc994", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "24caea4b-e095-48d7-a45c-0fd333e19d68": {"doc_hash": "67758f81135f3945670d44613e765076385c7360a93afdf2fd96f7e7d616a6ed", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "c1a9cecf-6886-4cb1-b02d-d7a07e34d12a": {"doc_hash": "72f9c837028bd3386be2f407dda6bc7ef1e587872d910045a285be1a03dbae9d", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "4919713e-763a-4e63-b4cd-b57a53f3f1b6": {"doc_hash": "078379d8f9825085779be0cf540a5ac814baffe053228a3690f428b76c5db5e3", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "31d66fb0-24b4-44f9-9986-ada6856d49dd": {"doc_hash": "c39d76d52f20d901ce9d92e4ecffed9058b9bd980e6535a943d462e288b53bcf", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "ad1e36ab-0bae-4714-8687-acfc830601d3": {"doc_hash": "7ed8fd86be39ff91c6141ef45b2033fb608f0931cbc241b4b99fef7d4d8b5ec1", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "79b34e17-380f-436c-825c-96a310e3f4ff": {"doc_hash": "39eeff8a1de0f68ef8f52ba141e41012ae2c844be2ff383eca9c34cb944857d7", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "64c220ca-d6b6-4b94-a469-94a252986bb9": {"doc_hash": "67ba1a7b039f6cf844b2a7e86d7b87dac8da0ed3ba1eb189fa6fab46f4646583", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "29f3f899-4c91-4698-b2b9-ccd5ef394322": {"doc_hash": "8bca03f15185acbeeb2a2bae3ce185edcea817ee265d445e50473eea46623034", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "157f87e1-6aaa-4c33-8d19-736b6efecb1b": {"doc_hash": "2e5f7b2f5e9dd42a55e17092b3dbc73da7eebd07862c8d4c4666bedbfa60c3c6", "ref_doc_id": "52547411-6af4-47ea-af2a-bb2cdd66e121"}, "6bca6a7d-1cb0-4499-a58f-9d134ce2f69b": {"doc_hash": "f484d4ee7e19a844d7dccb05f31c9e53cd36a84ffedc573917721a36cc418e78", "ref_doc_id": "70432d22-a097-4888-876b-20e363f3e3bc"}, "027e9116-3467-4307-84ae-9094104f49aa": {"doc_hash": "88a8784439ecb379d58e3676a91f81449d379e7583e8a5ddc1febf940eb6c378", "ref_doc_id": "70432d22-a097-4888-876b-20e363f3e3bc"}, "30115299-6f57-4d9a-853c-a051a237979e": {"doc_hash": "1796df2121190137eeca52fc2d70f299274cba33811d3dab76ab2101f768cb01", "ref_doc_id": "70432d22-a097-4888-876b-20e363f3e3bc"}, "364119f1-aaf5-4dd4-bdda-24be1e8011b1": {"doc_hash": "74ab4427f3ff65e3c3e8ddaf2dcce2b213de090de432d8b0c2956ae69f111f05", "ref_doc_id": "70432d22-a097-4888-876b-20e363f3e3bc"}, "82cb2082-b4f8-4e90-86bc-3ee22cb9c00e": {"doc_hash": "d19adc125d02f6462357fd3cfb6759b29943ee1441a90f909a60b6ae8d9a0e19", "ref_doc_id": "70432d22-a097-4888-876b-20e363f3e3bc"}, "e9ec22f5-df95-4f1a-9334-ccd53be5f68d": {"doc_hash": "79285d975d746d7560327c818222f23d42a2a02492a94b45d8b066ebab92f992", "ref_doc_id": "70432d22-a097-4888-876b-20e363f3e3bc"}, "3099ce00-86cb-4ac2-a684-72891ec36147": {"doc_hash": "2c2887b4de055d6525acd1245473f853443d0801454bb33d4fdb5111960020a0", "ref_doc_id": "70432d22-a097-4888-876b-20e363f3e3bc"}, "4ec78619-3de1-42a2-9842-aa80eb62b280": {"doc_hash": "227eab67a5c7dc9b45dd15e20ea46a7765538969f95514fb39d88f87a729737c", "ref_doc_id": "70432d22-a097-4888-876b-20e363f3e3bc"}, "5037ae06-a770-422c-9a33-3f2c2a8f674e": {"doc_hash": "a22804be12281fcc6568ad9a3df688506b74d281f9968cf3867cdb23290d9023", "ref_doc_id": "70432d22-a097-4888-876b-20e363f3e3bc"}, "e35924b7-507d-40d0-aa53-11240b0048bf": {"doc_hash": "d11c0e91b3850cac37524307e6d20dff8f48d14327bb480cb38a9b97daf6e763", "ref_doc_id": "70432d22-a097-4888-876b-20e363f3e3bc"}, "f8d62f02-00db-4c3d-8f2a-a9faa7e0dd5e": {"doc_hash": "653bed13dc2c7675163cca611709e5cf92c782f27c14e347a6abf0fe3d1098f0", "ref_doc_id": "754d642f-1f12-4807-bfdf-d35f9acfa49a"}, "61fce454-f2af-4931-a6f8-54bab198d2bc": {"doc_hash": "93d2da29b74e7736a0b90eb6212b6fefa34cb8d8e17efdf47d284f6258f362fa", "ref_doc_id": "ff4ec43f-3185-4206-9869-12e51438f08a"}, "3fda072e-32a8-4219-a6c7-ee2d70501069": {"doc_hash": "0734454c217636958d40a47ad2062f828929ee1b069f76db6cf4ae3620b963b2", "ref_doc_id": "ff4ec43f-3185-4206-9869-12e51438f08a"}, "02dc72fd-dd72-4f35-9a57-a50dee70a689": {"doc_hash": "4b4ad6ffc5774181be288b9a083eb18fc0bd77c7f05d8548a8a9c1f9dab1c0e9", "ref_doc_id": "ff4ec43f-3185-4206-9869-12e51438f08a"}, "e729fc0a-6007-4624-b3e6-50eb00127b17": {"doc_hash": "c2f3d2181937bf8060c47340f693346be86a1e87c8fe6044c1e4736c7913aab9", "ref_doc_id": "ff4ec43f-3185-4206-9869-12e51438f08a"}, "16926dcc-ae2c-484e-bf58-ff52cabc2fee": {"doc_hash": "2152c16eb878a3612945d7e19b94191d2e17caff357c6dc4a524e80b2f2b7ece", "ref_doc_id": "ff4ec43f-3185-4206-9869-12e51438f08a"}, "6eac4261-997d-4778-82bb-bd8ae883340e": {"doc_hash": "df44d233bd970edc8f71a31062aa07890c6afaf6daf0ffab2788344eb3598514", "ref_doc_id": "ff4ec43f-3185-4206-9869-12e51438f08a"}, "d5236aa6-5de0-4bdf-ae4f-765bb25e39de": {"doc_hash": "8ab6387f477fff2e9551df124cd01cdb6e91ca0e87d718f5664365aec9dad9ed", "ref_doc_id": "695df1ff-c27d-4015-ab41-0b563338101c"}, "9e0cca3e-44d0-4be8-9cb2-4c954589d5e9": {"doc_hash": "8b91a8d182e0597dfd03b8a21f178632990d6d590f84028c1acc65ee3db53ead", "ref_doc_id": "e84d20e8-2fad-4c78-a41a-fe1d76b8982b"}, "89ce199f-0986-4ea7-8a8d-4a761321bc78": {"doc_hash": "a3cdf1ac19af04c9fccbcfc6fe2cb777459f3ee4e46ca50c1c79423b861f4159", "ref_doc_id": "e84d20e8-2fad-4c78-a41a-fe1d76b8982b"}, "99dfbb03-be4e-476e-bb86-f58c24d06615": {"doc_hash": "7a3ab3be0d26bca819891d7582d1aba7e4a2150773e058bc117c6358d4b3e250", "ref_doc_id": "e84d20e8-2fad-4c78-a41a-fe1d76b8982b"}, "71aeb2c3-6bc5-4093-8f1e-71f119ed5b3e": {"doc_hash": "09ff7f39ecf03306e7ee78a800c2e43809ca9b4ab5f5079c489db420849464a2", "ref_doc_id": "8c3df90e-4a1d-4aea-a05d-533e0e763894"}, "e0503464-0b9c-4d38-adac-853e803938a5": {"doc_hash": "5f0facffe84dc0f2e06355dc5e71f486523b0ef6dafe0a30a3ff921521ca9ee9", "ref_doc_id": "3ce185f9-5529-409e-9658-656939bce4c8"}, "ab2ff440-c747-4404-aa24-ecafcb625ef7": {"doc_hash": "6144e49aaaae73b8dcc2476fcd36330af3d18f52443da764d99d39b6397888c1", "ref_doc_id": "3ce185f9-5529-409e-9658-656939bce4c8"}, "eb6ae795-f11e-49f3-9bce-0fb4b394454d": {"doc_hash": "41b21b6238453c663809f6aa56b2a56ab0aebdba914404cc1c7b7b1659ce26a3", "ref_doc_id": "3ce185f9-5529-409e-9658-656939bce4c8"}, "6856a033-1be7-4fd1-8212-c1b72d6bd9d8": {"doc_hash": "f1180cd5638940f320444026b3bd5adb5387f2737d95a48597826e015e483f8d", "ref_doc_id": "3ce185f9-5529-409e-9658-656939bce4c8"}, "29b6fa4b-ee96-4c21-ab0c-fc1101ca5fc9": {"doc_hash": "501bab0bb5083d6a840c736bd3d466cd5b4216cc32ce2417e10907f050f967af", "ref_doc_id": "039396cb-7fcb-40f4-8be7-eed53f885066"}, "a3c1c099-dfc9-4b28-85f8-8ed1304d2484": {"doc_hash": "1f67b47660e078bf7305fd27842707491d647aa3d35cdeb4e9cf1331f762cab7", "ref_doc_id": "8feaf2ba-529e-4c33-bab2-6c2c10f75ca1"}, "e4c06b65-1eaa-4add-a657-9371d2543139": {"doc_hash": "e2769e33abb4b10fbe29ba9ead0ff985bead0ea277768a8ea4e6b9281faaffea", "ref_doc_id": "8feaf2ba-529e-4c33-bab2-6c2c10f75ca1"}, "c3f9ae9a-8c3a-485b-9d27-c96a9080f261": {"doc_hash": "bf2e0fec7cbe085993035b9e2dfcdeed12c23afc1f20a35845e004c8bb6cf3df", "ref_doc_id": "8b533cdf-8511-46fb-942d-8ee9c9cb5db2"}, "ab8690a5-4c61-4bea-b4ab-6f0bef00826e": {"doc_hash": "0242e9386fc7b1296a17f5e1970c1e99addbab77a237be0f40e1d4a9e3080429", "ref_doc_id": "7f31e967-4279-40dd-a1a0-717238a4e3a2"}, "7914144c-42f1-47a2-ac09-dc31d1075ccc": {"doc_hash": "c9aec40c16fa9f4dcfea6eb57d652eb34f4fbf5dbb279216c24c98b6da1d91ff", "ref_doc_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d"}, "80e630cf-e520-400c-8abc-1cf63a21d9e2": {"doc_hash": "6b59cf0684aebfd0cb0e5347f718b62e716bb44267af2e22b236b1658022dfa0", "ref_doc_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d"}, "7427053f-65af-46f2-85df-80b58211589c": {"doc_hash": "e0185dd8737470f638130147330f0901a377f238fd4dfea4ad97e4b81505159e", "ref_doc_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d"}, "70c2deec-b132-4931-8392-4ace4758a43f": {"doc_hash": "2b7cf3a7ed38c7ef55fb51c78e2f952e4746c3795a9713600374dfb17389c5d6", "ref_doc_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d"}, "64c66de7-fd54-4c4b-ac15-4ede7845e255": {"doc_hash": "2aa3e7063d38c49cf7e8c6ca264a95ea4f1d9f92a039bfba14f6081254a32379", "ref_doc_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d"}, "166d1592-de26-485d-b6fb-c13ce3a75709": {"doc_hash": "8f23ae8a5738a0f867dcc1e0c3109f42d4223c9af7983315997526a6d73b2a78", "ref_doc_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d"}, "191532cf-ca29-4141-9fa5-a28e5726bd97": {"doc_hash": "4cc3e056059c2e0bf20af3fb3bc658134a84ceb2d505078dba098cf9cfb01dd1", "ref_doc_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d"}, "eb961eb5-ac6e-46cc-9e8b-f4cbece5f08b": {"doc_hash": "d0fd6bb323f95a5ab011acd783abaf8d450aa925cf0d3b9ab1c72026334e954b", "ref_doc_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d"}, "71747ed3-a2e4-4d85-9067-390ee1c36501": {"doc_hash": "1b1d540884b722f33ebcd3a2aba4f7959204700022129f099e2e6f2fc1ca10b9", "ref_doc_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d"}, "262082c9-3478-4c6f-a6aa-131eec9ed05f": {"doc_hash": "9bd93c75f205f5383f897c244f7e43538901cbfcb7dcc5f99d88b004bfe90855", "ref_doc_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d"}, "a632129f-4138-47aa-8a48-e6d1cae8a1eb": {"doc_hash": "69b4938e9c6de4c556a5eac4d2b7819d13c5f50e0a4db08226b5247a75664f77", "ref_doc_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d"}, "a9072523-6e39-41eb-ac3f-0abe25eb19e5": {"doc_hash": "61e46215b6e1d53271c411b7f342bcb67d3b605ac4a29b4f9ea6d89eaad497c5", "ref_doc_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d"}, "a8df7fa5-974c-4da5-a611-d197779cde55": {"doc_hash": "880029cb2d86032a2cf79aefd28cbda8ef1de3cf8b0e4f58697d16053accbb43", "ref_doc_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d"}, "c61be182-120e-4d8a-a862-4ecf8bbddaa3": {"doc_hash": "6fac4eed0bf8d3b234b2bd4d71efff69f9428fbf4819edd1cd9cf7b90d880592", "ref_doc_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d"}, "254ee87e-01a1-4f01-aa50-6273ff7f9be1": {"doc_hash": "7710ef1443fa24e9fd0f74c713bceba81b1632c258a84a3b68ef5d3e65f7060d", "ref_doc_id": "87c11357-987f-4f42-95c3-aa3cffd7e58d"}, "451e207d-fda7-4e4c-80c7-be237e88bdd4": {"doc_hash": "e637a7d5981147f99a5b7aabe10e82451bcd5e2baeab33ebce5bfdef0e4dfd2b", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "63dd53ad-dd51-4a81-9cf9-93753f7c30f4": {"doc_hash": "5b7c41fa543879878204f5b00e39b8b7149b108be9ac578f2103f057ada6742d", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "3fdcfcf6-27d3-4801-b172-6ee2eab36980": {"doc_hash": "7fd5c82034c87ef0731ca28caa2e6a5d5673350ca43833b59b9937ecb6e96d4a", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "427e59db-da42-4a54-9225-18e913ff5740": {"doc_hash": "5a6e24af42b356d2442f6773cc4bd9bc8c9395224f45e887ef67560013de5240", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "fdcffc1a-cfe6-4d22-83f7-5db2f6575c3b": {"doc_hash": "28f41280b396c88c4beff606a1eab4b74709d3251f13f31bddc218bb2bd2a61e", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "381a411f-a503-4460-8c7e-447e7163fc3f": {"doc_hash": "b3085c9edcf6fe8e4ded6b3af9cadbddae357736f45a4fab238562a7d9fd00b6", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "d63de384-f341-46f9-aa95-2a25ac03f46c": {"doc_hash": "058866ff0d547101710a40ac66a6b343157117c929c2eb255fbd6ed422dbf997", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "ca2b85ef-8a30-43df-b64f-3eecc124b63f": {"doc_hash": "567236662d41c4166e5a0216fcf82defcb39503365233c3daa18b023da329bb2", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "5d756f18-e20a-4b3e-a820-5e1c40553c49": {"doc_hash": "57b242de2b208d1b9ca51b4ed52e77c72f5fc1ed3414a202485546dd71931cc7", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "801e04b2-fd16-4ec3-89df-ee7a07c37ea6": {"doc_hash": "65d79b31e17d8230a6d589480de1e8e17e8ab624ce3d946c4ef2b2006e4ac01c", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "855b9474-f9e9-4984-9295-fa40be786b10": {"doc_hash": "b0fec0dd1b2596f65a9059a421411ae5dcebccd132a946b3b3d3006893be2cd9", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "2fc5d713-1d66-4331-983e-b99a9ea90174": {"doc_hash": "f47328a3cb31ee37d55eb5d83f03e165889c3271096f00236f97a75616137258", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "76cb6819-68f2-442b-aef7-710d5d260740": {"doc_hash": "117b2ba66f7fc5f380c5c0b9ae15b0a6c04ee4b91e5b24e14dfa92bd820bae7a", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "1e52513c-ec50-4123-b4f4-a4a9229674c9": {"doc_hash": "2b3dc49aca1832173875d2acbce97da0464b0a68da9254e91173c9f6af1d64de", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "741e2f26-8d88-4523-9c6d-ee91eb8cac19": {"doc_hash": "e2356db16d8afcb5b69390472d4d66b1e15a858ee9faed145fe56d7d63bbe86a", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "14985a43-3b15-43d4-b104-5662abb43f94": {"doc_hash": "debb5d1134fbe8b5d7a67683e94347c18a6e434d2ac1a47ac86ae20d86146e83", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "50a8d02f-cf28-480e-8037-e2ceb1d546de": {"doc_hash": "c374d92ce4130fd462afb0b0b5bb749cff82c342248786a05f2ea8bd44f20739", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "f589c643-4ede-4b63-a749-ccfd5dca919f": {"doc_hash": "776e37913b739e8234148a868d0ec6f77eec9693b247fce0cac1d87057de0e15", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "72fe4108-4802-4d0a-a7f7-e984cdf25ea1": {"doc_hash": "8a8df74c5e86babe94c71afc126703557a156ab66ee926c9fed8dac701da1e52", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "d0255fc9-f72e-405b-bfab-35d6082e957d": {"doc_hash": "792cb81cb572863b355dbf84499dc4548b24244bf263810f3173c3bcd9368481", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "c120f3b5-cbce-4cca-8493-71fbb4ae2eca": {"doc_hash": "f6d994d639bbcff723d92fa03a4a3130bf504a67071711667d8cc129981f1b5e", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "17aba320-251d-49d2-8508-deb2ff9b42a1": {"doc_hash": "e6d0e61b3763ce088ec2aec230b129a2cd8fa29a9adc61456a5c7902a537c3bb", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "936c1b93-e96e-4dda-b4ae-9500b45bf21b": {"doc_hash": "c19652e606d7a64bcd2a4c94af8112e7d6f84c8060a71b325ebe5246fcd0cd96", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "1264105b-65d5-44c2-9eb9-f9770e35a63a": {"doc_hash": "fb4fedd4854b057cda46a87f2e59817eb593410ee0e00bd92d7b51c60e78a983", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "ce43ab2d-dcd8-4f9e-beac-4e9e76ae5efb": {"doc_hash": "85812d129c41ce03f239ed056fcb0d0c7fa01f3d10628961167aac5833138b47", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "7ca8296b-6739-40fc-8495-dd11ebf2ebd3": {"doc_hash": "00dab9c78a6a47ae42c757abdd5b7babc416637da8f3859b9dcd1e3ad8ee5ad7", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "80e658e9-a765-4735-82fd-eee4a0b6239c": {"doc_hash": "7f129af4ada1113a7d3482c4b0bbc57d45b9788aeac6462c58153601da3cf16a", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "5f75ead6-c032-4e14-a00d-98c7346287ba": {"doc_hash": "4da6cdce0c6f53462af5d534150feb5d93f51c6726cc5f93d12d53abdeab33b1", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "246f56c9-6bcf-4add-9ea0-be401b1b4579": {"doc_hash": "6889b70609086b70a0f64bc99f8ef921028c53220eb2b7533b982d35f8cb2917", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "c70cd78e-2927-4f1b-a43f-b3c8311bace9": {"doc_hash": "c3c7478dc80fd6ab83e2f251fcd2ca32fb304094341078abc64e1e4e4818bdd4", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "9a2ea091-3ebc-43c8-b236-a68dece1c9e5": {"doc_hash": "42e8d643da94d22c1eb0e9adef82015508aa0591a5a42bcf52daf3333e9bc461", "ref_doc_id": "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3"}, "7ce563d7-bc10-47bb-a9d1-ac44943c4a67": {"doc_hash": "acb8f3a198b6d68a9fa119cbe343186876369a4d67fc72efb45fc3496856bc92", "ref_doc_id": "83178449-8605-45a3-a4c3-38c42742cd0b"}, "ef58a4cc-378b-485d-91ce-bb682e2af7b9": {"doc_hash": "f93e6b023a72b5a70bcc858a682f408270b3c33f49ce24b1a499cb1665267792", "ref_doc_id": "83178449-8605-45a3-a4c3-38c42742cd0b"}, "99238e0b-cafa-41f0-91c5-371bd7069d7a": {"doc_hash": "c1a9846d69bbb25ea5cc124450bc42fbac45cbb0aa60d648f88194fc606ee525", "ref_doc_id": "83178449-8605-45a3-a4c3-38c42742cd0b"}, "5d24d640-e7f7-40cd-8886-a511172725e4": {"doc_hash": "87de7086f59486ea88a346e1637e202a74d2497212a591f9341f0844020878c2", "ref_doc_id": "83178449-8605-45a3-a4c3-38c42742cd0b"}, "fe72c292-0947-413d-8c7d-b6465f9e78c3": {"doc_hash": "9fc5baae1d87945409df5885d31e3debf28feecabe35b199141789eee8f5ada5", "ref_doc_id": "83178449-8605-45a3-a4c3-38c42742cd0b"}, "fbb7679c-b0c9-4328-9728-e50fbfb3a6d9": {"doc_hash": "38b95475dc3ac044b36922c545a670a5abea67b6a1059e61d53f93749d91918b", "ref_doc_id": "83178449-8605-45a3-a4c3-38c42742cd0b"}, "21177c0e-b4b2-48c9-9e42-04014d734312": {"doc_hash": "e5330c5fa1924c28f34e97f92297b0e4aac2879efec94a3919f7580af1fd8ba8", "ref_doc_id": "83178449-8605-45a3-a4c3-38c42742cd0b"}, "2df0a1b2-4b61-44c1-97b6-b5f63d15affe": {"doc_hash": "c3fd29ee97905e1bda163cc080598d9255f8280a4aade7bcd4be113f2ec70fcb", "ref_doc_id": "83178449-8605-45a3-a4c3-38c42742cd0b"}, "0a216014-c47b-470e-9ee4-d41557f94f92": {"doc_hash": "aee51fad3e435d7eb7622f28b2b7e6823b63b73328f84f7ef5e8ecb059bedac3", "ref_doc_id": "83178449-8605-45a3-a4c3-38c42742cd0b"}, "7184336b-0d3c-4398-9656-f8b5c89952f1": {"doc_hash": "d9b5c65ffb4ed1a670bdab1ca6cf964b7cdfbcf2194fd4f66918cc240217e0d8", "ref_doc_id": "83178449-8605-45a3-a4c3-38c42742cd0b"}, "de8a79d3-2e44-4c2f-89b1-0ce602a4fa0c": {"doc_hash": "203d84b7e0803345d0496824b4c9fd8e8ed32041cd936f0a628c501a1217a47e", "ref_doc_id": "83178449-8605-45a3-a4c3-38c42742cd0b"}}, "docstore/ref_doc_info": {"c2d4ecd8-80af-4811-aeb7-84c417570b17": {"node_ids": ["2c7921ac-edc5-4133-bba2-f4f6debdb32c", "22b9e2c7-576c-4dff-bfdd-fb6c75621b8b", "5413af4a-22b9-4676-a8d5-f55728ed7129", "dbf59b49-9c74-42eb-b446-2f14fa1a0cdf", "6a4c3325-344d-4265-9eff-adbd2b83442a", "5f0f71e1-f964-4192-995f-0f4dafeb8517", "df89fb75-4664-4f23-966a-ad1c04439526", "7bcd24d9-1dee-41fc-8abf-becee8eedf41", "650f6f1c-4be8-484f-8c16-7eed75e4e07a", "a6953132-ca6d-4655-afdd-4948f4802fd6", "0e11b6df-df35-4157-a52f-b4fd5b74314b", "dbf3184b-9333-4b5d-a715-5402ac4cbe4b", "db62eeb3-a078-464c-8f16-a113c169e830", "25290bdd-dcfd-4730-ac0e-833d6599992d", "79413521-8cc5-4f05-a815-ed34d9f8bfbd", "8479a757-f1f4-4e11-98d8-dfb2aa6a1901", "526af04e-87a0-429c-8bb3-cab5c8167ae5", "dd27bca1-1151-490d-975b-a48a6f56c8d8"], "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Fir st Quar ter Results\n1/30/2020\nRevenues of $47.9 Billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $0.90 and Adjusted Diluted EPS of $1.76\nAdjusted Diluted EPS Guidance Range Raised to $7.55 to $7.80 for Fiscal 2020\nThe Board of Directors Increased the Quarterly Dividend Rate by 5% to $0.42 per share\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020 first\nquarter ended December 31, 2019, revenue increased 5.4 percent to $47.9 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $0.90 for the December quarter of fiscal 2020, compared to $1.84\nin the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 10.0\npercent to $1.76 in the fiscal first quarter.\n", "original_text": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Fir st Quar ter Results\n1/30/2020\nRevenues of $47.9 Billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year\nFirst Quarter GAAP Diluted EPS of $0.90 and Adjusted Diluted EPS of $1.76\nAdjusted Diluted EPS Guidance Range Raised to $7.55 to $7.80 for Fiscal 2020\nThe Board of Directors Increased the Quarterly Dividend Rate by 5% to $0.42 per share\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020 first\nquarter ended December 31, 2019, revenue increased 5.4 percent to $47.9 billion. ", "page_label": "1", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a3bf5850-52b8-4bdc-a178-03658af66ae1": {"node_ids": ["44f372a0-8695-4e66-892c-9dc9305b2ab5", "53091b22-d050-4b64-b486-448280843464", "2e64faf6-545c-4a0c-8e9e-08d9883eb128", "6113c6f8-65be-4057-9fe4-a22122b21d63", "23e30c4d-4353-4a16-b580-fecbfd9f3468", "ac9e7c6b-76b9-4cba-ab66-93413020ee4e", "55cc2121-bdc0-411c-bb4c-f31a75d4a71d", "a7211189-9530-4937-95f3-9ef4975fb93b", "6e6f1486-ca85-4eea-94d6-87ee0a3e8f4a", "a202ab79-2817-4344-9d2f-d334719d494b", "b0183999-bcdd-4cf2-9176-35ce31347879", "98e32e69-caa4-4237-ad35-609446642b27", "8b06ac51-2c3e-4725-83e8-d590f46b7cae", "1bd46823-1830-47fb-baeb-fd4b1cde0166", "d4e9efd4-614a-46a3-81ca-bc2d0dd2de55", "845e37ac-32ba-4be0-b1a5-786e41553a77", "fdfcf14e-f6d1-49c1-af53-06ac10b8eee3", "0c4c5d93-ba08-40bd-956d-6aea53a72f22", "82d187db-0558-4e4a-8a92-afd3b64a5dfb"], "metadata": {"window": "Gross Pr ofit $1.2B $1.2B\nOperating Expenses $968M $748M\nOperating Income $263M $495M\nInterest Expense, Net $31M $31M\nEffectiv e Tax Rat e 18.7% 21.0%\nNet Income A ttributable t o ABC $188M $365M\nDilut ed Earnings P er Shar e $0.90 $1.76\nDilut ed Shar es Outstanding 208M 208M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2020, revenue was $47.9 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 5.2 percent increase in Pharmaceutical Distribution Services revenue and a 10.5 percent\nincrease in revenue within Other.\n", "original_text": "Gross Pr ofit $1.2B $1.2B\nOperating Expenses $968M $748M\nOperating Income $263M $495M\nInterest Expense, Net $31M $31M\nEffectiv e Tax Rat e 18.7% 21.0%\nNet Income A ttributable t o ABC $188M $365M\nDilut ed Earnings P er Shar e $0.90 $1.76\nDilut ed Shar es Outstanding 208M 208M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "723c9482-4103-4254-a210-9e3956cb44bf": {"node_ids": ["804e7ca4-ebd0-45be-a150-c66b6ecb812e", "16bb6b03-b80a-4fa0-ae3f-b546e71cdd82", "a8d2e1a0-52e8-40a5-b38e-fa1bd44a3600", "8fc90634-da50-41f1-8692-c568a6b0835b", "0bdf68b0-4808-4b4b-a7a5-1fef3c950c8b", "5d46bc53-5592-41a7-9948-139202afb4b6", "fa668d3a-12b7-442f-8384-0fa70eb747ad", "28968693-b6a9-4c75-aee7-9e8ccaec02b3", "c7e38d26-321d-4c64-9aeb-de63f6bc319a", "8e269996-0e1c-49cc-a27c-21c02f3810c7", "972b0841-21da-454c-a2c8-6f2e70ddf685", "d53fde0a-92c2-4e9f-9026-d10843577a60", "dda2f501-6a41-4c7e-84c0-7653d3aecf92", "ae7c9e41-3248-4ed9-84c7-d0d53514afcd", "926a7a82-479d-4cac-88f2-f75894627bac", "879206a6-8305-471c-8a12-9ac7d9e3f425", "28c7a494-95a7-4a4d-a3ac-3bad994755c2", "20349348-bcd5-4f56-8376-5f71d63c4a9a", "357e0bd7-53a0-4764-af41-da7a73fad089", "8c9ee8f4-243e-4ca2-8b10-99b49a0433a0"], "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2020 were 207.5\nmillion, a 3.0 percent decline versus the prior fiscal year first quarter primarily due to share repurchases.\n PharMEDium Updat e\nIn late January 2020 the Company decided to exit the PharMEDium compounding business and as a result, the Company will\ncease all commercial and administrative operations related to this business.  The decision to exit the PharMEDium business\nwas due to a number of factors including, but not limited to, ongoing operational, regulatory, and commercial challenges,\nsuch as PharMEDium's decision in January 2020 to suspend production at the compounding facility in New Jersey pending\nfacility upgrades related to the air handling and filtration systems.  In addition to the PharMEDium impairment charge of $138\nmillion recognized in the three months ended December 31, 2019, the Company expects it will impair the majority of the\nremaining $55 million of PharMEDium tangible assets and all of the remaining $185 million of PharMEDium intangible assets\nin the three months ending March 31, 2020. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2020 were 207.5\nmillion, a 3.0 percent decline versus the prior fiscal year first quarter primarily due to share repurchases.\n", "page_label": "3", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "184fa4e1-1db9-4e77-8864-26dc435d74b9": {"node_ids": ["c1581e41-a4a4-41e6-a452-4e21fab22558", "1e4a22a4-b3c0-4e1d-a95a-b1f09824c204", "bece5fa0-8aa5-4104-b2c5-4b74f3122c67", "9658a6a2-6e12-4d63-90fc-f63a213e3a37", "cba2d70c-cdad-46b6-b026-063643080512", "5f118632-66c9-4c3f-9cb9-075676311afd", "1c109620-fea0-4c0a-b750-a718a980fb07", "57225f17-2276-46e5-8377-56fad3d48a5d", "e2473259-f2da-49e5-b83c-9d5397542fa6", "0289cfbf-8bc4-4188-9ee9-87b0bfbd3d4a", "7624d26e-0fcd-4a3f-bf3f-1552e31132ff", "22785523-de8f-4466-a78a-faf742f63007", "bffd99ba-4de1-4e21-baf3-620fadda7bd0", "bec5f817-0978-466d-bfe1-5ad077d1289d", "9a6c43ba-f101-42b9-a965-93fb3b45a841", "49bad4e8-e24b-40e5-aee8-286a905775ae", "40d5c900-8b3d-4790-b23e-dba7249bd8e6", "edea6586-b8ab-4f23-9aad-fa1fe0de13de"], "metadata": {"window": "fiscal 2020 compared to $1.60 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income, a\nlower share count, and lower net interest expense.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2020 were 207.5 million, a 3.0 percent decline versus the\nprior fiscal year first quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation. ", "original_text": "fiscal 2020 compared to $1.60 in the previous fiscal year\u2019s first quarter, driven by the increase in adjusted operating income, a\nlower share count, and lower net interest expense.\n", "page_label": "4", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "52547411-6af4-47ea-af2a-bb2cdd66e121": {"node_ids": ["efdd3fc6-f7c8-40d6-afc2-0d9d196fc1df", "8eed639c-85f9-4a02-8f70-08308819df7f", "1cd1bf29-5404-4fe9-a5c6-1e509c5a4da6", "9e5d4320-1921-4d36-a183-9e395ef79add", "d4bfb4de-f3fb-4433-9647-a2e08d70741e", "817263f8-f92c-492a-8dc9-251982396838", "7128346f-1b03-4a9c-91b5-697a2b5fa368", "327f8c5f-5a43-4173-8daa-a393f5a27dff", "25130bb8-745c-4ef3-98dc-4f91a69f6ccb", "5d632b23-468e-4b26-b031-e70475f2fbe2", "bf370e98-773d-4cc5-b978-eff847d764e6", "0448c0cd-c8b5-4f40-8e42-53b5ddce6cce", "f3db4352-d0e6-45b6-b366-3b1091202940", "9eeaafd2-6d78-4501-9d7a-344f0fae2039", "59b2e735-7979-45b1-ba87-5177f2749af0", "81568d60-e603-47d7-a146-d6d7cde8e983", "0eb21732-c70a-44de-ab95-9a68af724509", "5b0dcbf3-25c2-41a7-97a3-9ed81a75e698", "79a3b09f-b8ff-4e55-846b-8aabb1dd4ec9", "f74f134c-7e51-49e1-84dd-5a1cb1370589", "ec2b42d8-d176-4042-9fed-c3bf8a0f5ca0", "24caea4b-e095-48d7-a45c-0fd333e19d68", "c1a9cecf-6886-4cb1-b02d-d7a07e34d12a", "4919713e-763a-4e63-b4cd-b57a53f3f1b6", "31d66fb0-24b4-44f9-9986-ada6856d49dd", "ad1e36ab-0bae-4714-8687-acfc830601d3", "79b34e17-380f-436c-825c-96a310e3f4ff", "64c220ca-d6b6-4b94-a469-94a252986bb9", "29f3f899-4c91-4698-b2b9-ccd5ef394322", "157f87e1-6aaa-4c33-8d19-736b6efecb1b"], "metadata": {"window": "AmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s strong performance, opportunistic\nshare repurchases and the exit of our PharMEDium business.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $7.55 to $7.80, up from the previous range of $7.30 to $7.60.\n Additional expectations now include:\nAdjusted operating income growth in the mid-single digit percent range, up from the low-to mid-single percent range;\nPharmaceutical Distribution Services segment operating income growth in the mid-single digit percent range, up from\nthe low- to mid-single digit percent range;\nWeighted average diluted shares are now expected to be approximately 208 million, down from the previous expectation of\nbetween 209 million to 210 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n", "original_text": "AmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s strong performance, opportunistic\nshare repurchases and the exit of our PharMEDium business. ", "page_label": "5", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "70432d22-a097-4888-876b-20e363f3e3bc": {"node_ids": ["6bca6a7d-1cb0-4499-a58f-9d134ce2f69b", "027e9116-3467-4307-84ae-9094104f49aa", "30115299-6f57-4d9a-853c-a051a237979e", "364119f1-aaf5-4dd4-bdda-24be1e8011b1", "82cb2082-b4f8-4e90-86bc-3ee22cb9c00e", "e9ec22f5-df95-4f1a-9334-ccd53be5f68d", "3099ce00-86cb-4ac2-a684-72891ec36147", "4ec78619-3de1-42a2-9842-aa80eb62b280", "5037ae06-a770-422c-9a33-3f2c2a8f674e", "e35924b7-507d-40d0-aa53-11240b0048bf"], "metadata": {"window": "Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "original_text": "Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "page_label": "6", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "754d642f-1f12-4807-bfdf-d35f9acfa49a": {"node_ids": ["f8d62f02-00db-4c3d-8f2a-a9faa7e0dd5e"], "metadata": {"window": "(unaudited)\n\u00a0\n\u00a0 \u00a0Three\nMonths Ended \n December 31,\n2019 \u00a0% of\nRevenue \u00a0Three\nMonths Ended \n December 31,\n2018 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a0$45,392,452 \u00a0\u00a0\u00a0 \u00a05.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a044,094,872 \u00a0\u00a0\u00a0 \u00a05.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,231,214 \u00a0\u00a02.57% \u00a01,297,580 \u00a0\u00a02.86% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0685,953 \u00a0\u00a01.43% \u00a0656,585 \u00a0\u00a01.45% \u00a04.5%\nDepreciation and amortization \u00a0104,515 \u00a0\u00a00.22% \u00a0122,500 \u00a0\u00a00.27% \u00a0(14.7)%\nEmployee severance, litigation, and other 2 \u00a039,309 \u00a0\u00a0\u00a0 \u00a040,672 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of long-lived assets 3 \u00a0138,000 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0967,777 \u00a0\u00a02.02% \u00a0819,757 \u00a0\u00a01.81% \u00a018.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0263,437 \u00a0\u00a00.55% \u00a0477,823 \u00a0\u00a01.05% \u00a0(44.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss \u00a02,842 \u00a0\u00a0\u00a0 \u00a03,097 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a031,007 \u00a0\u00a0\u00a0 \u00a042,170 \u00a0\u00a0\u00a0 \u00a0(26.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0229,588 \u00a0\u00a00.48% \u00a0432,556 \u00a0\u00a00.95% \u00a0(46.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a043,020 \u00a0\u00a0\u00a0 \u00a040,803 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "original_text": "(unaudited)\n\u00a0\n\u00a0 \u00a0Three\nMonths Ended \n December 31,\n2019 \u00a0% of\nRevenue \u00a0Three\nMonths Ended \n December 31,\n2018 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$47,864,742 \u00a0\u00a0\u00a0 \u00a0$45,392,452 \u00a0\u00a0\u00a0 \u00a05.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a046,633,528 \u00a0\u00a0\u00a0 \u00a044,094,872 \u00a0\u00a0\u00a0 \u00a05.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,231,214 \u00a0\u00a02.57% \u00a01,297,580 \u00a0\u00a02.86% \u00a0(5.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0685,953 \u00a0\u00a01.43% \u00a0656,585 \u00a0\u00a01.45% \u00a04.5%\nDepreciation and amortization \u00a0104,515 \u00a0\u00a00.22% \u00a0122,500 \u00a0\u00a00.27% \u00a0(14.7)%\nEmployee severance, litigation, and other 2 \u00a039,309 \u00a0\u00a0\u00a0 \u00a040,672 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of long-lived assets 3 \u00a0138,000 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0967,777 \u00a0\u00a02.02% \u00a0819,757 \u00a0\u00a01.81% \u00a018.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0263,437 \u00a0\u00a00.55% \u00a0477,823 \u00a0\u00a01.05% \u00a0(44.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss \u00a02,842 \u00a0\u00a0\u00a0 \u00a03,097 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a031,007 \u00a0\u00a0\u00a0 \u00a042,170 \u00a0\u00a0\u00a0 \u00a0(26.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0229,588 \u00a0\u00a00.48% \u00a0432,556 \u00a0\u00a00.95% \u00a0(46.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a043,020 \u00a0\u00a0\u00a0 \u00a040,803 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "page_label": "7", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ff4ec43f-3185-4206-9869-12e51438f08a": {"node_ids": ["61fce454-f2af-4931-a6f8-54bab198d2bc", "3fda072e-32a8-4219-a6c7-ee2d70501069", "02dc72fd-dd72-4f35-9a57-a50dee70a689", "e729fc0a-6007-4624-b3e6-50eb00127b17", "16926dcc-ae2c-484e-bf58-ff52cabc2fee", "6eac4261-997d-4778-82bb-bd8ae883340e"], "metadata": {"window": "Net income \u00a0186,568 \u00a0\u00a00.39% \u00a0391,753 \u00a0\u00a00.86% \u00a0(52.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interest \u00a01,072 \u00a0\u00a0\u00a0 \u00a01,899 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$187,640\u00a0\n\u00a00.39% \u00a0$393,652\u00a0\n\u00a00.87% \u00a0(52.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0$1.86 \u00a0\u00a0\u00a0 \u00a0(51.1)%\nDiluted \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0$1.84 \u00a0\u00a0\u00a0 \u00a0(51.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0212,054 \u00a0\u00a0\u00a0 \u00a0(2.9)%\nDiluted \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0213,969 \u00a0\u00a0\u00a0 \u00a0(3.0)%\n_____________________________________\n1Includes a $13.3 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $7.1 million of\nPharMEDium remediation costs in the three months ended December 31, 2019.  Includes an $87.3 million gain from antitrust\nlitigation settlements, a $22.0 million reversal of a prior period assessment relating to the New York State Opioid Stewardship\nAct, $17.9 million of PharMEDium remediation costs, and a $3.0 million LIFO credit in the three months ended December 31,\n2018.\n\u00a0\n 2Includes $0.8 million of employee severance, $24.7 million of litigation and opioid-related costs related to legal fees in\nconnection with opioid lawsuits and investigations, and $13.8 million of other costs in connection with acquisition-related deal\nand integration costs, business transformation efforts, and other restructuring initiatives in the three months ended December\n31, 2019.  Includes $4.8 million of employee severance, $14.5 million of litigation costs related to opioid lawsuits and\ninvestigations, and $21.4 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended December 31, 2018.\n\u00a0\n", "original_text": "Net income \u00a0186,568 \u00a0\u00a00.39% \u00a0391,753 \u00a0\u00a00.86% \u00a0(52.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss attributable to noncontrolling interest \u00a01,072 \u00a0\u00a0\u00a0 \u00a01,899 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$187,640\u00a0\n\u00a00.39% \u00a0$393,652\u00a0\n\u00a00.87% \u00a0(52.3)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$0.91 \u00a0\u00a0\u00a0 \u00a0$1.86 \u00a0\u00a0\u00a0 \u00a0(51.1)%\nDiluted \u00a0$0.90 \u00a0\u00a0\u00a0 \u00a0$1.84 \u00a0\u00a0\u00a0 \u00a0(51.1)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,008 \u00a0\u00a0\u00a0 \u00a0212,054 \u00a0\u00a0\u00a0 \u00a0(2.9)%\nDiluted \u00a0207,517 \u00a0\u00a0\u00a0 \u00a0213,969 \u00a0\u00a0\u00a0 \u00a0(3.0)%\n_____________________________________\n1Includes a $13.3 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $7.1 million of\nPharMEDium remediation costs in the three months ended December 31, 2019. ", "page_label": "8", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "695df1ff-c27d-4015-ab41-0b563338101c": {"node_ids": ["d5236aa6-5de0-4bdf-ae4f-765bb25e39de"], "metadata": {"window": "GAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,231,214 \u00a0\u00a0$967,777 \u00a0\u00a0$263,437 \u00a0\u00a0$229,588 \u00a0\u00a0$43,020 \u00a0\u00a0$1,072 \u00a0\u00a0$187,640 \u00a0\u00a0$0.90 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,492 )\u00a0\u2014\u00a0\n\u00a0(8,492 )\u00a0(8,492 )\u00a0(1,974 )\u00a0\u2014\u00a0\n\u00a0(6,518 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a013,281 \u00a0\u00a0\u2014 \u00a0\u00a013,281 \u00a0\u00a013,281 \u00a0\u00a03,087 \u00a0\u00a0\u2014 \u00a0\u00a010,194 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a07,135\u00a0\n\u00a0(9,030 )\u00a016,165\u00a0\n\u00a016,165\u00a0\n\u00a03,757\u00a0\n\u00a0\u2014\u00a0\n\u00a012,408\u00a0\n\u00a00.06\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(33,566 )\u00a033,566\u00a0\n\u00a033,566\u00a0\n\u00a07,801\u00a0\n\u00a0(436 )\u00a025,329\u00a0\n\u00a00.12\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(39,309 )\u00a039,309\u00a0\n\u00a039,309\u00a0\n\u00a09,136\u00a0\n\u00a0\u2014\u00a0\n\u00a030,173\u00a0\n\u00a00.15\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nlong-lived\nassets \u00a0\u2014\u00a0\n\u00a0(138,000 )\u00a0138,000\u00a0\n\u00a0138,000\u00a0\n\u00a032,071\u00a0\n\u00a0\u2014\u00a0\n\u00a0105,929\u00a0\n\u00a00.51\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "original_text": "GAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2019 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,231,214 \u00a0\u00a0$967,777 \u00a0\u00a0$263,437 \u00a0\u00a0$229,588 \u00a0\u00a0$43,020 \u00a0\u00a0$1,072 \u00a0\u00a0$187,640 \u00a0\u00a0$0.90 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,492 )\u00a0\u2014\u00a0\n\u00a0(8,492 )\u00a0(8,492 )\u00a0(1,974 )\u00a0\u2014\u00a0\n\u00a0(6,518 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a013,281 \u00a0\u00a0\u2014 \u00a0\u00a013,281 \u00a0\u00a013,281 \u00a0\u00a03,087 \u00a0\u00a0\u2014 \u00a0\u00a010,194 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a07,135\u00a0\n\u00a0(9,030 )\u00a016,165\u00a0\n\u00a016,165\u00a0\n\u00a03,757\u00a0\n\u00a0\u2014\u00a0\n\u00a012,408\u00a0\n\u00a00.06\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(33,566 )\u00a033,566\u00a0\n\u00a033,566\u00a0\n\u00a07,801\u00a0\n\u00a0(436 )\u00a025,329\u00a0\n\u00a00.12\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(39,309 )\u00a039,309\u00a0\n\u00a039,309\u00a0\n\u00a09,136\u00a0\n\u00a0\u2014\u00a0\n\u00a030,173\u00a0\n\u00a00.15\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nlong-lived\nassets \u00a0\u2014\u00a0\n\u00a0(138,000 )\u00a0138,000\u00a0\n\u00a0138,000\u00a0\n\u00a032,071\u00a0\n\u00a0\u2014\u00a0\n\u00a0105,929\u00a0\n\u00a00.51\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "page_label": "9", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e84d20e8-2fad-4c78-a41a-fe1d76b8982b": {"node_ids": ["9e0cca3e-44d0-4be8-9cb2-4c954589d5e9", "89ce199f-0986-4ea7-8a8d-4a761321bc78", "99dfbb03-be4e-476e-bb86-f58c24d06615"], "metadata": {"window": "Adjusted Non-\nGAAP \u00a0$1,243,138\u00a0\n\u00a0$747,872\u00a0\n\u00a0$495,266\u00a0\n\u00a0$461,417\u00a0\n\u00a0$96,898\u00a0\n\u00a0$636\u00a0\n\u00a0$365,155\u00a0\n\u00a0$1.76\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nperiod \u00a03.3 %\u00a02.3 %\u00a05.0 %\u00a08.2 %\u00a014.1 %\u00a0\u00a0 \u00a06.4 %\u00a010.0 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.57% \u00a02.60%\nOperating expenses \u00a02.02% \u00a01.56%\nOperating income \u00a00.55% \u00a01.03%\n_____________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2018 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,297,580 \u00a0\u00a0$819,757 \u00a0\u00a0$477,823 \u00a0\u00a0$432,556 \u00a0\u00a0$40,803 \u00a0\u00a0$1,899 \u00a0\u00a0$393,652 \u00a0\u00a0$1.84 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from antitrust \u00a0 \u00a0\n10", "original_text": "Adjusted Non-\nGAAP \u00a0$1,243,138\u00a0\n\u00a0$747,872\u00a0\n\u00a0$495,266\u00a0\n\u00a0$461,417\u00a0\n\u00a0$96,898\u00a0\n\u00a0$636\u00a0\n\u00a0$365,155\u00a0\n\u00a0$1.76\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "page_label": "10", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8c3df90e-4a1d-4aea-a05d-533e0e763894": {"node_ids": ["71aeb2c3-6bc5-4093-8f1e-71f119ed5b3e"], "metadata": {"window": "litigation\nsettlements \u00a0(87,279 )\u00a0\u2014 \u00a0(87,279 )\u00a0(87,279 )\u00a0(18,470 )\u00a0\u2014 \u00a0(68,809 )\u00a0(0.32 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(3,029 )\u00a0\u2014 \u00a0\u00a0(3,029 )\u00a0(3,029 )\u00a0(641 )\u00a0\u2014 \u00a0\u00a0(2,388 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation costs \u00a017,911\u00a0\n\u00a0(2,584 )\u00a020,495\u00a0\n\u00a020,495\u00a0\n\u00a04,337\u00a0\n\u00a0\u2014\u00a0\n\u00a016,158\u00a0\n\u00a00.08\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York State\nOpioid Stewardship\nAct \u00a0(22,000 )\u00a0\u2014\u00a0\n\u00a0(22,000 )\u00a0(22,000 )\u00a0(4,656 )\u00a0\u2014\u00a0\n\u00a0(17,344 )\u00a0(0.08 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(45,152 )\u00a045,152\u00a0\n\u00a045,152\u00a0\n\u00a09,555\u00a0\n\u00a0(506 )\u00a035,091\u00a0\n\u00a00.16\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(40,672 )\u00a040,672\u00a0\n\u00a040,672\u00a0\n\u00a016,980\u00a0\n\u00a0\u2014\u00a0\n\u00a023,692\u00a0\n\u00a00.11\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax Reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,203,183\u00a0\n\u00a0$731,349\u00a0\n\u00a0$471,834\u00a0\n\u00a0$426,567\u00a0\n\u00a0$84,905\u00a0\n\u00a0$1,393\u00a0\n\u00a0$343,055\u00a0\n\u00a0$1.60\u00a0\n2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.86% \u00a02.65%\nOperating expenses \u00a01.81% \u00a01.61%\nOperating income \u00a01.05% \u00a01.04%\n_____________________________________\n11", "original_text": "litigation\nsettlements \u00a0(87,279 )\u00a0\u2014 \u00a0(87,279 )\u00a0(87,279 )\u00a0(18,470 )\u00a0\u2014 \u00a0(68,809 )\u00a0(0.32 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(3,029 )\u00a0\u2014 \u00a0\u00a0(3,029 )\u00a0(3,029 )\u00a0(641 )\u00a0\u2014 \u00a0\u00a0(2,388 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation costs \u00a017,911\u00a0\n\u00a0(2,584 )\u00a020,495\u00a0\n\u00a020,495\u00a0\n\u00a04,337\u00a0\n\u00a0\u2014\u00a0\n\u00a016,158\u00a0\n\u00a00.08\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York State\nOpioid Stewardship\nAct \u00a0(22,000 )\u00a0\u2014\u00a0\n\u00a0(22,000 )\u00a0(22,000 )\u00a0(4,656 )\u00a0\u2014\u00a0\n\u00a0(17,344 )\u00a0(0.08 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(45,152 )\u00a045,152\u00a0\n\u00a045,152\u00a0\n\u00a09,555\u00a0\n\u00a0(506 )\u00a035,091\u00a0\n\u00a00.16\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(40,672 )\u00a040,672\u00a0\n\u00a040,672\u00a0\n\u00a016,980\u00a0\n\u00a0\u2014\u00a0\n\u00a023,692\u00a0\n\u00a00.11\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax Reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,203,183\u00a0\n\u00a0$731,349\u00a0\n\u00a0$471,834\u00a0\n\u00a0$426,567\u00a0\n\u00a0$84,905\u00a0\n\u00a0$1,393\u00a0\n\u00a0$343,055\u00a0\n\u00a0$1.60\u00a0\n2\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.86% \u00a02.65%\nOperating expenses \u00a01.81% \u00a01.61%\nOperating income \u00a01.05% \u00a01.04%\n_____________________________________\n11", "page_label": "11", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "3ce185f9-5529-409e-9658-656939bce4c8": {"node_ids": ["e0503464-0b9c-4d38-adac-853e803938a5", "ab2ff440-c747-4404-aa24-ecafcb625ef7", "eb6ae795-f11e-49f3-9bce-0fb4b394454d", "6856a033-1be7-4fd1-8212-c1b72d6bd9d8"], "metadata": {"window": "1Amount represents the final measurement period adjustment to the one-time transition tax on historical foreign earnings and\nprofits through December 31, 2017.\n\u00a0\n 2The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n\u00a0\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$46,036,828 \u00a0\u00a0$43,744,381 \u00a0\u00a05.2%\nOther \u00a01,846,984 \u00a0\u00a01,670,938 \u00a0\u00a010.5%\nIntersegment eliminations \u00a0(19,070 )\u00a0(22,867 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,864,742 \u00a0\u00a0$45,392,452 \u00a0\u00a05.4%\n\u00a0 \u00a0Three Months Ended December 31,\nOperating income \u00a02019 \u00a02018 \u00a0% Change\nPharmaceutical Distribution Services \u00a0$391,694 \u00a0\u00a0\u00a0$373,207 \u00a0\u00a0\u00a05.0%\nOther \u00a0104,479 \u00a0\u00a0\u00a098,934 \u00a0\u00a0\u00a05.6%\nIntersegment eliminations \u00a0(907 )\u00a0\u00a0(307 )\u00a0\u00a0\u00a0\n12", "original_text": "1Amount represents the final measurement period adjustment to the one-time transition tax on historical foreign earnings and\nprofits through December 31, 2017.\n\u00a0\n", "page_label": "12", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "039396cb-7fcb-40f4-8be7-eed53f885066": {"node_ids": ["29b6fa4b-ee96-4c21-ab0c-fc1101ca5fc9"], "metadata": {"window": "Total segment operating income \u00a0495,266 \u00a0\u00a0\u00a0471,834 \u00a0\u00a0\u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,492 \u00a0\u00a0\u00a087,279 \u00a0\u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(13,281 )\u00a0\u00a03,029 \u00a0\u00a0\u00a0\u00a0\nPharMEDium remediation costs \u00a0(16,165 )\u00a0\u00a0(20,495 )\u00a0\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a0\u00a022,000 \u00a0\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(33,566 )\u00a0\u00a0(45,152 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(39,309 )\u00a0\u00a0(40,672 )\u00a0\u00a0\u00a0\nImpairment of long-lived assets \u00a0(138,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u00a0\nOperating income \u00a0$263,437 \u00a0\u00a0\u00a0$477,823 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a01.94% \u00a0\u00a02.01% \u00a0\u00a0\u00a0\nOperating expenses \u00a01.09% \u00a0\u00a01.16% \u00a0\u00a0\u00a0\nOperating income \u00a00.85% \u00a0\u00a00.85% \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a019.01% \u00a0\u00a019.45% \u00a0\u00a0\u00a0\nOperating expenses \u00a013.35% \u00a0\u00a013.53% \u00a0\u00a0\u00a0\nOperating income \u00a05.66% \u00a0\u00a05.92% \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a02.57% \u00a0\u00a02.86% \u00a0\u00a0\u00a0\nOperating expenses \u00a02.02% \u00a0\u00a01.81% \u00a0\u00a0\u00a0\nOperating income \u00a00.55% \u00a0\u00a01.05% \u00a0\u00a0\u00a0\n13", "original_text": "Total segment operating income \u00a0495,266 \u00a0\u00a0\u00a0471,834 \u00a0\u00a0\u00a05.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,492 \u00a0\u00a0\u00a087,279 \u00a0\u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(13,281 )\u00a0\u00a03,029 \u00a0\u00a0\u00a0\u00a0\nPharMEDium remediation costs \u00a0(16,165 )\u00a0\u00a0(20,495 )\u00a0\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a0\u00a022,000 \u00a0\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(33,566 )\u00a0\u00a0(45,152 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(39,309 )\u00a0\u00a0(40,672 )\u00a0\u00a0\u00a0\nImpairment of long-lived assets \u00a0(138,000 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u00a0\nOperating income \u00a0$263,437 \u00a0\u00a0\u00a0$477,823 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a01.94% \u00a0\u00a02.01% \u00a0\u00a0\u00a0\nOperating expenses \u00a01.09% \u00a0\u00a01.16% \u00a0\u00a0\u00a0\nOperating income \u00a00.85% \u00a0\u00a00.85% \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a019.01% \u00a0\u00a019.45% \u00a0\u00a0\u00a0\nOperating expenses \u00a013.35% \u00a0\u00a013.53% \u00a0\u00a0\u00a0\nOperating income \u00a05.66% \u00a0\u00a05.92% \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nGross profit \u00a02.57% \u00a0\u00a02.86% \u00a0\u00a0\u00a0\nOperating expenses \u00a02.02% \u00a0\u00a01.81% \u00a0\u00a0\u00a0\nOperating income \u00a00.55% \u00a0\u00a01.05% \u00a0\u00a0\u00a0\n13", "page_label": "13", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8feaf2ba-529e-4c33-bab2-6c2c10f75ca1": {"node_ids": ["a3c1c099-dfc9-4b28-85f8-8ed1304d2484", "e4c06b65-1eaa-4add-a657-9371d2543139"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAdjusted gross profit \u00a02.60% \u00a0\u00a02.65% \u00a0\u00a0\u00a0\nAdjusted operating expenses \u00a01.56% \u00a0\u00a01.61% \u00a0\u00a0\u00a0\nAdjusted operating income \u00a01.03% \u00a0\u00a01.04% \u00a0\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2019 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,232,604 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 12,568,816 \u00a0\u00a012,386,879 \u00a0\nInventories 11,686,466 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,277,714 \u00a0\u00a01,147,483 \u00a0\nPrepaid expenses and other 189,216 \u00a0\u00a0163,244 \u00a0\nTotal current assets 28,954,816 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,442,383 \u00a0\u00a01,770,516 \u00a0\n14", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\nAdjusted gross profit \u00a02.60% \u00a0\u00a02.65% \u00a0\u00a0\u00a0\nAdjusted operating expenses \u00a01.56% \u00a0\u00a01.61% \u00a0\u00a0\u00a0\nAdjusted operating income \u00a01.03% \u00a0\u00a01.04% \u00a0\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "14", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8b533cdf-8511-46fb-942d-8ee9c9cb5db2": {"node_ids": ["c3f9ae9a-8c3a-485b-9d27-c96a9080f261"], "metadata": {"window": "Goodwill and other intangible assets 8,846,162 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 773,377 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $40,016,738 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $29,181,860 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 916,107 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 532,489 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 30,630,456 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,636,114 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 289,047 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,895,453 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 496,587 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,069,081 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity\n$40,016,738\u00a0\n\u00a0$39,171,980\u00a0\n\u00a0\n\u00a0\nAMERISOURCEBERGEN CORPORATION\n15", "original_text": "Goodwill and other intangible assets 8,846,162 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 773,377 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $40,016,738 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $29,181,860 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 916,107 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 532,489 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 30,630,456 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 3,636,114 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 289,047 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,895,453 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 496,587 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,069,081 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity\n$40,016,738\u00a0\n\u00a0$39,171,980\u00a0\n\u00a0\n\u00a0\nAMERISOURCEBERGEN CORPORATION\n15", "page_label": "15", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7f31e967-4279-40dd-a1a0-717238a4e3a2": {"node_ids": ["ab8690a5-4c61-4bea-b4ab-6f0bef00826e"], "metadata": {"window": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\n\u00a0 \u00a02019 \u00a02018\nOperating Activities: \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0$186,568 \u00a0\u00a0$391,753 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1\u00a0341,020 \u00a0\u00a0206,905 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0\u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(307,204 )\u00a0(658,890 )\nInventories \u00a0(630,980 )\u00a0(898,775 )\nAccounts payable \u00a0787,037 \u00a0\u00a01,498,643 \u00a0\nOther \u00a0(233,631 )\u00a0(60,668 )\nNet cash provided by operating activities \u00a0142,810 \u00a0\u00a0478,968 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0\u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(67,305 )\u00a0(79,233 )\nCost of acquired companies, net of cash acquired \u00a0\u2014 \u00a0\u00a0(52,398 )\nOther \u00a04,966 \u00a0\u00a04,013 \u00a0\nNet cash used in investing activities \u00a0(62,339 )\u00a0(127,618 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0\u00a0 \u00a0\u00a0\nNet (repayments) borrowings \u00a0(13,981 )\u00a08,442 \u00a0\nPurchases of common stock 2 \u00a0(135,128 )\u00a0(239,008 )\nExercises of stock options \u00a020,113 \u00a0\u00a022,400 \u00a0\nCash dividends on common stock \u00a0(83,088 )\u00a0(85,535 )\n16", "original_text": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31,\n\u00a0 \u00a02019 \u00a02018\nOperating Activities: \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0$186,568 \u00a0\u00a0$391,753 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1\u00a0341,020 \u00a0\u00a0206,905 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0\u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(307,204 )\u00a0(658,890 )\nInventories \u00a0(630,980 )\u00a0(898,775 )\nAccounts payable \u00a0787,037 \u00a0\u00a01,498,643 \u00a0\nOther \u00a0(233,631 )\u00a0(60,668 )\nNet cash provided by operating activities \u00a0142,810 \u00a0\u00a0478,968 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0\u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(67,305 )\u00a0(79,233 )\nCost of acquired companies, net of cash acquired \u00a0\u2014 \u00a0\u00a0(52,398 )\nOther \u00a04,966 \u00a0\u00a04,013 \u00a0\nNet cash used in investing activities \u00a0(62,339 )\u00a0(127,618 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0\u00a0 \u00a0\u00a0\nNet (repayments) borrowings \u00a0(13,981 )\u00a08,442 \u00a0\nPurchases of common stock 2 \u00a0(135,128 )\u00a0(239,008 )\nExercises of stock options \u00a020,113 \u00a0\u00a022,400 \u00a0\nCash dividends on common stock \u00a0(83,088 )\u00a0(85,535 )\n16", "page_label": "16", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "87c11357-987f-4f42-95c3-aa3cffd7e58d": {"node_ids": ["7914144c-42f1-47a2-ac09-dc31d1075ccc", "80e630cf-e520-400c-8abc-1cf63a21d9e2", "7427053f-65af-46f2-85df-80b58211589c", "70c2deec-b132-4931-8392-4ace4758a43f", "64c66de7-fd54-4c4b-ac15-4ede7845e255", "166d1592-de26-485d-b6fb-c13ce3a75709", "191532cf-ca29-4141-9fa5-a28e5726bd97", "eb961eb5-ac6e-46cc-9e8b-f4cbece5f08b", "71747ed3-a2e4-4d85-9067-390ee1c36501", "262082c9-3478-4c6f-a6aa-131eec9ed05f", "a632129f-4138-47aa-8a48-e6d1cae8a1eb", "a9072523-6e39-41eb-ac3f-0abe25eb19e5", "a8df7fa5-974c-4da5-a611-d197779cde55", "c61be182-120e-4d8a-a862-4ecf8bbddaa3", "254ee87e-01a1-4f01-aa50-6273ff7f9be1"], "metadata": {"window": "Other \u00a0(9,977 )\u00a0(10,009 )\nNet cash used in financing activities \u00a0(222,061 )\u00a0(303,710 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents \u00a0(141,590 )\u00a047,640 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period \u00a03,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period \u00a0$3,232,604 \u00a0\u00a0$2,540,156 \u00a0\n_____________________________________\n1Includes a LIFO expense of $13.3 million and an impairment of long-lived assets of $138.0 million in the three months ended\nDecember 31, 2019.  Includes a LIFO credit of $3.0 million in the three months ended December 31, 2018.\n\u00a0\n 2Purchases of common stock in the three months ended December 31, 2019 includes $14.8 million of September 2019\npurchases that cash settled in October 2019 and excludes $9.4 million of December 2019 purchases that cash settled in January\n2020.  Purchases of common stock in the three months ended December 31, 2018 includes $24.0 million of September 2018\npurchases that cash settled in October 2018 and excludes $10.8 million of December 2018 purchases that cash settled in\nJanuary 2019.\n", "original_text": "Other \u00a0(9,977 )\u00a0(10,009 )\nNet cash used in financing activities \u00a0(222,061 )\u00a0(303,710 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents \u00a0(141,590 )\u00a047,640 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period \u00a03,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period \u00a0$3,232,604 \u00a0\u00a0$2,540,156 \u00a0\n_____________________________________\n1Includes a LIFO expense of $13.3 million and an impairment of long-lived assets of $138.0 million in the three months ended\nDecember 31, 2019. ", "page_label": "17", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7450a1cc-e6eb-43e7-ab5d-6f7d40252ac3": {"node_ids": ["451e207d-fda7-4e4c-80c7-be237e88bdd4", "63dd53ad-dd51-4a81-9cf9-93753f7c30f4", "3fdcfcf6-27d3-4801-b172-6ee2eab36980", "427e59db-da42-4a54-9225-18e913ff5740", "fdcffc1a-cfe6-4d22-83f7-5db2f6575c3b", "381a411f-a503-4460-8c7e-447e7163fc3f", "d63de384-f341-46f9-aa95-2a25ac03f46c", "ca2b85ef-8a30-43df-b64f-3eecc124b63f", "5d756f18-e20a-4b3e-a820-5e1c40553c49", "801e04b2-fd16-4ec3-89df-ee7a07c37ea6", "855b9474-f9e9-4984-9295-fa40be786b10", "2fc5d713-1d66-4331-983e-b99a9ea90174", "76cb6819-68f2-442b-aef7-710d5d260740", "1e52513c-ec50-4123-b4f4-a4a9229674c9", "741e2f26-8d88-4523-9c6d-ee91eb8cac19", "14985a43-3b15-43d4-b104-5662abb43f94", "50a8d02f-cf28-480e-8037-e2ceb1d546de", "f589c643-4ede-4b63-a749-ccfd5dca919f", "72fe4108-4802-4d0a-a7f7-e984cdf25ea1", "d0255fc9-f72e-405b-bfab-35d6082e957d", "c120f3b5-cbce-4cca-8493-71fbb4ae2eca", "17aba320-251d-49d2-8508-deb2ff9b42a1", "936c1b93-e96e-4dda-b4ae-9500b45bf21b", "1264105b-65d5-44c2-9eb9-f9770e35a63a", "ce43ab2d-dcd8-4f9e-beac-4e9e76ae5efb", "7ca8296b-6739-40fc-8495-dd11ebf2ebd3", "80e658e9-a765-4735-82fd-eee4a0b6239c", "5f75ead6-c032-4e14-a00d-98c7346287ba", "246f56c9-6bcf-4add-9ea0-be401b1b4579", "c70cd78e-2927-4f1b-a43f-b3c8311bace9", "9a2ea091-3ebc-43c8-b236-a68dece1c9e5"], "metadata": {"window": "Act is excluded because it is unusual, non-recurring and non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket. ", "original_text": "Act is excluded because it is unusual, non-recurring and non-cash. ", "page_label": "18", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "83178449-8605-45a3-a4c3-38c42742cd0b": {"node_ids": ["7ce563d7-bc10-47bb-a9d1-ac44943c4a67", "ef58a4cc-378b-485d-91ce-bb682e2af7b9", "99238e0b-cafa-41f0-91c5-371bd7069d7a", "5d24d640-e7f7-40cd-8886-a511172725e4", "fe72c292-0947-413d-8c7d-b6465f9e78c3", "fbb7679c-b0c9-4328-9728-e50fbfb3a6d9", "21177c0e-b4b2-48c9-9e42-04014d734312", "2df0a1b2-4b61-44c1-97b6-b5f63d15affe", "0a216014-c47b-470e-9ee4-d41557f94f92", "7184336b-0d3c-4398-9656-f8b5c89952f1", "de8a79d3-2e44-4c2f-89b1-0ce602a4fa0c"], "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; the (credit) related\nto the New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation,\nand other; and impairment of long-lived assets; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items.  In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for\nthe three months ended December 31, 2018.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it eliminates the per share impact of the items that are outside the control of the Company or that we\nconsider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; the (credit) related\nto the New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation,\nand other; and impairment of long-lived assets; in each case net of the tax effect calculated using the applicable effective tax\nrate for those items. ", "page_label": "19", "file_name": "CEN-Q1-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 171634, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}